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3Abstract
Diet and Endothelial Function in Healthy Young People
Cardiovascular disease (CVD) is the most common cause of death globally; yet,
its pathogenesis and early development are only partially understood.
Atherosclerosis begins early in life and is strongly associated with CVD risk
factors including diet. Certain dietary patterns and components in particular n-3
fatty acids have been shown to protect against CVD. However, the mechanisms
through which diet operates are largely unknown.
The aim of this PhD was to investigate associations between habitual diet
and the development of atherosclerosis. Participants in a randomised controlled
trial investigating effects of supplementation with DHA – an omega 3 fatty acid –
provided a convenience sample for this epidemiological dietary study. The main
RCT outcome measure was brachial artery endothelial function measured
noninvasively using vascular ultrasound (FMD). Secondary outcomes were
conventional CVD risk factors including blood pressure and serum lipid
concentrations.
A generalised food frequency questionnaire (FFQ) targeting all food
groups was used to assess the whole diet, and from this, data were used to
derive dietary patterns. Relationships between dietary patterns, FMD and CVD
risk factors were then investigated. A short FFQ for assessment of n-3 LC-PUFA
was designed and validated as no previous questionnaire was available. Red
cell membrane fatty acids provided biomarkers of fatty acid status. These were
used to validate the new FFQ and to investigate relationships of n-3 fatty acids
with atherosclerosis development.
Three dietary patterns were identified using principal component analysis.
A healthy dietary pattern was associated with lower carotid artery intima media
thickness in women in the highest compared with the lowest quintile for this
dietary pattern score (mean difference: -0.07mm, 95% CI: 07 -0.1, -0.03, P =
0.002). A healthy dietary pattern was also associated with lower blood pressure,
4heart rate, VLDL-cholesterol and triglyceride concentrations. Dietary patterns
were not directly related to FMD.
Higher DHA status was associated with lower FMD in women (mean
difference in absolute amounts: -0.08 mm, 95% CI: -0.1, 0.03; P = 0.001). Of
other outcomes higher DHA status was associated with waist:hip ratio and fasting
blood glucose only. Higher EPA status was associated with lower heart rate
(mean difference -3 beats per minute. 95% CI: -7, 1; P = 0.01), and lower
triglyceride and VLDL concentration.
In the RCT FMD was lower in DHA supplemented compared to control
groups (mean difference in absolute amounts: -0.03 mm; 95% CI: -0.005 to -
0.06 mm; P = 0.02). In secondary analysis this effect was confined to men. Of
other outcomes, only triglyceride (mean difference: -28%, 95% CI: -40% to -
15%; P<0.0001) and VLDL concentration were significant lower in DHA
supplemented individuals compared to controls.
Collectively these findings suggest that protective effects of diet
against the early development of atherosclerosis operate via reductions in
conventional CVD risk factors, rather than via direct effects on endothelial
function.
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Diet and Endothelial Function in Healthy Young People
Introduction
Atherosclerotic cardiovascular disease (CVD) is the most common cause of
death worldwide,1 yet its pathogenesis and early development are only partially
understood. Impairment of vascular endothelial function is central to the early
atherosclerotic process. Endothelial dysfunction can be measured noninvasively
and is evident in early life long before clinical signs of atherosclerosis emerge.
Conventional CVD risk factors, present from as early as the first decade of life,
strongly affect endothelial function (EF) and hence the development of
atherosclerosis and CVD.
Risk factors for CVD most strongly implicated in the development of
atherosclerosis include raised blood pressure (BP), dyslipidaemia, type 2
diabetes mellitus (T2DM) and obesity - all of which are strongly linked to diet. Diet
is, therefore, an important modifiable risk factor for atherosclerosis. It is currently
uncertain whether diet has direct effects on EF or whether dysfunction operates
via CVD risk factors.
Certain dietary patterns and specific nutrients are proposed to be protective
against the development of atherosclerosis. The strongest protective evidence is
for ‘healthy’ or ‘prudent’ dietary patterns, characterised by higher intakes of fruits,
vegetables and fish. Within healthy dietary patterns the strongest evidence is for
the role of n-3 fatty acids, in particular long chain polyunsaturated fatty acids
(LC-PUFA) found in high concentrations in fish and fish oils.
A large body of epidemiological evidence supports the role of n-3 fatty acids in
primary prevention of CVD. Despite this, a causal association has not been
established. Although randomized intervention trials have shown beneficial
effects of n-3 LC-PUFA supplementation, these trials have focused on secondary
prevention and few studies have investigated the influence of n-3 LC-PUFA on
the primary prevention of atherosclerosis. Preliminary evidence now suggests
that n-3 LC-PUFA may have a favourable effect on EF or coronary artery disease
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(CAD) and this could be one mechanism for their benefits in both the primary and
secondary prevention of CVD.
The role of n-3 LC-PUFA in the development of atherosclerosis was investigated
with a randomised controlled trial (RCT) of n-3 LC-PUFA supplementation in
healthy young people. The primary outcome was EF measured in the brachial
artery using non-invasive vascular ultrasound.
Assessment of background diet is essential in understanding diet-disease
relationships. However, diet is difficult to measure accurately and quantitative
measures of intake cannot easily be achieved. An alternative approach is the
study of dietary patterns and relationships with health outcomes. Food frequency
questionnaires (FFQ) provide information about habitual dietary intake and can
be applied in dietary pattern analysis.
The aim of this PhD was to investigate relationships between habitual diet and
the development of atherosclerosis. A generalised FFQ targeting all food groups
was used to assess the whole diet, and from this, data were used to derive
dietary patterns. Relationships between dietary patterns, EF and CVD risk
factors were then investigated. A short FFQ for assessment of n-3 LC-PUFA was
designed and validated as no previous questionnaire was available. Red cell
membrane fatty acids provided biomarkers of fatty acid status. These were used
to validate the new FFQ and to investigate relationships of n-3 fatty acids with
atherosclerosis development.
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Chapter 1
Cardiovascular Disease and its Risk Factors
The cardiologist's diet: If it tastes good, spit it out.
Section 1: Background
1.1 Cardiovascular Disease
The International Classification of Diseases, Tenth Revision (ICD-10) ranks
circulatory diseases as the largest single cause of death across England and
Wales (33% of all deaths in 2009: ONS, 2011).2 Although rates vary across
population groups, this pattern is consistent worldwide.1 The term ‘cardiovascular
diseases’ (CVD) encapsulates coronary heart disease (CHD – heart attacks),
cerebrovascular disease (stroke), hypertension (raised BP), peripheral artery
disease, rheumatic heart disease, congenital heart disease and heart failure.
Internationally, the potential for preventing atherogenesis - the underlying
pathology of the cardiovascular system in many diseases - is well understood and
acknowledged (e.g., Kavey et al., 2003),3 but requires changes in tobacco use,
levels of physical activity and diet 1 and has thus far been unsuccessful.
1.1.1 Prevalence of Cardiovascular Disease
In its 2011 global survey, the World Health Organization (WHO) reported an
estimated 17 million annual deaths from CVD.1 Within this estimate, CHD
accounted for 7.2 million deaths and 5.7 million were due to stroke. By 2020,
WHO predicts almost 25 million people will die each year from CVD. The most
recent Health Survey for England that addressed CVD and its risk factors (2006)
reported a high prevalence of CVD that was similar in men and women (13.6 and
13.0% respectively).
1.1.2 Global Burden of CVD
The prevalence of CVD mirrors stages of epidemiologic transition. In areas
where infectious diseases and malnutrition still prevail, e.g. Sub-Saharan Africa,
rural India and South America, these diseases account for most deaths and CVD
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mortality and morbidity is low (5-10%). As infectious diseases and malnutrition
decrease, CVD and its risk factors increase.4 Economically developing countries
are now following similar trends to industrialized nations where rising income is
accompanied by an increase in degenerative or “man-made” diseases that reflect
effects of changing lifestyle on health.5
Whilst people in low- and middle-income countries are now more exposed to
CVD risk factors they have less access to preventative measures, such as
education and health care, than more affluent countries. In contrast, regions at
an advanced stage of epidemiologic transition, including Western Europe, North
America and Australia are able to focus more on prevention and delaying the
onset of CVD to later in life.6 Therefore, more people in low- and middle-income
countries who develop CVD will die from it and at younger ages than in more
affluent settings.
1.2 Clinical Signs of Cardiovascular Disease
Most CVD deaths result from CHD which targets the heart and blood vessels.
1.2.1 Coronary Heart Disease
Coronary heart disease is the single most common CVD (WHO, 2011)1 and
includes myocardial infarction (MI) and angina (chest pain on exertion). CHD
commonly results from atherosclerosis (Section 1.3), which may restrict the flow
of blood to the heart muscle (myocardium) and compromise cardiac function.
Clinical symptoms include shortness of breath and angina. Unstable arterial
plaques are particularly dangerous as they may become dislodged from the
artery wall and permanently block blood flow leading to ischaemia (relative or
absolute restriction of blood flow leading to permanent tissue damage).7
1.2.2 Cerebrovascular Disease
Cerebrovascular disease results from damage to blood vessels supplying the
brain, restricting blood flow and causing ischaemia. Thromboembolism (the
dislodging of a blood clot (thrombus) which then occludes arteries serving the
brain) is the commonest cause of ischaemic brain disease or stroke.8
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Atherosclerosis increases the likelihood of fatal thromboembolism by decreasing
arterial diameter.9
1.3 Atherosclerosis
Atherosclerosis is a disease in which arteries are narrowed as a result of lipid-rich
lesions (plaques) that form in the blood vessel lining (endothelium), causing it to
thicken. Understanding the atherosclerotic process requires knowledge of arterial
wall structure.
1.3.1 Arterial Wall Structure
The structure of a normal artery consists of three distinct layers (Figure 1-1).
The innermost layer (intima) is very thin, comprising a matrix of extracellular
tissue (proteoglycans and collagen). The intima is separated from the arterial
lumen by a single layer of endothelial cells and connects to the medial layer
(media) via a sheet of elastic fibres (internal elastic lamina). The media is made
up mainly of smooth muscle cells. The outermost layer, the adventitia, consists
of connective tissue, fibroblasts and smooth muscle cells.
Figure 1-1 Structure of a normal artery (nature.com)
1.3.2 Initiation of Atherosclerosis
The earliest stage in the development of atherosclerosis is a generalised
disturbance of vascular function. This leads to the formation of ‘fatty streaks’ in
the vascular endothelium of large arteries.10 Over time endothelial dysfunction
27
results in thickening of the arterial intima and media and the eventual
development of plaque.11
Fatty streaks arise when the vascular endothelium develops lesions that allow
entry of ‘foam cells’ to the sub-endothelial space. Foam cells are formed from
lipid rich cells that originate as monocytes, then differentiate into macrophages
which take up lipid from the sub-endothelial space to become foam cells.12 This
accumulation of lipid-rich debris and the migration of smooth muscle cells to fatty
streaks can lead to the development of more established fibrous lesions. These
complex fibrous lesions can grow, forming large plaques that may block the
arterial lumen, either partially or completely and impair or occlude blood flow.
The advancement of atherosclerosis is complex and involves interactions
between foam cells, T-lymphocytes, smooth muscle cells, cytokines and
numerous biological processes.
1.3.3 Role of Inflammation in Atherosclerosis
There is substantial evidence that chronic inflammation is central to the
atherosclerotic process.13 During chronic inflammation, modified lipoproteins,
monocyte-derived macrophages and T-cells interact with normal cellular
elements of the arterial wall and can trigger the atherosclerotic process. Raised
concentrations of inflammatory markers are indicators of atherogenesis.
1.3.4 Role of Adhesion Molecules in Atherosclerosis
Entry of mononuclear cells to the endothelium is facilitated by specific adhesion
molecules. These include: vascular cell adhesion molecule-1 (VCAM-1),
intracellular adhesion molecule-1 (ICAM-1), and selectins p and e.14-18
1.3.5 Role of Lipoproteins in Atherosclerosis
The main lipid contributors to atherosclerotic lesions are low density lipoprotein
cholesterol (LDL) particles, in particular small dense LDL, remnant lipoproteins
(or β-very low density lipoprotein (VLDL)) and lipoprotein a (Lpa).  Lipoproteins 
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are taken up by macrophages and become foam cells. LDL receptors on the cell
surface also have a major role in lipid accumulation.
1.3.6 Early Origins of Atherosclerosis
Research conducted into the origins of atherosclerosis shows conclusively that it
begins in early life.19-21 Development and progression of atherosclerosis in
children and young people are influenced by risk factors such as obesity,
hypertension, insulin resistance, T2DM, dyslipidaemia and smoking. For
example the Pathobiological Determinants of Atherosclerosis in Youth (PDAY)
and Bogalusa heart studies both found strong relationships between CVD risk
factors and early signs of atherosclerosis.19, 22 Therefore, the primary prevention
of atherosclerotic disease should begin in childhood, a strategy supported by
public health policy, for example from the American Heart Association (AHA).23
1.4 Clinical Assessment of Atherosclerosis
Arterial stiffness and endothelial dysfunction are important risk factors in the
aetiology of CHD. The vascular endothelium is the primary site of dysfunction in
CVD and endothelial dysfunction is reported in patients with clinical CVD as well
as in healthy individuals who may have CVD risk factors such as smoking,
hypertension, dyslipidaemia, obesity and diabetes, but who have no clinical signs
of disease.24, 25
Vascular function describes the regulation of blood flow, arterial pressure,
capillary recruitment and filtration and central venous pressure. Mechanisms are
complex and include interactions between intrinsic factors (e.g. nitric oxide [NO]
and eicosanoids) and extrinsic systems (e.g. sympathetic and parasympathetic
innervation, adrenaline, angiotensin, vasopressin). Components of vascular
function include hypertension, arterial stiffness and endothelium-dependent
vasodilatation. These are strongly associated with cardiovascular mortality and
are therefore important risk factors that may be targeted with interventions
including modifications to diet and lifestyle.26-28 Endothelial function can be
measured in peripheral arteries non-invasively using vascular ultrasound
techniques and provides a surrogate measure of coronary artery function. The
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most widely used technique is flow mediated dilatation (FMD), which is usually
performed on the brachial artery (Section 1.4.1.1). Studies have demonstrated a
close relationship between endothelial function of the peripheral and coronary
circulations.29 Brachial artery FMD is also closely related to the angiographic
extent of CAD.30
Arterial stiffness is the result of structural and functional changes in the blood
vessel wall. Increased collagen and calcium deposition that occurs with vascular
ageing reduces arterial elasticity.31 The presence of fatty streaks or arterial
plaques increases arterial intima media thickness (IMT) which also contributes to
arterial stiffness. IMT thickness can be measured non-invasively with vascular
ultrasound techniques (Section 1.4.1.2). Together these structural and functional
changes increase the risk of atherosclerosis.
1.4.1 Measurement of Vascular Structure and Function
Non-invasive vascular ultrasound techniques are established as valid and reliable
tools that can be used clinically to identify individuals at risk of CVD.32 Vascular
structure is commonly assessed through measurement of common carotid artery
intima media thickness (CCA-IMT).33 Arterial stiffness can also be evaluated
using measures of arterial compliance (distensibility)34 and pulse wave velocity
(PWV).33 FMD is widely used to assess EF.24, 35, 36
1.4.1.1 Measurement of Vascular Function
Endothelial function can be assessed in either the coronary or peripheral
circulation. For detailed methodology used in coronary artery endothelial function
please see Lane, 2006.37 Peripheral arteries provide a surrogate measure of
coronary artery endothelial function and can be measured non-invasively using
FMD. The brachial artery is most commonly used although carotid, superficial
femoral and radial arteries have also been used. FMD is an endothelium-
dependent process (EDV) where conduit arteries dilate in response to a flow
stimulus. FMD is expressed as the change in diameter divided by the baseline
diameter and can be measured with acceptable accuracy using high resolution
ultrasound techniques and edge detection software.38 During this process,
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increased shear stress to the vascular endothelium, a single layer of cells lining
the internal vascular wall, activates endothelial nitric oxide synthase (eNOS), an
enzyme that prompts the intimal smooth muscle layer to relax and release
vasodilators including NO. Ultrasound imaging can be used to measure changes
in arterial diameter that occur during dilatory responses.24, 35
The artery is imaged using B (brightness) -mode ultrasonagraphy, a technique
that produces a two-dimensional image from ultrasound echoes (Figure 1-2).
Blood flow to the forearm is restricted using a high pressure cuff inflated to supra-
systolic pressure (Figure 1-3). Pressure is maintained for five minutes and
occludes blood flow to the limb. Release of the cuff causes shear stress from
ischemia-induced hyperaemia which stimulates the release of NO causing
vasodilation. Ultrasound measurements, taken at baseline and during the peak
vasodilatory response, provide a measure of endothelial function. Endothelial
dysfunction is characterised by reduced vasodilation, increased permeability and
activation of inflammatory pathways. For a detailed description of procedures for
assessment of vascular structure and function in this PhD thesis please see
Chapter 5.
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Figure 1-2 Brachial Artery Image
Figure 1-3 Scan set up for FMD
FMD is considered the most reliable technique for measurement of EDV.36
Although there are several physiological, equipment-related and operator-related
variables that can affect the reliability of this technique,35 comparison with a
“gold-standard” technique (intravascular ultrasound) has shown good
reproducibility of baseline measurements.39 Intra-individual variation within
measurement session was acceptable (1.1% (extremes 0.06-2.0%) as was inter-
operator variation (4.6%). However, intra-individual variation between sessions
was considerable (13.9%).39 Therefore the technique is recommended as
suitable for group comparisons but may not be suitable as a follow-up parameter
for clinical investigations in individuals.
32
Other older methods to measure EF include the L-arginine test,40 measurement
of forearm blood flow (FBF) using venous plethysmography41 and digital pulse
amplitude tonometry.42
1.4.1.2 Measurement of Vascular Structure
Early atherosclerosis can also be detected through assessment of arterial
stiffness or elasticity. Arterial stiffness is determined by the relationship between
the change in arterial volume, the resultant distending pressure and the structural
properties of the arterial wall e.g. collagen and elastin. Arterial stiffness can also
be measured using non-invasive ultrasound techniques.37 Arterial stiffness
correlates closely with the extent of atherosclerotic disease27 and with
cardiovascular risk factors (even from early childhood).19 Arterial stiffness is
usually estimated from arterial distensibility, which is measured as the change in
arterial diameter of a peripheral artery caused by pulse pressure.43 A smaller
change in arterial diameter in response to pulse pressure indicates a stiffer artery.
Alternatively, arterial stiffness can be assessed through measurement of the
pulse wave velocity, i.e. the time it takes the pulse wave to travel a given distance
(between pulse points). Typically, pulse wave propagation velocity between the
carotid and femoral or carotid and radial pulses is measured.44 Measurement is
also carried out non-invasively using vascular ultrasound and magnetic
resonance imaging (MRI).45
Sub-clinical atherosclerosis can be evaluated through the measurement of
CCA-IMT using high resolution ultrasound. Increased carotid arterial wall
thickness indicates the presence of fatty streaks or fibrous plaques. Population
studies have found associations between increased CCA-IMT and progression of
coronary artery disease.46, 47 Therefore, measurement of CCA-IMT is prognostic
of future cardiovascular events. A region of the common carotid artery, typically
1.0 cm proximal to the origin of the carotid bulb, is identified by B-mode
ultrasonagrophy. The distance between the luminal-intimal surface and the
media-adventitial interface represents the IMT.
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Figure 1-4 Ultrasound image of common carotid artery
IMT is the distance between the intima lumen and adventia boundaries as depicted above.
Collectively, therefore, measures of vascular function, such as FMD and arterial
distensibility, provide unique tools for the investigation, non-invasively, of the
early origins of CVD. These measures are closely associated with cardiovascular
risk factors and, at least in older individuals, show some prognostic value.
Moreover, unlike other cardiovascular outcomes, these techniques can be used
to measure the earliest stages of the atherosclerotic process in children, thereby
avoiding some of the confounding effects of risk factors later in life on
programming of adult CAD. Finally, early vascular dysfunction provides a
potential mechanism that links factors in early life with later CVD.
1.5 Cardiovascular Disease Risk Factors
Risk factors for CVD include some that are immutable, such as age, gender and
ethnicity and others that are modifiable. Key risk factors that are potentially
modifiable include high BP, high blood cholesterol concentration, tobacco use,
dietary factors, physical inactivity, T2DM and disposition. Targeting reduction of
these risk factors offers an opportunity to minimise the risk of developing clinical
CVD.
1.5.1 Non-modifiable Risk Factors
There are many CVD risk factors that cannot be changed. These are discussed
below.
1.5.1.1 Gender and CVD Risk
In most developed countries, CHD is the leading cause of death in both women
and men1 despite CHD prevalence being higher in males than females.1 Sex
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differences in the pathophysiology, presentation and treatment of CHD are well
recognized, but how these relate to CHD incidence is unclear.
For many decades, research investigating sex differences in CHD focused on a
protective role of oestrogen, as CHD prevalence among pre-menopausal women
was low.48 The difference in CHD mortality between men and women narrowed
considerably between 1994 and 2006 (ORs 1994 - 1995 1.44 versus 2004 - 2006
1.03), which may have been due to increased awareness of heart disease in
women leading to improved diagnosis and management of risk factors.49
Environmental factors, such as diet and lifestyle may interact with gender to
influence CVD risk. For example, secular changes in dietary fat consumption in
England and Wales during the years 1921 to 1949 showed a similar pattern to
changes in the sex ratio in mortality from CHD. Mean per capita fat consumption
was positively correlated with the sex ratio for CHD mortality in men (r = 0.79,
95% CI: 0.70 - 0.86, P < 0.01) and inversely correlated to mortality in women
(r = -0.30, 95% CI: -0.49 - -0.06, P < 0.01).50
1.5.1.2 Age and CVD risk
The age at which CHD first manifests varies according to gender and
geographical location. Presentation with first MI has been reported as 9 years
lower for men than women in all regions of the world.51 Variations in age at first
presentation of MI occur geographically with the youngest cases reported in
South Asia (median age 53 years) and the Middle East.
1.5.1.3 Ethnicity and CVD risk
Differences in CVD risk and mortality are apparent between ethnic groups. For
example, a survey investigating the 10 leading causes of death in the United
States (US) reported the age adjusted death rates for CHD and cerebrovascular
diseases were 1.3 and 1.5 times greater, respectively, for the black than the white
population.52 The reasons for this are unclear but risk factors are likely to be
important contributors. The risk of having at least one uncontrolled CVD risk
factor in non-white US veterans was twice that of white US veterans (95% CI: 1.8
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- 2.3).53 Differences in socioeconomic status may also be important.54 Lower
educational levels are consistently reported in association with CVD for non-white
compared with white populations.55 Evidence for disparities in CVD risk factors
between white and non-white populations (British and Caribbean blacks, African–
Americans and South Asians) continues to emerge.56-58
Men and women in Britain, whose families originate from India, have about 40%
greater CHD mortality than nationals of European descent. This higher
prevalence of CVD among migrant South Asians may be partly explained by
socioeconomic differences.59 However, when South Asian migrant populations
are compared with indigenous controls, increases in obesity, cholesterol and
insulin levels are notable, suggesting that nutritional factors influence increased
CHD risk.60
In conclusion, non-modifiable risk factors do not act independently to increase
CHD risk but are markers of modifiable risk factors.
1.5.2 Modifiable CVD Risk Factors
The worldwide prevalence of modifiable risk factors for CVD is extremely high - it
is estimated that only 2-7% of the world’s population have none and more than
70% have multiple risk factors.4 Importantly, CVD risk is potentially modifiable; 8
preventable risk factors (tobacco use, physical inactivity, raised BP, raised blood
glucose, raised blood cholesterol, alcohol use, high body mass index [BMI] and
low fruit and vegetable intake) account for 61% of total CVD deaths.51
Until recently, knowledge of modifiable risk factors was based on studies
conducted in populations of European origin. The INTERHEART study51
investigated the strength of associations of CVD risk factors with health outcomes
in a large multinational study designed to estimate risk in a more universally
representative population, thus reducing bias introduced by regional and ethnic
variations. Smoking (odds ratio [OR] 2.87 for current versus never) and
increased levels of certain plasma lipoproteins (ApoB/ApoA1 [OR 3.25 for top
versus lowest quintile]) were the two strongest risk factors, followed by
36
psychosocial factors (OR 2.67) history of T2DM (OR 2.37) and hypertension (OR
1.91).
1.5.2.1 Income Inequalities
Relationships between income inequality and CVD risk have been reported both
between and within nations. Cross-national studies comparing nations
undergoing recent economic/political transition report positive associations
between higher income inequality and selected CVD risk factors, particularly BMI
and obesity.61 In the UK in 2006, for example, CVD and many of its risk factors
were highest in low income groups.62 This was particularly marked in younger
people (< 35 years), where income was the greatest predictor of CVD. Greater
disparity was seen for men: those in the lowest two quintiles for income had
greater CVD risk compared with those in the highest 3 (prevalence > 20% versus
< 18%) whereas women in the highest (prevalence 20%) and two lowest quintiles
fared worse than those in the middle quintiles (prevalence 15%).
1.5.2.2 Obesity
Obesity is the consequence of a positive energy balance occurring when energy
intake is higher than expenditure over a long time. Excess nutrition impairs
systemic metabolic homeostasis and elicits stress.63 It also activates an
inflammatory process leading to increased circulating levels of pro-inflammatory
cytokines, adipokines (hormone-like molecules produced by adipocytes) and
other inflammatory markers. Adipokines (e.g. leptin, adiponectin, resistin and
vistatin), and other chemical mediators such as tumor necrosis factor-alpha,
interleukin-6, plasminogen activator inhibitor-1, lipoprotein lipase, acylation
stimulating protein, cholesterol ester transport protein, estrogens,
angiotensinogen and insulin-like growth factor-1 are present in increased
concentrations in obese patients. These have various adverse effects on the
cardiovascular system by creating a pro-inflammatory and prothrombotic state as
well as causing endothelial damage and vascular hypertrophy.64, 65 This results
in a chronic active inflammatory condition that is associated with the development
of a range of diseases. Obesity is known to directly impact CVD risk as well as
indirectly through individual risk factors, as discussed below.
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1.5.2.3 Direct Effects of Obesity on CVD risk
Obesity is an independent predictor of CAD, as observed in several studies.66-68
For instance, the Framingham Heart Study, which followed the health of a 1948
born cohort and two subsequent generations in Framingham, Massachusetts,
found that younger men (age < 50 years) who weighed more than 130kg
demonstrated a two-fold increased risk of coronary disease compared with lighter
men (< 110kg). For women, the risk increased 2.4-fold and remained after
adjustment for other major CVD risk factors.67
The UK Health Survey for England (HSE) study (2006) found that abdominal
obesity appeared to double the risk (OR 2.24) for acute MI.62
In the PDAY study, autopsy atherosclerotic plaques were highly correlated with
the amount of abdominal fat and with BMI.22 Obesity accelerates atherosclerosis
decades before clinical manifestations appear even after adjustment for other risk
factors including raised cholesterol, hypertension, smoking and increased
glycosolated haemoglobin (HbA1c).67 There are also direct effects of obesity on
the heart and the cardiovascular system for example, cardiomyopathy prevalence
is increased in obese individuals.69 Several factors primarily caused by obesity,
such as increased blood volume, elevated cardiac output, left ventricular
hypertrophy and left ventricular diastolic dysfunction also play a role in causing
heart failure.70 Furthermore, the incidence of sudden cardiac death and
arrhythmias is increased in obese individuals.71
1.5.2.4 Indirect Effects of Obesity on CVD Risk
Obesity is characterized by increased storage of fatty acids in an expanded mass
of predominantly white adipose tissue. Central or abdominal obesity is marked by
increased visceral adipose tissue (dispersed around the omentum, intestines and
peri-renal areas,72 which is mainly white adipose tissue. Visceral adipose tissue
is more metabolically active than peripheral adipose tissue, and is involved in the
control of metabolism through energy homeostasis, adipocyte differentiation and
insulin sensitivity.73 Furthermore, white adipose tissue regulates the production
of anti-inflammatory molecules integral to metabolic and immune pathways. In
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individuals with abdominal obesity, there is an increase in inflammatory markers
as well as the occurrence of a prothrombotic state.74
Chronic inflammation, associated with obesity, results in overproduction of
adipokines and hormones,75 as well as insulin resistance, which in turn
predisposes to the development of T2DM.76 Both chronic inflammation and
insulin resistance are strongly associated with endothelial dysfunction and the
initiation and progression of atherosclerosis.77
In most obese subjects, plasma free fatty acid (FFA) levels are increased as a
result of both overconsumption of dietary fat and increased lipolysis.78 Increased
FFAs inhibit insulin signalling and are thus implicated in the development of
insulin resistance.79 Furthermore, they may impair vasodilatory responses and
are also implicated in endothelial dysfunction.80 Obesity has been weakly
associated with higher total cholesterol and LDL concentrations (r ~ 0.05 - 0.15)
and more strongly with lower HDL, higher BP and insulin resistance.81-83
1.5.2.5 Blood Pressure
Hypertension is an important public-health challenge worldwide and has been
identified as one of the most preventable causes of premature death.84 Based on
a single measurement greater than 140 mm Hg for systolic or 90 mm Hg for
diastolic BP, approximately one in four adults, worldwide, would be classified as
hypertensive.85 Currently, this equates to about one billion individuals, and this
number is expected to grow to > 1.5 billion, about one third of the world’s
population, by 2025. The greatest increases will be seen in low to middle income
countries undergoing transition. Clearly this represents a large burden both to
global health and economics.
There is a greater prevalence of hypertension in overweight compared with
normal weight individuals. In men, hypertension prevalence is 15% in those with
BMI <25 and 42% in those with BMI >30; in women, prevalence is 15% and 38%,
respectively.86 Therefore weight management has an important role not only in
the prevention of metabolic syndrome but also in maintaining healthy cardiac
function.
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The effects of obesity on hypertension are proposed to operate via the renin-
angiotensin-aldosterone and sympathetic nervous systems.87 Increased activity
of these systems may result in salt-sensitive hypertension.88 The role of salt in
hypertension is discussed in Section 1.6.2.
1.5.2.6 Insulin Resistance
Insulin resistance in adipocytes results in reduced uptake of circulating lipids and
increased hydrolysis of stored triglycerides (TG). Increased mobilization of stored
lipids in these cells elevates FFAs in plasma. Elevated FFAs reduce muscle
glucose uptake, and increase liver glucose production, which both contribute to
elevated blood glucose levels. Ultimately, if compensatory mechanisms are
unable to maximize glucose utilization in this dearth of insulin, T2DM may result.
1.5.2.7 Dyslipidaemia
Dyslipidaemia is a syndrome characterised by overproduction or deficiency of
specific lipoproteins and lipids. Presentation is usually marked by raised total
serum cholesterol (TC) and changes in the ratio of potentially harmful cholesterol
sub-fractions (non-high density lipoprotein cholesterol [HDL]) to potentially
beneficial HDL concentration in the blood.
Triglyceride concentrations are often raised in tandem with other lipid fractions or
may singularly indicate dyslipidaemia. Increased serum TG is often seen in
association with high carbohydrate intake. In particular, high glycaemic index
foods are implicated.89 The combination of low HDL, increased TG-rich
lipoprotein remnants and small dense LDL particles characterizes an atherogenic
lipoprotein phenotype and increases overall CVD risk.90, 91
The presence of an atherogenic lipoprotein phenotype, particularly in combination
with insulin resistance, contributes to increased risk of CHD. Small dense LDL
particles have increased atherogenicity compared with larger LDL, possibly due
to their greater propensity to be transported into the sub-endothelial space
(Section 1.3), their increased binding to arterial proteoglycans and high
susceptibility to oxidative modification.90
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1.5.2.8 Endothelial Dysfunction
Deterioration in EF and arterial stiffness are early events in the development of
CVD (Section 1.3). Endothelial dysfunction is reported in patients with all types
of CVD, including CHD, peripheral arterial disease and chronic heart failure.
Furthermore, patients who have CVD risk factors such as smoking, hypertension,
dyslipidaemia, obesity and diabetes, but who have no clinical signs of disease,
often display endothelial dysfunction.24, 25 Lifestyle factors, including diet, have
been shown to affect EF - in particular, diets high in fat are considered a risk
factor for the development of atherosclerosis.92, 93
1.5.3 Cardiovascular Risk Factor Stratification
There are now 3 methods for assessing CVD risk in the UK: Framingham,71
ASSIGN94 and QRISK.95 The Framingham risk assessment tool is limited by its
development in an historic American population, and by the fact that it makes no
allowance for family history of premature CHD or ethnicity. ASSIGN and QRISK
are based on UK populations and do make allowance for social and lifestyle
factors known to influence CVD risk. Current guidance for prevention of CVD in
the UK is provided by the joint British Societies for Cardiology, Hypertension,
Diabetes and Heart Health.96
1.5.4 Primary Prevention Strategies
Industrialization and technical advancements occurring over the last 50 years
have led to changes in lifestyle that are strongly associated with increased CVD
risk. Interventions aimed at reducing CVD risk through behavioural modification
have demonstrated the strength of these associations. The Multiple Risk Factor
Intervention Trial (MRFIT) was a multi-centre trial conducted by the US National
Heart Lung and Blood Institute (NHLBI) that investigated the effect of a
multifactor intervention programme on CHD mortality in 12,866 men with high
CVD risk.97-100 Men were randomly assigned either to an intervention providing
treatment for hypertension, counselling and advice for cigarette smoking, diet and
cholesterol reduction, or to their usual healthcare. Over a seven year follow-up,
risk factor levels declined to a greater extent in the intervention group but no
difference in CHD mortality was reported.101 After longer term follow-up (10.5
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years), however, CHD mortality was significantly lower (10.6% [P < 0.01]) for men
in the intervention group.102 This effect persisted at 16 years when 370 men in
the intervention group and 417 men in the control group had died from CHD.
This represents an 11.4% lower mortality rate for intervention versus control (95%
CI: -23% - 1.9%).103
Caution should always be used when interpreting data from follow-ups that
extend beyond the a priori stated study period, as validity may be compromised.
For example, in many cases investigators do not continue to collect the same
amount of data as in the trial itself because of cost considerations. Moreover,
some patients will decline to participate in the extension or may change
behaviours that are influential on the original trial outcomes. However, findings
from intervention studies such as MRFIT and cohort studies including the
Framingham Heart Study67, 104 in the US and the Caerphilly Prospective Heart
Disease Study in Wales105 have directly influenced Government primary
prevention strategies to manage the risks of hypertension and
hypercholesterolemia.106
1.6 Nutritional Determinants of CVD Risk
The relationship between dietary factors and CVD has been a focus of research
for many years. Evidence from the Seven Countries study, a 20-year study of
about 12,000 men between the ages of 40 and 59 from 15 communities in Italy,
Greece, Yugoslavia, the Netherlands, Finland, Japan and the United States,
reported a clear and predictable pattern that linked diet to CHD prevalence.107
Throughout the Mediterranean (Greece, and Southern Italy) and Asian (Japan)
regions - where vegetables, grains, fruits, beans and fish predominate in the diet -
heart disease was found to be rare. Conversely, populations consuming mainly
red meat, cheese and other foods high in saturated fat - such as in the US and
Finland - had high rates of CVD.107 The Seven Countries Study was one of the
first in humans to suggest a link between dietary fat and CHD risk. Death rates
were positively related to high energy intake from saturated fatty acids (SFA) and
negatively to dietary energy from monounsaturated fatty acids (MUFA).108
Moreover, there were great differences in CHD mortality at similar blood
42
cholesterol levels, suggesting that fat intake, rather than cholesterol levels, may
be linked to fatality.
The Seven Countries Study, together with data from animal models that showed
diets high in cholesterol and saturated fat were associated with atherosclerosis,
led Gordon (1988) to propose the diet-heart hypothesis.109 Gordon postulated
that dietary saturated fat and cholesterol played a primary role in the
development of atherosclerosis and CHD in humans. This prompted more
research in the form of prospective cohort studies and RCTs.
The relationship between diet and CVD is complex. Much confusion stems from
the lack of definitive data regarding recommended diets and their potential health
benefits. Overall, however, substantial evidence supports the hypothesis that
dietary factors are important in the development of CVD and have been shown to
have both protective and detrimental effects.110 Relationships between dietary
factors have been reported in association with a range of CVD risk factors
including, obesity, hypertension, insulin resistance and dyslipidaemia. These are
discussed in Sections 1.6.1 – 1.6.4 below.
1.6.1. Dietary Fat and CVD Risk
Mechanisms for increased CVD risk are closely linked to and are often proposed
to operate via obesity.75 Fat is the most energy dense of the three
macronutrients and is a major source of dietary energy. High intake of fat,
particularly saturated fat, has been directly linked to obesity development in many
studies. Fat is therefore highly implicated in CVD risk and has been the focus of
many studies investigating relationships of diet and cardiovascular health.
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1.6.1.1 Epidemiological studies investigating fat and CVD risk
The effects of dietary fat, both quantity and type, on the primary prevention of
CVD have been investigated in numerous epidemiological studies.111-127 In one
of the earliest studies the Ireland-Boston Diet-Heart Study reported an
association of dietary saturated fat with CHD mortality.111 This large cohort study
of about 1,000 middle-aged men used diet scores to estimate CHD mortality risk.
Higher dietary scores for saturated fat and cholesterol were associated with
increased CHD risk (relative risk [RR] 1.60). Conversely, high diet scores for fruit
and vegetable intake were protective (RR 0.57). Although unable to demonstrate
causality, this study provides support for the diet-heart hypothesis that first
proposed a link between dietary fat and CHD; however, confounding cannot be
ruled out because it is not possible to determine whether diet is a marker for other
health behaviours.
A study of more than 10,000 health-conscious adults followed for 13 years in the
UK reported an increased risk of CHD mortality with increasing intake of
saturated fat and dietary cholesterol (death rate ratios in the third compared with
the first tertile: 329 (95% CI: 150 - 721); 277 (95% CI: 157 - 796) respectively (P
for trend <0.01).115 Similarly, in the US, a lower intake of saturated fats was
associated with lower CHD risk in elderly men.125 The size of the beneficial effect
was attenuated by fruit and vegetable consumption, suggesting that benefit was
in part derived from other dietary components. It can be argued here that, as in
the study of Mann (1997), high fruit and vegetable intake is a marker for health-
conscious behaviour in general.115
Although many studies support an association between SFA intake and CVD risk
confounding is a possibility and RCT data are needed to underpin public health
messages.111, 112, 115, 120, 125
1.6.1.2 Randomised Controlled Trials - Fat and CVD Risk
Relatively few RCTs have investigated relationships between dietary fat and
CVD.128-132 Dayton and colleagues (1969) carried out one of the earliest
intervention studies investigating effects of substituting saturated for unsaturated
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fat.129 The aim was to reduce serum cholesterol and minimize the risk of
atherosclerosis. The intervention led to a 14% greater reduction in baseline
cholesterol concentration compared with control. However, adjustment for
baseline serum cholesterol concentration revealed that most of the effect was
encountered in men with starting levels above the median (6.0 mmol/l). After 8
years follow-up, the incidence of all primary and secondary end-points was
greater for the control compared with the intervention group (47.7% versus 31.3%
[P = 0.02]).
The Women’s Health Initiative Randomized Controlled Dietary Modification Trial
delivered intensive behaviour modification sessions over a nine year period,
aiming to reduce total fat intake to less than 20% of calories and to increase
intake of fruit, vegetables and grains. At final follow-up (mean participation 8.1
years), modest effects were reported for some but not all CVD risk factors.
Diastolic BP and LDL were reduced by 4.3% and 3.55mg/dl respectively.
However, no differences in levels of HDL, TG, glucose or insulin were found.131
Clearly results from these studies are equivocal and it is questionable whether
long-term interventions that impose severe restrictions on diets of free living
individuals are justified.131 It is possible that effects of interventions have a long
latency phase as demonstrated in the MRFIT study where no difference was
seen in CHD mortality after 6-8 years follow-up (Section 1.5.4). However, at
longer follow-up, of about 10 years, a significant reduction in CHD mortality was
reported for the intervention group.102
1.6.1.3 Fat Quality and CVD Risk
Many observational studies have examined relationships between
polyunsaturated fatty acids (PUFA), in particular LC-PUFA of the omega (n) -6
and n-3 series and CHD.113-115, 117-119, 121, 123, 126, 127, 133 Observations by Bang
(1976)134 and Dyerberg (1975)135 found associations between high fish
consumption and reduced CHD risk among native Greenlanders, which focused
studies on the role of n-3 LC-PUFA. Protective effects of n-3 LC-PUFA have
been reported in some114, 117, 119, 123, 126, 133, 136 but not all studies.113,115, 118 The
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role of n-3 LC-PUFA in primary prevention of CVD, a key focus of this PhD, is
discussed more fully in Chapters 2 and 3.
There is reasonably strong evidence to suggest trans-fatty acids (TFA) (found in
some margarines, vegetable shortenings and processed baked and deep fried
foods) are associated with increased CHD risk.116, 137 In controlled metabolic
studies, TFA have been shown to raise LDL and lower HDL plasma
concentrations.138-144
1.6.2 Effects of Sodium Chloride on Blood Pressure
The incidence and severity of hypertension are affected by nutritional status and
high intake of certain nutrients. For example, high sodium chloride (salt) intake is
reported to predispose to hypertension,145 and in many populations, salt intake
exceeds dietary requirements. The UK Scientific Advisory Committee on
Nutrition (SACN) issued a report in 2003 which concluded that there was
evidence for a direct association between salt intake and high BP.146 The report
found that on average, people consumed 9g of salt per day and following their
evidence review, SACN recommended that consumption of salt should be
reduced by one-third to no more than 6g per day for adults.
Findings from large studies including the International Study of Macro- and Micro-
nutrients (INTERMAP), a multi-national cross-sectional epidemiologic study of
4,680 men and women aged 40-59 from four countries (China, Japan, UK and
US) and INTERSALT which studied over 10 thousand adults in 32 countries
support SACN’s findings but highlight important geographical variations.
INTERMAP found that in China and Japan a higher incidence of stroke correlated
with a higher intake of sodium whereas no such relationship was found among
UK and US populations.147
Overall, however, intensive interventions, designed to reduce salt intake, have
produced only minimal reductions in BP during long-term trials.148 The role of
dietary salt in hypertension development therefore remains unclear.
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1.6.2.1 Nutrients and Blood Pressure
Some nutrients may be beneficial for BP. Potassium,149 n-3 PUFA,150 vegetable
protein151 and vitamin D145 have all been associated with BP lowering. Diets,
such as DASH (Dietary Approaches to Stop Hypertension) that have been
designed specifically to prevent or help in the treatment of hypertension
demonstrate antihypertensive effects in the short term.152 However, long-term
effects of such diets are unknown and because many dietary changes are
needed, compliance may be sub-optimal.149 Furthermore, changing many
aspects of diet makes it difficult to draw conclusions regarding the benefits of
individual dietary components for BP.
The optimal macronutrient intake trial to prevent heart disease (OmniHeart) study
compared three diets that differed in macronutrient composition: a carbohydrate-
rich diet (58% carbohydrate, 15% protein and 27% fat), a higher protein diet (48%
carbohydrate, 25% protein and 27% fat) and a higher unsaturated fat diet that
had 10% more unsaturated fat and 10% less carbohydrate (48% carbohydrate,
15% protein, and 37% fat). All three diets reduced systolic BP compared with
baseline. However, greater reductions were seen where carbohydrate was
replaced with protein (1.4 mm Hg [P = 0.002]) or MUFA (1.3 mm Hg [P =
0.005]).153 In summary, more controlled trials investigating effects of specific
nutrients on BP are needed before definitive conclusions can be made.
1.6.3 Dietary Management of Type-2 Diabetes
Low-fat, high carbohydrate diets have been the cornerstone dietary intervention
in the prevention and management of T2DM.79 The biggest single risk factor for
progression of insulin resistance to diabetes is obesity; low-fat, high carbohydrate
diets are recommended to help achieve and/or maintain ideal bodyweight. Such
diets are successful in the management of obesity and are consequently
advocated as part of diet and lifestyle interventions that include advice for
physical activity.154
More recently, alternative diets such as low-carbohydrate, high-protein diets155
and low-glycaemic-index and low-glycaemic-load diets have been suggested as
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equally effective in obesity management.156, 157 However, the role of
carbohydrate in the development of T2DM is controversial.
1.6.4 Dietary Management of Dyslipidaemia
Individuals with atherogenic dyslipidaemia are likely to be overweight. Therefore
dietary interventions aim to both reduce obesity and improve the lipid profile.
Until quite recently, dietary approaches for the management of dyslipidaemia
have focussed on energy restricted diets with lower dietary fat, particularly
saturated fat, being replaced with other macronutrients.
A lower intake of fat and, in particular, saturated fat is recommended for
prevention of CVD.158 In the UK, dietary requirements (dietary reference values –
DRVs) for population groups are set by the Committee on Medical Aspects of
Food and Nutrition Policy.159 COMA recommends no more than 35% of total
energy should come from fat with saturated fat contributing no more than 11% of
total energy intake. However, these recommendations were published in 1991
and do not reflect recent evidence. The most recent dietary survey from the
UK160 reported that mean intake of total fat complied with the DRV in all age/sex
groups except for women aged 65 years and over and men aged 65 years and
over for whom, on average, total fat provided 35.9% and 37.1% food energy,
respectively. Mean intakes of saturated fat exceeded the DRV in all age groups
and in adults aged 19 to 64 years accounted for 12.8% food energy. Current
dietary guidelines from the AHA recommend restricting consumption of fat to an
upper limit of 30% of daily caloric intake.161
In the US, the National Cholesterol Education Programme (NCEP) advises a
population approach targeting primary prevention and a clinical strategy for high
risk individuals. For management of high cholesterol in adults a multifactorial
lifestyle approach including reduced intake of saturated fats and cholesterol,
inclusion of therapeutic dietary options for enhancing LDL lowering, weight
reduction and increased physical activity is recommended.162
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1.6.4.1 Low Fat Diets in the Management of Dyslipidaemia
There is a wealth of evidence to show that reductions in saturated fat offer the
most effective dietary strategies for reducing total and LDL cholesterol levels, and
hence cardiovascular risk.163-165
Reducing dietary fat to between 15 and 20% can reduce total and LDL serum
cholesterol by 10 to 20%.139, 165, 166 Very low fat diets that recommend less than
15% energy from fat do not achieve further reductions and can be difficult to
adhere to. There are also concerns about adverse effects of low fat diets which if
followed long-term may increase the risk of nutritional deficiencies, for example of
essential fatty acids and fat soluble vitamins. Moreover, energy deficits arising
from fat reductions are often replaced by increased carbohydrate which is also
associated with adverse effects on the lipid profile. Reducing dietary fat can also
achieve both short- and long-term weight loss but may not always benefit the lipid
profile. For example, the Women’s Health Initiative Dietary Modification Trial
conducted among almost 50,000 overweight, post-menopausal diabetic females
in the US compared effects of a fat-reduced diet and a typical US diet. Women
taking part in an intervention to reduce total fat intake to 20% of calories and
increase intake of vegetables/fruits to 5 servings/day and grains to at least 6
servings/day achieved a significantly greater weight loss, compared with controls.
The difference was sustained 7.5 years after follow-up but no beneficial effects on
the lipid profile were reported.131
1.6.4.2 Fatty Acid Composition and the Lipid Profile
The Lyon Diet Heart Trial provides support for the idea that specific fatty acids
may be important mediators of the lipid profile. A diet enriched with n-3 PUFA
significantly reduced cholesterol compared with a Western-style diet.167 Although
this may have been partly an effect of the overall dietary pattern – a
Mediterranean style diet (higher in fruits, vegetables, wholegrain cereals, nuts,
seeds and legumes; and reduced in meat, eggs, dairy and non-oily fish) was
advised for the intervention group – the Lyon investigators concluded that n-3
PUFA was likely to be a major mediator of the protective effect provided by
traditional Mediterranean diets.168 However, the question remains open as
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studies investigating relationships between dietary patterns and the early origins
of CVD are lacking. Furthermore, there are no published reports of randomised
trials investigating the effects of n-3 fatty acids on the initiation of atherosclerosis
in young healthy people, free from clinical CVD.
1.6.4.3 Carbohydrate in the Management of Dyslipidaemia
High carbohydrate diets are reported to have adverse effects on the lipid profile.
In particular they produce a short-term increase in plasma TG concentration.169,
170 This has led to the development of alternative diets that aim to reduce obesity
and improve the lipid profile through carbohydrate restriction.
Examples of low-carbohydrate diets include the Atkins171 and Zone172 diets.
Studies examining effects of low carbohydrate compared with low fat diets on
CVD risk were most recently reviewed by Nordmann (2006).173 A meta-analysis
of RCT data found that low-carbohydrate diets led to greater weight reductions in
the short term (6 months) (weighted mean difference, -3.3kg; (95% CI: -5.3 - -
1.4kg). However, this was not maintained after 12 months (weighted mean
difference, -1.0kg; 95% CI: -3.5 - 1.5kg). Triglycerides and HDL also changed
more favourably in individuals assigned to low-carbohydrate diets (weighted
mean difference -0.25mmol/L; 95% CI: -0.43 - -0.06mmol/L); and for HDL
(weighted mean difference, 0.12mmol/L; 95% CI: 0.04 - 0.21mmol/L), but total
and LDL cholesterol changed more favourably in individuals assigned to low-fat
diets (weighted mean difference 0.14mmol/L; 95% CI: 0.03 -0.26mmol/L).
Low carbohydrate diets have been reported to have beneficial effects for the lipid
profile including reductions in TG and LDL and increases in HDL.174 However,
concerns have been raised regarding effects of low carbohydrate on LDL sub-
types. The most consistent finding in trials comparing low-carbohydrate with low-
fat diets has been increased LDL concentrations.175 Typically, small dense LDL
is raised whilst TG levels are low to normal - a combination representative of an
atherogenic lipoprotein profile.90
In general, diets that reduce carbohydrate but not total energy intake appear to
be at least as effective as low-fat, energy-restricted diets in inducing weight loss
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for up to one year.173 However, it is not clear whether benefits for the lipid profile
result from weight loss or through changes to the dietary macronutrient profile.176
1.6.4.4 Protein in the Management of Dyslipidaemia
High protein, energy reduced diets have been reported to increase satiety, induce
weight loss and to have beneficial effects on the lipid profile. However, energy
deficits are achieved through reductions in other macronutrients and in many
investigations it has not been possible to separate effects of carbohydrate
reduction and protein increase on appetite reduction and weight loss.
A series of weight-loss trials have manipulated protein and fat in energy-reduced
diets, but kept carbohydrate constant in attempts to separate the individual
effects of the diet components, but the results are not conclusive. For example,
Luscombe-Marsh (2005) reported no significant differences in satiety, weight loss
or plasma lipid concentrations when comparing high and low protein diets.177 In
contrast, increasing dietary protein from 15% to 30% of energy, at a constant
carbohydrate intake, led to significant weight loss.178
1.7 Chapter Summary
Cardiovascular disease continues to be the major cause of death throughout the
world. The epidemiologic transition occurring over the past few decades has lead
to an increase in deaths from CVD in low- and middle- income countries whilst
CVD prevalence represents a considerable health and economic burden in more
affluent countries. CVD is potentially modifiable and a range of risk factors are
implicated in its causation. Diet is an important risk factor and relationships
between nutrition and CVD have been the focus of many epidemiological studies.
Only a small number of prospective controlled trials investigating relationships
between dietary exposures and CVD risk and even fewer RCTs have been
completed; therefore robust evidence is lacking. The strongest evidence for the
role of diet in reducing CVD risk is an association with fruit and vegetable
consumption and healthy dietary patterns.
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Population studies, including The Seven Countries Study that linked dietary fat
with increased CHD risk, were the first to propose a primary role of saturated fat
and cholesterol in the development of atherosclerosis. Although dietary fat
remains a plausible causal candidate in the aetiology of CVD, its specific role is
undefined. This complicates conclusions regarding mechanisms through which
dietary fat exerts effects on CVD risk. Both quantity and quality of fat are
important. Saturated and trans-fatty acids are detrimental to CV health whereas
unsaturated fats, in particular those of the n-3 series confer protection.
In general, conclusions regarding specific effects of individual nutrients on CVD
risk are difficult to draw. Nutrients are not eaten in isolation but are consumed
together as part of diets. Similar nutrients coexist within foods and often cluster
together. Individual diets are often characterized by high intake of foods with
similar nutrient profiles. Individual dietary patterns often exclude food groups that
have protective effects on health. For example, diets based on processed foods
are typically high in fat, salt and sugar but low in fruit and vegetables. This high
degree of co-linearity for both foods and nutrients within diets makes studies of
relationships between single nutrients or foods and outcomes difficult to study.
One approach, that is becoming increasingly popular, is to study dietary patterns
in place of single foods or nutrients.
Atherosclerosis begins in early childhood and is the underlying pathological
process in most CVDs. The earliest stage of atherosclerosis manifests as
vascular dysfunction which can be measured non-invasively from as young as
five years of age. Relationships of diet with vascular function have been the
focus of recent research that is reviewed and discussed in the next chapter.
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Chapter 2
Diet and Endothelial Structure and Function
Human beings do not eat nutrients, they eat food
2.1 Introduction
Evidence suggests dietary factors play an important role in modulating
endothelial structure and function. Hence, relationships between diet and
vascular structure and function (vascular health) have been the subject of both
epidemiological and intervention studies.93, 179 Improvements in endothelial
health have been reported in association with many foods and beverages
including fruit, vegetables, fish, tea and red wine and with nutrients such as n-3
fatty acids, dietary vitamins C, D and E, carotenoids, flavonoids, alcohol and
fibre.180 A protective role of certain dietary patterns has also been reported in
more recent studies.92, 181
2.2 Dietary patterns and vascular health
Until recently, dietary studies aimed to establish relationships between single
foods or nutrients and EF.182 However, the complexity of diet, which is a
multifaceted exposure, is not well represented in such studies.136 In the real
world, free-living people eat foods and nutrients in a variety of combinations. The
single food or nutrient approach therefore has limitations. Dietary pattern
analyses, where foods and nutrients are summarized to produce patterns
describing usual intake, may provide more useful information.
There are many examples of beneficial effects of more ‘healthy’ or ‘prudent’
dietary patterns compared with traditionally less healthy ‘Western style’ patterns
on EF. For example, the Nurses’ Health Study compared the effects of two major
dietary patterns on EF in a large prospective study of more than 120,000 nurses
registered in the US.183 The study reported significantly lower levels of
inflammatory markers of endothelial dysfunction for women who consumed a
‘prudent’ diet compared with those consuming a ‘Western’ diet. For example, the
53
Western pattern was positively related to e-selectin (P < 0.001) – a marker of
endothelial dysfunction - whereas a prudent pattern showed an inverse
association (P < 0.001).
2.3 Mediterranean style diets and vascular health
Mediterranean style diets, which are characterised by a high content of n-3 fatty
acids, flavonoids and antioxidants are associated with cardioprotective effects.184
Interest in this area was prompted by the findings of the Seven Countries Study
which showed that CHD mortality was two- to threefold lower in Southern Europe
compared with Northern Europe and the US.185 Support for a beneficial effect of
Mediterranean style diets on CVD risk comes from meta-analyses that have
reported significantly reduced CVD risk in association with close adherence to
such diets (RR = 0.90; 95% CI: 0.87 - 0.93).186, 187
The importance of Mediterranean style diets for vascular health, as opposed to
CVD, is less clear. This is largely because populations and reported outcomes
differ between studies and diet affects other CVD risk factors. For example, in a
study of healthy volunteers in Greece, improvements in FMD were reported only
for subjects with central obesity following intervention to promote close
adherence to their traditional Mediterranean style diet (2.05% increase in FMD;
95% CI: 0.97 - 3.13%) whereas no effect was found in the control group (-0.32%;
95% CI: -1.31 - 0.67%).188 This suggests the effects of diet on FMD operate, at
least in part, by decreasing classical CVD risk factors.
Other studies have investigated arterial structure rather than function as an
indicator of CVD. For example, Shai and colleagues (2010) assessed changes in
CCA-IMT and vessel wall volume (VWV) in participants of the randomized
controlled DIRECT-Carotid trial (Appendix 1-2, Table 2-2).189 This study
compared two dietary strategies that aimed to achieve weight loss in middle aged
men and women. Benefits for IMT and VWV were reported in association with
both Mediterranean and low carbohydrate diets and operated largely through
reductions in BP. This suggests that benefits for endothelial structure may also
operate by reducing conventional CVD risk factors. The cardiovascular health
benefits of specific nutrients within Mediterranean style diets have been less well
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researched, largely because of difficulties in studying effects of single foods or
nutrients within the whole diet.
2.4 Dietary components and vascular health
There have been attempts to identify benefits of single foods or nutrients using
supplementation studies. However, there are few published reports of
randomised trials of adequate sample size and duration to inform public health
strategies in this area and no single nutrient or food has been identified to explain
dietary effects on atherosclerosis and its risk factors. Epidemiological studies
consistently report associations of n-3 LC-PUFA with a lower risk of CVD.190 This
has lead to these fatty acids becoming the focus of much research into dietary
determinants of CVD risk.
n-3 fatty acids have been shown to protect against secondary CVD, for example
in reducing the risk of subsequent heart attack, in both epidemiological135, 191-194
and experimental studies (Chapter 3, section 3.5.1).132, 195, 196 However, there
are few data from large scale RCTs investigating the role of n-3 PUFA in primary
prevention of CVD. n-3 fatty acids are the focus of Chapter 3 where their role in
relation to cardiovascular health is more fully discussed.
A comprehensive literature review was carried out of studies investigating the
effects of diet on vascular structure and function. The aim of the review was to
summarise evidence from healthy people, free from CVD.
2.5 Comprehensive Review of Diet and Vascular Health
2.5.1 Comprehensive Review – Methods
A systematic search of MEDLINE was carried out for published articles of studies
investigating dietary exposures in relation to vascular structure and function in
healthy individuals published between January, 1992 and September, 2012. This
period was chosen to capture the earliest non-invasive investigations of EF which
commenced in 1992.24
The search strategy was developed from concepts within the research question
according to the PICOS system.197 Search terms included MeSH and free text
terms identified as keywords in articles investigating diet and vascular health.
Key terms included “vascular structure,” “EF,” “FMD” “carotid intima-media
thickness,” “pulse wave velocity”, “atherosclerosis,” “coronary artery disease,”
“cardiovascular risk”. Full details of the search strategy can be found in
Appendix 1-1. A hand search of bibliographies of included studies was also
carried out and relevant experts were consulted to identify any omitted studies.
Inclusion of studies was limited to papers written in English and published in a
peer-reviewed journal between January, 1992 and June, 2012. Only studies
which met specific inclusion criteria (Box 1) were assessed.
Box 1 Study inclusion criteria
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Figure 2-1 Flowchart summary of literature search
Thirty-five reports were from studies investigating effects of short term dietary
interventions following ingestion of single meals, dietary supplements, food items
or beverages.80, 198-231 Most of these (n = 23) considered the effects of fat and/or
fatty acids80, 198-204, 206, 208, 209, 212, 214-219, 221, 222, 226, 227, 230 two of which also
considered the addition of red wine to diets of varying fat content.201, 203 The
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remaining 12 studies investigated caffeine,210, 211, 213 flavonoids 223 224, 231 vitamin
C,225, 228 champagne,229 cocoa,207 red wine205 and the NO precursor amino acid -
L-arginine (Appendix 1-2, Table 2-1).220
Thirty-six studies considered longer term interventions (Appendix 1-2, Table 2-
2).188, 189, 233-266 As with shorter term studies most of these reports (n = 21) were
of interventions comparing diets with differing fat and/or fatty acid composition.234,
235, 237, 238, 240, 242, 243, 245-248, 250, 252, 253, 255-257, 260, 261, 266, 267 Most of the remaining 15
studies investigated relationships between single dietary components and
endothelial health. These included, lycopene,244, 263 flavonoids,239 249, 259, 265
vitamins D258 and E,251 pistachio264 and walnuts.236 Five studies investigated
effects of dietary interventions. Four of these studied relationships between the
Mediterranean diet and vascular health,188, 233, 246, 254 and one considered the
DASH diet.241
Twenty eight studies reported results of observational studies.183, 268-294 All these
studies provided data relating to nutrient or food intake or dietary patterns and a
measure of vascular structure or function (Appendix 1-2, Table 2-3).
Six studies considered relationships between dietary patterns and vascular
health. Four related dietary patterns to measures of vascular structure268, 278, 285,
295 and two considered markers of EF.287. 183 No study investigating dietary
patterns considered FMD as an outcome. One study assessed adherence to the
Mediterranean diet in relation to PWV, a measure of arterial stiffness.290
Six studies considered fish and/or n-3 LC-PUFA intake.270, 274, 275, 282, 286, 293
Thirteen studies investigated micronutrients including Zinc,272, 294 Magnesium,272,
283 vitamins C,272, 279, 284 D269, 276 and E272, 284 and two assessed flavonoids280, 292.
Rissanen (2000 and 2003) investigated relationships between lycopene and
vascular structure.288, 289 The remaining 3 studies considered foods. Fruit and
vegetable consumption was the subject of two of these studies277, 291 and the third
investigated dairy foods.271
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2.5.2.1 Effects of fat on endothelial health
Studies investigating effects of fat intake on endothelial health were mainly short
term and most investigated the acute effects of fat on EF. Overall, studies
directly comparing high with low fat meals consistently reported detrimental
effects of high fat meals on EF.80, 198, 199, 203, 204, 209, 212, 215, 217, 219, 230 Studies that
compared effects of meals with differing fatty acid compositions were less
conclusive. For example, Berry (2008),221 Vogel (2000)204 and Ong (1999)200
reported that FMD decreased more following a meal high in MUFA than with a
high SFA meal. Four short-term studies considered effects of meals rich in PUFA
on FMD. Three of these reported improvements in FMD222, 226, 227 and one study
(Nicholls, 2006) found no difference in FMD according to meal fat type.218
Longer term interventions to alter dietary fat consumption have mainly compared
high fat diets with low fat Mediterranean style diets.188, 233, 241, 246, 248, 252, 255 FMD
improved with low fat Mediterranean style diets in three studies188, 246, 248 but no
benefits were seen in two studies.241 252 Four interventions investigated
relationships of Mediterranean style diets with vascular health either alone or with
additional components. For instance, two studies considered the effects of
interventions that aimed to improve compliance with Mediterranean style diets,188,
189 one study compared a Mediterranean style diet with the usual diet in a
Swedish population,233 and another investigated additional benefits of pistachio
nuts.254 One study considered the effects of the Dietary Interventions to Stop
Hypertension (DASH) intervention (a programme that aims to reduce
hypertension through dietary intervention) on FMD.241
2.5.2.2 Effects of n-3 fatty acids on endothelial health
Relationships between n-3 LC-PUFA and vascular health were reported in 15
longer term (two weeks to two years; Appendix 1-2, Table 2-2) controlled
intervention studies among healthy human subjects.234, 235, 237, 238, 240, 242, 243, 245,
247, 250, 253, 256, 260, 261, 266 Methods used to assess vascular function included
vasodilation of peripheral arteries in the micro-235, 243, 256 and macro
vasculature.204, 242, 253, 256, 266 Three studies used FMD to assess EDV in large
blood vessels considered to reflect coronary artery function.242, 253, 256 Six studies
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investigated relationships between diet and markers of endothelial activation.234,
237, 238, 247, 250, 261 Most studies were conducted in small samples (< 50
participants) and results are conflicting.
Six studies reported no benefits of fish oil supplementation for vascular health.237,
242, 245, 250, 253, 255, 260 Four of these were RCTs where sample size ranged from
38–312.242, 250, 253, 260 Only two of these studies assessed EF using FMD.242, 253,
255 Eight studies reported benefits for vascular health: improvements were
reported for FMD256 and EDV in the microvasculature235, 243, 245, 260, 266 or for
concentrations of vascular adhesion molecules (VAMs).247, 261 Two studies that
measured VAMs reported benefits of n-3 supplements for older men but adverse
effects in younger men.247, 261 This finding is supported by Cazzola (2007) who,
in a study of 93 younger men (mean age 26 years) reported increased VAMs
after supplementation with 4g EPA and DHA combined for 12 weeks.234
Several observational studies investigated associations of n-3 PUFA with
vascular health.270, 273-275, 282, 286, 293 Djousse and colleagues (2003) found a lower
prevalence of plaques and lower carotid IMT in a large cohort (n = 1,575) of
healthy Caucasians in association with ALA, the parent n-3 fatty acid. However,
no benefits were found in association with fish or n-3 LC-PUFA in this study.
Most other studies found benefits to measures of vascular structure or function
with fish and/or n-3 fatty acid consumption. One report from the MESA study
reported lower FMD for women with the highest fish intake.270
2.5.2.3 Effects of flavonoids on endothelial health
Eight intervention studies that investigated relationships of dietary flavonoids with
endothelial health assessed either brachial artery FMD 207, 223, 224, 231, 232, 239, 259, 265
or microvascular reactivity.249 Three studies considered tea consumption,223, 224,
239 all of which were of small sample size (≤ 30) and were short duration 
studies.223, 224, 239 All studies reported improvements in FMD following tea
consumption ranging from 4–7% increases in FMD from baseline. Effects were
seen at doses equivalent to usual dietary intake (i.e. with 100g flavonoids as
found in one standard mug of tea).
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The remaining 5 studies used various flavonoid rich foods including apples and
spinach,231 grapes,265 oranges (high in hesperidin)249 cocoa207 or soy.259 All
studies reported improvements in FMD, however, most were of short duration
and small sample size. The one large scale RCT that investigated effects of
flavonoids reported a reduction in FMD for men following 3 months
supplementation with soy protein, providing 118 mg isoflavones per day.259
Support for a protective effect of flavonoids on vascular health comes from two
large observational studies. Landberg (2010) reported from the US nurses study
that women in the highest quintile for flavonoid intake had lower concentrations of
VAMs compared with those in the lowest (P for trend = 0.012).280 Similarly, a
study of 433 post-menopausal women from the Netherlands reported lower PWV
in women in the highest compared with the lowest quintile of flavonoid intake (P
for trend = 0.07).292
Four studies considered the acute effects of wine on vascular health,201, 203, 205, 229
and of these, three found protective effects on vascular function. In one study,
the deleterious effects of a high fat meal were reduced when the meal was given
with red wine.203 Champagne wine led to increased endothelium-independent
but not endothelium-dependent vasodilatation 4–8 hours following
consumption.229 No such effect was seen when a beverage matched for alcohol,
carbohydrate and fruit content was given in one study.201, 229 However,
improvements for FMD were seen following consumption of red wine without
alcohol in another study.205
2.5.2.4 Effects of caffeine on endothelial health
Three studies considered the effect of caffeine on vascular health.210, 211, 213 All
three reported moderate increases in measures of aortic stiffness at doses
ranging from 80-300mg/d.
2.5.2.5 Effects of lycopene on endothelial health
Two studies reported results of interventions with lycopene, a carotenoid found in
high concentrations in tomatoes and other red/orange fruits and vegetables, to
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improve vascular health.244, 263 Both studies measured inflammatory markers in
middle-aged subjects following interventions to increase lycopene intake for
similar time periods. Thies (2012) reported no difference in markers of vascular
function or measures of arterial stiffness in a UK population following a 12-week
intervention period.263 However, Kim (2011) reported reductions in inflammatory
markers that correlated with increased lycopene concentrations.244 Conclusions
are difficult as the studies varied with respect to population and outcomes
studied. However, further support for a protective role for lycopene in vascular
health comes from two large scale observational studies in Finland. Middle aged
men were found to have higher CCA-IMT in association with low plasma
lycopene.288, 289
2.5.2.6 Effects of micronutrients on endothelial health
This review identified 11 studies investigating relationships between
micronutrients and vascular health. Four of these were intervention studies225, 228,
251, 258 and the remainder were observational studies.269, 272, 276, 279, 283, 284, 294
Nutrients investigated included vitamins C, D and E and minerals zinc and
magnesium.
Three small studies considered the relationship between vitamin C (ascorbic
acid) and measures of vascular function.225, 228, 284 One study reported improved
blood flow following ascorbic acid infusion during exercise.228 The second
intervention study found no benefits for FMD following a large oral dose of
ascorbic acid.225 One small observational study that compared FMD in healthy
men reported a 20% lower FMD for men with lower vitamin C intake. However,
effects were confined to obese men. One large epidemiological study does,
however, provide evidence to support the hypothesis that vitamin C is protective
for vascular health: a report from the Atherosclerosis Risk in Communities (ARIC)
study found a significant inverse association between vitamin C intake and CCA-
IMT in more than 10,000 middle-aged men and women.279
Studies of vitamin D suggest that supplementation provides benefits for
individuals who have low levels. An intervention to increase vitamin D status in
23 asymptomatic vitamin D deficient subjects reported improvements in FMD
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following supplementation with 300,000 IU (7.5 µg) of vitamin D given
intramuscularly once monthly for 3 months.258 The role of vitamin D in vascular
health is supported by observational study findings that higher FMD is associated
with higher status.269, 276
Only one trial investigating the role of vitamin E in vascular health was identified.
Plasma vitamin E was not related to PWV, a measure of vascular structure, in 20
post menopausal women supplemented with 400 IU (268 mg) alpha tocopherol
for 10 weeks.251 This conflicts with the epidemiological Atherosclerosis in
Communities (ARIC) study which found a significant inverse relationship between
vitamin E and CCA-IMT in women.279
There were no interventions of mineral supplementation to improve vascular
health. However, habitual zinc intake was inversely related to CCA-IMT in a large
study of more than 4,000 healthy adults in South Korea. Men and women in the
highest quintile for zinc intake had a reduced risk of subclinical atherosclerosis
(5th versus 1st quintile, OR 0.64, 95% CI 0.45 - 0.90).296 Similarly, dietary
magnesium intake was inversely associated with CCA-IMT in women
participating in the ARIC study.283
2.5.2.7 Effects of diet on endothelial health
There were four reports of whole diet interventions to improve vascular health.188,
233, 241, 246 Three studies assessed effects of Mediterranean style diets188, 233, 246
and one considered the DASH diet.241 Two studies investigated effects of the
Mediterranean diet on EF with conflicting results. In a randomised cross-over
study, Ambring (2004) found no benefits for FMD in a group of healthy individuals
who followed a Mediterranean style diet for four weeks compared with controls
consuming their usual Swedish diet.233 In contrast, Rallidis and colleagues
(2009) reported an increase in FMD for an intervention group who were instructed
to follow a Mediterranean style diet under close supervision for two months.188 In
a third study, markers of endothelial activation were reduced in a group of 20
healthy subjects randomised to a Mediterranean style diet for 4 weeks.
Endothelial progenitor cells, indicative of a healthy endothelium, were higher
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following the intervention.246 Hodson (2010) reported no change in FMD for a
group of 27 healthy adults following the DASH diet.241
Two studies considered in this review investigated effects of nuts: pistachio254 or
walnuts236 on endothelial health. The addition of pistachio nuts to a
Mediterranean diet was reported to improve FMD in 32 healthy young men.
Compared with Mediterranean diet only, a pistachio enriched diet produced a
30% increase in FMD (P = 0.002). Walnuts had no effect on arterial stiffness, in
a group of 30 healthy males randomised to receive a 15g/day supplementation of
walnuts for 4 weeks.236
The two remaining studies considered the effects of garlic, an alanine rich plant
(Turner, 2004)264 and ʟ-arginine, the precursor to NO.220 Garlic supplements,
providing 10 mg/day aliin (equal to about 3 garlic cloves) did not improve arterial
stiffness in 75 healthy volunteers. Mariotti (2007) manipulated amino acid
content of meals to investigate the role of dietary L-arginine in NO production.
Dietary L-arginine had no effect on endothelial structure or function.220
2.6 Discussion
The current evidence from this review of the relationship between diet and
vascular health suggests that healthy dietary patterns, mostly characterised by
higher intakes of fruits, vegetables and fish protect against atherosclerosis
development in healthy people (Table 2-3).183, 268, 278, 285, 287, 295 Large scale
epidemiological studies have shown reductions in arterial stiffness,278, 285, 295
markers of endothelial dysfunction including PWV268 and inflammatory
markers.183, 287 It is not possible to conduct intervention studies of dietary
patterns, which are described post priori, however, studies of specific diets
support a protective role of healthy dietary patterns.
2.6.1 Diets and Dietary Patterns
Mediterranean style diets are shown to confer protection against the development
of atherosclerosis in observational290, 291 and experimental studies.188, 248, 297, 298
Improvements in EF following a Mediterranean style diet for a brief period have
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been reported in subjects at low188, 248 or moderate297 risk of CVD and in patients
with T2DM.299 Studies in individuals free from CVD risk factors have not always
reported benefits for EF.233 However, differences in study design including
intervention duration, dietary assessment methods, outcomes, sample sizes and
population health status make conclusions difficult to draw.
As with dietary patterns, exact mechanisms through which specific diets protect
against CVD are difficult to elucidate. This is largely because diets are complex,
contain many components and affect other CVD risk factors. Mediterranean style
diets may benefit vascular function indirectly through reductions in classical CVD
risk factors. For example, the DIRECT-carotid study reported regression in
carotid IMT in middle-aged men following either a Mediterranean style diet or one
reduced in fat or carbohydrate. However, adjustment for confounders suggests
that this was mediated mainly by a weight loss-induced decrease in BP.189 Other
studies have reported benefits of a Mediterranean diet for the lipid profile, which
may in turn affect endothelial structure and function.297, 300 The mechanisms
through which specific diets improve vascular health are therefore unknown.
2.6.2 Dietary Components
Experimental studies that have intervened with specific dietary components
provide evidence for some foods and nutrients that characterise healthy diets and
dietary patterns. This review found many dietary and nutrient interventions that
modified vascular structure and function in healthy people to varying extents
(Appendix 1-2, Tables 2-1 & 2-2). Acute ingestion of high fat meals directly
impaired vascular function in most studies. The mechanism for FFA related
endothelial dysfunction cannot be drawn from this review. However, it is likely that
the elevated and extended post prandial lipaemia that is often reported following
high fat meals plays a role (Chapter 3, Section 3.7.4.5).
2.6.2.1 Dietary Fat
Diets high in fat, and particularly those high in saturated and/or trans fats, are
considered a risk factor for the development of atherosclerosis.92, 93 High
saturated fat intake leads to increased circulating lipoproteins and free fatty acids
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which may stimulate pro-inflammatory pathways and increase oxidative stress
(Chapter 3, Section 3.7.4). Furthermore, studies have shown that high fat meals
induce endothelial activation, increase inflammatory cytokine production and may
also have independent adverse effects on the vascular endothelium.301 Studies
investigating the effects of fat intake on EF have mainly been short term as the
adverse effects on health from habitual high fat diets are well recognised.302
Long term RCTs that increase dietary fat intake would be unethical and thus,
evidence underpinning the role of long term high fat consumption on vascular
health only comes from observational studies.
Endothelial activation increased in several studies in response to high fat
consumption indicated by increased serum concentrations of inflammatory
cytokines and VAMs. Another possible explanation for adverse effects of high fat
meals on EF is increased production of reactive oxygen species (ROS) by FFAs.
Ceriello (2002) reported FFA directly enhanced ROS production after
consumption of a high fat meal and was closely associated with endothelial
dysfunction.303 The proposed mechanism for the effect of FFA on ROS
production is via up-regulation of the enzyme nicotinamide adenine dinucleotide
phosphate (NADPH). Inhibition of NADPH by antioxidants has been shown to
prevent FFA-induced endothelial dysfunction.304
2.6.2.2 Fatty acid composition
The type of fat is important in the effect of diet on vascular health. This review
found that specific fatty acids have different effects on EF. In particular,
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been shown
to improve EF at least in vitro305 in short-term post prandial studies of acute
ingestion222, 226, 227 and in longer-term studies among healthy individuals235, 243, 245,
247, 256, 260, 262, 266 The role of n-3 fatty acids in vascular protection is as yet
unclear. However, the physiological effects of EPA and DHA that reduce
vascular reactivity and maintain vascular integrity through the production of less
inflammatory mediators are likely to be important (Chapter 3, Section 3.4.3.1).306
Both EPA and DHA reduce cardiac arrhythmia.307, 308 EPA may also protect
against thrombosis309, 310 through the inhibition of platelet cycloxygenase.
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Lowering plasma triglycerides,311, 312 increasing endothelial nitric oxide93 and
attenuating inflammation313 have also been proposed as additional mechanisms
by which n-3 fatty acids might favourably influence the risk of atherosclerosis.
Consumption of nuts, rich in the n-3 parent fatty acid alpha-linolenic acid (ALA)
(Chapter 3, Section 3.4.3) has been reported to benefit EF in healthy subjects.
Adding walnuts236 or pistachio nuts254 to diets was beneficial for FMD in two short
term small trials. Results from such small non-randomised studies cannot inform
dietary strategies but rather generate hypotheses for future investigations.
Observational studies support the findings of intervention trials and report
associations between higher consumption of fish or n-3 LC-PUFA with reduced
risk of atherosclerosis.275 For example, the Multi-Ethnic Study of Atherosclerosis
(MESA) found significant associations between fish intake and markers of
endothelial inflammation and activation. n-3 LC-PUFA intakes were inversely
associated with plasma concentrations of biomarkers independent of other CVD
risk factors.275
Several studies investigating associations of n-3 LC-PUFA with CCA-IMT report
conflicting findings. For example, Djousse and colleagues (2003) found no
associations of fish or n-3 LC-PUFA consumption with IMT in a large cohort (n =
1,575) of healthy Caucasians.273 Conversely, Ebbesson and colleagues (2008)
reported a protective effect of fish intake on IMT in Alaskan Inuit, age 35 and
older (n = 686).274 These two studies differed in many ways. Djousse (2003)
studied individuals participating in a North American study (NHLBI Family Heart
Study) who were chosen either at random or on the basis of a higher than
expected risk of CAD. Ebbesson (2008) studied an indigenous population of
Inupiat who were largely village dwellers with a hunter-gatherer existence.
Therefore, comparisons between these two studies are difficult to make. Reliable
conclusions cannot be drawn from only two studies and further research is
needed to further to define the relationship between n-3 LC-PUFA consumption
and vascular health.
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2.6.2.3 Polyphenols
Previous studies suggest that EF could be protected by the addition of nutrients
with antioxidant functions, such as polyphenols, to high fat meals. For example,
red wine was shown to attenuate the adverse effects of a high fat diet on FMD.203
Red wine contains several polyphenolic compounds that have antioxidant
properties.314 Consumption of polyphenols from various sources is associated
with a decreased risk of CVD.315 Furthermore, vitamins with antioxidant functions
have also been reported to protect against endothelial dysfunction. For example,
Plotnik (1997) reported that impaired EF observed after a high-fat meal could be
prevented by concomitant treatment with vitamins E and C.316 This suggests that
postprandial endothelial dysfunction could be mediated by an oxidant mechanism
and that consumption of polyphenols and other antioxidants could also have a
beneficial effect. Support for this comes from mechanistic studies in animal
models. For example, wine and grape products improved EF in isolated arterial
rat tissue.317
Most data support the idea that teas and the flavonoids they contain are able to
improve NO bioavailability and thereby increase endothelium-dependent
vasodilatation in healthy subjects.318 A recent meta-analysis of intervention
studies investigating the effects of teas on endothelial health in subjects free from
or with pre-existing CVD risk factors supports the possibility that moderate
consumption of tea enhances FMD.319
2.6.2.4 Micronutrients
Vitamins, including antioxidant vitamins A, C and E, and vitamin D have all been
suggested to benefit vascular health.181 Oxidative stress has a central role in the
development of CVD and is proposed to affect EF through inflammation and
reduced NO availability.13 Therefore many studies investigating the effects of
nutrients with antioxidant properties, including vitamins C and E and carotenoids,
have been conducted to evaluate their role in CVD. There remains debate on the
benefits of vitamin C supplementation on vascular function in healthy people and
those with hypertension.228, 320
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This review identified two cross-sectional studies269, 276 and one intervention
study investigating vitamin D.258 Collectively these studies provide support for
vitamin D supplementation in deficient individuals. The mechanism cannot
clearly be deduced from the findings of the intervention study that lower
concentrations of serum 25(OH)D (the inactive form of vitamin D) were
associated with lower FMD. One proposed mechanism is that the association
could be partly mediated by vascular endothelial cell conversion of inactive
25(OH)D to 1,25(OH)2D, the active form. Reduced expression of vitamin D
receptors and 1-α hydroxylase, the enzyme needed to convert inactive to active 
vitamin D, was found in endothelial cells of vitamin D-deficient subjects compared
with vitamin D-sufficient subjects.  A strong relationship between levels of 1-α 
hydroxylase and FMD, is consistent with this possibility. Reduced expression of
vitamin D receptors and 1-α hydroxylase in vitamin D-deficient subjects may have 
limited the conversion of 25(OH)D to 1,25(OH)2D, attenuated vitamin D signalling
in the vascular endothelium and contributed to lower FMD.
There is insufficient evidence for a role of vitamin E in vascular health.
Epidemiological evidence suggests a protective effect for vitamin E in plaque
formation. In two large prospective studies, one in women and one in men,
vitamin E intake, in the form of dietary supplements, was associated with
decreased risk of CHD.321, 322 Knekt (2004) found dietary vitamin E intake to be
associated with reduced mortality from CHD in both men and women.323
However, it is possible that the use of supplements was a marker of health
conscious behaviour in these epidemiological studies.
The one intervention trial identified here found no benefit of vitamin E
supplementation for PWV in post menopausal women.251 In a randomized trial of
a supplement containing 50 mg/d of α-tocopherol versus placebo in male Finnish 
smokers, supplementation failed to significantly affect the rate of ischemic heart
disease mortality over the study period.324 In the ARIC study, the use of dietary
supplements accounted for some of the association of vitamin E with vessel wall
thickness seen among the older women but not in the men. In fact, in the ARIC
study, vessel wall thickness was greater in men taking vitamin E supplements
compared with those not receiving vitamin E.
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It is unclear why dietary supplements were related to less wall thickening in the
older women but not the older men in ARIC. Possible sources of error including
supplement use should be considered: 1) length of use was not ascertained; 2)
frequency of use was not determined 3) appropriate dosage was not considered
and 4) interactions with other foods and nutrients were not considered. Length of
use is important because wall thickening occurs over a long time period. It is
possible that fewer men were long-term users. Frequency of use gives a
measure of compliance and is also important. It is possible that men may have
been more intermittent users. Dosage is also important. For example, men
being larger on average than women may have required larger doses.
Interactions with other micronutrients might be relevant; for example, vitamin E
may be absorbed more readily when taken with fat. Other components of foods
rich in vitamin C and E may be the protective factor, rather than the vitamins
themselves. Finally, other protective aspects of life-style may be associated with
reduced wall thickness. In this case, differential effects of supplement use would
be seen, for example, if the protective factor was correlated with vitamin use in
women but not in men.
Few studies evaluated effects of lycopene, a potent antioxidant found in
carotenoid compounds, on EF. In a study of healthy men with low fruit and
vegetable (and therefore lycopene) intake, Kim and colleagues (2011) reported
reductions in inflammatory markers in association with high doses (15mg/day) of
lycopene given for 8 weeks.244 Further studies are needed before findings can
be generalised to wider populations, including females and individuals with higher
fruit and vegetable consumption.
Overall, evidence for the use of micronutrients in protection of vascular health is
lacking and most studies found no benefit for supplementation in healthy people.
This is similar to conclusions drawn previously regarding the benefits of
micronutrients for the treatment of hypertension. A large scale randomised
primary prevention study including >5,000 healthy adults found that
supplementation with antioxidants at nutritional doses had no effect on the risk of
developing hypertension.325
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2.7 Limitations
There are limitations to this review. Firstly, restricting the search to articles
written in English may have led to omission of important findings. Secondly, due
to heterogeneity of studies, comparisons between them were difficult. Carotid-
femoral PWV is considered the gold standard measurement in assessment of
arterial stiffness; however, investigators use a range of techniques in its
measurement. Similarly, FMD is considered the gold standard for assessment of
EF and only a small number of studies used this technique and RCTs are
considered the most rigorous form of scientific evaluation but few have been
undertaken in this area.
In many studies, interventions were short, ranging from 1 hour to 28 days, sample
sizes were small and doses given and outcomes measured varied. Because diet
in free-living humans is highly individual and influenced by many other factors it is
difficult to randomise individuals to specific diets for time periods that may effect
change and allow comparisons of effects of diets on outcomes. Furthermore,
food and nutrients are metabolised differently according to individual
characteristics.
2.8 Conclusions
A growing number of intervention studies have investigated short and long term
effects of diet on endothelial health. Whilst acute studies that investigate short
term effects of foods and nutrients on vascular structure and function are
informative they cannot evaluate effects of habitual diet. To date, 33 prospective
controlled trials including only 6 RCTs have been completed, and robust evidence
for effects of diet on vascular health is lacking.
There is consistent evidence for increased risk of endothelial dysfunction with
consumption of high fat meals. However, most studies are of short duration and
evidence for effects of habitual high fat consumption on the vascular endothelium
is scarce. There is some evidence to suggest that replacing a proportion of SFA
with PUFA, particularly n-3 LC-PUFA may offer benefits. However, further
investigation in RCTs is required. To our knowledge, no RCT investigating
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effects of n-3 LC-PUFA on EF in healthy young individuals, who are free from
CVD and have a low prevalence of risk factors, has yet been completed. In the
absence of data from RCTs, evidence to underpin public health measures must
be drawn from observational studies.
A small number of observational studies support an association of healthy diets
with benefits for vascular health. One large scale epidemiological study suggests
there are benefits for the endothelium in association with Mediterranean style
diets.295 However, Mediterranean style diets differ across countries and the
current evidence is insufficient for firm conclusions to be drawn about specific
diets. Most studies investigating effects of habitual diet on vascular structure
and/or function used dietary pattern analysis. Longer term studies are difficult to
conduct as adherence to prescribed diets by free living humans is unlikely.
Furthermore, the period over which diet could affect measurable changes in
endothelial structure and function is unknown.
To my knowledge, only six studies have investigated associations of dietary
patterns with vascular structure or endothelial function. Four of these
investigated relationships of dietary patterns with arterial stiffness.268, 278, 281, 285
Two studies assessed EF but these were in older adults and no study measured
FMD.183, 287 Effects of dietary patterns on EF in healthy young people are not
known, and further research is required.
Data from existing studies are insufficient to make public health
recommendations for the role of specific diets and nutrients in primary prevention
of atherosclerosis in healthy young people. Therefore, the present study
investigates relationships between diet and endothelial dysfunction, the earliest
indicator of atherosclerosis, in a group of healthy young adults, focussing on the
role of n-3 LC-PUFA and dietary patterns.
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Chapter 3
Omega 3 Fatty Acids and Cardiovascular Disease
Fish oil is a whale of a story that not surprisingly gets bigger with every telling
- Rogans, 1987
3.1 Introduction
Reports suggesting a relationship between fish intake and CVD risk began to
emerge in the late 1970’s, when observational studies among the Greenland Inuit
people whose diet was based on fish found a lower incidence of CVD.134, 135 This
finding was subsequently extended to other high fish eating populations including
Japanese,192 South Pacific Islanders193 and Alaskans.326
Increasing evidence now supports the hypothesis that fish is an important food
and benefits for health, from high consumption of marine foods, can be attributed
to their fatty acid content.275, 327, 328 Epidemiological evidence and data from
RCTs consistently report positive relationships between consumption of fish,
(mostly at intakes providing about 1g combined eicosapentaenoic acid [EPA,
C20:5 n-3] and docosahexaenoic acid [DHA, C22:6 n-3] per day), and reduced
cardiovascular mortality and morbidity.329-331
3.2 Historical Background
Historically, fish was a valuable commodity for seafaring nations, providing both
food and trade resources. In fact, during the middle ages, wealth and power in
the North Sea region was largely dependent on the herring industry.332 Rivalry
over fishing rights has even led to wars between seafaring nations including the
Dutch, French and English. The Battle of Herrings, in which the French
requisitioned a fleet of ships delivering herring to the English army at Rouen, took
place in 1429 and demonstrates the value of the targeted cargo.333 Later, in
1703, competition for fishing rights led the French to undertake a further attack
this time on a Dutch fishing fleet.332
By contrast, the 20th century “cod wars” occurring between Iceland and Britain
through the 1950’s and 70’s were more sedate. However, disagreements over
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fishing limits were sufficient to bring these two NATO allies to the brink of war.
Such incidents serve to demonstrate the considerable value of fish both as a food
and an economic resource.332
3.3 Health Benefits of n-3 Fatty Acids
Benefits of marine foods are suggested to derive from their fatty acid content.
Fatty acids were first described in 1929 by Burr and Burr from the United
States.334 However, it was not until 1937, when British physiologist Hugh Sinclair,
proposed a relationship between deficiency of certain fatty acids and higher
prevalence of Western disease, that possible benefits of fatty acids for long-term
health were considered.335 To investigate further Sinclair studied the Inuit people
indigenous to Greenland. During his first visit in 1944 he noted that although the
Inuit had the highest intake of fat in the world they did not suffer from the non-
communicable diseases characteristic of Western societies. Moreover, he noted
that the type of fatty acids habitually consumed differed between Inuit and
Western populations; the Inuit diet being high in essential fatty acids.
Subsequent analyses showed that the Inuit diets were richer in PUFA, the ratio to
SFA was 0.84 as compared with 0.24 in Danes. PUFA were predominantly of the
linolenic class (n-3) in Eskimos and the linoleic class (n-6) in Danes.191
Danish investigators, Bang (1976) and Dyerberg (1975) later confirmed a lower
prevalence of CHD in the Inuit population and attributed this to their marine food
based diet.134 135 They also reported relationships between markers of CVD and
a reduced incidence of heart attacks. Most lipid fractions were lower in the local
Inuit population compared with both indigenous Caucasians and the migrant Inuit
population living in Denmark leading to the conclusion that diet explained the
almost complete absence of coronary atherosclerosis in indigenous
Greenlanders.135
This hypothesis was supported by associations between changes in dietary
habits such as fat consumption and disease.336 Rapid expansion of populations
in Europe, America and Australia created a need for more food. In the early 20th
century rapid advances in food technology occurred as manufacturers strove to
meet this need. The hydrogenation of fat was a major advancement allowing the
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transformation of fats and oils to more stable forms that could be stored and
transported more readily. This led to the introduction of saturated and trans fatty
acids to the food market. At the same time, the decline in the herring industry
reduced the availability of n-3 fatty acids and changed the dietary fatty acid ratio
in favour of n-6 fatty acids. Wide scale adoption of fat hydrogenation
technologies and the demise of the herring industry were accompanied by a
sharp rise in CHD.336
3.4 Nature of Fatty Acids
When Burr and Burr (1929) first described fatty acids they knew that they were
essential to health but knew little about their structure, function or the
mechanisms through which these benefits operated.337 Numerous texts and
articles now describe the structure, function and metabolism of fatty acids in
detail, and are briefly summarized below in Sections 3.4.1 - 3.4.2.
3.4.1 Structure of Fatty Acids
Fatty acids are simple lipids comprising a straight chain of 6-24 carbon atoms
each attached to one or two hydrogen atoms.338 The hydrocarbon chain
terminates in a hydrophilic carboxylic acid group at one end and a hydrophobic
methyl group at the other. The terminal groups and the number of double bonds
present in the hydrocarbon chain determine the lipids’ structural and physiological
properties (Figure 3-1).
Saturated fatty acids contain no double bonds and therefore each carbon atom
bonds with adjacent carbon, hydrogen or oxygen atoms. This allows a maximum
number of hydrogen atoms in the fatty acid molecule which is termed ‘saturated’.
The presence of one or more double bonds in the chain reduces the number of
hydrogen atoms and the molecule becomes unsaturated. Monounsaturated fatty
acids contain one double bond and polyunsaturated fatty acids two or more.
The position of the first double bond in the carbon chain is indicated by the letter
n counting from the methyl (CH3) end (Figure 3-1). For example, a fatty acid
where the first double bond attaches to the 3rd carbon atom from the terminal
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methyl group is termed n-3. Polyunsaturated fatty acids form two series with the
first double bond occurring either at position 3 or 6 on the carbon chain. These
are termed n-3 and n-6 respectively.338
Double bonds allow the fatty acid to change its form (isomerism) to either a cis or
trans configuration and this influences the molecular properties (Figures 3-
1a and b). Most naturally occurring fatty acid double bonds are in the cis
configuration a property that confers fluidity.
Figure 3-1 Structural representation of an n-3 fatty acid
Figure 3-1a Structural representation of a Cis fatty acid
Figure 3-1b Structural representation of a Trans fatty acid
Fatty acids are found in plasma, either as free fatty acids (FFA), or attached to a
glycerol backbone as part of a TG molecule (Figure 3-2). The type of fatty acids
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and their position on the TG molecule affects the molecule’s properties. The
position marked FA 1, 2 or 3 in figure 3-2 is also referred to as sn 1, 2 or 3. Fatty
acids are also essential constituents of cell membrane phospholipids. Membrane
lipids are essential in a number of biological functions from membrane trafficking
to signal conduction.338, 339 A bipolar lipid bilayer provides a semi permeable
barrier allowing compartmentalisation within cells and separation of ions and
solutes (Figure 3-3). This enables specialised functions of organelles and
maintains cell membrane electric potentials.340
Figure 3-2 Triglyceride Structure
Figure 3-3 Lipid bilayer (source: Google Images,TutorVista.com)
3.4.2 Essentiality of Fatty Acids
Mammals lack an enzyme needed to insert double bonds between adjacent
carbon atoms at positions 1-6 of the hydrocarbon chain.341 (Figure 3-1).
Therefore, there is a dietary requirement for linoleic acid (LA, C18:2 n-6) and
alpha linolenic acid (ALA, C18:3 n-3), essential fatty acids (EFA) of the omega-6
and omega-3 series respectively.
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LC-PUFAs are produced through a process of desaturation and elongation of
fatty acid hydrocarbon chains (Figure. 3-4).343 The dietary requirement for EFA’s
is relatively small but nevertheless important. In the UK it is recommended that
LA should provide at least 1% and ALA at least 0.2% of total daily energy
intake.159
Biologically important fatty acids include arachidonic acid (AA, C20:4 n-6),
derived from LA, and EPA and DHA formed from the parent n-3 fatty acid, ALA.
These have important physiological roles, for example, both AA and EPA are
precursors to eicosanoids, chemicals with multiple functions in a number of
important processes including mediation of chemical reactions and regulation of
inflammation (Figure3-5). 343
Figure 3-4: Formation of Long Chain Polyunsaturated Fatty Acids
(Adapted from De Caterina et al.,(2001)) 343
3.4.3 Metabolism of Fatty Acids
The parent fatty acids of both the n-6 and n-3 series are derived from plant oils.
High sources of ALA include flaxseed, rapeseed, soya and some nuts e.g.
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walnuts and almonds. Sunflower and corn oils are the predominant sources of
LA in Western diets. LC-PUFA are formed from the parent fatty acids or taken in
directly from dietary sources. n-3 LC-PUFA are found in marine based plants and
micro-organisms such as phytoplankton, seaweeds and algae or from animals
that feed directly on plant sources (e.g. fish and poultry) (Box 1). Metabolism of
LC-PUFA results in the production of eicosanoids, regulatory compounds that
have direct effects on human health.344
3.4.3.1 Eicosanoids
Eicosanoids are formed from non-esterified or free fatty acids (FFA) that must
therefore be in constant supply. A pool of LC-PUFA is maintained from dietary
sources and through hydrolysis of storage material, for example from cell
membrane phospholipids.
Dietary LC-PUFA are directed through one of three metabolic pathways and
regulated by enzyme availability. The acyl-COA pathway regulates oxidation and
storage, the cycloxygenase and lipoxygenase pathways provide prostaglandins,
thromboxanes, prostacyclins and leukotrienes respectively. Fatty acids compete
for enzymes in all pathways and the balance of eicosanoids produced depends
on the availability of fatty acids (Figure 3-5).{De Caterina R., 2001 3498 /id}
Eicosanoids are implicated in many disease processes, primarily through their
role as mediators of the inflammatory response.346, 347 Eicosanoids produced
from n-6 fatty acids are generally pro-inflammatory compared with those from n-3
fatty acids. Therefore diet, as a provider of fatty acid substrates, is an important
regulator of eicosnaoid production.
Eicosanoids form four distinct families: prostaglandins, protacyclins,
thromboxanes and leukotrienes (Figure 3-5). Each family further divides into
separate series. Different activities within series help explain the health effects of
n-3 and n-6 fatty acids.348 High dietary intake of n-6 fatty acids leads to a
predominance of arachidonic acid (AA) in cell membrane phospholipid. In this
instance AA is the major substrate for eicosanoid production and pro-
inflammatory mediators are favoured. Diets higher in n-3 fatty acids allow partial
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replacement of AA acid by EPA and a less inflammatory eicosanoid profile
results.
Figure 3-5 Eicosanoid metabolism and function
3.5 Cardioprotective Effects of n-3 Fatty Acids
Various mechanisms through which n-3 LC-PUFA exert beneficial effects on
health have been proposed. Several large scale human studies have reported
benefits for a range of CVD risk factors including prevention of arrhythmia,349
decreased platelet aggregation,350, 351 improvements in endothelial function,352, 353
reductions in BP,354, 355 plasma TG,356, 357 and inflammatory response,358 as well
as inhibition of platelet activation and other anti-atherosclerotic effects.262, 359
3.5.1 n-3 LC-PUFA and CVD Risk Reduction
Benefits of n-3 LC-PUFA from fish and fish oil supplements have been shown for
both primary and secondary prevention of CVD. Many epidemiological studies
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have provided evidence for relationships between fish intake or n-3 FA status and
reduced risk of CHD and CVD outcomes.360-365 The relationship is strongest for
fatal heart attacks. For instance, Albert and colleagues (1998) reported from the
US Physicians Health Study that higher consumption of fish was associated with
a lower risk of sudden cardiac death in men (Relative Risk (RR) = 0.48; 95%
confidence interval (CI): 0.24 - 0.96 [P = 0.04] for once weekly compared with
once monthly consumption).361 Lemaitre (2003) also reported a decreased risk of
fatal CHD for older adults in association with n-3 fatty acid status (RR = 0.32;
95% CI: 0.13 - 0.78 [P = 0.01]).363 This strong association with fatal CHD
suggests anti-arrhythmic properties of n-3 LC-PUFA are likely to confer protection
(Section 3.6.2).
More recently a large prospective cohort study including 25,573 men and 28,653
women reported decreased risk of acute coronary syndrome for men consuming
the highest quantities of fatty fish.365 A 33% reduction in risk was found for men
in the highest quintile of fatty fish intake (>6g/day) compared with those in the
lowest quintile. A lower risk was found for women raising the possibility of gender
differences regarding benefits of fish consumption.
Long-term fish intake may be more beneficial than short term intake. The
Zutphen study, conducted among a large cohort of older men, reported an
inverse association between long term fish intake and sudden coronary death
(Hazard Ratio (HR) = 0.46; 0.27, 0.78) for long term intake compared with recent
consumption.364 The effect was most marked in the younger age group (40-50
years) and declined between age 50 (HR = 0.32; 95% CI: 0.13 - 0.80) and 80
years (HR = 1.34; 95% CI: 0.58 - 3.12). Benefits were seen at relatively low n-3
intakes of around 250mg EPA and DHA combined daily that offered greater
protection compared with no intake. No further benefit was associated with
intakes greater than 250mg/day, suggesting a threshold around this level of
intake.
3.5.2 Recommendations for LC-PUFA Intake
Adults in the UK consume on average 10 and 11g per day of oily fish for men and
women respectively.160 This would provide approximately 150mg per week n-3
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LC-PUFA depending on the type of fish (Box 2). Current advice from the UK
Scientific Advisory Committee for Nutrition (SACN) is to consume two portions of
fish per week, one of which should be oily.366 Based on an average 100g portion,
this would provide approximately 450mg/day n-3 LC-PUFA. Concentrations of n-
3 LC-PUFA are highest in fish, particularly oily fish, although some plant sources
are available.
Box 2: Dietary sources of n-3 Fatty Acids
S
W
1Sources of n-3 Alpha Linolenic Acid Per 100g (g)
Rapeseed oil 9.6
Soya oil 7.3
Flaxseed oil 22.8
Walnuts 7.5
Almonds 0.27
Sources of n-3 LC-PUFA
Oily Fish
Herring – fresh, frozen or preserved 1.8
Mackerel – fresh or frozen 2.8
Kippers – fresh, frozen or canned 3.5
Pilchards – canned 3.0
Tuna – fresh or frozen 1.3
Trout –fresh or frozen 1.3
Sardines – fresh or canned 2.3
Sild or skippers – canned 2.7
Salmon – fresh or canned 1.9
Shellfish
Crab (fresh) 1.1
Mussels 0.7
Prawns 0.1
White Fish
Cod 0.26
Haddock 0.17
Plaice 0.32
White Meat
Chicken 0.1-0.33
Turkey 0.3
Liver 0.1
Enriched Foods
Eggs 0.35 (per egg)
Milk 0.25-0.482
ource: Fatty Acids: 7th supplement to the 5th edition of McCance and
iddowson’s The Composition of Food Ministry of Agriculture Fishery and Foods,
998.367
Bread 0.47
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3.6 n-3 LC-PUFA and secondary prevention of CVD
The strongest evidence for a protective role of n-3 LC-PUFA is for secondary
prevention of CHD. Data from epidemiological studies, RCTs and meta-analyses
provide support for this hypothesis.
3.6.1 Dietary interventions in secondary prevention of CVD
The first clinical trial in humans investigating n-3 LC-PUFA effects on CVD was
The Diet and Re-infarction Trial (DART).195 Burr and colleagues performed this
RCT in a large group of men with a previous heart attack (n = 2,033).
Participants were randomised to receive different types of dietary advice: (1) to
reduce fat intake and increase the ratio of polyunsaturated to saturated fat, (2) to
increase oily fish, or (3) to increase cereal fibre intake or to a control group that
received no dietary advice. There were no reported benefits from the fat or fibre
advice. However, a 29% reduction in all cause mortality occurred in 1,015 men
advised to eat two large portions of oily fish per week, (providing about 200 to
400mg n-3 LC-PUFA daily in total), when compared with the 1,018 men who had
not received such advice. This difference was entirely attributable to a reduction
in deaths from heart disease. Of note, the incidence of heart attacks was not
lower and this suggests the reduced mortality was due to anti-arrhythmic
properties of n-3 LC-PUFA (Section 3.6.2).
Since DART, numerous trials have investigated effects of n-3 LC-PUFA on
secondary prevention of CHD. The most notable include the GISSI Prevenzione
196 and JELIS studies.132 In the GISSI study participants with a previous MI were
randomised either to receive: (1) supplements of n-3 LC-PUFA (1g daily,
n = 2,836), (2) vitamin E (300mg daily, n = 2,830), (3 ) both LC-PUFA and vitamin
E (n = 2,830), or (4) no supplementation (control, n = 2,828) for 3.5 years.
Treatment with n-3 LC-PUFA significantly reduced all cause mortality (relative
risk (RR) 0.59; 95% CI: 0.36 - 0.97 [P = 0.037]) and was largely attributed to a
decrease in sudden death (RR 0.47; 95% CI: 0.219 - 0.995 [P = 0.048]).196
The JELIS study added further support for promoting consumption of LC-PUFA.
18,645 Japanese patients with a history of CAD and TC ≥6.5mmol/L were 
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randomised to receive either 1.8g/d EPA with cholesterol lowering medication
(statin) (n = 9,326) or to statin only (control; n = 9,319). Patients were followed
up to 5 years and fewer coronary events were reported in the intervention group
compared with controls (intervention: 262 (2.8%), control: 324 (3.5%)
[P = 0.011]).132
Overall, the most important effect of n-3 fatty acids in secondary prevention is a
reduction in mortality following MI. These effects are proposed to operate
primarily through anti-arrhythmic actions.
3.6.2 Anti- arrhythmic effects
More than half of all deaths from CHD are sudden, occurring within one hour of
symptoms of an acute MI. These are attributed to sustained ventricular
arrhythmias.349 Gudbjarnason and Hallgrimsson (1976) were the first to suggest
anti arrhythmic properties of LC-PUFA following investigations in animal
models.368 In these experiments, dietary fat was manipulated in rats. Saturated
fat was replaced by either MUFA or LC-PUFA for 3 months, after which
ventricular fibrillation was induced. Fatal ventricular fibrillation was significantly
reduced by both n-6 (Fatalities: 2/25(8%) and n-3 (fatalities: 0) PUFA but not by
MUFA (fatalities: 9/25 (36%) or saturated fatty acids (SFA) (fatalities: 10/24
(46%).369
Anti-arrhythmic actions of n-3 LC-PUFA were further investigated in non-human
primates. Marmoset monkeys fed diets supplemented with n-3 LC-PUFA-rich
tuna fish oil for 24 months had significantly elevated mean ventricular fibrillation
threshold compared with those fed a diet supplemented with saturated animal fat
or a reference diet not supplemented with fat. Dietary tuna fish oil was
associated with a low incidence of sustained fibrillation episodes and an absence
of fatalities.370 Studies have been criticized because of possible confounding
factors (e.g., by effects from non-fat dietary components, physical activity and
other lifestyle factors) occurring in long-term dietary studies in animals.
Mechanistic studies provide support for these findings.308, 371-373 However, short-
term studies such as these, based on acute ingestion of LC-PUFA, cause
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increases in plasma concentrations of n-3 LC-PUFA that may not be achievable
in free living subjects. Studies in free living human subjects are therefore needed
to demonstrate biological effects of n-3 LC-PUFA.
3.6.2.1 Mechanisms for anti-arrhythmic effects of n-3 Fatty Acids
Proposed mechanisms for anti-arrhythmic effects of n-3 LC-PUFA include actions
to reduce excitability of cardiomyocytes (heart cells).374 Evidence comes from
studies in animal models374-376 where n-3 fatty acids were reported to modulate
ionic currents in rat cardiomyocytes.377 Specifically, they have been shown to
inhibit fast sodium377-379 and calcium currents380 responsible for rapid
depolarisation in cell membranes during MI. Rapid depolarisation makes heart
muscle more excitable and induces arrhythmia. n-3 LC-PUFAs favour
polarization and decrease the risk of fatal arrhythmias.349
3.7 n-3 LC-PUFA and primary prevention of CVD
Several studies have reported cardioprotective effects of n-3 LC-PUFA.132, 327, 381-
384 These have largely been attributed to lipid-lowering actions that are well
established.299 Additionally, anti-inflammatory, antioxidant and anti-thrombotic
actions could also have major roles.385 The vascular endothelium has a major
role in many CVDs and dysfunction is an early indicator of atherosclerosis.
Endothelial dysfunction occurs as a result of reduced NO and increased oxidative
stress (Figure 3-6). As reviewed in Chapter 2, many studies have demonstrated
a protective role of n-3 LC-PUFA in primary prevention of CVD by improving
endothelial function. A large body of evidence also supports protective effects of
n-3 LC-PUFA for classical CVD risk factors. Evidence and potential mechanisms
are discussed below.
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Figure 3-6 Proposed mechanisms for a protective role of n-3 LC-PUFA in
endothelial dysfunction
Adapted from Balakumar and Tanja (2012).385
3.7.1 n-3 LC-PUFA and hypertension
Clinical trials and 3 meta-analyses, involving subjects with and without HT,
dyslipidaemic patients, diabetics and elderly subjects confirm the hypothesis that
n-3 LC-PUFAs are able to slightly, but significantly reduce BP.386 Two meta-
analyses independently concluded that n-3 LC-PUFA reduces BP in a dose
dependant manner (-0.66/0.35mmHg/g n-3 LC-PUFA) at intakes ≥3g/d.387, 388
Antihypertensive effects of fish oils have mainly been achieved at relatively large
doses (4-15g/day) with n-3 LC-PUFA provided as a dietary supplement.389 390-392
Dietary n-3 LC-PUFA has also been reported to benefit BP. However,
interventions provided high intakes that were not representative of usual diet. For
example, daily fish meals that provided 3-4g/day of n-3 fatty acids reduced BP in
overweight patients receiving treatment for hypertension.393
There are few published reports of studies among healthy subjects free from HT.
One study reported no benefits of n-3 LC-PUFA for HT.394 However,
interpretation may be hampered by the design of this trial. Participants were first
randomised to diets rich in either SFA or MUFA then after 3 months, were further
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randomised to n-3 LC-PUFA or placebo. Differences in background diet were
apparent between groups. For example, higher dietary fibre and lower
cholesterol were observed in the MUFA diet group. These and other dietary
factors are known to influence BP, and it was not possible to exclude effects of
multiple dietary exposures on BP in this trial.
A recent meta-analysis of RCTs investigating anti-hypertensive effects of n-3
LC-PUFA concluded that high intake of fish oil reduced BP. Effects were larger in
older populations (>45 years) and in those with pre-existing HT.355 The dose was
high in most trials (median dose: 3.7g/day) and effect sizes moderate: fish oil
reduced SBP by 2.1mm Hg (95% CI: 1.0 - 3.2 [P < 0.01]) and DBP by 1.6mm Hg
(95% CI: 1.0 - 2.2 [P < 0.01]). Effects of n-3 LC-PUFA were attenuated in
double-blind trials and where sample size was larger suggesting trials with
smaller sample size may be subject to publication bias.
3.7.1.1 Mechanisms for anti-hypertensive effects
The physiological mechanisms by which n-3 fatty acids may reduce BP are not
well-established. Explanations include reductions in heart rate (HR) and vascular
resistance with high n-3 LC-PUFA intake.354 A decrease in HR is reported in
most studies investigating cardiovascular benefits of n-3 fatty acids.395 DHA
appears to have the strongest effect.388 n-3 LC-PUFA also reduces angiotensin-
converting enzyme activity, angiotensin II formation and activates the
parasympathetic nervous system leading to increased arterial compliance of both
small and large arteries.
3.7.2. n-3 LC-PUFA and the Lipid Profile
In 1948, the rising burden of CVD in the US prompted the initiation of the
Framingham project; the initial aim of which was to identify risk factors for CHD
(Chapter 1, Section 1.5.2.3). Raised blood cholesterol was identified as a major
risk factor and a strong correlation was seen between increasing CV events and
rising TG.104, 396, 397
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Lipoprotein sub-particles were also found to be influential. For example, low
levels of HDL cholesterol were as much a risk factor for CHD as high LDL
cholesterol. Data from Framingham suggest that high TG level is a risk factor for
CAD particularly when plasma LDL to HDL cholesterol ratio is greater greater
than 5.0. Furthermore, TG rich lipoproteins varied in their propensity to
atherogenicity (Section 3.7.3.3). Evidence from observational and experimental
studies provides strong support for a relationship between TG and CVD.398, 399, 400
These are discussed in detail below in (Section 3.7.3). Lipoprotein metabolism is
central to the understanding of its role in CVD. Therefore an overview is provided
in the following section.
3.7.3 Lipoprotein Metabolism
Lipoproteins are metabolised via two biochemical pathways. The exogenous
route deals with dietary lipids whereas hepatic lipoproteins are processed via the
endogenous pathway.
Fig. 3-7 Lipoprotein Metabolism (Google images, nature.com)
3.7.3.1 Exogenous Pathway
The small intestine absorbs dietary lipids for example from TG, phospholipids,
and cholesterol. These combine with apolipoprotein (apo) B-48 to form
chylomicrons (CM). Newly formed (nascent) CM are secreted into lymphatic
vessels from where they pass via the thoracic duct into the bloodstream.
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Nascent CM accept apo from HDL particles to form mature HDL. CM activate
lipoprotein lipase (LPL), an enzyme which catalyzes the hydrolysis of TG to
glycerol and FFAs for use in respiration or for storage (see Figure 3-2 for TG
structure). Once hydrolyzed, CM become remnant particles which continue
circulating until they interact, via apoE, with specific remnant receptors found
mainly in the liver. CM transport TG to the liver, VLDL transports newly
synthesised TG from the liver to adipose tissue, LDL transports cholesterol from
the liver to the tissues and HDL returns cholesterol from the tissues to the liver
(Figure 3-7).
3.7.3.2 Endogenous Pathway
The liver is an important source of lipoproteins, principally VLDL. TG and
cholesterol combine with apoB-100 to form nascent VLDL particles. Lipoproteins
apoC-II and apo-E, acquired from HDL, are required to form mature VLDL.
Mature VLDL particles circulate and are hydrolysed by LPL to release glycerol
and FFA. Hydrolyzed VLDL particles become VLDL remnants that circulate and
are eventually absorbed by the liver in an interaction involving apo-E and remnant
receptors. Further hydrolysis may take place in the liver through the action of
hepatic lipase. This releases glycerol and FFA, leaving behind LDL. LDL
particles are cholesterol rich and can be absorbed by the liver and peripheral
cells. LDL binds to specific (LDL) receptors on target tissues via apoB-100 or
apo-E. Elevated lipoproteins increase the risk of CHD. In particular lipoprotein a
(Lpa), remnant lipoprotein particles are implicated. Dietary fats have an important
role in CHD risk through their influence on plasma lipoprotein concentrations.
3.7.3.3 Atherogenicity of Lipoprotein Particles
Atherogenic properties of lipoproteins are determined by a number of factors.
Size influences their likelihood of entry to the sub-endothelial space and small
particles are more readily taken up. ApoB has a high affinity for attachment to the
sub-endothelial matrix and does this via a vast network of specialised molecules
(proteoglycans) on its surface. Susceptibility to oxidation is also important.
Modification by oxygen of apoB makes it more palatable to macrophages so
encourages greater uptake and subsequent foam cell formation.401
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Atherogenic lipoproteins such as CM and VLDL remnants are generated during
post-prandial lipaemia (PPL) – a non-fasting state following a meal. Extended or
frequent PPL increases the risk of oxidative modification of LDL and the
production of small-dense LDL particles which are widely considered to be the
most atherogenic lipoprotein particles. Prolonged or frequent PPL increases TG
flux through plasma thereby raising the likelihood of oxidative modification of
lipoprotein particles.
3.7.4 Effects of n-3 LC-PUFA on the lipid profile
The fatty acid content and profile of the diet influences PPL. Diets high in SFA
increase total and LDL cholesterol and stimulate transfer of cholesterol to VLDL
and CM remnants. MUFA appear to have little effect on PPL itself but may
reduce apoB-48 and circulating remnant particles.402 n-3 LC-PUFA reduce both
fasting and postprandial TG levels.
Fish oils have repeatedly been shown to reduce plasma TG in a dose-dependent
manner.357 Early investigations used preparations containing both EPA and DHA
as reviewed in Harris.356 Both EPA and DHA reduced serum TG with the
greatest effects seen in patients with raised serum TG (hypertriglyceridaemia -
HTG).403 Both parallel (n = 29) and crossover (n = 36) studies have drawn the
same conclusions: TC was not affected by n-3 consumption, LDL cholesterol
concentrations rose by 5-10% and HDL cholesterol by 1-3%. The greatest
benefit was seen for TG concentrations which decreased by 25-30%. In early
studies, benefits of n-3 LC-PUFA were mainly attributed to EPA, an assumption
based on the fact that the only commercially available source of fish oil,
Menhaden oil, contained more EPA than DHA (18% vs 9%).299 All these trials
used supplements containing large doses of fish oil (2-5g/day combined EPA and
DHA (EPA/DHA).
Recently, Sanders (2011)253 supplemented a group of healthy older individuals
(aged 45–70 years) with lower doses of combined EPA and DHA (0.4–1.8g/day)
for a period of 12 months. A reduction of 16% in TG concentration was reported
for the group receiving the highest level of supplementation (P for trend 0.014).
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Based on results from early trials, researchers focussed mainly on supplements
combining EPA and DHA. However towards the late 1990s studies investigating
separate effects of EPA and DHA were initiated. It is currently uncertain whether
EPA or DHA or both together are responsible for the protective effect. One trial
among healthy subjects reported only a small benefit of EPA supplementation on
TG reduction.404 However, this study provided a much lower dose EPA
(1.8g/day) than previous studies (Table 3-1).
DHA can be synthesised from ALA (C18:3 n-3) in mammals. However, its
formation is limited as there is competition with LA for enzymes central to
desaturation and elongation processes405 (Figure. 3-4). Studies investigating
effects of single preparation DHA mostly used supplements providing about
1.6g/day.406-412 Two studies used slightly higher doses 2-3g/day)412, 413 and
achieved similar reductions in TG (Table 3-1).
Most studies investigating effects of n-3 on the lipid profile included small sample
sizes (n = 13–60) and interventions varied in duration from 1 to 12 months.
However, collectively these studies provide support for a beneficial effect of n-3
LC-PUFA on TG, achieving reductions in the range of 5-25% in healthy
individuals and between 15-50% in individuals with pre-existing dyslipidaemia.
Effects on other lipid fractions, however, are not so clear. Some studies report
beneficial effects on HDL cholesterol whereas others have found no such effect.
Some studies have reported increases in total and LDL cholesterol (Table 3-1).
3.7.4.1 Effects of combined EPA and DHA
Beneficial effects of n-3 LC-PUFA on the lipid profile are most pronounced among
people with higher CVD risk. In one example twenty-two patients with pre-
existing CAD were given 3.4g/ day of EPA/DHA for 4 weeks. Serum TG was
reduced by 17% and HDL was unchanged.414 Effects are even greater in
individuals with HTG.
Thirteen HTG patients were supplemented with either a concentrated ester of
combined EPA and DHA or with a TG-rich fish oil for twelve weeks in a
randomized crossover design intervention study. Doses ranged from 2-4g/day
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and both oils reduced TG by 50%. LDL cholesterol increased by 18% and apo-B
by 23%.415 A similar reduction was reported in patients with severe HTG (500–
2000mg/dL). In forty patients supplemented with 3.4g/day EPA and DHA for four
months TG reduced by 45% compared with patients randomized to placebo.416
The large reduction in TG could be due either to the longer supplementation
period or to a greater effect in individuals with more severe HTG.
n-3 dose in most studies equated to a pharmaceutical dose rather than a level
usually seen in the diet. In a randomized study in 28 HTG patients comparing
3.4g/day Omacor (providing 1.88g EPA and 1.48g DHA) (Omacor, Pronova
Biocare, Oslo, Norway) with Gemfibrozil (Pfizer, USA), a fibrate preparation of the
treatment of HTG, both treatments reduced TG (Omacor 39%, Gemfibrozil 42%).
Both HDL and LDL cholesterol concentrations increased as a result of the
intervention.417
Increases in LDL cholesterol are reported from many n-3 supplementation studies
418-420 which is of potential concern. For example, in one randomized study
among 33 men with raised cholesterol (hypercholesterolemia [HC]),
supplementation with 3.4g/day EPA and DHA for 6 weeks, reduced TG greatly
(by 39%) however, a concomitant increase in LDL cholesterol (9%) was also
reported.418 Similarly, Calabresi and colleagues reported that supplementation
with Omacor reduced plasma TG by 27-44% and although TC did not change
LDL increased by 20-25%.419, 420
Increases in HDL cholesterol are reported in some studies and this may be
beneficial (Table 3-1). For example in a randomized, double blind study of 43
hypertensive patients 3.4g/day Omacor reduced TG by 21% and increased HDL
by 5% (P < 0.01). No significant changes in total or LDL cholesterol were
observed.391
Findings from larger studies support those from the smaller studies reviewed
here. In a randomized trial of 10 week’s duration Bonaa (1992) compared
5.1g/day fish oil containing EPA and DHA with 6g/day corn oil in 156 subjects. A
21% reduction in TG was reported for subjects randomised to fish oil.390 In a 6
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month randomized study of 935 individuals with HTG, 1.7g/day EPA and DHA
also reduced TG by on average 21% and this time using a lower dose of fish
oil.421 A concomitant increase in HDL cholesterol was also reported.
Increasing the intervention period by 1-2 years resulted in a further monthly
decrease in TG for individuals supplemented with n-3 LC-PUFA and an increase
in controls supplemented with corn oil (intervention: -1.3%, control: +0.35%
[P < 0.001]). HDL cholesterol increased in both groups but to a greater extent in
the intervention group (intervention: 1.1%; control: +0.55% [P = 0.002]). It is
currently uncertain whether a longer duration of supplementation may have
greater long term benefits. Furthermore adherence to such long-term
interventions could prove difficult.
3.7.4.2 Separate Effects of EPA and DHA
The relative contributions of EPA and DHA to cardiovascular health remain to be
elucidated. Investigations into independent effects of EPA and DHA have been
hampered by a lack of availability of purified extracts of individual fatty acids.299
Data from RCTs have only recently begun to emerge - reviewed most recently by
Mori & Woodman (2006)422 and Ryan (2009).299 Studies investigating both
combined and independent effects of EPA and DHA have been conducted in a
range of subjects including healthy,253, 406-410, 423-426 hypertensive,427
dyslipidaemic,428, 429 and overweight individuals.430 (Table 3-1) The individual
effects of EPA and DHA are considered below.
3.7.4.3 Controlled trials with EPA
To date five controlled studies have investigated separate effects of EPA on
serum lipids and lipoproteins. These studies report reductions in TG of between
5 and 21%.404,425, 427-428, 429 In most trials, supplements provided about 4g/day
EPA. One trial provided a lower dose (1.8g/day) and this proved ineffective in
lowering TG in patients with angina.404 Control groups were either given placebo
oils including olive oil,427, 429 or corn oil425 or received no intervention.
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3.7.4.5 Controlled trials with DHA
Twelve controlled trials examined effects of DHA on the lipid profile in adults.406-
413, 431-434 A dose of approximately 1.5–1.8g DHA/day was used in most trials.
DHA reduced TG by about 12-24% in 9/12 trials. Only two trials reported
substantially smaller or no reduction in TG. One trial conducted among children
with familial hyperlipidaemia reduced TG by only 5%434 and the earliest trial by
Conquer and colleagues (1996) reported no change in TG where doses between
0.75 and 1.5g/day were given.407 Hamazaki and colleagues (1996) observed no
benefits for TG concentration where dosage was based on bodyweight (10
capsules for ≤50kg, 11 capsules for >50kg but <55kg and 12 capsules for >55kg).  
Larger decreases in TG occurred in patients with pre-existing dyslipidaemia.410
However, Geppert and colleagues (2006) supplemented healthy vegetarians with
a lower dose (0.9g/day) and still reported a mean reduction in TG of 23%.432
3.7.4.6 Effects of n-3 LC-PUFA on Lipoprotein sub-particles
LDL cholesterol increased in a number of supplementation studies either with
EPA and DHA combined preparations417-419, 435 or DHA alone407, 409, 411-413, 428, 429,
432, 434 but in only one trial supplementing with EPA only.404
An increase in LDL particle size following DHA supplementation was reported in
one study among diabetic subjects.427 This may be important because LDL
particle size is an important risk factor for CVD. Dyslipidemia is seen in
association with T2DM and is marked by an accumulation of small dense LDL
particles in plasma. These are more likely to form potentially harmful compounds
by reacting with sugars (glycation) or oxygen (oxidation) and may contribute to
endothelial dysfunction also seen in T2DM. Small dense LDL is also associated
with increased CCA-IMT, a recognised risk factor for atherosclerosis.436
Very low density lipoprotein cholesterol (VLDL) is a particularly atherogenic
lipoprotein.90, 437 Several studies have reported reductions in VLDL in association
with n-3 supplementation.417-419, 428, 438 Studies supplementing with combined
EPA and DHA preparations have reported reductions in VLDL of 20-65%.
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HDL cholesterol increased by between 8 and 15% in 4 studies using combined
EPA and DHA preparations,391, 420, 421, 439 Smaller increases of 5 and 7%
respectively were reported in two studies using EPA alone.404, 428 The most
consistent benefits for HDL cholesterol are reported in association with DHA
supplementation where 9/12 studies reported increases ranging from 5-17%.406-
408, 411-413, 432-434 No significant differences in serum lipid concentrations were
reported at baseline in any trials. Beneficial effects on lipoprotein sub-fractions
were reported in some studies. For example, HDL2 increased by 12-37% in
three studies407, 427, 429 – the greatest increase was seen in dyslipidaemic
subjects.429
3.7.4.7 Mechanisms for effects of n-3 LC-PUFA on lipoproteins
Reductions in plasma TG seen in association with n-3 LC-PUFA are thought to
be the result of decreased hepatic VLDL production and secretion440 and
increased post-prandial clearance.340 Evidence from animal models can help
explain why, in some cases, fish oil may increase LDL. Huff and Telford (1989)
investigated effects of fish oils on lipoprotein turnover in pigs and reported
increased production of smaller VLDL particles which are more likely to be
converted to LDL.441
Controlled metabolic studies have found that fish oils prevent increases in plasma
TG. The effect was largely attributed to inhibitory effects of fish oil on VLDL
production. Reductions in a range of atherogenic lipoprotein particles including
CM remnants, LDL, Apo B, C and E have also been reported with fish oil
supplementation.340, 403 For example DHA supplementation inhibits Apo CIII an
inhibitor of lipoprotein lipase (LPL). LPL controls TG plasma clearance.
Therefore restriction of Apo CIII by DHA enhances TG clearance.442
3.7.4.8 Summary of n-3 effects on the lipid profile
Dietary n-3 fatty acids from fish and fish oil have profound hypolipidemic effects in
healthy subjects and in HTG patients. Reductions in TG and VLDL are reported
in association with EPA and DHA both combined and in separate formulations.
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There is no evidence for the superiority of EPA or DHA when given singularly.
LDL concentration is seen to increase in many studies and changes in particle
size have also been reported.
Effects on HDL are less conclusive, in some studies HDL is seen to increase
whereas others report no effects or decreases. The mechanism of the
hypolipidemic action of the n-3 LC-PUFA in fish oil is well documented.440, 443
Synthesis of TG and VLDL in the liver is greatly reduced by n-3 LC-PUFA as is
the turnover time of VLDL in plasma.
In general n-3 LC-PUFA reduce serum TG concentrations by 25-50%. Total
cholesterol is not affected, LDL concentrations tend to rise by 5-10% but the more
buoyant LDL sub-fractions associated with a less atherogenic phenotype may be
favoured.419 HDL cholesterol increases by between 1 and 17% improving the
total to HDL cholesterol ratio. Effects on LDL particle size can be largely
attributed to DHA rather than EPA.299 Triglycerides and HDL cholesterol are
widely accepted to be major determinants of LDL particle size.299 However, TG is
reduced by both EPA and DHA and it is therefore unlikely that TG is the major
determinant of LDL particle size in the supplementation trials reviewed here.
Rather, effects of n-3 supplementation on proteins, with central roles in
lipoprotein metabolism, for example cholesterol-ester transfer protein (CETP) and
hepatic lipase, should also be considered when forming dietary guidelines.
It is possible that placebo oils used as comparators in many trials reported here
may have produced independent effects on the lipid profile. For example, olive
oil contains a high concentration of omega-9 MUFA which has been shown to
have beneficial effects on CVD risk.167, 444-447 Furthermore, n-6 PUFA is
consistently reported to lower total and LDL cholesterol and in some studies
HDL.141 In view of this guidelines for fat intake have advocated MUFA in
preference to n-6 PUFA as a replacement for SFA. The rationale for this is that
n-6 PUFA may reduce both detrimental LDL and beneficial HDL. However,
recent meta-anlayses have concluded that overall replacing SFA with n-6 PUFA
increases HDL and decreases LDL whilst replacement with MUFA has no
benefits for LDL. Replacement of carbohydrate or SFA with unsaturated fatty
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acids produces a rise in HDL and this is greatest in association with MUFA.447, 448
With respect to CVD, the most critical actions of n-3 fatty acids are those that
affect the vascular endothelium (Chapter 2).
3.8 Summary and Conclusions
There is no doubt that dietary n-3 fatty acids are important for health. Firstly,
there is a dietary requirement for the parent n-3 fatty acid, ALA, which is essential
to health and cannot be synthesised within the human body. Secondly, longer
chain fatty acids have important biological roles and although they can be
produced from the parent n-3 fatty acid ALA conversion is slow. Therefore there
may be benefits from direct consumption of n-3 LC-PUFA.
A large body of observational and experimental evidence supports the hypothesis
that n-3 fatty acids are important in primary prevention of CVD. However,
evidence from RCTs is lacking and causality cannot be assumed. Data from
controlled trials are equivocal and it is unclear whether supplemental n-3 fatty
acids influence CVD development either in people at high risk of CVD or in
healthy populations. Data informing secondary prevention are more convincing
and several large trials provide compelling evidence for a role of n-3 LC-PUFA in
protection from recurrent myocardial infarctions and death from CHD.132, 196
Dietary assessment has been poorly conducted in both primary and secondary
prevention studies and few have used validated methods to assess n-3 fatty acid
intake. Therefore the role of dietary n-3 in CVD risk is unclear. There is an
urgent need for further well-designed randomised controlled trials investigating
separate effects of LC-PUFA on primary CVD risk in young, healthy populations,
unlikely to be affected by CVD. Such trials should incorporate rigorous and
pertinent dietary assessment measures.
Clearly, more data are needed to inform public health advice targeted at primary
prevention of CVD and clinical guidelines for secondary prevention. Data should
ideally come from well designed RCTs. The aim of this present study was to
conduct such a trial in which effects of DHA on vascular structure and function
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were investigated in a group of young healthy adults, free from CVD and with
minimal modifiable risk factors.
Interventions could include supplementation with n-3 fatty acids or advice to
increase dietary intake. In either case, accurate dietary assessment is essential
to inform dietary strategies. A valid method for assessment of n-3 fatty acid
intake is needed and could prove a useful tool both clinically and in research. A
further aim of this study was to develop such a tool.
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Table 3-1 Controlled trials of EPA and DHA on the lipid profile
Author, setting, year Study design
Mean Change from Baseline (%)
Diet/Dose (g/d) Duration
(weeks)
TG LDL HDL VLDL
EPA & DHA
Eritsland,
Sweden, (1989)414
Randomised, single-blind, parallel study among patients with
stable CHD (n = 22)
EPA/DHA (3.4) 4 -17 NR NR NR
Kestin,
Australia, (1990)418
Randomised, single-blind, parallel study among
normotensive men with mild HC (n = 33).
EPA/ DHA (3.4) 6 -39** +9** None -58**
Simons,
Australia, (1990)415
Randomised double-blind cross over study among patients
with:
Primary (n = 9) or Marked HT (n = 4).
EPA/DHA
(2.8)
(4)
12 -50 +18* None NR
Bonaa,
Norway, (1992)449
Randomized, single-blind, parallel study among 156 healthy
men and women, aged 34-60 years.
EPA/ DHA (6) 10 -21** None None NR
Lungershausen
Australia, (1994)391
Randomized double-blind placebo-controlled cross-over trial
in hypertensive patients (n = 43).
EPA/DHA (3.4) 6 -21** None +15** NR
Grundt,
Norway, (1995)450
Randomised, double-blind, parallel study among patients
with combined hyperlipidaemia (n = 57).
EPA/DHA (4) 12 -28* None None NR
McKeone,
Norway, (1997)451
Randomised, double-blind, parallel study among male and
female patients with severe HT (n = 19).
EPA/DHA (4) 6 -26† None None NR
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Author, setting, year Study design
Mean Change from Baseline (%)
Diet/Dose (g/d) Duration
(weeks)
TG LDL HDL VLDL
Harris
US, (1990)438
Prospective study of patients with HT (n = 10). EPA/DHA
(4.5)
(7.5)
(12)
18 -46**
-54**
-61**
None
+23**
+28**
None
None
None
-59**
-65**
-65**
Harris,
US, (1993)452
Double-blind crossover design study of eight healthy
volunteers.
EPA/DHA
(1g/10kg BWT)
4 -40** <1 <1 NR
Harris,
US, (1997)439
Prospective, double-blind, placebo-controlled trial among
patients with HT (n = 42).
EPA/DHA (4) 16 -45 +31 +13 NR
Sirtori,
Italy, (1998)421
Prospective, double-blind, placebo-controlled trial among
patients with HT and other CV risk factors (n = 935).
EPA/DHA (2) 24 -21** None +8 NR
Stalenhof,
Netherlands, (2000)417
Randomised, double-blind, parallel study among patients
with HT (n = 28).
EPA/DHA (4) 12 -37** +29** +11** -49**
Calabresi,
Italy, (2000)419
Randomised, double-blind, crossover study among patients
with HC (n = 14).
EPA/DHA (3.4) 8 -27† +21† +15† -18
EPA only
Grimsgaard
Norway, (1997)425
Randomised, double-blind, parallel study among healthy
men (n = 234).
EPA-EE
(4)
7 21** None None NR
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Author, setting, year Study design
Mean Change from Baseline (%)
Diet/Dose (g/d) Duration
(weeks)
TG LDL HDL VLDL
1Mori,
Norway,(2000)429
Randomised, double-blind, parallel study among overweight
and dyslipidaemics (59).
EPA-EE
(4)
6 18 None None NR
Woodman,
Australia, (2002)427
Randomised, double-blind, parallel study among
hypertensivesand type 2 diabetics (n = 59).
EPA-EE
(4)
6 -19* None None NR
Nestel
Switzerland, (2002)428
Randomised, double-blind, parallel study among patients
with dyslipidaemia (n = 41)
EPA
(3)
7 -23* None +5 -29**
Yamamoto,
Japan, (1995)404
Randomised, non-blind, parallel among healthy individuals
(n = 22, 12 intervention v 12 control).
EPA
(1.8)
16 -6 +2 +3 NR
DHA only
Conquer ,
Canada, (1996)407
Randomised, double-blind, parallel study among healthy
vegetarians (n = 24)
DHA
(1.62)
6 -9 -7* +17** NR
Conquer,
Canada,(1998)406
Randomised, double-blind, parallel study among healthy
subjects of Asian Indian background (n = 22, 14 male).
DHA
(0.75)
(1.5)
6 -17
-6
-9
None
+5
+5
NR
NR
Hamazaki,
Japan, (1996)410
Randomised, double-blind, parallel study among healthy
vegetarians (n = 24).
DHA FO
(1.5-1.8)a
24 None None None NR
Agren,
Netherlands, (1996)409
Randomised, single-blind study among healthy males(n =
55).
DHA FO
(1.68)
15 -15 +9 0 NR
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Author, setting, year Study design
Mean Change from Baseline (%)
Diet/Dose (g/d) Duration
(weeks)
TG LDL HDL VLDL
Grimsgaard
Norway,(1997)425
Randomised, double-blind, parallel study among healthy
men (n = 234).
DHA-EE
(4)
7 26** None +4*** NR
Nelson,US,
(1997)431
Randomised, single-blind trial among healthy volunteers (n =
6).
DHA
(6)
13 -12** -1 -9 NR
Mori,
Australia, (2000)453
Randomised, double-blind, parallel study among overweight
male patients with dyslipidaemia (n = 59).
DHA 4g 6 20** +8 None NR
Woodman,
Australia, (2002)432
Randomised, double-blind, parallel study among
hypertensives and type 2 Diabetics (n = 59, 39 male).
DHA-EE
(4)
6 -15* None 12* NR
Nestel,
Switzerland, (2002)428
Randomised, double-blind, parallel study among
dyslipidaemics (n = 38).
DHA-EE
(3)
7 -32 +5 +9 31**
Geppert ,
Germany, (2006)432
Randomised, double-blind, parallel study among healthy
vegetarians (n = 106, 27 males).
Algal DHA
(0.94)
8 -23*** +11*** +7** NR
Wu,
Taiwan, (2006)433
Randomised, single-blind, parallel study among healthy
female vegetarians (n = 27).
Algal DHA
(2.14)
6 -18 -3 +6 NR
Sanders,
UK, (2006)411
Randomised, double-blind, parallel study among healthy
Vegetarians (n = 79).
Algal DHA
(1.5)
4 -14* +7* +10* NR
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Author, setting, year Study design
Mean Change from Baseline (%)
Diet/Dose (g/d) Duration
(weeks)
TG LDL HDL VLDL
Davidson,
US, (1997)412
Randomised, double-blind, parallel study among
hyperlipidaemics (n = 27).
TG-DHA
(1.25)
(2.50)
6 -21
-18†
+9
+14
+6 +6
Engler,
US, (2004)434
Randomised, double-blind, crossover study among children
with familial hyperlipidaemia (n = 20).
DHA
(1.2)
6 -5 +8 +5
Kelley,
US, (2008)413
Randomised, double-blind, parallel study among male
patients with hypertriglyderidaemia.
(n = 34).
DHA
(3.0)
12 -24** +15** +7** NR
Abbreviations: HT, hypertriglyceridaemia; HC, hypercholesterolemia; EE, Ethyl Ester; FO, fish oil.* Statistically significant difference from baseline
values (P ≤ 0.05) or ** (P ≤ 0.01) or *** (P ≤ 0.001), †=significance not reported, 1 =Comparison with placebo, NR=not reported.
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Chapter 4
Dietary Assessment
How much cheese is a handful? How much more or less is a cupful? What is the
capacity of a glass, a tumbler, or a soup ladle? What is the difference between a
suspicion and a pinch? How much more is a good pinch? How much wine is a
little, how many olives a few? When a book says a tin of chopped almonds or
pomegranate juice what are you supposed to understand by that?”
Elizabeth David (1913-1992)
4.1 Introduction
The importance of nutrition for health was first recognised through associations
between diet and deficiency diseases such as scurvy, beriberi and rickets and
stunting in children. The observation of the famous British naval surgeon, James
Lind (1716-1731), who noted in a group of sailors attending the HMS Salisbury,
that “they all in general had putrid gums, the spots and lassitude, with weakness
of their knees” amounts to the first description of scurvy, a disease resulting from
deficiency of ascorbic acid more commonly known as vitamin C.454 Similar
observations among sailors led to the identification of further diseases arising
from nutritional deficiencies. For example, sailors living on a diet based on
refined rice developed signs of a disease termed beriberi which was later
attributed to thiamine deficiency.455
Pellagra, which results from deficiency of niacin, was first recognized in early
settlers of the US who existed on a restrictive diet based largely on corn meal.455
Their failure to use traditional food preparation methods, established by native
cultivators, led to the trapping of niacin within corn kernels which reduced its
bioavilability and led to deficiency. Although unable to describe the mechanism
for this, Native Americans knew that treating corn with lime, an alkaline solution,
prevented disease, enabling them to remain healthy on a predominantly corn
meal diet. Early priorities in healthcare therefore focused on defining and
providing nutritionally-adequate diets that could support growth and development
and maintain health.
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Defining nutritional intakes for groups of people within specific populations,
however, is a challenge for public health policy makers. In 1987 the UK
Committee on Medical Aspects of Food and Nutrition Policy (COMA) reviewed its
Recommended Daily Amounts (RDAs) of food energy and nutrients for people in
the UK. The panel moved from RDAs to Dietary Reference Values (DRVs) with
the aim of giving clearer guidance (DH, 1991).159
4.2 Dietary Reference Values
Assessment of dietary adequacy is usually made by comparison with a reference
that defines a level of intake required to prevent deficiency. For example, in the
UK, guidelines for the general public reflect recommendations for nutrient intake
based on advice from COMA and the Scientific Advisory Committee on Nutrition
(SACN). These recommendations are based on conclusive evidence where
possible.
In 1991, the Department of Health published DRVs which cover a range of
intakes for most nutrients.159 Dietary recommendations are usually set at a level
considered adequate for almost all healthy people within a population, and for
many nutrients the ideal recommended intake termed the reference nutrient
intake (RNI) is set at two standard deviations above the estimated average
requirement (EAR). The RNI is considered adequate for most (97.5%) of the
population. The EAR represents an amount that will meet the needs of 50% of
the population. A lower reference nutrient intake (LRNI) is set at two standard
deviations below the EAR and would meet the needs of only a very small
percentage of the population (2.5%) with the lowest nutritional needs. This model
assumes that individual requirements are normally distributed (Figure 4-1).
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Figure 4-1 Graphical representation of dietary reference values (dtonline.org)
4.3 Nutritional Epidemiology
Understanding diet-disease relationships is crucial in the identification and
management of nutrition related disease that can arise from both nutritional
deficiency and excess. Studies of diet and disease can provide evidence to
inform public health. However, it is essential that reliable dietary assessments
are made in such studies as public health recommendations should only be
based on reports that include valid measures of nutritional intake i.e. that have an
acceptable level of accuracy and precision.456 This is also important in clinical
practice where accurate dietary assessment is needed to inform appropriate
nutritional interventions to redress deficiencies or excesses.457 Most nutrition
research studies are conducted within populations – termed nutritional
epidemiology.
Nutritional epidemiology evolved out of the necessity to understand the role of
diet in disease among populations. The science has a long history and evidence
for the role of diet in the development of chronic disease first emerged in the
scientific literature as far back as the eighteenth century.458 Large scale studies
of food consumption began in the 20th century with dietary surveys. These were
designed to provide information about what people ate and aimed to provide a
basis for improving dietary practices. Dietary surveys are complex and there are
many practical problems in their planning, organization and implementation. For
example, reconnaissance of the survey area is needed to glean information about
the environment and socio-demographic setting. Statistical planning is essential
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to the selection of an appropriate representative population sample and, perhaps
most importantly, foods must be described accurately and the calorific and
nutrient values of as wide a range of foods as possible calculated and compiled
into food composition tables. The importance of comprehensive nutrient
databases and their limitations are discussed in Section 4.5.3.4. The design of
studies requiring dietary assessment varies depending on their study objective.
Possible study designs used in nutrition research studies are discussed below.
4.3.1 Descriptive Epidemiological Research
Observational studies allow the investigation of relationships between dietary
exposures and disease outcomes. Possible designs include cross-sectional,
cohort or case-control studies.
4.3.1.1 Cross-sectional Studies
Nutritional surveys such as the National Diet and Nutrition Survey (NDNS),
previously carried out periodically (approximately every 10 years and now a
rolling programme) in the UK, are usually cross sectional. Data collected in such
surveys inform associations between food and/or nutrients or dietary patterns and
health outcomes both within and between populations. Dietary assessment
methods used in national surveys are mainly quantitative and allow estimations of
both type and quantity of foods (including beverages) and nutrients consumed at
the population level. For example, in the UK NDNS, seven days of weighed
records are collected.160 Multiple day weighed food records are considered to be
the “gold standard” method that is closest to the truth and likely to provide the
most valid estimate of dietary intake.459 However, in reality there is no gold
standard for measurement of dietary intake as all methods are prone to bias.460
4.3.1.2 Correlation Studies
As well as population surveys, food consumption studies investigate relationships
of diet with specific disease outcomes. Throughout the last and present century
many large scale studies have been instigated with this specific aim. Early
epidemiological investigations of diet and disease are mainly correlation studies
that compare disease prevalence with consumption of specific foods. Examples
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include the work of Armstrong and Doll (1975) that described the relationship
between meat consumption and the incidence of colon cancer among women
from 23 countries.461
Interpretation of correlation studies is hampered by the existence of confounders
affecting disease risk that may also vary between areas of high and low
incidence. Furthermore, most surveys used food disappearance data, which
make assumptions about food consumed by individuals on the basis of what is
bought. Surveys do not always take into account wastage or extra foods
consumed from household stores. Therefore, as all foods bought may not
necessarily be consumed by the study population assessments based on
household food shopping records do not accurately reflect intake.
4.3.1.3 Case-control Studies
An alternative approach to cohort studies is the case-control study design in
which subjects are recruited on the basis of the presence or absence of
outcomes of interest. This enables comparisons between groups of individuals
with differing dietary habits. Many studies investigating diet-disease relationships
use retrospective methods to assess dietary intake in individuals developing
specific disease states. Such studies are strongly biased by participants’ abilities
to accurately recall past dietary intake.
In some studies exposure is determined prospectively and is therefore free from
recall bias. However, other sources of bias are likely in these studies including
behavioural changes that may occur as a result of being observed (Section
4.5.3).
4.3.1.4 Limitations of Descriptive Epidemiological Studies
The complexity of diet further hampers the study of diet-disease relationships.
Diet is not a single exposure but rather a collective of multiple exposures. For
example, within a population individuals eat many of the same foods which in turn
contain the same nutrients. Therefore, many or all individuals within the study
population may be exposed to the same hypothesized causal agents. Dietary
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behaviours also tend to cluster in sub-groups that share similar lifestyle
characteristics such as income, smoking and alcohol habits. Ethnicity and
familial risk factors are additional correlates with dietary behaviours and these
factors may collectively or independently influence the risk of developing chronic
disease. It is important to control for possible confounding variables in analyses
of diet disease relationships. However, the aim of epidemiological studies is to
study heterogeneous populations where possible to gain the most accurate
assessments of diet in free living individuals.
Effects of nutrition on disease usually develop over time. Therefore the time lag
between previous dietary exposures and disease development may occlude
causal relationships. Cross sectional and retrospective cohort studies are
therefore limited in their ability to detect diet-disease relationships. Observational
studies are further complicated by possible changes in dietary habits that may
occur during the period between dietary exposure and disease development. For
example, a lack of correlation between dietary fat and serum cholesterol
concentrations was reported in studies from the United States.462 Conversely,
cohort studies have consistently reported relationships between dietary fat and
specific fatty acids with increased risk of CVD.463
One major disadvantage of observational epidemiological studies is that they are
unable to determine causality; an experimental study design is needed for this.
However, it is not always ethical to test hypotheses about diet/disease
relationships. For example, a wealth of epidemiological data supports the
hypothesis that diets high in saturated fat increase the risk of CHD and it would
therefore not be ethical to randomize human subjects to high fat diets to make
comparisons with respect to health outcomes. In this instance prospective cohort
studies are more likely to provide useful data on habitual diet that can be
correlated with health outcomes.
Prospective cohort studies are useful in generating hypotheses that can inform
experimental research. Once identified, a diet or dietary pattern that is strongly
associated with health benefits can be applied to experimental research. For
example, it is possible to compare diets with recognized health benefits, such as
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a Mediterranean style diet with a diet common to a population. Limitations of
such studies include the likelihood that effects on disease development
attributable to diet may be small and studies investigating diet-disease
relationships may therefore require large sample sizes. Furthermore, adherence
to specific diets by healthy free-living individuals is difficult to achieve.241
4.3.1.5 Experimental Nutrition Research
Experimental research allows specific hypotheses about diet-disease
relationships to be tested and the most robust study design is the RCT which
ideally should be conducted as a double-blind experiment. In this type of study
effects of potentially confounding variables are minimized through random
allocation of participants to intervention or placebo groups. With this study
design it is possible to create differences between groups with a magnitude
sufficient to make comparisons of effects attributable to a specific exposure.
Following intervention, groups are compared and differences between outcomes
of interest assessed. This allows estimation of disease risk in relation to
exposures (e.g. nutrient or food) of interest.
Experimental studies among humans are expensive to conduct and should only
be considered after evidence from animal models or from observational
epidemiological human studies has generated hypotheses that warrant further
investigation. RCTs lend themselves most appropriately to investigations using
single nutrients that can be provided as pills or capsules.464 However,
interventions incorporating advice to follow specific dietary guidelines have also
been widely used.465
Whatever study design is selected, in all nutrition research assessment of diet is
essential. However, collecting accurate information about dietary intake is
notoriously difficult to achieve.466 No dietary assessment method has yet been
identified that is completely accurate, precise, affordable and feasible for use in
both experimental and observational studies. The challenge to researchers is to
collect information about dietary intakes that are as close to the truth as is
reasonably possible within the constraints of the study. The aim of the present
study is to investigate the relationship of diet to the risk of developing of CVD
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which requires knowledge of food consumption at the individual level. The
following sections therefore focus on dietary assessment methods used at an
individual level.
4.4 Dietary Assessment Methods
To examine the relationships between diet and disease, dietary assessment
methods are needed that can identify individuals consuming specific foods and
nutrients of interest or who can be characterised by specific dietary patterns. It is
essential to clarify the study aims and thus identify the type of dietary information
required. Methods can be either quantitative or qualitative as dictated by the
research question. This thesis used both quantitative and qualitative methods to
investigate relationships between diet and vascular function.
4.4.1 Quantitative Dietary Assessment
Various methods of quantitative dietary analysis can be used depending on
whether the intention is to: 1) describe the mean intake within the study
population; 2) determine the proportion of a population at increased risk; 3)
categorise an individual on the basis of their level of intake; or 4) describe
absolute intake in individuals. Methods 1 and 2 are useful for reporting intake at
the group level; for example to evaluate the level of intake or identify the
proportion of the population at risk of deficiency following supplementation with
foods or nutrients or fortification of specific foods. Methods 3 and 4 are more
useful in a clinical setting, to identify individuals’ levels of disease risk. For
example, in this thesis classification into divisions of population intake is used to
identify low and high consumers of n-3 LC-PUFA and examine relationships with
CVD risk.
The quantitative approach to dietary assessment requires methods that can
correctly classify individuals according to their level of nutrient or food intake with
an acceptable degree of accuracy. This is feasible provided the dietary
assessment method’s relative validity has been assessed against a superior
measure of intake. Describing the absolute magnitude of intake for a specific
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food or nutrient is the most error prone assessment to attempt and therefore
qualitative dietary assessment has gained popularity in recent years.
4.4.2 Qualitative Dietary Assessment
There is a growing consensus that a more holistic multifaceted approach is
needed to better understand the relationship between diet and health particularly
for assessment of dietary behaviours in free living humans.467 In reality, people
eat meals made up of a combination of foods, which are themselves a complex
mixture of nutrients. Furthermore, foods are eaten in different combinations and
in different ways. For example, meal pattern varies greatly with some preferring
traditional patterns, based on 3-4 meals per day and others inclined to ‘graze’ on
more frequent eating episodes.
4.4.2.1 Dietary Pattern Analysis
Recently, dietary pattern analysis has emerged as an alternative or
complementary approach to examine the relationship between diet and the risk of
chronic diseases. Instead of looking at individual nutrients or foods, dietary
pattern analysis examines the effects of overall diet. Dietary patterns represent a
broader picture of food and nutrient consumption, and may thus be more
predictive of disease risk than individual foods or nutrients.
Two methods are most frequently used to derive dietary patterns. One approach
is to use scores or indexes based on a priori hypotheses about the role of dietary
factors in disease prevention.468 One pattern that is universally accepted as
beneficial in CVD prevention is the Mediterranean diet. The degree of adherence
to Mediterranean style dietary patterns can be estimated using scoring systems
of which the most widely used is the Mediterranean diet score. The original
Mediterranean diet score proposed by Trichopoulo et al., (1995) comprised eight
components: high MUFA to SFA ratio; high consumption of legumes; cereals
(including bread and potatoes); fruits and vegetables; low consumption of meat
and meat products; and milk and dairy products, and moderate alcohol
consumption.469 Subsequent scores have been modified to accommodate local
dietary habits and secular changes (e.g. tMED,470 aMED,471 or rMED,472). In
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recent meta-analyses of studies using such scoring systems, a higher degree of
adherence to the Mediterranean diet was associated with a reduction in CVD
mortality.186, 187 Effect sizes ranged from a relative risk of 0.4 to 0.9.
A second approach is to derive dietary patterns from dietary assessment data
using principal component analysis (PCA). The aim of this technique is to reduce
the number of foods in a dataset by grouping foods of similar characteristics
together. PCA attributes a score or factor loading to food groups based on the
sum of the daily frequency of intake of foods comprising each group. This
identifies patterns characterised by significant consumption of specific foods. A
detailed description of PCA is given in Chapter 6, Section 6.5.9. Dietary
patterns derived from these methods have been examined in relation to
nutritional and disease biomarkers and various health outcomes, and generally
show the desirable dietary pattern to be consistent with prevalent beliefs about
what constitutes a “healthful” diet. Observational studies suggest that “healthful”
dietary patterns are associated with significant but modest risk reduction (15%-
30%) for all-cause mortality and CHD.473
More recently a third method in dietary pattern research has emerged. Ranked
Regression Analysis (RR) uses data from two types of observed variables known
to be related to outcomes of interest to derive dietary patterns. In RR food group
data derived from FFQ can be used in conjunction with biomarkers of disease
status. For example Liese and colleagues (2009) used RR to examine
relationships between dietary patterns and common carotid artery IMT.281 A set
of dietary variables were derived from FFQ and combined with a data set
describing fibrinogen and plasminogen activator inhibitior 1 concentrations,
recognised CVD risk factors, in the same subjects. The mathematical basis of
RR is similar to factor analysis but it is applied to two sets of variables as
opposed to only one.281
Defining a “healthful” or “healthy” diet in specific terms is a challenge for health
professionals and researchers. Most countries have produced national dietary
guidelines that offer general advice regarding foods that constitute a healthy diet
and the proportions in which they should be eaten. For example in the U.K. the
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eatwell plate is a policy tool that is used to depict the Government’s
recommendations on healthy diets (Figure. 4.2). The model aims to make
healthy eating easier to understand by giving a visual representation of the types
and proportions of foods needed for a healthy and well balanced diet. Dietary
messages are notoriously difficult to convey and are interpreted and acted on
differently by individuals. Furthermore, compliance with dietary
recommendations is shown to be poor in national diet and nutrition surveys.160
Therefore, variance in day-to-day nutritional intake is likely to be high among
individuals.
Figure 4-2 The Eatwell Plate (used with permission from the UK Food
Standards Agency)
Even though much progress has been made as a result of the development of
ever more sophisticated instruments and methods for dietary intake assessment,
the relationship between diet and health is still not fully understood and no perfect
dietary assessment method exits. Methods that aim to provide fully or semi-
quantitative dietary intake assessments are discussed below.
4.5 Dietary Assessment Tools
There are a number of methods available for dietary assessment. These fall
largely into two categories: prospective and retrospective There are several
dietary assessment tools available for assessing nutrient intakes; these are
summarised in Table 4-1 and briefly described below.
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4.5.1 Prospective Methods of Dietary Assessment
Prospective dietary assessment methods collect data recorded at the time of
eating.
4.5.1.1 Weighed Records
The weighed records method is generally considered to be the most accurate
prospective method of dietary assessment.474 However, it is not practical for use
in many studies as it is expensive, time consuming and places a considerable
burden on both study participants and investigators. For example, Bingham and
colleagues (1997) reported that 16 days of weighed records were necessary to
assess usual dietary intake.459 Moreover, despite their rigour, weighed records
often highlight underreported energy and nutrient intakes due to participants
neglecting to collect intake data comprehensively.475, 476 Secular changes that
include an increase in the amount of food consumed outside the home make this
method increasingly more difficult. The weighed record method requires
participants to provide detailed description of foods and beverages consumed on
a meal by meal basis. All foods and beverages intended for consumption must
be accurately measured against an appropriate scale. Amounts consumed can
then be calculated by deducting food or drink left over and recorded in a booklet
provided by the researcher. The main disadvantage of the weighed record
method is that it places a considerable burden on participants who must be both
literate and numerate.477 Although methods have improved greatly in recent
years, for example, with the provision of digital ‘smart’ scales able to
automatically record and log food items, weighed intakes still place considerable
burden on study participants. Moreover, the practice of detailed food recording is
likely to introduce bias. For example, participants may change their eating habits
to make the process less time consuming, or simply to appear compliant.
4.5.1.2 Observed Weighed Inventory
The observed weighed inventory method is the most arduous method for the
researcher. All foods and beverages offered must be weighed before the meal is
taken and all non-consumed food weighed at the end of the meal. The
advantage is a high level of accuracy in quantifying amounts consumed.
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Disadvantages include a high risk of bias as the participants are observed and
therefore likely to change usual behaviours or to be influenced by the presence of
the researcher. The risk of bias in nutrition research studies is discussed more
fully in Section 4.5.3.
4.5.1.3 Estimated Food Records
Estimated food records rely on participants’ reports of amounts of food and drink
consumed based on comparisons with household measures. The amount of food
eaten is described in spoons or cups, measured with a simple ruler or compared
to a recognised household object. For example a piece of cheese may be
compared to a matchbox, a potato to a standard egg etc. Food models, scales
and photographs can all be useful in improving dietary assessments (Figure 4-3).
Photographs of average portion sizes tend to result in underestimates of portion
size. However, Nelson and colleagues reported that the use of a photographic
atlas illustrating a range of portion sizes was associated with relatively small
errors (Nelson, et al., 1994).478 Clearly, however, assessments can only provide
an approximation of dietary intake.
Figure 4-3: Tools used to improve dietary intake estimates (author’s copyright)
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4.5.2. Retrospective Methods of Dietary Assessment
Retrospective dietary assessment methods collect data about food eaten in the
(usually recent) past.
4.5.2.1 Twenty-Four Hour Recall
An alternative method which may be more feasible in research studies, is the 24-
hour recall method. This involves the collection of single or multiple records of
dietary intake based on the previous day’s intake. Pioneered by Burke (1947),479
this widely used method shifts the burden away from participants and towards the
investigator who is able to collect comprehensive information about dietary intake
over the 24 hour period preceding interview. Careful questioning allows
investigators to make estimates about portion size and help quantify intake.
Information can be collected at personal interviews or by telephone. Twenty-four
hour recalls conducted by telephone have been described by several
investigators.480-482 Morgan and colleagues (1987) compared the use of
telephone with personal interview dietary assessments and concluded that the
telephone interview provided comparable data with less effort and cost.
Response rates were 71-81% for telephone interviews compared with 72–83%
for personal interviews.483
A major advantage of this method is that it can be completed in a short time (10-
20 minutes) and places minimal burden on study participants. However, this will
vary according to participants’ abilities and lifestyles. For example a less literate
person may take longer to describe their dietary intake and an individual who
prepares food from scratch may also need longer to describe ingredients,
cooking methods etc. Previous researchers have reported a range of 5-67
minutes as necessary for 24-hr recall collection.484
As with all dietary assessment methods there are certain limitations. For
example, a single 24-hour recall will provide a “snap shot” reflecting only a single
day’s intake and is unable to offer a valid estimate of habitual intake.485 This can
be overcome by collecting several days of records that will capture information on
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day to day dietary variation and aid description of habitual diet.486
Representation of all days, including weekend days is important as variability in
food intake has been reported to be higher on weekend- compared with week-
days.487 Although weekend collections may increase investigator workload it is
likely that more foods habitually eaten will be captured.488, 489 Where possible,
attempts to include assessments made during different seasons should be made.
Seasonality affects food availability in some populations and intake differs
according to the time of year for various reasons.
Where the aim is to collect multiple 24-hour recall records this is best done by the
same researcher to reduce inter-operator variability. Although variability between
investigators can be considerable, standardisation of methodology, for example
the use of training protocols for interviewers, has been shown to reduce inter-
operator variation. Detailed examples of training protocols used in the US
National Heart Lung and Blood Institute studies that included extensive dietary
assessment can be found online.490
The 24-hour recall method has been successfully used in many studies including
national dietary surveys491 492 493 and large intervention trials such as MRFIT.494
It has been validated in several populations including elderly housebound
adults,495 British school children496 and overweight adult men in the US.497 In
summary, the 24-hour recall method can be relatively inexpensive, places a lower
burden on study participants compared with weighed intakes and may be feasible
for large scale studies.
4.5.2.2 Dietary History
The dietary history method involves a face to face interview conducted by the
investigator who is usually a dietitian or nutritionist. This method is widely used in
clinical practice to help dietitians make assessments about nutritional adequacy.
During the interview, the investigator uses an open question technique to gain
insight into usual dietary practises. Examples of questions include: “When do
you usually have your first food or drink Mrs Brown?” Using this method, the
investigator attempts to avoid leading the interviewee into providing answers they
may want to hear such as, for example, “I always eat breakfast and have a
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healthy bowl of wholegrain cereal.” An advantage of dietary history over dietary
recall is that the interviewer collects information relating to habitual intake rather
than a record of a given day’s intake. This may be more useful in studies where
the aim is to assess diet disease relationships. However, where assessment of
temporal relationships between nutrient intake and outcomes is required a dietary
recall may be more appropriate. The diet history method also allows detailed
questioning to collect information about portion size, cooking methods etc.
Disadvantages include a high level of dietary expertise from the interviewer and a
considerable time commitment from the participant which therefore make this a
costly option.
4.5.2.3 Food Frequency Questionnaire
Semi-quantitative information can be collected using dietary questionnaires.
Food frequency questionnaires (FFQ) are used to provide retrospective
information about which foods or food groups are regularly eaten and the
frequency of their consumption. This information can then be used to provide
estimates of food and nutrient consumption or to describe dietary patterns.
FFQs require participants to indicate their frequency of consumption of certain
foods. The questionnaire can be either self- or investigator-administered. In
either case, a detailed explanation is required before completion to ensure
accurate reporting. FFQs can be sent out to participants with detailed
instructions. Ideally, this should be supported by verbal instructions given by
telephone. Preferably, FFQs can be administered while participants attend the
research centre. In this scenario investigators can provide more detailed
explanation and instruction and provide help during the completion process.498
Advantages of FFQs include: 1) they are usually self-administered so place less
burden on researchers; 2) they take less time to complete than detailed food
records; 3) less time is needed for coding and entry to nutrient analysis
programmes. They may also be more appropriate in some study designs, for
example when information about habitual diet or dietary patterns is required.499
Disadvantages include: 1) FFQs are semi-quantitative only; 2) they tend to
underestimate energy and macronutrient intake500 and overestimate micronutrient
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intake501 and 3) there is loss of detailed information as foods are grouped
together.
In general, FFQs are widely accepted to be the most appropriate method for
dietary assessment in studies of diet-disease relationships.458 However, it is
important to consider whether the FFQ is appropriate for use in the population
under study. For example has the FFQ been validated in the study population or
a comparable sample. During the 1950s investigators developed FFQs and
evaluated their role in dietary assessment.502-503, 474 Heady (1961) was the first to
demonstrate that reported frequencies of food intakes was highly correlated with
weights consumed over several days.504 The earliest practical application of the
FFQ method was in 1976 when Nichols and colleagues used an FFQ in the
Tecumseh Heart Study.505 In this study, failure of the FFQ to detect an
association of fat intake with serum cholesterol led to decreased interest in the
use of FFQs. However, since this study, serum cholesterol has been identified
as a poor indicator of dietary change because it does not accurately reflect short
term dietary fat consumption.107 Therefore, the biochemical marker, rather than
the dietary assessment tool may have been the limiting factor.
In summary, weighed records have been shown to be the most accurate
quantitative method of dietary assessment. However, they are expensive, time
consuming, invasive and therefore impractical for use in many research studies
and clinical assessments. A major quest of nutrition epidemiology has been to
identify dietary assessment methods that are able to assess usual diet and yet be
suitable for large numbers of participants. This requires demonstration of validity
of other methods, traditionally against the “gold standard” weighed food record.
Validation is particularly important in dietary assessment studies because
methods are prone to error. These are discussed in the following section.
4.5.3 Sources of Error in Dietary Assessment
“Accurate estimates of the dietary intake of free-living individuals are
required for nutritional research, epidemiology, and clinical medicine.
However, all dietary assessment techniques rely on information
supplied by the subjects themselves and so the validity of results is
uncertain”
(Bingham & Cummings, 1985).506
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Measurement errors in dietary assessment occur both randomly and
systematically. Random errors may be introduced by day-to-day variations in
dietary intake or as a result of measurement error. Whether fluctuation results
from genuine day-to-day variations or measurement errors, provided an adequate
number of daily records are collected per individual the average value from
repeated measures will approximate the true value.458 This is not true for
systematic errors, however, which occur for example when dietary intake
reporting is influenced by participation in a study, a phenomenon known as the
Hawthorne effect.
The Hawthorne Effect was first reported following research investigating methods
of increasing productivity in the Western Electrical Company's Hawthorne Works
in Chicago during the 1920’s and 30’s. The finding of interest was that no matter
what change was introduced to working conditions, the result was increased
productivity.507 When applied to nutrition research the Hawthorne effect may lead
individuals to either over- or under-report intake of certain foods and distort the
truth. Standardised questionnaires are particularly prone to systematic errors.
For example, when a food regularly consumed by an individual is omitted or a
question misunderstood the truth cannot be reached even with collection of
multiple records.
Errors in dietary assessment affect both within and between subject
measurements. There are three major sources of error in dietary assessment
methodologies: 1) respondent; 2) interview and 3) database errors. These are
discussed briefly below in Section 4.5.3.1 – 3.
4.5.3.1 Respondent errors
Researchers report a variety of influences on the ability of participants to provide
accurate reports including, educational, social and motivational factors.508 509
Age, sex and environment have important influences on food intake memory. For
example recall is reported to be better in women compared with men and in
younger compared with older individuals.510 To provide reliable details of dietary
intake respondents must have a reasonable knowledge of food, good
communication skills and a reliable memory. Memory aids can be helpful in
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obtaining accurate information regarding foods and the quantities eaten. For
example, prompts can be used to help the respondent’s memory. With careful
probing the interviewer can uncover snack foods eaten whilst watching television
or socialising. Checklists are also useful and can help respondents feel secure in
reporting foods perceived as treats. Furthermore, suggesting named foods can
help recall. However, it is important to suggest at least 3 alternatives to minimise
bias. Visual reminders can also be helpful and food models and packaging are
often used as memory aids. These have the added advantage of assisting with
portion size estimation.
With the exception of weighed records and many (non-quantitative) FFQs,
participants must also be able to estimate quantities of foods and beverages
consumed. Although descriptions of portion size may help achieve a more
accurate assessment, this is frequently estimated inaccurately and a high degree
of variation between perceived and actual standard portion size is commonly
reported.511, 512 Some researchers have reported photographs as useful aids to
improve estimation of food portion size.511, 513 Guthrie (1984) reported an error
margin greater than 50% where no aids were used in assessments of food
portion size.511 Similarly, Pietinen and colleagues (1988a & 1988b) reported that
the use of photographs improved agreement between semi-quantitative
assessment methods and weighed records.514, 515 More recently, Nelson and
colleagues compared the use of photographs depicting average portion size with
those depicting a range of portion sizes and found that the use of a series of eight
photographs greatly reduced errors in size perception.478, 516
4.5.3.2 Interview errors
Errors that occur during the interview process arise for several reasons and may
be attributed to the interviewer, the participant or a combination. One of the main
sources of error in dietary assessment is misreporting, comprising both under-
and over-reporting. Misreporting introduces severe error not only in the
estimation of energy intake, but also in that of other nutrients, and may be a
result of participants’ poor ability to accurately recall intake and to describe
portion size.517 Memory is highly influential and may be suppressed or distorted
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either of which may result in the unintentional omission or addition of foods.518
Emphasis should be placed on careful questioning using open style interviews
(Section 4.5.2.2). One strategy to reduce error is to incorporate quality control
assessments for interviewers participating in large scale studies. For example, in
the International Collaborative Study of Macro- and Micronutrients and Blood
Pressure (INTERMAP) study dietary interviewers were intensively trained and
recalls taped. Recordings were used to highlight areas requiring retraining or
work to improve performance.519
4.5.3.3 Coding and Database errors
After collection, dietary records must be coded and entered to a nutrient
database. A codebook is essential to ensure standardisation. This should give
food codes and advice as to which specific foods they should be used for. In
some cases, decisions regarding which code to use will be straightforward whilst
in others nutrition knowledge and training is essential in the selection of the most
appropriate food code. For example in most cases a boiled egg is simply that
and usually only one code will be appropriate but for other foods, that can be
prepared or cooked in several ways, judgements must be applied. A
comprehensive code book can help guide decisions for example by prompting
data entry staff to check for additional information. Where this information is not
available standard (default) coding decisions can be applied.
Where a quantified assessment is required food densities and average portion
size information is also required. In some cases additional information may be
needed to determine the most appropriate code. For example, details of usual
food preparation and/or cooking methods can aid the food code decision.
There are several stages in the coding process where errors can be introduced.
Firstly, food codes may be inappropriate. For example, if a code allocated to a
particular food has not been analysed for the nutrient of interest, total intake for
that nutrient will be underestimated. Secondly, mistakes may occur in the coder’s
interpretation of the food record. For example, the study participant reports daily
consumption of a specific food but the coder omits to refer to additional
information. This could lead, to the selection of a food higher in a certain nutrient
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than that actually consumed. For example, additional information indicates that
the participant removes excess fat from meat; in this case the coder should have
the opportunity to select a food code that reflects this. However, failure to use
additional information may lead to an incorrect choice of food code. Thirdly the
coder misreads or wrongly transcribes information from the code list to the data
entry sheet and the wrong food is entered to the dietary analysis programme.
For the purpose of epidemiological studies the food composition database should
be comprehensive, complete and current. Information on all nutrients and other
food constituents is essential and the database should be updated to reflect
secular changes in food consumption. Dietary analysis programmes available in
the UK are based on the data set of foods and nutrients in McCance and
Widdowson’s The Composition of Foods and its supplements published by the
Royal Society of Chemistry (McCance and Widdowson’s The Composition of
Foods, 5th Edition, 1993.520
4.5.3.4 Sources of Error in Food Composition Analysis
The earliest analyses for McCance and Widdowson’s Composition of Foods
began early in the previous century when McCance first identified the need for
accurate quantification of carbohydrate in the management of diabetes.
Recognising that the currently available American food tables omitted to separate
available from non-available carbohydrate, McCance embarked on the production
of a more accurate food database, based on UK foods. With a grant from the UK
Medical Research Council, he began with the analysis of fruits and vegetables
(McCance in McCance and Widdowson’s The Composition of Foods, 5th Edition,
1993).
A database designed for the purpose of food analysis should include raw and
cooked foods and ideally branded samples and recipes. Sampling is an
important consideration and the quality of data should ensure ‘fitness for the
purposes for which it should be used’.521 Values in McCance and Widdowson’s
were derived from direct analysis of foods using carefully designed sampling
protocols. Most values were derived from pooled samples where foods
purchased from different shops were combined. Ten samples were used in most
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cases. These were typically chosen to account for variations within product
ranges including ratio of baked beans to tomato sauce etc. Therefore, values in
these food tables have been derived from careful analyses and are
representative of foods commonly consumed in the UK. However, it is important
to appreciate that variation occurs between individual foods and foods change
over time. For example the nutritional content of fresh foods will vary according
to growing season, soil and storage conditions. Different cooking methods may
be used, affecting, for example, water retention and nutrient content.
Furthermore, cooking durations and food preparation methods can affect
nutritional content and nutrient availability.
When undertaking dietary analysis researchers must consider the extent to which
available databases accommodate foods reportedly consumed by their study
participants and compromises may be necessary. For example, seemingly exact
information with regard to energy or nutrient content may be available for a given
brand of food from the manufacturer. However, analysis is unlikely to have been
conducted with the same rigour as that undertaken by McCance and colleagues.
Furthermore, current food labelling regulations mean that manufacturers are not
legally required to provide full nutritional composition data. Spot checks on
manufacturers’ food label data have reported inaccuracies and researchers may
be wise to base their analyses on a representative sample rather than on
manufacturers’ less accurate data.522
4.5.3.5 Adjustment errors
Body size is also reported to influence dietary intake assessments where
overweight and obesity are commonly associated with underreporting of energy
intake.523-525 For example, in studies using the doubly labelled water method for
estimation of energy intake, obese women underreported energy intake
compared with lean counterparts.526 Evidence of under-reporting in obese
individuals also comes from a study among Canadian adolescents where females
were more likely to under-report compared with males and under-reporting
increased with increasing weight status for both sexes.527 It is also important to
consider the energy contribution of foods. For example, an individual’s intake of
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a given nutrient may appear high or low unless adjusted for the total energy
consumed.
No method has yet been devised that can measure usual intake with absolute
accuracy and therefore no method can be truly validated. Different methods can,
however, be compared and the weighed inventory method is considered the best
reference for this purpose.528 However, for reasons discussed above, collection
of weighed food records is not possible in many studies. Where it is not feasible
to use the weighed inventory method, alternative methods can be used. Possible
limitations of these have been discussed above. However, steps can be taken to
minimise bias by using validated dietary assessment methods.
4.6 Validity of dietary assessment methods
The errors discussed above affect the validity of dietary assessment. Validity
encompasses elements of accuracy and precision. Accuracy describes how
close a measured value is to its actual or true value. Measurement of energy
intake can be used as an example to illustrate this. Accuracy of energy intake
estimates from dietary reports can be assessed using doubly-labelled water,
which provides a precise measure of metabolisable energy intake among free-
living individuals, as a reference.529 Precision relates to its ability to reproduce
results i.e. the consistency of the questionnaire to measure intake in the same
individual at different time points. With regard to precision, it is important to
appreciate that absolute reproducibility is unlikely to be achieved due to the risk
of bias. For example, dietary intake is likely to show true variation at different
time points.
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Figure 4-4 Illustration of precision and accuracy as independent
concepts. Each column (A, C and B, D) has the same precision
and each row (A, B and C, D) has the same accuracy (google
images, yorku.ca).
Validity of a dietary assessment tool can be assessed by comparison against a
superior measure of intake either from an alternative dietary assessment
instrument or using biomarkers of intake. However, it is well recognised that no
perfect standards exist and so dietary assessment cannot be performed with one
hundred percent accuracy. Therefore, the exact truth cannot be known and
validity can only be assessed relatively. It has often been stated that there is no
gold standard that can be used to validate prospective methods of dietary
assessment in free living people.459 This led to a quest for alternative standards
against which dietary assessment tools could be compared. Over the last few
decades several biomarkers have been identified that provide a quantitative
measure of dietary intake that does not rely on reports of food consumption.459, 530
4.6.1 Biochemical Markers of Dietary Intake
The advantage of measuring biomarkers of intake is that they do not rely on
subjects’ abilities to recall intake or on their compliance with recording methods.
Furthermore they are less susceptible to measurement error (Section 4.5.3).
Bingham and colleagues conducted an extensive validation study to examine the
validity of dietary assessment methods for use in the UK arm of the European
Prospective Investigation of Cancer (EPIC, Section 4.7.1). Validity was
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assessed by comparing intake of nitrogen, potassium and carotene from 7 day
weighed records with three biochemical markers of intake: 1) 24-hour urinary
nitrogen; 2) 24-hour urinary potassium; and 3) serum carotenoids respectively.
Completeness of 24 hour urine collections was verified against the
P-aminobenzoic acid (PABA) check technique.531  This showed that ≥16 days of 
weighed records and eight 24-hour urine collections were needed to assess
dietary intake. The protocol was then used to assess the validity of a range of
dietary assessment methods. Three methods were considered suitable for use in
EPIC – a 7-day food diary, a FFQ and a 24-hour recall.
Several biomarkers have been investigated to assess their use as indicators of
dietary intake. Alkylresorcinols, phenolic lipids present in the outer parts of wheat
and rye grains, have been proposed as specific dietary biomarkers of whole-grain
intakes and concentrations in plasma, urine and adipose tissue used as dietary
biomarkers of wholegrain intake in several small intervention studies.280, 532
Measurement of urinary sodium via 24-hour urine collections can be used to
validate dietary sodium dietary533 and 24-hour urinary iodine excretion has been
reported as a useful biomarker for validating dietary milk and other dairy foods in
pregnant Norwegian women.534
Folate, vitamin B12, iron, and zinc are particularly important nutrients for women
of childbearing age. Fayet and colleagues (2011) assessed the relative validity of
a FFQ by comparing estimated dietary intake with biomarkers of folate, vitamin
B12, iron, and zinc.535 Significant correlations between biomarker and nutrient
intakes were found for folate (r = 0.37 [P < 0.01]) and vitamin B12 (r = 0.27
[P < 0.01]). The validity of the Northern Sweden FFQ for assessing dietary
intakes of folate, vitamin B12, riboflavin and vitamin B6 was also assessed by
comparison with plasma levels of these nutrients.536 Nutrient intakes estimated
by the FFQ were moderately correlated with plasma levels (range: 0.13-0.33),
demonstrating similar validity to that of FFQs used in other studies.537, 538, 539, 540
Biomarkers of fatty acid status provide useful objective measurements against
which dietary assessment instruments can be compared. Although biomarkers
do not reflect absolute intake, measurement of fatty acids in various biological
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samples reflects proportional intake of fatty acids.541 Suitable biomarker tissues
include adipocytes,542 plasma phospholipids or cholesterol esters543 and
erythrocytes (RBC).544 Plasma fatty acids reflect recent intake (over 3-4 days)
whereas adipocyte and RBC concentrations provide information about long term
fatty acid intake (over several months). A major disadvantage of adipocyte fatty
acid measurement is that sample collection is invasive and painful and therefore
often not acceptable to study participants. As a result plasma or RBC
concentrations are most commonly assessed.
Both plasma phospholipids and cholesterol ester fatty acid concentrations
correlate reasonably well with dietary estimates from FFQs. Correlation
coefficients between dietary and plasma PUFA (expressed as % total FAs) for
plasma phospholipids and cholesterol esters were r = 0.25 and r = 0.31
respectively.545 Confirmation that plasma and erythrocyte FA’s reflect recent and
longer term dietary intake respectively and therefore serve as biomarkers comes
from intervention studies where plasma or RBC FA concentrations were
significantly higher in supplemented versus non-supplemented individuals.546 253
Harris and Thomas (2009) suggest that RBCs may be the preferred tissue for
assessing n-3 LC-PUFA status.544 In a study assessing biological variability of
RBC and plasma FA concentrations within subject variability was lowest in RBCs
(4.1% ± 1.9 vs. 15.9 ± 6.4%).
4.7 Studies including dietary assessments of n-3 LC-PUFA
Observational and experimental studies investigating relationships between n-3
LC-PUFA and vascular health have used various dietary intake assessment tools
to track compliance with interventions or predict disease risk. Most investigators
have adapted comprehensive tools that have been used previously for example
in national surveys or large scale epidemiological studies.
4.7.1 The EPIC Food Frequency Questionnaire
The European Prospective Investigation into Cancer and Nutrition (EPIC) was
designed to investigate the relationships between diet, nutritional status, lifestyle
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and environmental factors and the incidence of cancer and other chronic
diseases. This large-scale study recruited over half a million (520,000) people in
ten European countries: Denmark, France, Germany, Greece, Italy, The
Netherlands, Norway, Spain, Sweden and the United Kingdom.547 The methods
used to assess diet in such large studies must be of good technical quality,
feasible and acceptable to local populations. Extensive methodological studies
were carried out to test the validity of dietary questionnaires for proposed use in
EPIC. Three dietary methods were adopted: a self-completed dietary
questionnaire, an interview-based dietary questionnaire or a FFQ, where the
participants estimate their average frequency of intake of a list of foods over the
previous 12 months) combined with a seven-day record.530 In the present RCT
the EPIC Norfolk FFQ was used to monitor compliance and assess relationships
between dietary exposures and risk of primary CVD.
4.7.1.1 The EPIC FFQ for assessment of n-3 fatty acid intake
The validity of the EPIC FFQ for assessment of n-3 LC-PUFA was evaluated in a
large study of 3,000 EPIC participants. Plasma phospholipid n-3 PUFA
concentrations were used as biomarkers of fish intakes and compared with
estimates from 4 dietary assessment methods (FFQ, health and lifestyle
questionnaire, 7-day diary, and first-day recall from the 7-day diary). Correlations
between fish consumed and plasma phospholipid n-3 PUFAs were not
substantially different between the 4 dietary methods.548
4.8 Dietary Assessment in Studies of n-3 LC-PUFA and vascular
health
Dietary n-3 LC-PUFA intake has been assessed only in some studies
investigating their relationship with vascular health.188, 237, 242, 243, 245, 248, 252, 253, 382,
428, 429, 549, 550 Details of studies with summaries of dietary assessment
methodologies can be found in Appendix 1-2, tables 2-2 and 2-3. To the author’s
knowledge, no study has yet been published where a validated method for
assessment of n-3 LC-PUFA in the specific study population was used or
developed. Methods available for evaluating intake of n-3 LC-PUFA and
specifically those found mainly in oily fish (EPA, DHA) are scarce.
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Various FFQs have been validated in the UK population against a range of
biochemical markers of intake and/or reference dietary assessment methods.459,
537 FFQs that cover all foodstuffs can be long and complicated, imposing a
considerable burden on participants and therefore compromising reliability of the
method. Compressing the questionnaire, by grouping foods together, can lead to
a loss of detailed information and underestimate intake of specific nutrients. This
is an example of random error discussed earlier (Section 4.5.3). Where
measurement of a single or few nutrients is required a shorter FFQ focussing on
those nutrients may be more practical.
A Pubmed review identified 20 published reports of studies that aimed to validate
a method for dietary assessment of n-3 LC-PUFA. These have been conducted
in various locations: 5 from Scandinavia, 4 each from Australia and Japan, 3 from
North America and one each from France, Spain and the UK. Thirteen studies
assessed FFQ either against a reference dietary assessment method501, 551, 552 or
a biomarker (Table 4.2).546, 553-560 All studies that compared dietary intake
assessments with an objective biomarker reported moderate to good correlations:
EPA (r = 0.21-0.58), DHA (r = 0.32-0.53).
4.9 Conclusions
FFQs are a feasible method for dietary assessment of n-3 LC-PUFA. There is no
validated FFQ for assessment of n-3 LC-PUFA in the UK where the population
and dietary habits differ. Such an instrument, if shown to be valid, would provide
a much needed practical tool that is both inexpensive and less arduous for
researchers and clinicians to use in studies and clinical practice and poses the
least burden on study participants. A major aim of the present study was
therefore to develop a FFQ for assessment of n-3 LC-PUFA intake in the UK.
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Table 4-1 Dietary Intake Assessment Methods
Dietary Assessment Method Brief description Advantages Disadvantages
Prospective methods
Weighed records Participants are taught to weigh
and record the food and its weight
immediately before eating. Leftover
food is also weighed.
Accurate. Does not rely on memory. Expensive, time consuming.
May lead to change in usual diet.
Requires high degree of participant
co-operation. Places large burden on
investigators and participants.
Estimated records Subjects are taught to keep records
using standard household
measures.
Simpler and less demanding. Allows
rapid, low-cost assessment. Less
likely to lead to dietary changes.
Lower accuracy when compared with
weighed records.
Observed weighed records Involves trained researcher to visit
subject at meal times and weigh
food to be consumed. The
researcher then returns to weigh
leftover food.
Useful where subjects are unable to
keep records for themselves e.g.
children.
Demanding for subjects and
investigators. Expensive.
Retrospective methods
Records combined with direct
analysis (duplicate portion)
Food composites collected after
completion of dietary surveys.
Complete duplicate portions of all
foods are collected prior to
consumption over a whole day.
Aliquots of foods collected during
dietary surveys are analysed.
Necessary when accurate values in
food composition tables are not
available.
Very demanding and expensive.
Difficult to obtain co-operation from
participants.
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Dietary Assessment Method Brief description Advantages Disadvantages
24-hour recall
(single or multiple pass)
Dietary intake data collected by
means of interview when
individuals are asked to describe
food intake over the previous 24
hours or for the previous day.
Multiple pass (recalls for more than
one day) give better estimate of
habitual intake.
Quick and simple to perform. Places
minimal burden on subjects.
Difficulties in recalling intake
accurately. Problems with describing
foods and portion sizes.
Requires trained observer.
Multiples are required to describe
habitual intake.
Dietary history Assesses an individual’s food
intake and usual meal pattern.
Information is best obtained by a
nutritionist or relevantly trained
person.
Provides information about diet
spanning long time period. Requires
minimal input from subjects.
Focuses on regular patterns,
therefore irregularities may be
overlooked. Highly subjective.
Food Frequency Estimates frequency of food
consumption over a specified time
period.
Cheap, simple and quick method.
Subjects can self complete. Coding
allows rapid data entry. Provides
information about habitual dietary
intake. That can be used to identify
dietary patterns.
Development of questionnaire is time
consuming.
Data collected may not be
comprehensive.
Not fully quantitative – conversion to
nutrient or food group data requires
extra work.
With the exception of dietary history and food frequency questionnaires considerable time would be required for accurate coding in the above methods.
This would place considerable burden on investigators and cost implications for research.
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Table 4-2 Crude and adjusted correlations for dietary methods versus reference methods in studies of n-3 LC-PUFA dietary assessment
Author, year
(location)
n Dietary assessment method
validated
Reference methods Crude Energy
Adjusted
Andersen, 1998.
(Norway).546
119 FFQ Subcutaneous Fat EPA: 0.52*†
DHA: 0.49*†
Marckman, 1995.
(Denmark).561
24 3 x 7d weighed food records Subcutaneous fat EPA: 0.40†
DHA: 0.66†
Sullivan, 2006.
(Australia).553
53 FFQ As % Total Erythrocyte membrane
Fatty Acids
EPA: 0.40* Ϯ 
DHA: 0.39*Ϯ 
Hodge, 2007.
(Australia).554
4439 FFQ Plasma
Phospholipid Fatty Acids
EPA: 0.18*
DHA: 0.4*Ϯ 
EPA: 0.40*
DHA: 0.78*
McNaughton, 2007.
(Australia).555
43 FFQ
Weighed Record
Plasma
Phospholipid Fatty Acids
EPA: 0.21*
DHA: 0.32*Ϯ 
EPA: 0.22*
DHA: 0.43*Ϯ 
Hjartaker, 1997.
(Norway).556
234 FFQ Serum
Phospholipid Fatty Acids
EPA: 0.58*
DHA: 0.53*Ϯ 
Andersen, 1999.
(Norway).546
135 FFQ Serum Total Fatty Acids EPA: 0.51*†
DHA: 0.38*†
Sasaki, 2000.
(Japan).562
42/44≠ DHQ Serum
Phospholipid Fatty Acids
EPA: 0.64/0.61≠† 
DHA: 0.46/0.46≠† 
EPA: 0.64/0.65 ≠ 
DHA: 0.44 Ϯ/0.59†
Kuriki, 2003.
(Japan). 563
94 7-d weighed record Plasma Total Fatty Acids Adjusted data only EPA: 0.57†
DHA: 0.57 Ϯ 
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Author, year
(location)
n Dietary assessment method
validated
Reference methods Crude Energy
Adjusted
Kobayashi, 2001.
(Japan). 564
87 7-d weighed record Serum Phospholipid Fatty Acids EPA: 0.75†
DHA: 0.50†
EPA: 0.89†‡
DHA: 0.61†‡
Tokudome, 2001
(Japan).551
79 FFQ 28-d weighed record EPA: 0.25/0.26††
DHA: 0.26/0/29††
EPA: 0.39/0.32††
DHA: 0.43/0.31††
Paalenen, 2006.
(Finland).501
294 FFQ 3-d weighed record Total n-3
LC-PUFA:
0.35/0.20 ≠ 
Broadfield, 2003.
(UK). 552
31 FFQ 3-d weighed record EPA: 0.59‡
DHA: 0.55‡†
EPA: 0.50*
DHA: 0.37*
Astorg, 2008.
(France). 565
276/257≠ Multiple 24-hour recalls Serum total Fatty Acids EPA: 0.24/0.27‡≠ 
DHA: 0.23/0.29‡≠ 
London; 1991.
(USA).557
115 FFQ Adipose Fatty Acids Total Marine FA:
0.48*†
Sublette, 2011.
(USA).558
61 FFQ Plasma total Fatty Acids EPA: 0.38*†
DHA: 0.50* Ϯ 
Mina, 2007.
(Australia).559
91 FFQ As % Total Erythrocyte membrane
Fatty Acids
EPA: 0.47* Ϯ 
DHA: 0.0.33* Ϯ 
Amiano, 2001
(Spain). 566
120 Diet History Serum Phospholipid
Cholesterol Ester Fatty Acids
EPA: 0.52*†‡
DHA:0.62
EPA: 0.55*†‡
DHA:0.50
Lucas, 2009.
(Canada).567
65 FFQ As % Total Erythrocyte membrane
Fatty Acids
EPA+DHA: 0.42‡ Ϯ 
From marine foods.
* Spearman correlation, †Significant at P < 0.001, ‡Pearson correlation, Ϯ Significant at P < 0.05, ≠ Men/women, †† Pearson/Spearman correlation 
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Chapter 5
General Methods
By three methods we may learn wisdom: First, by reflection, which is noblest;
Second, by imitation, which is easiest; and third by experience, which is the
bitterest (Confucius).
Section 2: Methods
5.1 Introduction
This PhD project was part of a randomized controlled trial designed to investigate
the effects of supplementation with the n-3 LC-PUFA, DHA, on vascular function
and risk factors for CVD in healthy young adults. The primary outcome was
endothelial dysfunction, an early stage in the atherosclerotic process.
Previously, our research group assessed endothelial function using FMD in
young adults aged 20-28 and showed an association between FMD and both
plasma and red cell DHA concentrations.568 A similar association was seen for
CVD risk factors including plasma glucose, insulin and TG concentrations. This
suggests that higher n-3 LC-PUFA concentrations may have a protective role
against endothelial dysfunction in young healthy adults who are unlikely to have
established CVD. Plasma DHA concentration correlated with dietary fish intake,
and a dose-response association between DHA concentration and FMD was
reported that was independent of the lipid profile. This suggests that dietary
supplementation with n-3 LC-PUFA could be causally related to improved FMD in
this population. Furthermore, associations of FMD with n-3 LC-PUFA levels in
the normal dietary range suggest that an improvement in endothelial dysfunction
could be achieved by moderate increases in n-3 LC-PUFA intake.
Evidence from epidemiological studies suggests that high fish consumption is
associated with a lower risk of CVD (See Chapter 2, Section 2.4). This
association is likely to be mediated by the high levels of the n-3 LC-PUFAs EPA
and DHA found in highest concentrations in fish oil. An inverse correlation
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between the dietary intake of these fatty acids and CVD has been shown in most
of these studies.180, 235, 243, 256, 270, 275, 299, 340, 353, 386, 430, 434, 568-578
Despite the strong epidemiological data, a causal association between n-3
LC-PUFA intake and the prevention of CVD has not been established. Although
randomized intervention trials have shown beneficial effects of n-3 LC-PUFA
supplementation, these trials have focused on secondary prevention and few
studies have investigated the influence of n-3 LC-PUFA on the primary
prevention of atherosclerosis or coronary artery disease. However, preliminary
evidence now suggests that n-3 LC-PUFA may have a favourable effect on
endothelial function and this could be one mechanism for their benefits in both
the primary and secondary prevention of coronary artery disease.
5.1.1 Hypotheses
The aims of the RCT were to test the hypotheses detailed below in sections
5.1.1.1 and 5.1.1.2.
5.1.1.1 RCT Primary Hypothesis:
Hypothesis 1: n-3 LC-PUFA supplementation improves vascular function (flow-
mediated endothelial dependent dilation, (FMD)) in healthy young adults.
5.1.1.2 Secondary Hypotheses:
Hypothesis 2:n-3 LC-PUFA supplementation improves CVD risk factors
including blood pressure, fasting insulin, glucose, CRP and lipids.
Hypothesis 3:Effects of n-3 LC-PUFA supplementation on vascular function are
influenced by gender and lifestyle factors, including smoking.
Hypothesis 4:The magnitude of n-3 LC-PUFA effects differ according to
supplement dose.
138
The aims of this PhD thesis were to examine relationships of diet with vascular
structure and function in healthy young adults. The study was conducted in
parallel with the RCT which provided a convenience sample.
In Chapter 2, a comprehensive review found strong evidence for a beneficial
effect of ‘prudent’ or ‘healthy’ dietary patterns on primary prevention of CVD.
Evidence for the role of specific dietary components within such patterns
suggested fish and n-3 LC-PUFA play a major role in the protective effect. The
following hypotheses were formed on the basis of current evidence for the
relationship of diet and primary CVD.
Hypothesis 1: Dietary patterns are associated with vascular structure and
function in young healthy adults.
Hypothesis 2: Components within dietary patterns, specifically n-3 LC-PUFA are
associated with vascular structure and function.
Evidence suggests that associations of diet with vascular function may operate
through classical CVD risk factors such as blood pressure, lipid concentrations,
insulin resistance and obesity. Therefore the following hypotheses were
formulated:
Hypothesis 3: Dietary patterns are associated with CVD risk factors in young
healthy adults.
Hypothesis 4: Components within dietary patterns, specifically n-3 LC-PUFA are
associated with CVD risk factors in young healthy adults
Reliable assessment of n-3 LC-PUFA intake is essential in studies investigating
relationships between fatty acids and health outcomes. Therefore a secondary
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aim of this PhD was to develop and validate a FFQ (FishFQ) designed
specifically to assess n-3 LC-PUFA intake. A FFQ designed to collect
information on usual intake of foods rich in DHA and EPA was developed and
tested as part of the RCT. This formed the basis for the following additional
hypotheses:
Hypothesis 5: A FishFQ specifically designed to assess dietary n-3 LC-PUFA
has acceptable validity when compared against a reference dietary assessment
method (multiple 24-hour dietary recalls) and biomarkers of n-3 LC-PUFA intake
using the method of triads.
Hypothesis 6: The FishFQ is able to accurately classify individuals according to
thirds of n-3 LC-PUFA intake.
Hypothesis 7: The FishFQ is reliable and results can be reproduced at different
time points.
5.2 Study Design
The study was a double-blind, parallel group, placebo-controlled randomized trial
conducted at the Medical Research Council (MRC) Childhood Nutrition Centre
(CNRC), University College London (UCL) Institute of Child Health (ICH),
London, between 2003 and 2008. Participants were randomly assigned to DHA
supplementation or control groups using a randomisation list generated by an
independent statistician and held at a collaborating centre (Martek, Biosciences
corporation, Maryland, USA). The assigned dietary group was allocated using
numbered, sealed, and opaque envelopes and all participants and research staff
were blind to the dietary assignment. FMD and other study outcomes were
measured during a 1-day visit to the research centre before and after 4 months of
dietary intervention. All subjects were asked to participate in post-intervention
measurements irrespective of whether they complied with the study protocol
(intention to treat).
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5.2.1 Subjects
Participants included members of a population previously studied by our research
group who were now aged 28–34 years. These subjects were originally identified
by sending a letter of invitation to a random sample of individuals born at the
Cambridge Maternity Hospital between 1969 and 1975. The group was chosen
because concise records of birth and growth had been kept. A total of 326 (157
males and 169 females) subjects were potentially available. Members of this
cohort were traced by sending a letter to their GP (Appendix 2-1). A letter of
invitation explaining the study was sent to these previous and potential
participants (Appendix 2-2). Additional younger adult volunteers were recruited
from students, staff and their friends and families at UCL. An “all users email”
was sent through the UCL email network and posters were placed on notice
boards in UCL buildings (Appendix 2-3). An article, written by myself, was
placed in the professional journal of the British Dietetic Association ‘Dietetics
Today’ inviting members to participate. Further participants were recruited by
word of mouth.
Individuals who were aged 18-37 years, clinically well at the clinic visit, and free
from chronic disease likely to affect FMD (e.g. insulin dependent diabetes), were
eligible. Those who were pregnant, on unusual diets, or taking regular
medication or n-3 PUFA supplements were excluded. This initial contact was
followed by a telephone call for a full discussion of any issues raised. During this
call the procedure for providing informed consent was explained and participants
were given ample time (at least two weeks) to consider whether they would like to
take part in the study. A patient information sheet with a fuller explanation of
study procedures was sent to potential participants (Appendix 2-4).
5.2.2 Sample size
The minimum projected sample size was 256 subjects (128 each in n-3 LC-PUFA
supplemented and placebo groups). The sample size was adequate to detect a
0.35 standard deviation (SD) difference in FMD between randomized groups at
5% significance and with 80% power. The study was therefore conservatively
powered, as most risk factors for endothelial dysfunction are associated with a
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0.5 to 1 SD reduction in FMD579 and interventions to improve endothelial function
(e.g. exercise training) have often produced a greater than 1 SD improvement in
FMD580. Furthermore, a previous study by our group suggested that a 1%
increase in plasma DHA level was associated with a 0.5 SD increase in FMD568.
Supplementation was set at 1.6g/day – a level that was considered more than
adequate to produce a 1% improvement in red cell n-3 LC-PUFA concentration.
Supplementation for 4 weeks with 0.9g/day n-3 PUFA has been shown to
increase red cell membrane n-3 fatty acid concentration by 0.76%.581
5.2.3 Inclusion Criteria
Inclusion criteria were: aged 18-37 years, willing to participate, clinically well at
the first clinic visit, and no clinical diagnosis of atherosclerosis. Exclusion criteria
were: women who were pregnant at the initial visit, chronic disease likely to affect
endothelial function (e.g. insulin dependent diabetes), adherence to unusual diets
and currently taking n-3 supplements.
5.2.4 Ethical Approval
Ethical approval was applied for and granted from the Metropolitan Multi
Research Ethics Committee, Lewisham, London. The trial was registered on the
International Standard Randomised Controlled Trial Register as follows: ISRCTN
no. 19987575 (http://www.controlled-trials.com).
5.2.5 Participant flow through randomized trial
Participants attended for assessment at the Childhood Nutrition Research Centre
(CNRC), Institute of Child Health (ICH), University College London (UCL) on two
occasions: visit 1, at which baseline measurements were taken, preceded the
intervention and visit 2, where measurements were repeated following
supplementation, was arranged as close to the end of the 16 week intervention
period as possible. At the first visit, the study was explained to the subjects by
one of four CNRC researchers who were fully trained in good clinical practice
(GCP) and research governance. Informed consent was provided by all
participants to take part in the study and additionally, if willing, participants gave
consent to provide a blood sample (Appendix 2-5 & 2-6).
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The study was conducted in CNRC and Department of Vascular Physiology (VP),
at UCL/ICH. Travelling and other expenses were refunded and overnight
accommodation provided where necessary. Participants were given £50 on the
day of their last clinic visit, as a thank you for their time and inconvenience. Flow
charts outlining the study protocol and the experimental flow of subjects through
the trial can be found in Appendix 2-7.
5.2.6 Intervention
Subjects were randomized to receive either 1.6g/day DHA or placebo (olive oil).
For comparison, the level of supplementation was approximately twice that used
in a study (0.9g/day fish oil) that showed a 29% reduction in mortality in a fish
supplemented group.195 However, the level of supplementation was half that
used in several other studies and in the trial on the effects of n-3 LC-PUFA on
coronary bypass graft patency.582 The level of supplementation was lower than
that safely used in previous studies and that recommended for Maxepa®
capsules in the British National Formulary. This level of n-3 LC-PUFA intake is
also equivalent to approximately 1 large portion of oily fish (e.g. herring or
salmon) per day and is therefore within a plausible dietary range for the
population. Supplementation of less than 3g of n-3 LC-PUFA per day has been
categorized as GRAS (Generally Regarded As Safe) by the US Federal Drug
Authority.190
5.2.6.1 Supplement and placebo details
The supplement took the form of 8 x 500mg gelatin capsules containing DHA rich
oil providing 200mg DHA as triglycerides per capsule (DHA-S). More specifically,
DHA-S oil is a mixed triglyceride, meaning that the oil contains a mixture of
triglyceride molecules, most of which have at least one DHA molecule. As in
most natural food sources of DHA, the DHA in DHA-S oil is found primarily at the
sn-2 position on the glycerol backbone of a triglyceride molecule, with the
remainder at sn-1 and sn-3 positions (Chapter 3, Figure 3-2). The source of this
oil was the microalgae Schizochytrium sp. Approval for the use of this DHA rich
oil as a novel food was recommended in the UK by the Advisory Committee on
Novel Foods. Subsequently approval was obtained from the European
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Commission as a novel food ingredient under EC regulation no. 258/97.583
Placebo capsules took the same form and contained 500mg olive oil per capsule.
Eight capsules were taken daily providing a total of 4g olive oil/day. All capsules
were provided by Martek Biosciences Corporation (Maryland, US, now DSM
Nutritional Lipids).
DHA is a 22-carbon omega-3 fatty acid with six double bonds (also referred to as
n-3), and is designated 22:6n-3 or 22:6 omega-3. It is considered an omega-3 or
n-3 fatty acid because its first double bond occurs on the third carbon from the
methyl or “omega” end of the molecule. DHA is highly lipophilic and, due to the
large number of double bonds, has a low melting temperature and is a liquid (oil)
rather than solid (wax) at room temperature.
5.2.6.2 Compliance Monitoring
Compliance was monitored with regular phone calls and/or text messages sent
by a member of the research team. Attempts were made to contact each
participant weekly. During these calls, participants were asked to answer
investigator defined questions relating to the participant’s health during the
preceding seven days or since the previous contact, where the interim period
exceeded seven days (Appendix 2-8). During compliance monitoring telephone
contacts, researchers requested participants to provide a 24-hour recall of dietary
intake. For each participant, the aim was to collect 7 dietary recalls during the
intervention period; these should ideally be representative of typical week and
weekend days. Full details of the design and development of the methods for
collection of 24-hour dietary recall can be found in Chapter 6, Section 6.4.1
Compliance was further assessed by counting remaining capsules at the end of
the intervention period.
5.2.6.3 Biological Markers of n-3 Consumption
Assessment of erythrocyte membrane concentrations of n-3 PUFA was carried
out prior to supplementation to assess fatty acid status. Measurements were
repeated post-supplementation to provide objective evidence of compliance with
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supplementation and for assessment of dietary changes in fatty acid status that
would reflect consumption. Blood was obtained by venepuncture between 0900
and 1100 after an overnight fast. All procedures were carried out by trained staff
in accordance with the study protocol and CNRC standard operating procedures
(SOP). Red cell membranes were prepared on the day of collection and all
samples stored at -70o C prior to analysis. Briefly, whole blood was prepared in
lithium-heparin with phosphate buffered saline and centrifuged to remove the
buffy coat. Red cells were washed 3 times with saline, by re-suspension and
centrifuging. The samples were thawed only once immediately before analysis.
Red cell ghosts were analysed for n-3 fatty acid concentrations by Omegametrix
using the methodologies of Professor Clemens von Schacky.
(http://www.omegametrix.eu). Individual fatty acids were measured and reported
as a percentage of total red cell membrane fatty acids.
5.2.7 Dietary assessment
The EPIC FFQ was used to assess participants’ usual diet during the year prior
to enrolment. The FFQ was administered again at the end of the
supplementation period to assess diet during the intervention period to ascertain
whether there were any systematic changes in diet as a consequence of
participating in the study.
A separate FFQ was designed specifically for assessment of n-3 LC-PUFA intake
(FishFQ). This was to be validated in the RCT participants. The FishFQ was
administered before and after the RCT intervention period. Full details of
administration of the EPIC and FishFQs are given in Chapter 6, Section 6.2.
The relative validity of the FishFQ was assessed by comparison with erythrocyte
membrane concentrations of n-3 LC-PUFA and a reference dietary assessment
method - multiple 24-hour recalls of dietary intake. A full description of the
development and use of dietary assessment methods is given in Chapter 6.
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5.3 Outcome measures
All measurements were made by investigators who were blind to the
supplementation status of the subjects. The measurements were carried out at
baseline and after 4 months supplementation.
5.3.1 Vascular Measurements
All vascular studies were performed in a temperature controlled (22o C to 26o C)
vascular laboratory by one of two trained operators. Subjects were rested supine
for 10 minutes before measurements.
5.3.1.1 Brachial Artery Flow Mediated Dilatation
The principal trial outcome was FMD of the brachial artery. Participants were
asked to avoid foods with high fat content during the morning preceding the scan
as these have been reported to affect FMD.198 In addition, they were asked to
refrain from ingesting substances that may affect flow-mediated vascular
reactivity, including caffeine584, tobacco585 and vitamin C.284
Participants were asked to lie flat on an investigation couch, with the top half of
their body as close to the scanning table as possible. Long-sleeved clothing was
removed to expose the upper arm. The height of the couch was adjusted to
achieve alignment with an adjacent arm rest. A pneumatic FMD cuff was placed
around the forearm immediately below the elbow (1cm distally to the medial
epicondyle, Figure 5-1).
Room and skin temperature may influence blood vessel diameter.39 Therefore
room temperature was recorded to ensure the optimal range of 24–26° C.
Similarly skin temperature was recorded and if lower than 31° C, a heat pack was
applied to raise the temperature. During measurement of FMD it is essential to
ensure that participants are both comfortable and warm as unnecessary
movements during the study could affect image quality.
Electrocardiogram (ECG) leads for measurement of cardiac activity were
positioned below the left and right clavicles and one approximately 5 cm right of
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the umbilicus. A blood pressure cuff was placed on the left arm. The right arm
was placed in an arm rest at an angle of 70–90 degrees to the body (Figure 5-2).
The brachial artery was imaged in longitudinal section, 5-10 cm above the elbow,
using a 5-10 MHz linear array transducer and an Acuson 128XP/10 system
(Accuson, Aspen, Siemens, Malvern, Pennsylvania, USA). The transducer was
fixed using a stereotactic clamp and fine position adjustments made when
necessary using micrometer screws.
Figure 5-1: Medial epicondyle reference point for cuff positioning in FMD
(Google images, copyright Mayo Clinic.com)
Figure 5-2: Correct arm and pneumatic cuff positioning in FMD
(used with permission, Vascular Physiology Department, UCL/ICH)
Room lights were dimmed to create a relaxed environment for the scan.
Participants were requested to remain as still as possible throughout the
procedure. Ultrasound gel was placed on the crown of the biceps brachial
muscle. The ultrasound probe was positioned on the gel and manipulated until a
satisfactory image was obtained of a brachial artery section (Figure 5-3).
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Figure 5-3: Brachial artery image obtained using Doppler ultrasound
Brachial artery diameter was measured with edge detection software (Brachial
Tools, Iowa City, Iowa). Ultrasound calipers were used to mark the boundaries of
the arterial lumen as shown above (Figure 5.3). ECG gated end diastolic B-mode
images were digitized and stored off line sequentially every 3 seconds throughout
the scan procedure for later arterial diameter measurements. Blood pressure was
monitored using an automated oscillometric device (Accuson, Aspen, Siemens,
Malvern, Pennsylvania, USA) before and after FMD measurement and resting
heart rate recorded using the three lead ECG linked to the Accuson 128XP/10
ultrasound machine.
The pneumatic cuff was inflated around the forearm to 300 mm Hg for 5 minutes
followed by rapid deflation causing a large increase in blood flow, (reactive
hyperemia). Participants were asked to remain still for the duration of the scan,
which took 11 minutes in total (1 minute resting, 5 minutes cuff inflation and 5
minutes post cuff deflation). The resting and post hyperemic blood flow velocities
were measured in the centre of the imaged artery using pulsed wave Doppler
ultrasound.
Reactive hyperemia was calculated from the maximal flow within the first 15
seconds after deflation of the pneumatic cuff, relative to baseline flow. FMD was
expressed as the absolute maximal change between pre- and post-hyperemic
brachial artery diameter adjusted for pre-hyperemic diameter using regression
analysis586 and as a percentage change from baseline arterial diameter.
Absolute change in diameter was chosen as the primary outcome because it is
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independent of baseline arterial diameter, which contributes to sex differences in
FMD expressed as a percentage change. The reproducibility and detailed
methodology for measuring flow mediated endothelial dilation has been
previously described.586-588
5.3.1.2 Brachial Arterial Distensibility
Arterial distension was measured in the same arterial section selected for FMD
assessment. The ultra-sound probe was aligned with the M-mode (motion-mode)
cursor positioned at right angles to the arterial lumen over the clearest defined
section of the artery on the B-mode image. A five-second segment of the radio
frequency signal was recorded by a separate Wall Tracking System (Ingenious
Medical Systems, Arnhem, Netherlands) at a rate of 800 Hz (one frame per
millisecond) and the initial frame (amplitude waveform) displayed. Two sample
volumes were set coinciding with the arterial wall-lumen interfaces and the
relative position of the walls within these volumes were measured every 25
milliseconds (around one fifth of the expected time for an upstroke) using a
displacement detection algorithm based on the cross-correlation model for
corresponding segment of the radio frequency lines. The mean change in
diameter between diastole and systole over the five-second period was used as
the measure of arterial distension. Three distension measurements were made
and an average recorded. Previously reported coefficients of variation for
measurements of diameter and distension using this technique are 2-3%.586
Blood pressure was measured in the left brachial artery using an oscillometric
device (as above), at the same time that distensibility was measured in the right
arm to provide a representative measure of pulse pressure in the right brachial
artery. Arterial distensibility was determined at both the brachial and carotid
arteries.
5.3.1.3 Carotid Artery Distensibility
The carotid artery was imaged using B-mode ultrasonography at a region 1 cm
proximal to the origin of the bulb of the right and left common carotid artery. The
transducer was manipulated such that the near wall of the carotid artery was
parallel to the transducer footprint and the lumen maximized in the longitudinal
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plane. A M-mode recording was made with the M-mode cursor perpendicular to
the vessel wall. Three images of each B-mode and M-mode in different
directions (anterior, lateral, medial) were recorded and the images digitized and
saved on a computer. Brachial blood pressure was recorded at 5 minute
intervals throughout the period of ultrasound scanning. The artery diameter
changes for assessing carotid distensibility and the distensibility coefficient were
analyzed as described previously.589
5.3.1.4 Carotid Artery Intima-media Thickness (IMT)
The left common carotid was imaged 1 cm proximal to the bifurcation.
Longitudinal images of the far wall intima-media interface (M-line) were clearly
defined and recorded on videotape for later analysis. The distance between the
leading edge of the intima and the media-adventitia was measured with ultrasonic
calipers (Chapter 1, Figure 1.4). Three measurements were taken in both the
right and left common carotid and mean IMT calculated as described.590 Briefly,
video frames were digitized using a video frame grabber and assessed with
software incorporating an edge-detection algorithm specifically designed for use
with ultrasound scanning that enables automatic detection, tracking, and
recording of the lumen/intima and media/adventitia interfaces.591 The distance
from the leading edge of the first to the second echogenic line was measured as
posterior wall IMT.46
5.3.1.5 Pulse Wave Velocity
Pulse wave velocity measures the velocity of the blood pressure pulse
waveform.592 A pressure tonometer (SPC-301 Millar Instruments, Houston,
Texas, USA) was used to record the pulse pressure waveform transcutaneously
in the underlying artery. This was recorded simultaneously with an ECG signal,
which provided an R-timing reference. Pulse pressure recordings were
performed consecutively at two superficial artery sites. Integral software was
applied to process each set of pulse pressures (Sphygmocor version 7.1,
Scanmed, UK). The software uses ECG waveform data to calculate the mean
time difference between the R-waves and the pressure waves on a beat-to-beat
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basis. Pulse wave velocity is calculated using the mean time difference and
arterial path length between the two recording points.
5.3.2 Biochemical and hematological cardiovascular risk factors
Blood was obtained by venepuncture between 0900 and 1100 after an overnight
fast. Biochemical and haematolgical risk factors for CVD were measured
including fasting insulin, glucose, lipid profile and C-Reactive Protein (CRP).
These measurements were carried out in the laboratories of Great Ormond Street
Hospital, London according to SOPs. Red cell and plasma concentrations of n-3
LC-PUFA were determined before and after the intervention using standardized
methods in the laboratories of Professor von Schacky (omegametrix) and
expressed as a percentage of total fatty acids.
5.3.3 Anthropometry
Height, weight, waist, hip and limb circumferences were measured using
standard equipment and protocols.
5.3.3.1 Height, weight and BMI
Height was measured using a portable stadiometer accurate to 0.1 cm (Holtain
Instruments Ltd., Crymmych, UK) and weight using electronic scales accurate to
0.1kg (Seca Instruments, Hamburg, Germany). Body mass index (BMI), defined
as the individual's body weight divided by the square of his or her height was
calculated using Quetelet’s formula Body mass (kg) / Height (m) 2. 593
5.3.3.2 Limb circumferences
Waist, hip and limb circumferences were measured using a non-stretchable,
calibrated tape measure (Chasmors, London, UK). All limb circumferences were
measured on the left side of the body to achieve standardisation. Procedures
were repeated 3 times and the best mean measurement used in analyses.
5.3.4 Body composition
5.3.4.1 Measurement of Skinfold Thickness
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Triceps, biceps sub-scapular and supra-iliac skinfolds were measured in
duplicate on the left side of the body using skinfold calipers (Holtain Instruments
Ltd., Crymmych, UK) and the mean value obtained.
5.3.4.2 Estimation of body fat from skinfold thickness
Percentage body fat was estimated from the sum of skinfold thickness at four
sites using prediction equations of Durnin & Womersley (1974) and Siri (1961).
594-596 The equations of Durnin & Wormsley use skinfold thickness
measurements to predict body density. Provided that body density is known
proportions of lean and fat mass can be estimated using Siri’s equation which
uses the generic equation first described by Brozek (1963).597 This equation is
based on Archimede’s Principle and allows the calculation of lean or fat free
mass and fat mass based on assumed densities of these two body compartments
where fat is assumed to have a constant density of 0.9kg/l and fat free mass of
1.1kg/l.
W1 = (1/D x (d1 x d2/d2-d1)) – d1/ (d2 – d1)
Where:
W1 = Fraction of fat
d1 = Density of fat
d2 = Density of fat free mass
D = Body density (body density/body volume)
5.3.5 Sociodemographic factors
5.3.5.1 Educational status
Educational status was categorised according to the possession or not of a
university degree.
5.3.5.2 Social class
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Social class was determined based on the subject’s occupation according to the
Registrar General’s Classification (OPCS, 1991).598 In this system five basic
social classes, recognised by the Office of Population Censuses and Surveys
(OPCS), are applied:
I Professional occupations
II Managerial and Technical occupations
III Skilled occupations
(N) non-manual
(M manual
IV Partly skilled occupations
V Unskilled occupations
In the present study a dichotomous division between manual and non-manual
workers was applied to allow useful comparisons with previous published studies.
Students were classified as non-manual.
5.3.6 Lifestyle factors
5.3.6.1 Smoking practice and alcohol consumption
Data describing lifestyle factors including smoking habits were collected using a
short questionnaire (Appendix 2-9). Smoking exposure was verified by
measurement of salivary cotinine. Salivary cotinine analyses were conducted in
the laboratories of Professor Martin Jarvis, ICRF Health Behaviour Unit,
Department of Epidemiology and Public Health, UCL, London. Alcohol
consumption was assessed using the same lifestyle questionnaire.
5.3.6.2 Physical Activity Level
Habitual physical activity was assessed using the International Physical Activity
Questionnaire (IPAQ) questionnaire.599 Cardiovascular fitness was assessed
using a standardized, height specific, step test before and after the intervention
as described by Francis and Feinstein (1991).600
5.4 Statistical methods
Initial analyses were conducted on an intention to treat (ITT) basis. Student’s
t-test was used to detect differences in continuous normally distributed data
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between n-3 LC-PUFA supplemented and non-supplemented groups.
Chi-squared was used for dichotomous variables.
Secondary analyses include 1) multiple regression analyses to assess
differences between randomized groups after adjusting for possible differences in
baseline variables with potentially confounding effects (e.g. age, gender,
temperature, fasting serum lipids), 2) effects of n-3 LC-PUFA supplementation in
sub-groups such as smokers and 3) adjustment of the primary analyses for
factors thought to change with n-3 LC-PUFA supplementation (such as a
potential change in the lipid profile). The distributions of fasting VLDL,
triglyceride, insulin, CRP and cotinine concentration and sum of skinfold
thickness were right skewed and so were loge transformed and then multiplied by
100 prior to analysis.601 The standard deviation for 100 loge transformed data
represents the coefficient of variation of the original data, while coefficients
represent the percentage difference in absolute FMD per unit change in the
independent variable.
A dose-response relation between n-3 LC-PUFA levels and vascular function was
investigated by regressing vascular outcomes against n-3 PUFA concentration.
Multiple regression analysis was used to assess associations between changes
in vascular function with change in red cell n-3 LC-PUFA concentrations following
supplementation.
All analyses were conducted in SPSS for Windows (version 18.0; SPSS Inc.
Chicago) with statistical significance level at P < 0.05. Professor T J Cole at the
Institute of Child Health reviewed the statistical methods and sample size
calculations.
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Chapter 6
Validation and Dietary Assessment Methods
He who knows nothing is closer to the truth than he whose mind is filled with
falsehoods and errors.
Thomas Jefferson
6.1 Introduction
In recent years, nutritional scientists have recognized that the complexity of diet
and inherent errors in methods that aim to accurately describe the magnitude of
intake of individual foods and nutrients preclude wholly accurate assessments
using quantitative methods. Qualitative dietary assessment methods may
therefore be preferable to quantitative methods (Chapter 4, section 4.4.2). Over
the past decade dietary pattern analysis has emerged as an alternative or
complementary approach to examine the relationship between diet and the risk of
chronic diseases. In view of this, the present study aims to describe dietary
patterns within this group of young adults residing in the UK. It further aims to
investigate relationships of dietary patterns and components within it with study
outcomes.
The EPIC FFQ was one chosen dietary assessment tool in this study because it
has been validated in a similar UK population (Chapter 4, Section 4.7.1).
Furthermore, it has been used in previous studies undertaken by our research
group, in members of this population at a younger age where relative validity was
assessed using red cell folic acid as a biomarker.602 Permission was sought to
adapt the FFQ for use in the current study from the EPIC management
committee at the Strangeways Research Laboratory, University of Cambridge for
which full approval was given.
When considering specific dietary components within ‘prudent’ and
Mediterranean style dietary patterns strong evidence supports a protective role
for n-3 fatty acids and in particular n-3 LC-PUFA of which good dietary sources
include fish and fish oils. Therefore, it was hypothesized that dietary patterns
have an important role in the development of CVD and that n-3 LC-PUFA, in
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particular, may be beneficial to vascular health. A further major aim of this
dietary study therefore was to assess relationships between dietary n-3 LC-PUFA
and the earliest signs of CVD. This requires a valid method for dietary
assessment of n-3 LC-PUFA that is currently unavailable in the UK.
Assessment of dietary intake is an essential requirement of all studies
investigating relationships between food or nutrient exposure and health
outcomes and, as discussed in Chapter 4, Section 4.3, reliable dietary
assessments should be integral to research protocols because public health
recommendations should only be based on findings from studies that include
valid measures of nutritional intake. It is also important in clinical practice where
accurate dietary assessment is needed to allow practitioners to formulate
appropriate nutritional advice that aims to redress nutritional deficiencies or
excesses.
Methods available for evaluating n-3 LC-PUFA are scarce and there is a need for
a cost effective, non-invasive method that can be used in research and clinical
practice. Any new dietary assessment instrument must be compared to a
method that has been shown to have acceptable validity (Chapter 4,
Section 4.6). Although there are FFQs available which have been validated
amongst the UK population none is available that has been assessed objectively
for measuring dietary n-3 LC-PUFA intake. A major aim of this dietary study
therefore was to develop a FFQ for estimating n-3 LC-PUFA in this healthy young
UK population.
Erythrocyte membrane fatty acid concentration was assessed to provide an
objective measure of fatty acid status and verify compliance with supplementation
during the RCT. This also provided a biomarker of fatty acid intake against which
dietary assessment methods could be compared. A further aim of this study was
to investigate relationships between dietary n-3 LC-PUFA, estimated by dietary
assessment methods, and fatty acid status, determined by biomarker status, with
study outcomes including measures of vascular health and markers of CVD risk
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6.2 Dietary Assessment Methods
6.2.1 EPIC FFQ
Dietary assessment with the EPIC FFQ was undertaken as part of the RCT to
assess possible dietary change that may confound effects of supplementation
and/or influence CVD outcomes under study. A further aim was to analyse
dietary patterns in the study population to study relationships with CVD
outcomes.
The EPIC FFQ is a 10-page A-4 booklet designed to measure a participant's
usual food intake during the previous year. An example page is included in
Appendix 3-1. The FFQ consists of two sections: 1) a main section containing a
list of 130 foods and 2) a list of supplementary questions. Participants are asked
to indicate their usual frequency of consumption ranging from "never or less than
once/month" to "6 times per day" by ticking a box in one of nine frequency
categories (Figure 6-1). Example serving sizes are suggested based on
standard portions or household measures. For example, one piece of fruit, one
slice of bread, a glass of fruit squash, a cup of tea, or a tablespoon of cream.
The second section, at the back of the booklet, comprises 16 additional questions
on type and brand of everyday foods and cooking methods. For example, the
usual breakfast cereal eaten and type of milk used; whether visible fat was
removed from meat before cooking; the type of fat used in cooking and the
preferred method e.g. frying, roasting, grilling or baking.
Figure 6-1 Example line entry from EPIC FFQ
6.2.1.1 Administration of EPIC FFQ
The EPIC FFQ and a newly developed FishFQ (Section 6.3) were administered
both at baseline and following the 4 month supplementation period. The order in
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which questionnaires were given was determined by a randomisation procedure
to reduce the risk of bias. The same researcher administered the questionnaires
at the two study visits to reduce inter-operator variability. All members of the
research team were trained by me, a registered dietitian, in the administration of
the FFQ.
The first FFQ was explained to participants in full by a member of the research
team. Participants were left to complete the questionnaire alone, but encouraged
to ask for assistance if needed from the research team member allocated to their
dietary assessment, and who checked for completeness of entry after
completion. After completion of the first FFQ participants were given a short
break before the 2nd questionnaire was administered.
6.2.1.2 Development of analysis methods for EPIC FFQ
Questionnaires used in EPIC have been designed to work in conjunction with
specific supporting programmes. However, commercially available programmes
(e.g. CompEat (Carlston/Bengston) and Microdiet (Downlee systems) can also be
used effectively. In the present analysis, a dietary analysis instruction manual
was produced by me to use when converting dietary intake data collected with
the EPIC FFQ to nutrient data using the Microdiet nutritional analysis programme
version 2.8.8 (Appendix 3-2).
Research assistants were provided with the dietary analysis instruction manual
and fully trained in its application. The manual provided concise instructions for
selecting foods based on information given in the EPIC FFQ, including the
additional questions. Detailed food lists are given with corresponding food codes
drawn from McCance and Widdowson’s data on the composition of foods and its
supplements, produced by the UK Royal Society of Chemistry (Chapter 4,
Section 4.5.3.4). Participants were asked to indicate usual portion size by
comparison with photographs in the Ministry of Fishery and Foods (MAFF)
photographic atlas of food portion size.603 Where portion size information was
available this was used to estimate the amount in grams usually consumed of a
given food. Where no specific portion size information was available the
standard portion size was used.604
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A Microsoft excel template was created for calculation of food amounts in grams
consumed daily. The procedure is described in detail in Appendix 3-2. Briefly,
the amount in grams representative of either a standard or reported portion size
was entered to the excel template. A multiplication factor representing frequency
of intake was applied to give an average amount of food consumed daily. Food
codes were used to locate foods indicated as regularly consumed in the Microdiet
nutritional analysis programme. Once the appropriate food was recalled, the
amount consumed daily in grams, as calculated using the excel template, was
entered to the nutrient database.
6.3 FishFQ
Food frequency questionnaires which have been validated against various
biomarkers are available in the UK. However, to my knowledge there is only one
published validation study of a FFQ designed to measure n-3 LC-PUFA552 and
none is available that has been assessed objectively against a biomarker. As
discussed in Section 6.1 a major aim of this study is to develop and validate a
new FFQ (FishFQ).
6.3.1 Design of FishFQ
A prototype FishFQ was designed which focused on foods with the highest
concentration of n-3 LC-PUFA (Appendix 3-3). The questionnaire was adapted
from the EPIC FFQ, described in Section 6.2.1, which has been previously
validated for use in a population of similar age. The EPIC FFQ combines fish
and fish based foods in 6 line entries: fried fish, fish and fish cakes, white fish,
oily fish, shellfish and fish roe. The FishFQ allows separation of these foods and
also includes additional foods that contain significant amounts of n-3 LC-PUFA.
A food is considered a "good source" of a specific nutrient if it contains 10% more
of the daily value for a given nutrient than the comparison food.605 However,
there are no specific DRVs for DHA or EPA and therefore good sources cannot
be described in this way. For the purposes of this study, we included sources of
n-3 LC-PUFA identified through the most recent National Diet and Nutrition
Survey (NDNS) available at the time of study.606, 606606, 606606, 606606, 606606, 606606,
606606, 606606, 606606, 606606, 606606, 606606, 606605, 605606 Twenty-seven items were included
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in the original questionnaire which included seven frequency categories ranging
from never to more than twice daily.
6.3.2 Evaluation of FishFQ
The FishFQ was given to a sub-set of 20 participants who had agreed to take
part in the DHA supplementation RCT. After completing the questionnaire,
participants were asked to complete an evaluation form designed to assess
understanding and ease of use of the FishFQ. The evaluation form comprised
seven questions that addressed clarity, length and content, and asked whether
participants could complete the questionnaire unaided. One further question
sought the opinion of participants on the usefulness of assistance given by
researchers. The evaluation form can be found in Appendix 3-4 and results are
presented in Table 6-1.
Almost all participants (18/20, 90%) asked to evaluate the FishFQ thought the
content was clear, and (19/20, 95%) found it easy to understand. All indicated
that length was appropriate and only two people need further explanation and
assistance. Just over half said all foods that participants expected to be on the
questionnaire were included and 16 out of 20 said foods they usually ate which
they thought were sources of n-3 were not included. A summary of foods
expected to be included or eaten but excluded are listed in Box 6 below. All
participants indicated that explanations and help given by the research team
were adequate.
Box 6 Foods expected to be included or omitted from FishFQ
Expected but omitted Eaten but not included
Sunflower seeds/oil Omega 3 spreads
Canned tuna Omega 3 milk
Canned Herring Omega 3 yoghurt
Canned kipper Omega 3 eggs
Canned Mackerel
Skippers (Brisling)
Following evaluation, the questionnaire was amended to include foods reported
to be regularly eaten and that were sources of n-3 LC-PUFA. This included foods
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fortified with n-3 fatty acids, that were not included in the EPIC FFQ, and were
not available when data collection for the NDNS (2003) took place (Appendix
3-5). All oily fish were presented as either fresh or canned as some participants
reported consuming both types. Skippers (Brisling or Spratts), a small herring,
were included because they were reported to be consumed by three participants
during the evaluation. Supermarket reconnaissance and discussion with
manufacturers confirmed these as a popular product among consumers. Portion
size estimates were obtained by administering the FishFQ in conjunction with a
portion size booklet. The booklet was designed as part of this study and included
colour photographs of foods included in the FishFQ (Appendix 3-6). Foods were
photographed on standard dinner plates and a range of portion sizes were
included corresponding to small, medium and large portions as described.604
The amended questionnaire was designed in teleform (Cardiff software) scanned
data entry system to facilitate ease of data entry. The new FFQ included 31
items and a column where portion size could be clearly indicated. Nine
frequency choices were given for each food: never; one to two per month; one
per week; two to four per week; five to six per week, one per day two to three per
day, four to five per day, five to six per day. The higher frequencies were added
to accommodate newly emerging omega 3 enriched foods, for example milk, that
may have been consumed more frequently.
6.3.3 Administration of FFQ
The FishFQ was administered prior to and following supplementation.
Participants were asked to record how often on average they consumed each
item during the past year. The FFQ was adapted from the EPIC FFQ and
allowed separation of n-3 foods which were previously grouped together and
thereby aimed to improve estimates of intake. As for the EPIC FFQ, the
questionnaires were completed whilst the subject attended the research centre
and assistance was given, when requested, from myself or other trained
researchers (dietitians and nutritionists) who checked for completeness of entry
after completion.
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6.3.4 Analysis Methods of FFQ
The FishFQ was analysed in accordance with the dietary analysis manual
described in Appendix 3-2, Section 6.3.2. Two spreadsheets were designed in
Microsoft excel to provide templates for conversion of frequency data to amount
in grams of daily food consumption. Frequencies were multiplied either by
amounts in grams according to standard portion sizes604 or according to portion
sizes depicted in the omega-3 portion size booklet (Appendix 3-6).
6.3.5 Interim analyses
6.3.5.1 Agreement between dietary assessment methods
After administration of the FishFQ and the EPIC FFQ to the first 100 study
participants agreement between the two questionnaires was assessed using the
Bland and Altman (1986) technique.607 This method of analysis assesses
agreement of methods in groups, which is defined as the bias, and also assesses
agreement in individuals, defined as the limits of agreement (± 2 s.d. of the bias).
The relative bias was calculated as the mean difference in DHA and EPA intake
between the two FFQs. Results of the Bland and Altman analysis are reported in
Chapter 10, Section 10.3.1.
6.3.5.2 Agreement between portion size estimates
Agreement between standard and reported portion size estimates was also
assessed using the Bland and Altman technique. Results are reported in
Chapter 10, Section 10.3.2.
6.4 24-Hour Recall Method
6.4.1 Introduction
The 24-hour recall method was used to assess dietary intake in a sub-group of
participants. This method was included to provide a reference dietary
assessment method for validation of the newly developed FishFQ. Validity was
assessed using the method of triads – an estimating technique used in path
analysis (Section 6.5.4.1).
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6.4.2 Design of 24 hour recall method
The aim was to collect at least five days of 24-hour dietary recalls from willing
participants. During visit 1, the procedure for collection of 24-hour dietary recalls
was explained and only participants available and amenable to researchers
contacting them during evenings and weekends to conduct telephone interviews
were included. A dietary recall form was designed for the study based on a
previous form used in the INTERnational Study of Macronutrients, Other Factors
and Blood Pressure (INTERMAP) study. The form was designed to capture
information relating to 1) meal type, e.g. whether home prepared or eaten out, 2)
foods and drinks consumed during eating episode, 3) preparation methods, e.g.
use of fat and salt and 4) cooking methods. A column for the addition of a food
code was included and two extra columns allowed entry of either a standard
portion size (wt 1) or portion size estimated from selected food photographs from
the MAFF Photographic Atlas (wt 2).
6.4.3 Administration of 24-hour Dietary Recall
Twenty four hour recalls were collected during telephone interviews conducted by
research assistants who were qualified dietitians, nutritionists or dietetic
assistants as described previously.480-482 Morgan and colleagues (1987)
compared the use of telephone with personal interview dietary assessments and
concluded that the telephone interview provided comparable data with less effort
and cost. Response rates were 71-81 percent for telephone interviews compared
with 72–83 percent for personal interviews.483
Research assistants were trained by myself, a registered dietitan, who was
experienced in collection of dietary data in both clinical and research settings.
Participants were allocated sequentially to a research assistant who then
attempted to collect 7 recalls from each subject. Data collectors were asked to
obtain records representing each day of the week if possible. A summary sheet
was provided where research assistants could record progress in obtaining
records and monitor collection attempts.
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6.4.4 Analysis of 24-hour dietary recalls
Analysis of 24-hour recall was carried out by nutritionists and dietitians based at
the Strangeways Research Laboratory, University of Cambridge. This centre
was chosen because it uses a purpose built programme for analysis of 24 hour
recalls – Data Into Nutrients for Epidemiological Research (DINER).608 This
method uses data from McCance and Widdowson’s composition of foods
complemented with additional data from reliable sources. For example, only
about 30% of foods in McCance and Widdowson’s Composition of Foods have
been analysed for fatty acid content. When a food described on a dietary recall
form is entered and information on fatty acid content is unavailable, DINER uses
a mapping procedure to identify similar foods that do contain this information.
6.5 Validation of Dietary Assessment Methods
To assess compliance with the RCT protocol, we examined how supplementation
with DHA was reflected in the concentration of fatty acids in erythrocyte (red
blood cell [RBC]) membranes. To assess validity of dietary assessment methods
used in the study, we evaluated relationships between dietary fatty acids
measured against the EPIC and Fish FQs with multiple 24-hour dietary recalls
and biomarkers of fatty acid status.
6.5.1 Biomarkers of fatty acid status
Biomarkers of fatty acid used in the present study included the n-3 LC-PUFAs
DHA and EPA both separately and combined to provide an omega-3 index. The
omega-3 index is defined as EPA+DHA as a percentage of total RBC fatty acids
and has been proposed as a risk factor for CHD.609 The scientific basis for this
comes from two major studies where RBC EPA+DHA concentrations were
correlated with primary risk of cardiac arrest.360, 362 In both studies the risk of
sudden cardiac death was reduced by 90% in subjects with the highest compared
with the lowest n-3 concentrations. Harris and colleagues further propose cut-
points can be used to identify individuals at low, intermediate and high risk based
on their omega-3 status.609 Dose response studies were used to explore effects
of supplementation with EPA+DHA on RBC concentration. Doses of 500 and
1000 mg taken for 5 months achieved n-3 indices of 8 and 10% respectively.
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Applying these levels to results from previous studies it was estimated that a
cardioprotective effect was present at an index of 8% and the greatest risk of
CHD death was associated with an index below 4%. Intermediate risk fell
between these two points.610
6.5.2 Comparisons of EPIC FFQ with 24-hour recall and biomarker
A total of 324 subjects consented to participate in the RCT. All subjects agreed
to complete the EPIC FFQ at baseline. Questionnaires were assessed for
completeness and only one subject was excluded on the basis of an incomplete
EPIC questionnaire.
6.5.3 Comparisons of EPIC FFQ with biomarkers of fatty acid intake.
RBC fatty acid concentration was measured in 268 participants. Two hundred
and thirty two subjects completed the FFQ at baseline (visit 1) and post
intervention (visit 2). Please see Chapter, 10, Figure 10-4 for flow of subjects
through the dietary assessment study. There were no reports of supplements
containing fish or fish oils being used, therefore fatty acid intakes represent intake
from food alone. Intakes of fatty acids assessed with the EPIC FFQ were
adjusted for energy intake in regression analyses.
6.5.4 Validation of FishFQ
Validation of the FishFQ was achieved by comparing intake of DHA, EPA and
combined DHA+EPA (omega-3 index) as estimated by 5 days of dietary recall
and biomarkers (fatty acids as percentage total red blood cell membrane (RBC)
fatty acids). Therefore, only subjects who completed all these dietary
assessments were included in the validation study. Eight subjects were excluded
on the basis of inadequate completion of the FishFQ. Therefore 78 subjects
were included in the FishFQ validation study.
6.5.4.1 The Method of Triads
Studies assessing the relative validity of dietary questionnaires usually include a
reference dietary assessment method such as weighed records or multiple 24-
hour recalls of dietary intake. The correlation between measurements obtained
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using questionnaires (Q) and the subject’s true long-term intake (T) of foods or
nutrients can be estimated from the correlation between the two dietary
assessment instruments to provide a validity coefficient (pQT). As discussed in
Chapter 4, Section 4.5.3, however, random errors may introduce bias because
the same factors that affect the reference method may also affect the new
method under test.
Validation studies assume random errors between dietary assessment methods
are uncorrelated although in practice this is rarely the case, and inter method
correlations may be over-estimated.611 The use of biochemical markers in dietary
assessment studies reduces the risk of bias because random errors are likely to
be independent of those attributed to questionnaires and food records. The
problem of correlated errors can therefore be overcome with the use of triangular
comparisons. The present analysis applies the method of triads to assess
agreement between the new method (Q) (FishFQ), the reference dietary
assessment method (R) (24-hour recall) and the biochemical marker (M) (RBC
fatty acid concentration).
Triangular comparisons make the assumption that random errors are
independent but that each measurement has a linear relationship with the truth.
Structural equations can be applied to evaluate the contribution of systematic
scaling biases as described by Loehlin (2009).612 For investigations where
estimates of correlations between questionnaire measurements and true intake
values are required the method of triads can be applied (Figure 6-2).
Figure 6-2: Triangular comparisons between the questionnaire (Q),
reference method (R) and biochemical marker (M) using the method of
triads.
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Pearson’s correlation coefficients were calculated between the two dietary
assessment methods and between each dietary assessment and the biomarker
(i.e. FishFQ and 24-hour recall; FishFQ and biomarker; 24-hour recall and
biomarker). Correlations were evaluated as poor (r < 0.2), moderate (r = 0.2–0.6)
or good (r > 0.6).555
6.5.6 Classification into thirds of the population distribution
Agreement on category level between n-3 fatty acid intake estimated using the
EPIC and FishFQ and RBC concentrations was examined by classification into
appropriate portions of the distribution of intake and membrane concentration
respectively. The proportions of individuals classified in the same third of the
distribution (exact agreement) and into extreme thirds of the distribution (gross
misclassification) were calculated using descriptive statistical procedures to
identify cut points for equal thirds of the distribution. The crosstabs facility was
used to tabulate results.
6.5.7 Assessment of Reliability
Reliability of the EPIC and FishFQ was tested by administering the same dietary
questionnaires at baseline and 4 months later. Pearson’s correlation coefficients
were calculated to assess reproducibility.
6.5.8 Regression Analyses
General linear modelling was used to investigate relationships of dietary patterns
and n-3 fatty acids with measures of atherosclerosis and CVD risk factors. DHA
and EPA status was assessed through measurement of red cell membrane fatty
acid concentrations. Dietary patterns were derived using principal component
analysis (PCA) as described below.
6.5.9 Principal Component Analysis
Principal component or factor analysis is a mathematical technique, introduced
by Spearman (1904), which can be applied to reduce a complex dataset of many
components to a smaller set with fewer variables. PCA identifies linear
combinations of the original observed variables on the basis of a correlation
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matrix that accounts for most of the total variance in the data. Coefficients of
variation which define the linear combinations are termed ‘factor loadings’ and
represent the correlations of the variables in the original dataset. A large factor
loading indicates a variable is strongly associated with its component. The first
principal component extracted accounts for most of the variance in the sample.
Successive components explain the remaining variance and each component is
independent of others.
Extracting the optimum number of components is a challenge and several
selection methods have been proposed. The Cattell (1966)613 scree test and the
Kaiser (1960)614 rule are the most often used procedures to determine the
number of components. They are both based on inspection of the correlation
matrix eigenvalues which are calculated as the sum of each squared factor
loading for a given component. Cattell's recommendation is to retain only those
components above the point of inflection on a plot of eigenvalues ordered by
diminishing size. This allows a cut point to be set for selection of components
based on a visual trailing of factors on the plot (Figure 6-3).
Dietary data were collected using the EPIC FFQ as described in Section 6.2.1.1.
For deriving dietary patterns food items were re-classified into food groups based
on similar nutrient content and common usage. 52 food groups were identified
for further analysis. The sum of foods and beverages within each of the 52 food
groups was calculated to provide a total daily frequency of intake for foods or
beverages assigned to each food group.
Several food and beverage items were not categorized into food groups as they
were thought to reflect specific dietary behaviours (e.g. coleslaw, juice, tea, liver,
liver sausage, chicken or other poultry, fish roe). They were left as separate
items. Principal components analysis was conducted to identify the main dietary
patterns from the included food items.
All food groups entered in the PCA were expressed as the sum of daily frequency
of use. The first PCA on the 52 food groups was performed to produce a scree
plot of eigenvalues of the derived factors as described earlier. Three factors
were retained for further analysis based on the scree plot.
Figure 6-3: Scree plot for Principal Components Analysis of dietary data
collected at baseline using the EPIC FFQ
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was conducted on these three components to derive factor
ld allow interpretation of dietary patterns. The size of the factor
group within a component characterises its contribution to the
e. a larger food loading identifies a greater contribution of a
oup to a specific factor. To improve interpretability and minimise
etween the factors, factors were rotated with an orthogonal
.
pattern was characterised by high daily intakes of all kinds of
fruits, other fruits, oily fish, nuts, vegetarian foods, low fat dairy
als. The second factor was characterised by processed meats,
ducts, non oily fish products, savoury pies, combination meals,
oultry and the third factor was characterised by confectionary,
venient fish products, biscuits and cakes, potato products and
ks (Table 6-2). A merged table consisting of the food group
or scores was constructed and quintiles according to dietary
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pattern scores were calculated. Cut points for 5 equal groups were calculated
using the frequencies command in PASW statistics, version 18 and new variables
were created using the transform command.
6.5.10 Assessment of normality
Distributions of fasting VLDL, triglyceride, insulin, CRP and cotinine
concentrations and sum of skinfold thickness were right skewed and so were loge
transformed and then multiplied by 100 prior to analysis.601 The standard
deviation for 100 loge transformed data represents the coefficient of variation of
the original data, while regression coefficients represent the percentage
difference in outcome per unit change for the independent variable.601
6.5.11 General Linear Modelling
Linear regression was used to calculate unadjusted means of participant
characteristics, measures of vascular structure and function and CVD risk factors
in each quintile of dietary pattern score. In addition to the unadjusted analysis,
multivariate linear models were used to assess relationships between outcomes
and quintiles of dietary pattern score. Model 2, adjusted for age and sex, social
and lifestyle factors, total energy intake and CVD risk factors known to affect
outcomes including blood pressure, fasting lipid and insulin concentrations and
measures of obesity. Results of analyses of relationships between dietary
patterns and CVD risk factors are reported in Chapter 8.
Effects of dietary fats on health have been the subject of much diet-disease
research. In particular, as discussed in Chapter 3, health benefits associated
with long-chain n-3 LC-PUFA consumption have been widely reported.330
Although a large body of observational and experimental evidence supports the
hypothesis that these fatty acids are protective against secondary prevention of
CHD (Chapter 3, Section 3.5.1), and observational evidence further suggests
benefits for primary prevention of CVD (Chapter 3, Section 3.3), no experimental
studies have been conducted to investigate the hypothesis that n-3 LC-PUFA
protects against the development of atherosclerosis in healthy young adults.
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The present RCT was designed specifically to investigate the hypothesis that
supplementation with DHA benefits vascular function and is therefore protective
against development of primary CVD. Biochemical markers of fatty acid status
obtained as part of the RCT allowed investigations into associations of fatty acid
status with vascular health and CVD risk factors. Data obtained from red cell
membrane fatty acid analysis, as described in Chapter 5, Section 5.2.6.3 were
re-coded into quintiles of fatty acids expressed as a percentage of total red cell
membrane fatty acids (Chapter 5, Section 5.2.6.3).
The development of validated dietary assessment methods within the RCT also
allowed investigation of dietary exposures and CVD risk factors. Data were
sorted to quintiles of fatty acid intake according to dietary assessment using the
EPIC FFQ at baseline. The EPIC questionnaire was chosen in preference to the
new questionnaire as this provided the greatest subject number. Multivariate
linear regression was used to investigate relationships between n-3 LC-PUFA,
vascular structure and function and CVD risk factors. The same 2 multivariate
linear models were used to assess relationships between these outcomes and
quintiles of n-3 LC-PUFA intake according to dietary assessment and biomarker
status. Results of these analyses are reported in Chapter 9.
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Table 6-1 Evaluation of FishFQ
Strongly
Agree
Agree Disagree P
Content clearly explained 12 6 2
Easy to understand 14 5 1
Acceptable Length 10 10 0
Assistance required 2 0 18
Foods expected present 3 8 9
Foods expected missing 3 1 16
Explanations and help from
researchers
Excellent Good Fair Poor
5 13 2 0
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Table 6-2 Factor loading of various food items in the three principal components
identified (loadings above 0.25 are shown in bold)
Dietary Patterns
Food Item Health Conscious Meat Based Snack
Green Leafy Vegetables 0.686 0.007 0.004
Yellow Vegetables 0.569 -0.147 -0.040
Cruciferous vegetables 0.516 0.058 0.116
Alium Vegetables 0.388 0.148 0.244
Beans and Legumes 0.473 0.107 0.120
Other vegetables 0.645 0.035 0.160
Fresh Fruits 0.590 -0.084 0.077
Citrus Fruits 0.394 -0.067 0.038
Other Fruits 0.486 0.017 0.001
Tomatoes 0.401 0.471 0.033
Oily fish 0.465 -0.101 0.055
Non-oily fish and seafood 0.391 -0.091 0.328
Non-oily fish products 0.172 0.509 0.002
Convenient Fish Products -0.040 0.065 0.533
Red Meats 0.093 0.446 0.309
Processed meats -0.124 0.666 0.089
Organ meats 0.001 0.309 -0.065
Poultry 0.143 0.434 0.158
Eggs and egg products 0.170 0.172 -0.021
High-fat dairy products 0.047 0.587 -0.070
Low-fat dairy products 0.256 0.205 0.132
Nuts 0.318 -0.075 0.206
Vegetarian foods 0.300 -0.223 -0.162
Cereals 0.240 -0.028 -0.049
Whoegrain/meal products 0.322 0.338 0.014
Refined Grain Products -0.259 0.332 0.356
Potato Products 0.073 0.248 0.477
Combination meals -0.029 0.456 0.376
Savoury Pies -0.121 0.468 .143
Soups 0.278 0.235 0.085
Saturated fats -0.044 0.311 0.003
Polyunsaturated fat -0.070 0.170 0.108
Spreads (regular) -0.106 0.182 0.204
Spreads (low fat) 0.028 0.019 0.195
Low-fat dressings/sauces 0.388 0.186 0.069
High fat dressings/sauces 0.104 0.409 0.135
Coleslaw 0.152 -0.012 0.353
Salty snacks -0.161 0.255 0.581
Confectionary 0.041 -0.064 0.650
Biscuits and cakes 0.029 0.100 0.493
Dairy Dessert 0.098 0.231 0.347
Sugars and Preserves -0.175 0.178 0.264
High Energy Drinks -0.002 0.096 0.402
Low Energy Drinks 0.156 -0.168 0.288
Condiments 0.136 -0.043 0.241
Juice 0.172 0.227 0.167
Tea -0.019 0.216 -0.060
Coffee 0.058 -0.099 0.314
Chocolate Drinks 0.146 -0.047 0.306
Beer -0.071 0.213 -0.062
Wine 0.209 0.021 0.023
High alcohol beverages 0.102 -0.039 0.149
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Chapter 7
Docosahexaenoic Acid Supplementation, Vascular
Function and Risk Factors for Cardiovascular Disease; a
Randomised Controlled Trial in Young Adults
Our body is a machine for living. It is organized for that, it is its nature. Let life go
on in it unhindered and let it defend itself, it will do more than if you paralyze it by
encumbering it with remedies.
Leo Tolstoy
Section 3: Results
7.1 Introduction
Increased fish consumption has been shown to reduce the risk of CVD in both
epidemiological studies275, 327, 328 and RCTs329-331 (Chapter 3, Section 3.1). In
Chapter 2, Section 2.5.2.2 a comprehensive review found that beneficial effects
on vascular function are associated with dietary LC-PUFAs, in particular with
EPA (20:5n-3) and DHA (22:6n-3). It is well established that high intakes of n-3
LC-PUFA have antithrombotic effects that operate through the production of less
pro-inflammatory eicosanoids.382 However, such effects require high doses
(~15g/d) that are considered pharmacological and outside of the normal dietary
range (1-2g/d).
Alternative mechanisms that involve n-3-LC-PUFA include effects on endothelial
function. Metabolites derived from EPA and DHA may have protective roles
during endothelial activation but exact mechanisms remain elusive. In particular
DHA has been associated with improved endothelial function. In a previous
study we reported associations between greater erythrocyte membrane DHA
concentrations and endothelial function assessed using the FMD technique. In
smokers, n-3 fatty acids were positively related to flow-mediated dilatation (1%
increase in plasma DHA was associated with 0.045 mm (0.5 SD), 95% CI: 0.011,
0.079, increase in FMD [P = 0.01]).568
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To our knowledge, the current study is the first RCT to assess effects of DHA
supplementation on endothelial function in healthy young adults.
7.2 Methods overview
The hypothesis that supplementation with DHA improves endothelial function and
CVD risk factors was tested in healthy volunteers (n=324) aged 18-37 years.
Participants were randomly assigned to receive either supplements providing
1.6g/d DHA suspended in 2.4g olive oil or placebo containing 4g olive oil/day.
Both oils were contained in gelatinized capsules and given as 8 x 500mg
capsules for 16 weeks (Figure 7-1).
274 subjects completed the intervention and FMD was measured in the brachial
artery before and after supplementation in 268 subjects (Figure 7-1). Methods
are reported in detail in Chapter 5.
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Figure 7-1 Flow of Participants Through Randomised Controlled Trial
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7.3 Results
The characteristics of the study population are summarized in Table 7-1. CVD
risk factors in this young population compared favourably with those reported for
the general adult population in the UK.615 For example, mean BMI for men in the
n-3 in Healthy Young People (N3HYP) study was 24 compared with 27 and for
women was 23 compared with 28 in the Health Survey for England.615
7.3.1 Baseline characteristics of study participants
Most (242/324, 75%) participants were of white Caucasian origin (Figure 7-2).
About one third (113/324; 35%) were currently students and most participants
(57%) were in non-manual occupations (Table 7-1).
Figure 7-2 Ethnicity of study participants
Both intervention groups were closely matched for demographic, anthropometric
and socio-economic variables, biochemical and cardiovascular risk facts and
vascular measures at the baseline (randomisation) visit (Tables 7-1 to 7-3).
7.3.2 Compliance and Monitoring
Subjects were sent weekly text messages to remind and encourage consumption
of dietary supplements. Monitoring was carried out throughout the intervention
period by weekly telephone calls where information on compliance and adverse
events was collected. Data were available from 274 subjects (138 control; 136
test). There were no serious adverse events in either group and the supplements
were well tolerated. The most commonly reported side effects of
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supplementation were mild gastrointestinal discomfort. These are summarized in
Table 7-4.
Compliance with dietary supplements was assessed by counting the number of
capsules returned at the end of the intervention period and by measurement of
DHA status expressed as percentage erythrocyte total fatty acids (RBC%FA).
DHA supplemented individuals had higher red cell DHA concentration post-
intervention compared with controls (Table 7-5). DHA supplemented subjects
had a significant increase in RBC omega-3 index (DHA+EPA RBC%FA) following
supplementation (mean pre-intervention 6.5%, post-intervention 10.2%,
P < 0.0001). There was no increase in omega-3 index in control subjects
following intervention (6.2% pre and post intervention, P = 1). A greater
proportion of DHA supplemented individuals had an omega 3 index greater than
8% following supplementation compared with baseline (76%, n = 100/131, 22% n
= 35/160 respectively, P < 0.0001).
7.3.3 Primary Outcome
After adjustment for baseline diameter, absolute FMD of the brachial artery was
significantly lower in the DHA supplemented group compared with controls (mean
difference: -0.03 mm; 95% CI: -0.005 - -0.06 mm [P = 0.02]) (Table 7-7).
Adjustment for known confounders (age, sex, skin and room temperature, LDL
and TG concentrations) did not attenuate the effect which remained significant.
Other vascular outcomes did not differ between randomised groups.
7.3.4 Secondary Outcomes
There was no difference in blood pressure or fasting concentrations of insulin,
glucose or CRP between randomised groups. However, fasting concentrations of
VLDL and TG were lower in the DHA supplemented group compared with
controls (mean difference for VLDL: -28%; 95% CI:-15, – -40%; [P < 0.0001];
mean difference for triglycerides: -28%; 95% CI: -15 - -40% [P < 0.0001]).
Dietary characteristics, based on food intake data collected using the EPIC food
frequency questionnaire, were similar to those of the UK adult population
(Table 7-6). Fat intake was similar to that reported in the National Diet and
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Nutrition Survey published just prior to commencement of the RCT.606 For both
men and women saturated fat intake was above UK COMA recommendations but
slightly lower than in the NDNS.159 Monounsaturated fatty acid intake was below
the recommended intake.
Dietary intake of total fat and fatty acid sub-fractions amongst the study
population, estimated from the EPIC FFQ were compared with COMA
(1991,1994) recommendations.159, 616 Current advice from the UK Scientific
Advisory Committee for Nutrition is to consume two portions of fish per week, one
of which should be oily. This would provide approximately 450mg/day n-3
LC-PUFA. Total long chain n-3 polyunsaturated fatty acids met the
recommended amount. Intake of the n-3 essential fatty acid alpha linolenic acid
met the recommended intake for men and women.
7.3.5 Secondary analyses
The effect of DHA supplementation on FMD (expressed both as the absolute
maximal change between pre- and post hyperaemic brachial artery diameter
adjusted for pre-hyperemic diameter and maximal percentage change in
diameter) was confined to men (Table 7-7).(randomised dietary group x gender
interaction: P = 0.01). Mean arterial blood pressure was lower in males in the
intervention group following supplementation (randomised dietary group and
gender interactions for mean SBP [P = 0.04]).
There were no significant differences in energy, macronutrient and fatty acid
intakes in randomised groups at baseline and after completing the intervention
(Table 7-8).
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Table 7-1 Subject Characteristics at Baseline
All Males Females
n 324 120 204
Age, y 27.9 4.7 18.4 – 37.1 29 4.7 19-36.8 27.2 4.7 18.4 - 37
2Male gender, % , 37 120 - - - -- - - -
2Social class*:
Manual, %, n 43 139 - 44 53 - 42 86 -
Non-manual, %, n 57 185 - 56 67 - 58 118 -
2Current smoker,%, n 13 43 - 12 14 - 16 32 -
Weight, kg 68.2 13.8 40.7 - 125.2 76 10.9 48.8 – 101.1 63.6 13.2 40.7 – 125.2
Height, cm 169.7 9.2 148.0 – 193.6 177.3 7.4 155.7 – 193.6 165.3 7 148 – 181.1
Body mass index, kg/m2 23.6 3.9 15.5 – 44.4 24.1 3 17.7 – 31.1 23.3 4.4 15.5 – 44.3
% fat‡ 24.0 5.6 10.6 – 39.1 23.4 5.2 13.9 – 35.1 24.3 5.7 10.6 - 39
3Sum skinfolds†, mm 44.7 41 16.0 – 127.7 40.4 41 18 - 103 52 38.6 16 - 128
Waist circumference, cm 77.3 10.1 58.2 – 130.8 83.4 8.1 62.3 – 101.9 73.7 9.5 58.2 – 130.8
Waist:Hip ratio 0.8 0.07 0.6 – 1.0 0.84 0.09 0.7 - 1 0.7 0.05 0.6 – 0.9
Blood pressure, mm Hg
Systolic 112 11 78 – 157 117 10 78 -148.7 109 10 87 – 157
Diastolic 67 8 44 – 98 69 8 53 – 94.3 65 8 44 - 98
Mean Arterial 84 9 61 – 126 87 8 73 – 120.3 82 9 61 - 126
Pulse Pressure 45 6 20 – 67 48 6.2 20 - 67 44 6 29 - 61
Resting heart rate,
beats/min
66 9 36 – 100 64 11 44 - 95 68 10 38 - 99
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All Males Females
n 324 120 204
Total cholesterol, mmol/L 4.2 0.8 1.0 – 7.6 4.3 0.8 2.4 – 7.6 4.2 0.8 1.0 – 6.8
LDL cholesterol, mmol/L 2.4 0.8 0.1 – 5.0 2.6 0.8 1.3 - 4.7 2.2 0.7 0.1 0 5.0
HDL cholesterol, mmol/L 1.4 0.3 0.7 – 2.7 1.3 0.3 0.7 – 2.3 1.5 0.3 0.7 – 2.7
3VLDL cholesterol 0.4 50 0.1 – 2.3 0.4 55 0.1 – 2.3 0.4 46.3 0.1 – 2.0
Total:HDL cholesterol ratio 3.1 1.0 0.7 – 6.8 3.5 1 1.8 – 6.4 2.9 0.9 0.7 – 6.8
LDL:HDL cholesterol ratio 1.8 0.8 0.1 – 5.1 2.1 0.8 0.8 – 4.7 1.6 0.8 1.6 - 0.8
3Triglyceride, mmol/L 0.9 50 0.3 – 5.0 0.9 55 0.3 – 5.1 0.8 46 0.3 – 4.4
Glucose, mmol/L 4.8 0.5 3.3 – 7.4 5 0.5 3.9 – 7.4 4.7 0.5 3.3 – 6.4
3Insulin, pmol/L 25.7 59 3.1 – 257.2 24 58 3.9 - 219 26.8 60 3 - 257
3Insulin resistance (HOMA) 0.8 63 0.1 – 10.3 0.7 63 0.1 - 10 0.8 64 0.08 – 10.3
3CRP, mg/L 1.0 121 0.1 – 27.4 0.8 114 0.1 - 15 1.1 124 0.1 – 27.4
3Cotinine, ng/ml 1.6 255 0.0 – 544 1.6 273 0.05 - 545 1.6 244 0.06 - 523
Data are mean, SD except: 1 range, 2% (n) and 3geometric mean (coefficient of variation). <5% loss of n for some variables. *According to the Registrar
General’s Classification (OPCS, 1995), †Measured at 4 sites: triceps, biceps, sub-scapular and supra-iliac.‡ Estimated from the sum of skinfold thickness
using prediction equations of Durnin & Womersley (1974) and Siri (1961).
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Table 7-2 Subject Characteristics at Baseline according to randomized dietary group
Control DHA Supplemented
All Male Female All Male Female
n 162 162
Age, y 27.6 4.7 29.0 4.6 26.6 4.5 28.2 4.8 28.8 4.8 27.9 4.7
2Male gender, % , n 40 65 60 97 34 55 66 107
2Social class*:
Manual, %, n 42 68 35 23 46 45 44 71 54 30 38 41
Non-manual, %, n 58 94 65 42 54 52 56 91 45 25 62 66
2Current smoker, n 14 23 12 8 15 15 13 20 9 5 14 15
Weight, kg 68.9 13.4 76.7 11.7 63.7 11.9 67.4 14.1 75.1 9.8 63.5 14.4
Height, cm 170.5 9.3 177.9 8.0 165.6 6.6 168.9 9.0 176.7 6.6 165.0 7.4
Body mass index, kg/m2 23.6 3.5 24.2 2.8 23.2 3.9 23.6 4.3 24.1 3.2 23.3 4.8
% fat‡ 23.9 5.6 23.3 5.4 24.3 5.8 24.0 5.5 23.6 5.1 24.3 5.7
3Sum skinfolds†, mm 48.4 39 42.3 39 53.0 36 46.4 43 38.7 43 51.0 41
Waist circumference, cm 77.5 9.7 83.6 8.0 73.4 8.5 77.1 10.6 83.0 8.4 74.0 10.3
Waist:Hip ratio 0.8 0.07 0.8 0.05 0.7 0.05 0.8 0.07 0.8 0.06 0.8 0.05
Blood pressure, mm Hg
Systolic 113 11 118 10 109 10 111 11 114 8 109 11
Diastolic 67 8 69 8 65 7 67 8 68 7 66 8
Mean Arterial 84 9 88 9 81 8 83 8 86 6 82 9
Pulse Pressure 46 6 49 6 44 6 44 6 47 6 44 6
183
Control DHA Supplemented
All Male Female All Male Female
Resting heart rate,
beats/min
66 9 65 9 67 8 66 10 63 8 67 10
Total cholesterol, mmol/L 4.2 0.9 4.3 0.9 4.1 0.9 4.3 0.8 4.4 0.8 4.3 0.8
LDL cholesterol, mmol/L 2.3 0.8 2.5 0.8 2.2 0.8 2.4 0.7 2.6 0.7 2.3 0.7
HDL cholesterol, mmol/L 1.4 0.3 1.3 0.3 1.5 0.3 1.5 0.4 1.3 0.3 1.5 0.4
3VLDL cholesterol 0.4 50 0.4 56 0.4 46 0.4 50 0.4 55 0.4 46
Total:HDL cholesterol ratio 3.1 1.0 3.6 1.0 2.8 0.9 3.1 1.0 3.5 1.0 2.9 0.9
LDL:HDL cholesterol ratio 1.8 0.8 2.1 0.9 1.5 0.7 1.8 0.8 2.1 0.7 1.6 0.8
3Triglyceride, mmol/L 0.8 50 0.9 55 0.8 46 0.9 50 0.9 55 0.8 46
Glucose, mmol/L 4.8 0.5 5.0 0.5 4.7 0.4 4.8 0.5 4.9 0.5 4.7 0.5
3Insulin, pmol/L 25.5 58 24.3 58 26.4 58 25.9 61 23.8 58 27.0 62
3Insulin resistance (HOMA) 0.8 61 0.7 63 0.8 61 0.9 66 0.7 64 0.8 67
3CRP, mg/L 0.9 120 0.8 108 1.0 128 1.0 122 0.8 126 1.2 120
3Cotinine, ng/ml 1.8 261 2.0 280 1.6 250 1.5 249 1.2 266 1.6 242
Data are mean, SD except: 1 range, 2% (n) and 3geometric mean (coefficient of variation). <5% loss of n for some variables. *According to the Registrar
General’s Classification (OPCS, 1995), †Measured at 4 sites: triceps, biceps, sub-scapular and supra-iliac.‡ Estimated from the sum of skinfold thickness
using prediction equations of Durnin & Womersley (1974) and Siri (1961).
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Table 7-3 Vascular Variables at Baseline
All Control DHA Supplemented
All Male Female All Male Female
n 324 162 65 97 162 55 107
Brachial Artery mean s.d. range mean sd mean sd mean sd mean sd mean sd mean sd
Diameter, mm 3.2 0.6 1.9 – 4.9 3.2 0.6 3.7 0.4 2.8 0.3 3.2 0.6 3.8 0.4 2.9 0.4
Reactive hyperaemia, % 736 263 0 - 2289 713 249 713 232 778 240 759 276 665 216 808 292
Flow mediated dilatation,
mm
0.27 0.1 0.06 – 0.6 0.27 0.1 0.27 0.1 0.27 0.1 0.27 0.1 0.26 0.1 0.28 0.1
Flow mediated dilatation, % 8.4 3.7 1.1 – 23.9 8.3 3.7 7.1 3.3 9.1 3.7 8.5 3.7 6.8 3.2 9.3 3.7
1Distension, mm 0.09 0.04 0.01 –
0.22
0.08 0.04 0.09 0.04 0.08 0.04 0.09 0.04 0.1 0.04 0.09 0.04
Distension, % 12.3 5.6 0.6 – 34.5 11.4 5.4 10.0 3.8 12.5 6.1 13.2 5.8 11.1 4.3 14.0 6.1
Distensibility coefficient
1(x10-3.kPa-1)
9.1 4.3 0.7 – 34.9 8.4 3.9 7.3 2.7 9.2 4.4 9.8 4.7 8.8 5.5 10.3 4.2
Right Common Carotid 6.5 0.5 5.0 – 8.0 6.5 0.5 6.8 0.5 6.3 0.5 6.5 0.5 6.8 0.5 6.3 0.4
Diameter, mm 0.7 0.2 0.2 – 1.4 0.7 0.1 0.7 0.2 0.7 0.1 0.7 0.2 0.7 0.2 0.7 0.1
Distension, % 11.3 2.6 2.5 – 20.4 11.6 2.4 11.0 2.5 12.0 2.4 11.1 2.7 11.1 3.4 11.2 2.4
Distensibility coefficient %
(x10-3.kPa-1) 1
34.2 9.0 8.1 –
119.1
33.8 7.3 30.3 6.2 36.3 7.0 34.5 10.3 33.0 14.4 35.3 7.5
Intima-media thickness,
mm
0.55 0.08 0.4 – 1.0 0.54 0.08 0.56 0.1 0.53 0.07 0.54 0.07 0.56 0.08 0.54 0.07
Carotid-radial PWV, m/s 8.6 1.3 5.6 – 17.0 8.6 1.2 8.9 1.1 8.3 1.2 8.6 1.4 8.6 1.2 8.6 1.4
1n=110 in control and DHA supplemented groups. <5% loss of n for some variables
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Table 7-4 Symptoms reported by participants during compliance
monitoring
Number of Participants Reporting Symptoms
Symptom* All Control DHA
Supplemented
n 262 133 129
None, % (n) 85 (223) 86 (114) 84 (109)
Headache 7 3 4
Stomach Pain 8 3 5
Nausea 7 2 5
Bloating 13 6 7
Flatulence 21 12 9
Diarrhoea 8 4 4
Constipation 6 4 2
Itching 3 1 2
Skin rash/spots 4 2 2
Fatigue 4 1 3
Dizziness 3 2 1
Other Symptoms 8 3 5
Bleeding Gums 1 0 1
Cold/flu 2 1 1
Cough 1 0 1
Eyelids drooping 1 0 1
Thirsty 1 0 1
General Malaise 1 1 0
Menstrual
discomfort
1 1 0
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Table 7-5 Red Blood Cell Fatty Acid Concentrations Pre- and Post-Intervention
Control DHA Supplemented Comparison of Randomized
Groups (P)
All Male Female All Male Female All Male Female
n : Pre-intervention 156 65 91 160 54 106
n: Post-intervention 135 56 79 131 50 81
Docosahexaenoic, %
Pre-intervention 5.3 1.7 5.2 1.8 5.3 1.6 5.5 1.7 5.3 1.8 5.6 1.6 0.3 0.8 0.3
Post-intervention 5.3 1.8 5.1 1.8 5.4 1.7 8.9 2.6 8.8 2.7 8.9 2.5 <0.0001 <0.0001 <0.0001
Eicosapentaenoic, %
Pre-intervention 1.0 0.6 1.1 0.6 0.9 0.5 1.0 0.5 1.0 0.6 1.0 0.5 0.7 0.5 0.2
Post-intervention 0.9 0.5 1.0 0.5 0.9 0.5 1.3 0.6 1.2 0.6 1.4 0.6 <0.0001 0.01 <0.0001
n-3 index 1
Pre-intervention 6.2 2.1 6.2 2.3 6.3 2.0 6.5 2.1 6.3 2.3 6.6 2.0 0.3 0.9 0.2
Post-intervention 6.2 2.2 6.1 2.2 6.3 2.2 10.2 3.0 10.0 3.1 10.3 2.9 <0.0001 <0.0001 <0.0001
n-3 index ≥8%, %, n
Pre-intervention 19, 30 17, 11 21, 19 22, 35 22, 12 22, 23 0.3 0.3 0.5
Post-intervention 16, 22 16, 9 16, 13 76, 100 70, 35 80, 65 <0.0001 <0.0001 <0.0001
1n-3 index= Docosahexenoic + eicosapentenoic/ total fatty acid
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Table 7-6 Dietary energy and fat intakes at baseline assessed using EPIC FFQ compared with UK National Diet
and Nutrition Survey of adults aged 19-64 (Henderson, 2003) and COMA (1991) dietary reference
values (DH, 1991)
Nutrient N-3 HYP Study NDNS† COMA
All Males Females Males Females Males Females
n 323 119 204 219 210 N/A N/A
Energy (Mj/d) 9.4 (3.8-16.8) 10.3 (4.5-16.8) 8.9 (3.8-14.4) 8.9 (5-14.9) 6.3 (3.3-9.6) 10.6 8.1
Fat (% Energy) 34.4 (19.7-34.4) 34 (19.7-49.6) 34.6 (20-51) 35.8 (26-47.2) 35.4 (22.3-46.1) ≤33 ≤33 
Saturated Fatty
Acids (% energy)
11.8 (5.1-25.8) 11.7 (5.1-24.8) 11.8 (5.5-25.8) 13.2 (8.5-18.3) 13.2 (7.5-18.6)
MUFA (% Energy) 11.3 (5.2-20.1) 11.1 (5.9-17.7) 11.4 (5.2-20.1) 12.3 (8.7-16.7) 11.7 (7.5-16.9)
ALA (% Energy) 0.2 (0.04-0.8) 0.2 (0.04-0.6) 0.2 (0.05-0.8) 0.2 0.2
Cis n-3 PUFA (%
energy)
0.8 (0.2-1.4)- 0.8 (0.2-1.4) 0.8 (0.5-1.1) 1.0 (0.5-2.3) 1.0 (0.5-1.9)
n-3 LC-PUFA (%
Energy)
0.2 (0-1.1) 0.2 (0.01-0.71) 0.2 (0-1.1) - -
0.2g n-3-LC-PUFA/d
DHA (% Energy) 0.09 (0-0.6) 0.07 (0-0.4) 0.09 (0-0.6) - -
EPA (% Energy) 0.1 (0-0.4) 0.09 (0-0.3) 0.1 (0-0.4) - -
† Based on age group 25-34 years for comparison.
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Table 7-7 Vascular Variables and Cardiovascular Risk Factors Post-Intervention
Control DHA Supplemented Comparison of
randomized groups(P)
All Male Female All Male Female All Male Female
Completed study, %, n 85 138 88 57 84 81 84 136 91 50 80 86 0.4 0.4 0.4
Brachial Artery
Diameter, mm 3.2 0.5 3.7 0.3 2.9 0.3 3.2 0.6 3.8 0.4 2.9 0.3 0.9 0.3 0.3
Reactive hyperaemia,
%
713 232 632 253 700 200 735 243 672 228 773 246 0.5 0.4 0.9
Flow mediated
dilatation, mm
0.29 0.1 0.32 0.1 0.27 0.1 0.26 0.1 0.25 0.1 0.27 0.1 0.02 0.002 0.8
Flow mediated
dilatation, %
8.6 3.5 7.9 3.6 9.1 3.3 8.0 4.0 6.3 3.1 9.0 4.2 0.2 0.01 0.9
Distension, mm2 0.09 0.04 0.1 0.03 0.08 0.04 0.09 0.04 0.1 0.04 0.08 0.0
4
0.5 0.2 0.9
Distension, % 12.6 6.9 11.1 6.9 13.8 6.7 12.6 5.4 11.5 4.5 13.3 5.7 0.9 0.8 0.6
Distensibility
coefficient (x10-3.kPa-1)
8.9 4.0 7.5 2.5 10.0 4.7 9.2 3.7 8.3 3.2 9.7 3.9 0.6 0.2 0.7
Right Common Carotid
Diameter, mm 6.5 0.5 6.7 0.5 6.3 0.4 6.4 0.5 6.8 0.4 6.2 0.4 0.4 0.4 0.2
Distension, mm 0.7 0.1 0.7 0.2 0.7 0.1 0.7 0.2 0.8 0.2 0.7 0.1 0.4 0.5 0.07
Distension, % 11.4 2.4 11.0 2.8 11.7 2.1 11.2 2.5 11.2 3.0 11.3 2.2 0.6 0.7 0.2
Distensibility
coefficient %
34.1 7.8 30.2 6.6 36.9 7.4 34.0 7.5 31.3 7.0 35.6 7.3 0.9 0.4 0.3
Intima-media 0.55 0.09 0.56 0.1 0.5 0.07 0.55 0.07 0.56 0.06 0.5 0.0 0.7 0.9 0.3
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Control DHA Supplemented Comparison of
randomized groups(P)
All Male Female All Male Female All Male Female
Completed study, %, n 85 138 88 57 84 81 84 136 91 50 80 86 0.4 0.4 0.4
thickness, mm 7
Carotid-radial PWV,
m/s
8.6 1.3 9.0 1.3 8.3 1.2 8.5 1.5 8.8 1.3 8.4 1.6 0.8 0.3 0.6
Blood pressure, mm
Hg
Systolic 110 11 116 10 105 9 110 11 113 7 108 12 0.9 0.07 0.2
Diastolic 65 7 68 6 62 7 65 8 65 7 64 9 0.9 0.05 0.1
Mean Arterial 82 8 87 7 79 7 82 9 83 7 81 10 0.7 0.02 0.2
Pulse Pressure 45 7 49 6 43 6 45 6 48 5 43 6 0.5 0.3 0.7
Resting heart rate,
beats/min
64 9 63 10 65 8 64 9 61 8 65 10 0.7 0.2 0.7
Total cholesterol, mmol/L 4.2 0.8 4.3 0.9 4.2 0.8 4.4 0.8 4.5 0.9 4.4 0.8 0.1 0.2 0.3
LDL cholesterol, mmol/L 2.4 0.8 2.6 0.8 2.3 0.7 2.6 0.8 2.8 0.8 2.5 0.7 0.06 0.2 0.1
HDL cholesterol, mmol/L 1.4 0.3 1.3 0.3 1.5 0.3 1.5 0.4 1.4 0.3 1.6 0.4 0.08 0.04 0.6
3VLDL cholesterol, mmol/L 0.4 49 0.4 50 0.4 50 0.3 54 0.3 54 0.3 54 <0.0001 0.01 0.001
Total:HDL cholesterol ratio 3.2 1.0 3.5 1.0 2.9 0.9 3.1 1.0 3.4 1.0 3.0 1.0 0.8 0.6 0.7
LDL:HDL cholesterol ratio 1.8 0.8 2.1 0.9 1.6 0.7 1.9 0.9 2.1 0.9 1.7 0.8 0.6 0.9 0.3
3Triglyceride, mmol/L 0.8 49 0.9 49 0.8 49 0.6 54 0.7 54 0.6 54 <0.0001 0.009 0.001
Glucose, mmol/L 4.8 0.5 4.9 0.4 4.6 0.5 4.7 0.6 4.9 0.7 4.6 0.5 0.7 0.7 0.9
3Insulin, mU/L 27.7 55 28.5 58 27 54 29.3 61 29.0 67 29.5 58 0.4 0.8 0.3
3Insulin resistance 0.8 58 0.8 58 0.8 59 0.9 68 0.9 74 0.8 64 0.4 0.8 0.4
190
Control DHA Supplemented Comparison of
randomized groups(P)
All Male Female All Male Female All Male Female
Completed study, %, n 85 138 88 57 84 81 84 136 91 50 80 86 0.4 0.4 0.4
(HOMA), µm/L
3CRP, mg/L 1.0 114 1.0 110 1.1 118 1.0 123 0.6 111 1.2 123 0.7 0.06 0.6
Data are mean, SD except1 % (n) and 3geometric mean (coefficient of variation). <10% loss of n for some variables except 2 n=105
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Table 7-8 Dietary intakes before and after treatment with n-3 LC-PUFA by randomly assigned treatment groups
Control DHA Supplemented Comparison of
Randomized Groups (P)
All Male Female All Male Female All Male Female
n Pre-intervention 161 64 97 162 55 107
n Post-intervention 137 56 81 136 50 86
Energy (Mj/d)
Pre-intervention 9.1 2.8 10.2 2.9 8.4 2.5 9.8 2.5 10.5 2.5 9.4 2.5 0.04 0.83 0.05
Post-intervention 8.73 2.9 9.7 2.7 8.0 2.9 9.43 2.6 9.8 2.4 9.1 2.7 0.87 0.12 0.1
Protein (% energy)
Pre-intervention 16.1 3.5 16.6 3.5 15.8 3.4 15.8 2.6 16.6 2.6 15.4 2.5 0.67 0.88 0.6
Post-intervention 15.8 3.4 16.4 3.5 15.5 3.2 15.7 2.5 16.1 2.4 15.5 2.7 0.35 0.29 0.8
Carbohydrates (% energy)
Pre-intervention 49.4 7.2 48.3 6.8 50.1 7.5 50 7.0 49.6 6.7 50.3 7.2 0.75 0.86 0.9
Post-intervention 50.0 7.7 49.4 7.2 50.4 8.1 49.24 7.0 48.9 6.5 49.4 7.3 0.39 0.65 0.4
Fat (% energy)
Pre-intervention 34.4 5.8 33.8 5.5 34.8 6.0 34.4 5.5 34.2 5.4 34.4 5.5 0.66 0.44 0.9
Post-intervention 34.1 5.6 33.3 5.8 34.7 5.4 35.2 5.7 35.2 5.7 35.2 5.8 0.07 0.13 0.3
SFA (% energy)
Pre-intervention 11.9 3.2 11.8 3.1 12.0 3.3 11.7 3.0 11.7 3.3 11.6 2.8 0.4 0.76 0.4
Post-intervention 11.7 3.0 11.4 3.2 11.9 2.9 12.15 2.9 11.96 2.7 12.23 3.1 0.3 0.48 0.5
MUFA (% energy)
Pre-intervention 11.3 2.4 11 1.9 11.5 2.7 11.3 2.3 11.2 2.2 11.4 2.3 0.66 0.48 0.9
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Control DHA Supplemented Comparison of
Randomized Groups (P)
All Male Female All Male Female All Male Female
n Pre-intervention 161 64 97 162 55 107
n Post-intervention 137 56 81 136 50 86
Post-intervention 11.3 2.2 10.7 2.0 11.6 2.3 11.9 2.4 11.8 2.2 11.9 2.6 0.03 0.03 0.3
n-3 PUFA (% energy)
Pre-intervention 7.3 2.0 7.3 1.9 7.3 2.1 7.3 1.8 7.4 1.7 7.2 1.8 0.53 0.9 0.3
Post-intervention 0.17 0.08 7.0 1.8 7.2 2.0 7.4 1.8 7.75 1.9 7.3 1.7 0.74 0.23 0.9
ALA (% energy)
Pre-intervention 1.6 0.1 0.16 0.1 0.16 0.1 0.16 0.75 0.17 0.08 0.16 0.07 0.16 0.56 0.2
Post-intervention 0.17 0.08 0.16 0.06 0.17 0.09 0.09 0.07 0.17 0.09 0.16 0.08 0.74 0.48 0.8
DHA (% energy)
Pre-intervention 0.08 0.08 0.07 0.08 0.08 0.1 0.09 0.07 0.07 0.07 0.08 0.08 0.74 0.9 0.6
Post-intervention 0.093 0.08 0.07 0.08 0.097 0.1 0.09 0.07 0.088 0.07 0.098 0.09 0.3 0.9 0.6
EPA (% energy)
Pre-intervention 0.1 0.07 0.1 0.07 0.1 0.08 0.1 0.07 0.1 0.07 0.01 0.06 0.57 0.69 0.4
Post-intervention 0.1 0.08 0.08 0.07 0.1 0.09 0.11 0.09 0.12 0.11 0.1 0.07 0.3 0.08 0.8
EPA+DHA (% energy)
Pre-intervention 0.18 0.16 0.17 0.14 0.2 0.17 0.18 0.13 0.17 0.12 0.19 0.14 0.57 0.87 0.4
Post-intervention 0.17 0.16 0.14 0.1 0.2 0.18 0.2 0.16 0.21 0.19 0.19 0.14 0.53 0.06 0.8
1Randomized groups were compared using student’s independent samples t-test, changes from baseline were compared using student’s paired
samples t-test; 2Values are means, SD; 3P = 0.02, 4P = 0.04, 50.009, 60.01, 70.006, 8<0.001; All data were natural log transformed before analyses
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7.4 Discussion
A high dietary intake of n-3 LC-PUFA is thought to reduce the risk of CVD, but
evidence to support its advantages in healthy populations is scarce.328 In the
present study, we investigated the effect of DHA supplementation on
endothelial function and CVD risk factors and found no evidence to support a
beneficial effect on these outcomes. On the contrary, DHA supplementation
was found to have a small but significant negative effect on endothelial function
in men. However, beneficial effects on blood pressure in men and triglyceride
concentration in both sexes were shown. These data suggest that a high DHA
intake does not directly impact on endothelial function and that benefits for the
primary prevention of CVD operate via improvements for other CVD risk factors.
A growing body of evidence supports our findings.327, 328, 330, 331, 617-620
Improved endothelial function is one proposed mechanism for the protective
effect of n-3 LC-PUFAs on the development of atherosclerosis.180, 235, 243, 256, 353,
430, 434, 571-575, 578 However, most previous RCTs have been conducted in
patients at high CVD risk and relatively few studies have investigated this in
healthy individuals. Khan, 2003, reported that supplementation of 5g/d of tuna
oil for 8 months was shown to improve endothelial function in the peripheral
arteries of healthy volunteers.243 Similarly, supplementation with 1g/d fish oil for
14 days improved both endothelial dependent and endothelial-independent
vasodilatation of the brachial artery in healthy adults.256 The present study did
not support these findings. However, previous studies were small,256, 621did not
have a parallel, RCT design,243 investigated endothelial function in resistance
vessels, which may correlate poorly with FMD of conduit vessels such as the
brachial artery,573 or were conducted in older adults likely to already have
clinical signs of endothelial dysfunction.578 However, our findings are consistent
with a recent RCT in middle-aged adults at moderately increased CVD risk.
Sanders (2011) found no effect of n-3 LC-PUFA supplementation (up to 1.8g/d)
on FMD.253 Similarly, the MESA study, a cross-sectional study of more than
3000 adults aged 45-84 years, found higher consumption of non-fried fish was
associated with a 1 SD lower brachial artery diameter in men and 0.27%
smaller FMD in women.270 Collectively, therefore, together with these previous
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reports, our data support the hypothesis that, while n-3 LC-PUFA
supplementation may improve endothelial function in individuals with clinical
CVD disease574 or risk factors such as dyslipidaemia and type-2 diabetes
(McVeigh, 1993)575 there is little evidence to suggest a beneficial effect on
endothelial function in healthy adults.571
The detrimental effect of DHA supplementation on FMD in men was an
unexpected finding and requires further investigation. One possible explanation
is that n-3 LC-PUFA supplementation has been shown to increase markers of
endothelial activation. For example, soluble adhesion molecule concentration
increased in younger compared to older men.234, 247 The association between
fish intake and vascular function has been shown to vary by gender
previously.270 Furthermore, women metabolise n-3 LC-PUFA differently to men.
Compared with men, women have greater tissue DHA content,622 and a higher
capacity to metabolise α-linolenic acid to DHA.623
As in previous reports, we found no effect of DHA supplementation on vascular
measures such as carotid IMT569 and arterial stiffness.253 There was, however,
a small benefit of DHA supplementation on mean arterial blood pressure in men
but not women. Although the reasons for the sex difference are uncertain, our
data are consistent with earlier studies and meta-analyses,386 which showed
that low to moderate doses of DHA can lower blood pressure in healthy,
normotensive individuals without changes in endothelial function or arterial
stiffness.386
DHA supplementation reduced triglyceride concentration as reported in previous
studies.299, 569, 577 Importantly, this effect was seen in a healthy, young
population with triglyceride levels in the normal range. The size of the effect
(27% lower TG concentration) was similar to data from systematic reviews in
older adults 569, 577 that investigated higher n-3 LC-PUFA doses (approximately
2.7g/day).569 The present study found similar benefits but at lower levels of
supplementation that provided n-3 LC-PUFA within a feasible dietary range.
195
A dose-response association between red cell n-3 DHA and triglyceride
concentration was found and a greater benefit of DHA supplementation was
seen in individuals with higher pre-supplementation triglyceride levels.299, 569, 577
The mechanisms for this effect are unknown, but lower VLDL concentration with
DHA supplementation in the present study was consistent with the hypothesis
that n-3 LC-PUFAs decrease the hepatic production of triglyceride rich
particles.569
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Chapter 8
Relationships of Dietary Patterns with Vascular
Structure and Function and Classical CVD Risk Factors
They claim red meat is bad for you. But I never saw a sick-looking tiger.
~Chi Chi Rodriguez
8.1 Introduction
Substantial evidence supports the hypothesis that dietary factors have
protective effects on the development of CVD (Chapter 1, section 1.6).
Endothelial dysfunction is a major contributor to atherosclerosis and an
accepted independent predictor of CV events.36, 38 Dietary factors may
modulate EF either by decreasing inflammation and thereby endothelial
activation or by improving endothelium-dependent FMD in healthy subjects
(Chapter 2, Section 2.1). Specific foods and nutrients that may improve FMD
include fish and n-3 fatty acids and a protective role of certain dietary styles has
also been reported.92, 181
Diet also has a direct impact on classical CVD risk factors including, blood
pressure,260 dyslipidaemia624 and insulin resistance.79 Furthermore, classical
CVD risk factors have been shown to directly impact EF.625 The present study
aims to describe dietary patterns and to investigate associations of dietary
patterns and their components with vascular structure and function and CVD
risk factors in a group of healthy young adults.
8.1.1 Subject Characteristics
Three hundred and twenty three participants in the n-3-HYP study, a RCT of
DHA supplementation in healthy young adults, completed the EPIC FFQ at
baseline. Principal component analysis was performed as described in
Chapter 6, Section 6.5.9 and three predominant dietary patterns were
identified: health conscious (healthy), meat based (meaty) or high in
discretionary foods (snack). The healthy pattern was characterized by high
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loadings for fruit, vegetables, fish, low-fat dairy products, wholegrain foods, nuts
and vegetarian foods. The meaty pattern scored high on meat and meat
products, high fat dairy foods and refined carbohydrates (Box 8-1). Convenient
fish products, red meats, combination dishes, confectionary and savoury snacks
scored highest in the snack pattern.
Box 8-1 Food Groups Characterising Dietary Patterns
A one-way analysis of variance (ANOVA) was carried out to explore the
relationship of dietary patterns on study outcomes. Subjects were divided into 5
groups according to dietary pattern scores for further analysis. Interactions
between dietary patterns and gender were examined using general linear
models (GLM) with dietary pattern quintile x gender introduced as an interaction
term. Where interactions between gender and dietary patterns on outcomes
were identified separate analyses were conducted to investigate differing
relationships of diet with outcomes in men and women.
Trends in relationships between dietary pattern scores and outcomes were
analysed in GLM with dietary pattern score entered as a continuous variable.
Multiple linear regression analysis was used to adjust differences in outcomes
between dietary pattern score quintiles for potential confounding factors known
to be associated with outcomes under investigation. Subject characteristics
Pattern 1 – “Healthy”
Green, leafy vegetables, yellow vegetables, cruciferous vegetables, alium vegetables, other
vegetables; fresh fruits, citrus fruits, other fruits; oily fish, vegetarian foods, cereals and
wholegrain products.
Pattern 2 – “Meaty”
Red meats, processed meats, organ meats, poultry, high fat dairy products, refined grain
products, combination meals, savoury pies, tomatoes, high fat dressings and sauces, and
saturated fats.
Pattern 3 – “Snack”
Convenient fish products, combination dishes, salty snacks, confectionary, biscuits and
cakes, dairy desserts, refined grain products, potato products, high energy drinks, tea, and
coffee.
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according to dietary pattern quintiles are presented in Tables 8-1 to 8-6.
Regression models are presented in Tables 8-7 to 8-11.
8.1.2 Sociodemographic and anthropometric characteristics
People with high scores for the healthy pattern were more likely to be female
(47/64, 73% female compared with 17/64, 27% male, P for trend <0.001), more
likely to have a degree (P for trend = 0.01) and less likely to be centrally obese
as indicated by lower waist circumference (P for trend <0.002) (Table 8-1).
Conversely, there were more males in higher quintiles for the meaty dietary
pattern (37/64, 58% male compared with 27/64, 42% female) (Table 8-2). The
snack dietary pattern was associated with a less healthy lifestyle suggested by
a lower physical activity level for people in the highest compared with the lowest
quintile, 3 hours per day compared with one hour per day, (P for trend = 0.001).
There was also a trend towards higher waist circumference with increasing
scores on the snack pattern (P for trend = 0.03) (Table 8-3).
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8.2 Dietary patterns and vascular structure and function
Common carotid artery intima media thickness decreased with increasing score
on the healthy dietary pattern (P for trend = 0.04) (Table 8-4). In secondary
analyses this effect was confined to females (dietary pattern x gender
interaction on CCA- IMT: P = 0.04). After adjustment for arterial diameter and
room and skin temperature, mean CCA-IMT was 0.07 mm (12%) lower for
females in the highest compared with the lowest quintile for this dietary pattern
score (P = 0.002) (Table 8-7). This effect was attenuated after further
adjustment for confounders known to influence vascular structure and function
(age, sex, skin temperature, room temperature, social class, physical activity,
blood pressure, waist circumference, LDL cholesterol, triglycerides, fasting
insulin concentrations and energy intake) but almost remained significant (P =
0.05) (Table 8-7).
In contrast, a trend towards increasing brachial arterial distensibility was seen in
association with higher scores on the snack dietary pattern (P for trend = 0.05)
(Table 8-6). In secondary analyses this effect was confined to women (dietary
pattern x gender interaction on brachial artery distensibility: P = 0.002). The
effect size was large (difference between highest and lowest quintile 0.03mm
(43%) [P = 0.003]) (Table 8-7, Model 1) and remained after adjustment for
confounders (P = 0.02) (Table 8-7, Model 2).
There was no association of dietary patterns with FMD or other measures of
vascular function (Tables 8-4 to 8-6).
8.3 Dietary patterns and CVD risk factors
CVD risk factors including obesity, blood pressure, serum cholesterol,
triglycerides and insulin resistance were generally related to the three dietary
patterns in the expected directions with less healthy dietary patterns associated
with greater CVD risk (Table 8.1-3). These are discussed in detail below.
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8.3.1 Obesity
A significant negative association was seen for waist circumference and WHR
with healthy dietary pattern score. As dietary pattern score increased waist
circumference and WHR decreased (P for trend = 0.002 and <0.001
respectively) (Table 8-1).
In secondary analyses waist circumference was significantly lower in all
quintiles compared with the lowest quintile of healthy dietary pattern score
(mean difference for -highest minus lowest quintile = 5.7 cm; 95% CI:-9.1 - -2.2
[P = 0.001]) (Table 8-8, Model 1). After adjustment for potential confounders
(age and sex and energy intake) the effect was attenuated and no longer
significant (P for trend = 0.2) (Table 8-8, Model 2).
In contrast, there was a tendency toward greater obesity risk in association with
the meaty and snack dietary patterns. BMI increased by a mean of 1.2 points
between the lowest and highest quintiles of the snack dietary pattern score (P =
0.03) (Table 8-3). An increase in waist circumference and waist to hip ratio was
also associated with increased scores for the snack pattern (P for trend = 0.03
and 0.02 respectively) (Table 8-3). An increase in WHR was also seen in
association with increased scores for the meaty pattern (P for trend = 0.003)
(Table 8-2). These effects were independent of gender (P for gender x dietary
pattern score on BMI, waist circumference and waist hip ratio > 0.5 for all
dietary patterns).
After adjustment for potential confounders (age, sex and energy intake) the
effects were attenuated and no longer significant (Table 8-8, Model 2).
8.3.2 Blood Pressure
Systolic (SBP), diastolic (DBP) and mean arterial blood pressure (MAP)
decreased with increasing healthy dietary pattern score (P for trend < 0.001 for
all variables) (Table 8-1, Figure 8.2a). The effect size was large (mean
difference between highest and lowest quintiles of healthy dietary pattern score
for MAP -6.8 mm Hg; 95% CI:-9.9 - -3.7 [P < 0.001]) and was consistent for
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SBP, DBP and MAP (Table 8-9, Model 1). There were no significant
interactions of dietary patterns with gender on BP (P > 0.4 for all measures).
Figure 8-2a Mean (SD) arterial blood pressure according to quintiles of
healthy dietary pattern score
Adjustment for potential confounding factors (age, sex, waist circumference,
physical activity, social class, LDL cholesterol, triglycerides, fasting insulin and
energy intake) attenuated associations of the healthy dietary pattern with BP.
However, associations of MAP and DBP remained significant and a trend was
seen for SBP (P = 0.02 , 0.002, and 0.06 respectively) (Table 8-9, model 2).
The meaty dietary pattern was associated with increased BP (P for trend =
0.001 for all BP measures) (Table, 8-2, Figure 8-2b). The mean difference for
MAP between the highest and lowest quintile of meaty dietary pattern score
was 5 mm Hg (95% CI: 1.8, 7.9, [P = 0.002]) (Table 8-9, Model 1). The
greatest effect was for SBP (difference for SBP between highest and lowest
quintile = 7mm Hg, 95% CI: 3.2 - 10.5 [P < 0.001]). Adjustment for confounding
factors attenuated associations for DBP and MAP slightly but all relationship
between the meaty diet and BP remained significant (difference for SBP
between highest and lowest quintile = 5.5mm Hg, 95% CI: 2.1 - 8.8 [P < 0.001])
(Table 8-9, Model 2).
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Figure 8-2b Mean (SD) arterial blood pressure according to quintiles of
meaty dietary pattern score
8.3.3 Resting Heart Rate
Resting heart rate was lower by 6 beats per minute in the highest compared
with the lowest healthy dietary pattern score quintile (95% CI:-9.3 - -2.1 [P =
0.002]) and higher by 5 beats per minute in the highest compared with the
lowest snack dietary pattern score (95% CI: 1.5 - 8.7 [P = 0.006]) (Table 8-9,
Model 1). This effect remained after adjustment for confounding factors for
both dietary patterns (P for trend = 0.02 and 0.04 for the healthy and snack
patterns respectively) (Table 8-9, Model 2).
8.3.4 Serum lipid concentrations
The healthy dietary pattern was associated with a more favourable lipid profile.
Total cholesterol, LDL, VLDL and TG were lower in association with the healthy
dietary pattern (P for trend = 0.01 for TC and LDL and P < 0.001 for VLDL and
TG) (Table 8-1). Total cholesterol was lower by 0.5mmol/L (11%) (95% CI: -0.8
- -0.2) in the highest compared with the lowest quintile (P = 0.002), LDL was
lower by 0.4mmol/L (15%) (95% CI: -0.67 - -0.16 [P = 0.002]), VLDL by
0.2mmol/L (40%) (95% CI: -0.2 - -0.6 [P < 0.001]) and TG by 0.3mmol/L (25%)
(95% CI: -0.06 - -0.1 [P = 0.002]) (Table 8-10, Model 1). LDL cholesterol
increased with higher scores on the snack dietary pattern. No significant
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associations between the meaty pattern and serum lipid concentrations were
found.
The lipid profile improved as healthy dietary pattern score increased. The ratio
of total to HDL cholesterol decreased by 11% from 3.5 in the lowest to 3.1 in the
highest healthy dietary pattern score quintile (P for trend = 0.003) (Table 8-1).
In contrast, the ratio of total to HDL cholesterol was higher for participants in the
highest quintile for the snack dietary pattern (P for trend = 0.01) (Table 8-3).
The ratio of LDL (the more atherogenic lipoprotein particle) to HDL also
increased as scores on the snack dietary pattern increased (P for trend = 0.02)
(Table 8-3). There were no significant interactions between dietary pattern
scores and gender (dietary pattern x gender interaction: P > 0.1 for all variables.
Most associations of lipids with dietary patterns were attenuated and became
non-significant when adjusted for potential confounding factors: age, sex, WHR,
physical activity, social class, blood pressure, and energy intake. However,
associations of VLDL and TG with the healthy dietary pattern still showed a
trend that almost reached significance (P for trend = 0.06 for both variables)
(Table 8-10, Model 2).
8.3.5 Fasting serum insulin
Serum insulin concentration was associated with the healthy and snack dietary
patterns in opposite directions. Fasting insulin decreased across quintiles of
healthy dietary pattern score (P for trend = 0.04) (Table 8-1) and increased with
snack pattern score (P for trend = 0.02) (Table 8-3). A similar pattern was seen
for Insulin resistance (IR), as measured by HOMA. HOMA-IR score was 0.2
units (22%) greater in the highest compared with the lowest snack dietary
pattern quintile (95% CI: 0.06 - 0.5 [P = 0.01]) (Table 8-11, Model 1). Effects
were attenuated and no longer significant after adjustment for potential
confounding factors: age, sex, WHR, physical activity, social class, blood
pressure, serum lipids, and energy intake (Table 8-11, Model 2)
204
8.3.6 C-reactive protein
Serum CRP concentration, a maker of inflammation, was associated with the
snack dietary pattern (P for trend = 0.05) (Table 8-3). CRP concentration
increased with high scores on this pattern. A significant interaction between this
dietary pattern with gender on CRP was found (P for interaction 0.04) and the
effect was confined to females (P = 0.01). The effect size was considerable
(difference between highest and lowest quintile = 2.0mg/L [P = 0.01]) (Table 8-
11, Model 1). However, the effect was attenuated and the trend was no longer
significant after adjustment for potential confounding factors (Table 8-11,
Model 2).
8.4 CVD risk factors and vascular health
This study found that dietary patterns were directly related to arterial
distensibility – a measure of arterial stiffness. However, no direct relationship of
diet with vascular function was apparent. Direct associations of dietary patterns
and CVD risk factors were found. Therefore, correlation analyses were carried
out to investigate associations of CVD risk factors with vascular structure and
function.
8.4.1 Obesity and vascular health
This study found direct associations of obesity with measures of vascular
structure. Waist circumference and body mass index were positively associated
with CCA-IMT and negatively with right brachial and common carotid artery
distensibility. Effect sizes were moderate to high ranging from r = 0.23 for the
association of waist circumference with CCA-IMT to r = 0.29 for waist
circumference and RCCA distensibility (Table 8-12).
8.4.2 Blood Pressure, heart rate and vascular health
Moderate correlations were found between blood pressure and vascular health.
Systolic, diastolic and MAP were related to vascular structure. Effect sizes
ranged from r = -0.39 for MAP with RCCA distensibility to r = -0.31 for MAP and
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CCA-IMT. Heart rate was negatively associated with RCCA distension
(Table 8-12).
8.4.3 Serum lipids and vascular health
Total, LDL and VLDL cholesterol were negatively associated with RCCA
distensibility (r = -0.17, -0.21 and -0.16 respectively). LDL cholesterol was
positively associated with CCA-IMT (r = 0.12). TG was negatively associated
with RCCA distensibility (r = -0.16) (Table 8-13).
8.4.4 Strength of associations of risk factors with vascular health
The value of CVD risk factors in prediction of coronary events is an important
consideration. Therefore, regression analyses were carried out to identify the
proportion of variance in vascular measures attributable to select CVD risk
factors (Framingham factors). As diet is the major focus of this thesis, this
analysis included relationships between dietary patterns and vascular
outcomes. To allow comparisons with previous studies, the contribution of risk
factors that make up the Framingham risk score was also considered.
8.4.4.1 Variance due to dietary patterns
The proportion of the variance in vascular outcomes explained by dietary
patterns was quite small but nevertheless significant (Table 8-14). CCA-IMT
decreased by about 0.01 mm for each increase in dietary pattern score quintile.
This represents a 2% decrease from the study population mean CCA-IMT
(Chapter 7, Table 7-3). The proportion of variance explained by this dietary
pattern was 1%. Similarly, brachial artery distensibility decreased by 0.01mm
for each increase in snack dietary pattern score quintile which also accounted
for 1% of the variance in this outcome.
8.4.4.2 Variance due to Framingham risk factors
In multivariate analyses the total variance in vascular outcomes accounted for
by Framingham factors was 20, 9 and 6% for CCA-IMT, FMD and brachial
artery distensibility respectively. Two Framingham factors were excluded from
this analysis, presence of diabetes and use of hypertension medication, as
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these were exclusion criteria for the RCT. Univariate analyses found that age
and SBP were the risk factors that accounted for most of the variance in CCA-
IMT (10 and 9% respectively). Gender accounted for almost all the variation in
FMD attributable to Framingham factors. FMD was 2.3% greater in women
compared with men and this accounted for 9% of variance according to risk
factors. Gender and age were the main factors accounting for variance in
brachial artery distension. However, the snack dietary pattern contributed
equally with age to the total variance (Table 8-14).
8.5 Summary of Results
This study found direct associations of dietary patterns with measures of
vascular structure. High scores on a healthy dietary pattern were associated
with lower CCA-IMT, an accepted marker of sub-clinical atherosclerosis, in
women.626 This supports findings from previous studies that have identified
relationships between dietary patterns and CCA-IMT.281, 287 These are
discussed in Chapter 2, Section 2.5.2.
A higher score on the snack dietary pattern was associated with greater
brachial artery distension in women. This finding was unexpected as the foods
which characterise the snack pattern would largely be accepted as unhealthy
food choices. This is discussed in Chapter 11, Section 11.2.2. There were no
associations between dietary patterns and FMD in the present study.
Increased concentration of CRP, an inflammatory marker of endothelial
dysfunction, was associated with higher scores on the snack dietary pattern in
women. This supports findings from other studies where healthy dietary
patterns were associated with lower CRP concentration287 and less healthy
patterns with higher concentrations.627
Dietary patterns were associated with classical CVD disease risk factors.
Benefits for obesity, blood pressure, heart rate, lipid profile (lower
concentrations of VLDL and TG) and insulin resistance were suggested by
reductions in these risk factors as scores on the healthy dietary pattern
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increased. In contrast, CVD risk factors increased with scores on the meat and
snack dietary patterns. CVD risk factors that were related to dietary patterns in
this present study were moderately correlated with measures of vascular
structure. Therefore, this study suggests that diet has both direct and indirect
effects on the early development of atherosclerosis.
Data from this observational study provide evidence for an association of
dietary patterns in adulthood and primary development of CVD. These
findings are discussed fully in Chapter 11 where Implications for clinical
practice and future research are considered.
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Table 8-1: Subject Characteristics at Baseline According to Quintiles of Health Conscious Dietary
Pattern Score
n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Dietary Pattern Score 64 -1.2 (0.3) 65 -0.6 (0.1) 65 -0.1 (0.1) 65 0.4 (0.1) 64 1.5 (0.8)
Males 39 -1.2 (0.3) 27 -0.6 (0.2) 19 -0.1(0.1) 18 -0.4 (0.2) 17 1.6 (1.1)
Females 25 -1.1 (0.2) 38 -0.6 (0.1) 46 -0.1 (0.1) 47 -0.4 (0.1) 47 1.5 (0.7)
Gender (% male) 61 42 29 28 27 <0.001
Age, y 28.7 (4.8) 27.8 (5.1) 27.9 (4.9) 27.3 (4.7) 27.8 (4.2) 0.2
Males 29.1 (4.8) 28.9 (4.9) 28.9 (4.2) 28.2 (4.2) 29.6 (4.3) 0.9
Females 28.1 (4.7) 27 (5.1) 28 (4.7) 26.9 (4.9) (27.1) (3.9) 0.5
1Education:
with degree, %,(n) 60 (38) 59 (38) 74 (48) 68 (44) 71 (45) 0.01
Males 61 (23) 59 (16) 68 (13) 61 (11) 71 (12) 0.01
Females 72 (15) 70 (22) 76 (35) 70 (33) 72 (33) 0.02
1Social class:
Non-manual, %, (n) 55 (36) 55 (36) 57 (37) 57 (37) 59 (38) 0.7
Males 49 (19) 67 (18) 63 (12) 50 (9) 53 (9) 0.9
Females 68 (17) 34 (18) 54 (25) 60 (28) 62 (29) 0.7
1Current smoker,%, n 13 (8) 12 (8) 20 (13) 9 (6) 13 (8) 0.5
Males 46 (18) 15 (4) 32 (6) 28 (5) 47 (8) 0.7
Females 48 (12) 57 (21) 41 (19) 40 (19) 32 (15) 0.7
2Cotinine, ng/ml 2.6 (284) 0.8 (219) 3 (279) 1.4 (243) 1.4 (237) 0.2
Males 0.5 (275) 0.7 (248) 4.4 (311) 1.3 (246) 2.8 (2.0) 0.8
Females 4.8 (302) 0.9 (201) 2.6 (269) 1.4 (243) 1.2 (218) 0.2
Physical activity level,
hours/day
1.08 (1.6) 1.54 (1.9) 1.63 (1.8) 1.58 (2.1) 2.44 (2.1) 0.1
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n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Males 1.3 (1.6) 1.7 (1.9) 2.6 (2) 3.3 (2.6) 2.8 (2) 0.2
Females 0.7 (1.7) 1.4 (1.9) 1.24 (1.6) 0.9 (1.5) 2.34 (2.2) 0.003
Anthropometry and body
composition
Body Mass Index, kg/m2 24.6 (3.7) 23 (22.8) 23.2 (4.1) 23.5 (3.7) 23.8 (4.3) 0.5
Males 24.9 (3) 23.4 (3) 23.4 (2.9) 24 (3.1) 24.6 (2.7) 0.5
Females 24.1 (4.7) 22.7 (4.3) 23.1 (4.5) 23.3 (4) 23.5 (4.7) 1.0
Waist (cm) 81.9 (10.6) 77.6 (12.4) 75.4 (8.6) 75.8 (8.8) 76.2 (9) 0.002
Males 85.3 (9) 83.1 (8.9) 82.5 (7.9) 80.1 (7.4) 84.4 (7.4) 0.3
Females 76.6 (10.9) 73.5 (13.1) 72.4 (7.1) 74.2 (9) 73.2 (7.6) 0.4
Waist:Hip ratio 0.82 (0.07) 0.78 (0.07) 0.76 (0.06) 0.77 (0.07) 0.77 (0.06) <0.001
Males 0.85 (0.07) 0.83 (0.05) 0.83 (0.05) 0.83 (0.05) 0.83 (0.05) 0.3
Females 0.78 (0.05) 0.75(0.07) 0.73 (0.04) 0.74 (0.05) 0.74 (0.04) 0.09
2Sum skinfold, mm 53.3 (22.4) 46.9 (17.7) 51.0 (18.8) 53.1 (22.1) 52.8 (20.1) 0.5
Males 45.1 (41.3) 40 (39.4) 39 (41.5) 35.2 (39.2) 39.7 (41.9) 0.08
Females 54.7 (47.5) 46.4 (37.1) 51.5 (36.8) 54.9 (39.4) 52.9 (36.2) 0.6
% Fat (skinfolds) 23.9 (4.9) 25.2 (6.3 24.4 (5.2) 23.4 (6.1) 23 (5.2) 0.1
Males 23.1 (5) 22.7 (6.8) 23.1 (4.9) 24.4 (5.0)) 23.5 (6) 0.6
Females 25 (4.4) 26.4 (6.4) 24.9 (5.3) 23 (6.5) 22.8 (4.9) 0.004
Blood pressure, mm Hg
Systolic 63 115 (10) 65 113 (9) 65 111 (11) 65 112 (12) 63 108 (11) <0.001
Males 38 118 (10) 27 117 (9) 19 117 (10) 18 116 (7) 17 111 (12) 0.05
Females 25 110 (9) 38 110 (7.9) 46 109 (10) 47 111 (13) 46 106 (10) 0.1
Diastolic 69 (7) 68 (6) 66 (8) 68 (9) 63 (7) <0.001
Males 70 (8) 70 (7) 69 (9) 68 (7) 64 (6) 0.02
Females 68 (7) 67 (6) 64 (8) 67 (9) 63 (7) 0.008
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n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Mean arterial pressure 87 (8) 85 (6) 83 (9) 84 (10) 80 (9) <0.001
Males 89 (9) 88 (5) 87 (11) 87 (7) 84 (8) 0.05
Females 84 (8) 83 (6) 81 (8) 83 (11) 79 (9) 0.04
Resting heart rate, beats/min 68 (10) 68 (13) 66 (9) 98 (11) 62 (10) 0.02
Males 66 (11) 67 (16) 62 (9) 69 (12) 59 (8) 0.3
Females 72 (7) 68 (9) 67 (9) 68 (11) 63 (11) 0.001
†Total cholesterol, mmol/L 61 4.5 (0.9) 64 4.1 (0.9) 65 4.2 (0.7) 64 4.3 (0.9) 63 4.1 (0.7) 0.01
Males 37 4.5 (0.9) 26 4.3 (0.8) 19 4.2 (0.6) 18 4.4 (1) 17 4.0 (0.6) 0.02
Females 24 4.5 (0.8) 38 4 (0.9) 45 4.2 (0.9) 46 4.2 (0.8) 47 4.1 (0.7) 0.3
†LDL cholesterol, mmol/L 2.6 (0.8) 2.3 (0.7) 2.3 (0.7) 2.4 (0.8) 2.2 (0.6) 0.01
Males 2.7 (0.8) 2.6 (0.9) 2.4 (0.7) 2.7 (0.8) 2.3 (0.5) 0.2
Females 2.5 (0.9) 2.1 (0.6) 2.2 (0.8) 2.3 (0.8) 2.2 (0.7) 0.3
†HDL cholesterol, mmol/L 1.3 (0.3) 1.5 (0.4) 1.5 (0.4) 1.5 (0.3) 1.5 (0.4) 0.08
Males 1.2 (0.2) 1.4 (0.3) 1.4 (0.3) 1.3 (0.3) 1.3 (0.3) 0.5
Females 1.5 (0.4) 1.5 (0.4) 1.5 (0.4) 1.6 (0.3) 1.5 (0.3) 1.0
†2VLDL cholesterol 0.5 (0.3) 0.5 (0.3) 0.4 (0.3) 0.4 (0.2) 0.4 (0.2) <0.001
Males 0.5 (47) 0.4 (37) 0.4 (66) 0.4 (50) 0.3 (59) 0.01
Females 0.4 (40) 0.4 (49) 0.4 (44) 0.4 (45) 0.3 (50) 0.2
Total:HDL cholesterol ratio 3.5 (1.1) 3.0 (1.0) 3.1 (1.1) 2.9 (0.8) 3.1 (1.0) 0.003
Males 3.8 (1) 3.4 (1.1) 3.5 (1.1) 3.4 (0.6) 3.3 (1.0) 0.07
Females 3.1 (1.1) 2.7 (0.8) 2.9 (1) 2.8 (0.9) 2.8 (0.7) 0.5
LDL:HDL cholesterol ratio 1.7 (0.7) 1.7 (0.8) 1.7 (0.9) 1.7 (0.8) 2.1 (0.9) 0.008
Males 2.3 (0.8) 2 (1) 2 (0.9) 2.1 (0.6) 2 (0.8) 0.2
Females 1.8 (1) 1.5 (0.6) 1.6 (0.8) 1.6 (0.8) 1.5 (0.6) 0.4
†2Trigycerides, mmol/L 1.2 (0.7) 1.0 (0.6) 1.0 (0.7) 0.0 (0.4) 0.9 (0.5) <0.001
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n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Males 0.9 (59) 0.8 (50) 0.9 (66) 0.8 (37) 0.7 (47) 0.01
Females 0.9 (40) 0.9 (44) 0.8 (49) 0.8 (45) 0.8 (50) 0.2
†2Glucose, mmol/L 4.9 (0.5) 4.9 (0.4) 4.8 (0.5) 4.8 (0.5) 4.7 (0.4) 0.006
Males 5.0 (0.5) 5.0 (0.5) 4.8 (0.4) 4.9 (0.4) 5.0 (0.3) 0.4
Females 4.7 (0.4) 4.8 (0.4) 4.7 (0.6) 4.7 (0.5) 4.6 (0.4) 0.2
2†Insulin, pmol/L 28.5 (62) 28.5 (58) 29.9 (62) 28.5 (53) 27.8 (63) 0.04
Males 34.8 (63) 26.4 (59) 28.5 (47) 23 (48) 26.4 (57) 0.03
Females 28.5 (61) 38.9 (57) 30.6 (67) 31.3 952) 28.5 (63) 0.1
2Insulin resistance, (HOMA) 0.9 (69) 0.9 (60) 0.9 (67) 0.8 (59) 0.8 (61) 0.03
Males 0.9 (72) 0.8 (64) 0.8 (52) 0.7 (52) 0.8 (56) 0.05
Females 0.8 (66) 0.9 (57) 0.9 (73) 0.9 (59) 0.8 (63) 0.2
2CRP, mg/L 1.0 (127) 1.0 (105) 1.1 (135) 1.1 (120) 0.9 (115) 0.8
Males 0.7 (114) 0.7 (96) 0.9 (136) 0.5 (118) 1 (120) 0.2
Females 0.9 (133) 1.2 (109) 1.2 (135) 1.2 (122) 0.9 (116) 0.3
* Quintile 1 is the lowest quintile for dietary pattern score. ‡ P for trend across quintiles calculated with the dietary pattern score
quintile modelled on a continuous scale in general linear models. Data are mean, SD, except: 1 % (n) and 2 geometric mean
(coefficient of variation). † Measurements obtained after 12 hours fasting.
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Table 8-2: Subject Characteristics at Baseline According to Quintiles of Meat Based Dietary Pattern Score
n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Dietary Pattern Score 64 -1 (0.3) 65 -0.5 (0.1) 65 -0.2 (0.1) 65 0.2 (0.2) 64 1.4 (1.3)
Males 14 -0.9 (0.2) 18 -0.5 (0.1) 25 -0.2 (0.09) 26 0.2 (0.09) 37 1.3 (0.6)
Females 50 -1 (0.3) 47 -0.5 (0.1) 40 -0.2 (0.09) 39 0.2 (0.2) 27 1.5 (1.9)
Gender (% male) 22 28 38 40 58 <0.001
Age, y 27.7 (4.9) 28.3 (4.5) 27.8 (5) 28.2 (4.4) 27.4 (4.8) 0.6
Males 30.5 (4.9) 30 (5.1) 28.2 (4.7) 29.2 (3.7) 28.2 (5.1) 0.1
Females 27 (4.6) 27.6 (4.2) 27.6 (5.2) 27.5 (4.8) 26.3 (4.3) 0.7
1Education:
with degree, %, n 66 (42) 81 (53) 59 (37) 62 (40) 65 (41) 0.2
Males 64 (9) 78 (14) 56 (14) 69 (18) 56 (20) 0.3
Females 66 (33) 83 (39) 61 (23) 56 (22) 78 (21) 0.7
1Social class:
Non-manual, %, n 55 (35) 56 (36) 58 (38) 52 (34) 58 (38) 0.8
Males 50 (7) 50 (9) 52 (13) 54 (14) 65 (24) 0.3
Females 58 (29) 62 (29) 52 (13) 54 (14) 65 (24) 0.7
1Current Smoker, %, n 13 (8) 9 (6) 13 (8) 14 (9) 19 (12) 0.4
Males 10 (6) 12 (3) 16 (4) 0.05 (1) 0 0.9
Females 26 (7) 18 (7) 13 (5) 11 (5) 16 (8) 0.09
2Cotinine, ng/ml 38 26.1 (97.3) 42 22.2 (80.2) 39 16.0 (48.6) 39 22.5 (57.5) 39 37 (95.4) 0.5
Males 0.9 (1.5) 1.7 (3) 1.1 (3) 2.2 (3.2) 2.5 (2.9) 0.3
Females 1.9 (253) 1 (213) 1.2 (247) 2.1 (244) 4.4 (278) 0.7
Physical activity level,
hours/day
63 1.6 (2.1) 65 1.3 (1.6) 65 2.1 (2.2) 65 1.8 (1.9) 63 1.5 (2.0) 0.6
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n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Males 1.9 (1.8) 2 (1.8) 2.6 (2.3) 2.3 (1.9) 1.8 (2.2) 0.3
Females 1.5 (2.1) 1.1 (1.5) 1.8 (2.1) 1.4 (1.9) 1.1 (1.6) 0.8
Anthropometry and body
composition
Body Mass Index, kg/m2 64 23.3 (3.7) 65 23.8 (3.3) 65 24.2 (4.7) 65 23.9 (4.5) 64 22.8 (3.2) 0.6
Males 14 24 (3.6) 18 24.1 (2.1) 25 25 (2.7) 26 24.8 (3.2) 37 223.2 (3.1) 0.3
Females 50 23.1 (3.7) 47 23.7 (3.7) 40 23.8 (5.6) 39 23.3 (5.1) 27 22.1 (3.4) 0.5
Waist (cm) 75.5 (8.6) 76.8 (8.9) 79.3 (12.2) 77.8 (11.3) 77.3 (9) 0.2
Males 83.4 (10.3) 83.4 (7.2) 84.8 (6.7) 85 (8.4) 81.2 (8.3) 0.3
Females 73.2 (6.5) 74.2 (8.2) 75.8 (13.6) 73 (10.5) 72.1 (7) 0.5
Waist:Hip ratio 0.76 (0.07) 0.77 (0.6) 0.78 (0.07) 0.78 (0.07) 0.79 (0.07) 0.003
Males 0.84 (0.07) 0.82 (0.05) 0.84 (0.05) 0.85 (0.06) 0.83 (0.05) 0.9
Females 0.71 (0.05) 0.74 (0.04) 0.77 (0.07) 0.74 (0.04) 0.74 (0.05) 0.9
2Sum skinfold, mm 52.1 (20.8) 54.3 (23.2) 50.0 (18.2) 54.2 (20.1) 46.3 (19.0) 0.1
Males 36.5 (36) 40.4 (37) 44.8 (38) 44 (38) 37.5 (36) 0.8
Females 51.4 (39) 53 (45) 48 (36) 55.1 (35) 51 (35) 0.9
% Fat (skinfolds) 24.1 (5.9) 24.4 (5.8) 24.8 (4.9) 23.5 (5.4) 23.1 (5.8) 0.2
Males 23.3 (5.7) 24 (5.8) 24.1 (5.2) 23 (4.5) 23 (5.5) 0.6
Females 24.3 (6) 24.3 (5.8) 25.3 (4.8) 23.8 (6) 23 (6.4) 0.4
Blood pressure, mm Hg
Systolic 64 108 (10.6) 65 111 (9) 65 112 (10) 64 114 (12) 63 115 (10) 0.001
Males 14 114 (14) 18 114 (8) 25 114 (6) 26 120 (9) 36 119 (10) 0.01
Females 50 106 (9) 47 109 (9) 40 110 (12) 38 111 (12) 27 110 (11) 0.06
Diastolic 81 (8) 83 (7) 84 (9) 85 (10) 86 (9) 0.001
Males 67 (10) 66 (7) 68 (6) 70 (8) 70 (8) 0.06
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n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Females 64 (7) 65 (7) 67 (9) 65 (9) 66 (8) 0.2
Mean arterial pressure 81 (8) 83 (7) 84 (9) 85 (10) 86 (9) 0.001
Males 86 (10) 85 (7) 85 (6) 89 (9) 89 (8) 0.06
Females 80 (7) 82 (7) 83 (11) 83 (10) 82 (9) 0.1
Resting heart rate, beats/min) 64 (10) 67 (10) 67 (11) 68 (10) 66 (10) 0.1
Males 60 (6) 63 (11) 65 (9) 64 (9) 65 (10) 0.1
Females 65 (9) 67 (9) 68 (9) 69 (10) 65 (7) 0.09
†Total cholesterol, mmol/L 64 4.3 (1.0) 62 4.1 (1.0) 64 4.3 (0.7) 64 4.2 (0.8) 63 4.2 (0.8) 0.7
Males 14 4.5 (0.8) 16 4.2 (0.9) 25 4.2 (0.7) 26 4.5 (1) 36 4.3 (0.9) 0.9
Females 50 4.3 (0.9) 46 4.1 (1) 39 4.3 (0.7) 38 4.1 (0.7) 27 4.1 (0.7) 0.4
†LDL cholesterol, mmol/L 2.4 (0.9) 2.3 (0.7) 2.4 (0.7) 2.4 (0.8) 2.3 (0.7) 0.8
Males 2.7 (0.7) 2.5 (0.7) 2.5 (0.7) 2.7 (0.8) 2.5 (0.8) 0.6
Females 2.3 (0.9) 2.1 (0.7) 2.4 (0.7) 2.2 (0.7) 2.1 (0.7) 0.3
†HDL cholesterol, mmol/L 1.5 (0.4) 1.4 (0.3) 1.4 (0.3) 1.4 (0.3) 1.47 (0.3) 0.4
Males 1.3 (0.3) 1.2 (0.3) 1.2 (0.2) 1.3 (0.4) 1.4 (0.3) 0.4
Females 1.6 (0.4) 1.5 (0.3) 1.5 (0.4) 1.5 (0.3) 1.6 (0.3) 0.09
2VLDL cholesterol 0.4 (0.2) 0.5 (0.3) 0.4 (0.2) 0.5 (0.3) 0.4 (0.4) 0.7
Males 0.4 (63) 0.4 (45) 0.4 (46) 0.5 (49) 0.4 (65) 0.6
Females 0.4 (46) 0.4 (50) 0.4 (45) 0.4 (47) 0.4 (43) 0.5
Total:HDL cholesterol ratio 3.0 (1.1) 3.0 (1.0) 3.3 (1.0) 3.2 (1.1) 3.0 (0.9) 0.5
Males 3.5 (1) 3.7 (1.1) 3.5 (0.8) 3.8 (1.2) 3.3 (1) 0.5
Females 2.9 (1.1) 2.7 (0.7) 3.1 (1.1) 2.8 (0.8) 2.6 (0.6) 0.5
LDL:HDL cholesterol ratio 1.7 (0.7) 1.8 (0.9) 1.9 (0.8) 1.7 (0.7) 1.7 (0.9) 0.8
Males 2.1 (0.8) 2.2 (0.9) 2.1 (0.7) 2.3 (1) 1.9 (0.7) 0.3
Females 1.4 (0.5) 1.5 (0.7) 1.8 (0.9) 1.5 (0.5) 1.6 (0.9) 0.4
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n Q1* n Q2 n Q3 n Q4 n Q5 p‡
†2Trigycerides, mmol/L 0.9 (0.5) 1.0 (0.7) 1.0 (0.4) 1.0 (0.6) 1.0 (0.8) 0.6
Males 0.8 (55) 0.9 (63) 0.9 (46) 1.1 (0.5) 0.8 (0.7) 0.6
Females 0.8 (46) 0.9 (50) 0.8 (45) 0.8 (47) 0.8 (43) 0.6
†2Glucose, mmol/L 4.7 (0.5) 4.7 (0.5) 4.8 (0.6) 4.8 (0.5) 4.9 (0.4) 0.03
Males 4.9 (0.4) 4.9 (0.4) 5.1 (0.6) 4.9 (0.5) 5.0 (0.5) 0.6
Females 4.7 (0.5) 4.7 (0.5) 4.7 (0.4) 4.7 (0.5) 4.8 (0.3) 0.4
†2Insulin, pmol/L 28.5 (64) 28.5 (50) 29.2 (65) 31.3 (67) 28.5 (50) 0.9
Males 28.5 (63) 29.9 (40) 28.5 (63) 29.9 (65) 25 (55) 0.5
Females 27.8 (65) 28.5 (53) 33.4 (66) 34 (68) 34 (36) 0.4
2Insulin resistance, (HOMA) 0.9 (69) 0.9 (53) 1 (69) 1 (71) 0.9 (54) 0.8
Males 0.9 (64) 0.9 (42) 0.9 (71) 0.9 (73) 0.8 (61) 0.7
Females 0.8 (71) 0.8 (57) 1 (69) 01.1 (70) 1 (39) 0.5
†2CRP, mg/L 1.1 (1.7) 2.1 (4.6) 1.9 (2.7) 2.0 (4.3) 1.6 (2.8) 0.6
Males 0.9 (0.9) 0.8 (1.1) 0.8 (1.4) 0.8 (1.2) 0.8 (1.1) 0.7
Females 0.8 (114) 1.1 (14) 1.5 (109) 1.1 (128) 1.1 (120) 0.3
* Quintile 1 is the lowest quintile for dietary pattern score. ‡ P for trend across quintiles calculated with the dietary pattern score
modeled on a continuous scale in general linear models. Data are mean, SD, except: 1% (n) and 2geometric mean (coefficient of
variation).† Measurements obtained after 12 hours fasting.
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Table 8-3: Subject Characteristics at Baseline According to Quintiles of Snack Dietary Pattern Score
n Q1* n Q2 n Q3 n Q4 n Q5 P ‡
Dietary Pattern Score 64 65 65 65 64
Males 20 -1 (0.2) 20 -0.5 (0.09) 37 -0.2 (0.1) 21 0.2 (0.1) 22 1.2 (0.7)
Females 44 -1.05 (0.3) 45 -0.5 (0.1) 28 -0.2 (0.1) 44 0.2 (0.1) 42 1.7 (1.1)
1Male gender, %, (n) 31 (20) 31 (20) 57 (37) 32 (21) 34 (22) 0.6
Age, y 27.4 (4.8) 27.3 (4.6) 29.2 (4.5) 27.1 (4.7 8.6 (4.8) 0.2
Males 28 (5.1) 28.2 (5.2) 29.8 (4.2) 29.5 (4.5) 28.6 (5) 0.4
Females 27.1 (4.7) 26.9 (4.3) 28.3 (4.8) 26 (4.5) 28.6 (4.7) 0.4
1Education:
with degree, %, (n) 61 (39) 71 (45) 72 (46) 62 (40) 67 (64) 0.1
Males 60 (12) 70 (14) 64 (23) 52 (11) 68 (15) 0.5
Females 41 (27) 72 (31) 82 (23) 66 (29) 67 (28) 0.2
1Social class:
Non-manual, %, (n) 53 (34) 52 (33) 62 (40) 52 (33) 69 (44) 0.09
Males 60 (12) 55 (11) 59 (22) 52 (11) 50 (11) 0.6
Females 50 (22) 49 (22) 54 (18) 50 (22) 79 (33) 0.02
1 Current Smoker , %, (n) 21 (13) 13 (8) 9 (6) 14 (9) 2 (7) 0.004
Males 30 (6) 30 (6) 38 (14) 29 (6) 41 (9) 0.004
Females 50 (15) 50 (15) 57 (16) 39 (17) 29 (12) 0.2
2Cotinine, ng/ml 30 (82.5) 15.2 (74.3) 17.2 (50) 29.2 (87.2) 31.5 (88.2) 0.6
Males 3.3 (289) 1.6 (297) 1 (263) 1.2 (249) 2.2 (298) 0.4
Females 3.4 (253) 0.7 (161) 1.7 (245) 2.5 (276) 1.3 (267) 0.2
Physical activity level,
hours/day
2.9 (5.8) 1.8 (1.7) 1.8 (2.1) 1.4 (1.6) 1.1 (1.7) 0.001
Males 2.85 (2.1) 2.4 (1.9) 2.4 (2.3) 1.7 (1.6) 1.1 (1.7) 0.008
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n Q1* n Q2 n Q3 n Q4 n Q5 P ‡
Females 2 (2.4) 1.5 (1.5) 1 (1.5) 1.3 (1.7) 1 (1.7) 0.01
Anthropometry and body
composition
Males
Females
64
20
44
65
20
45
65
37
28
65
21
44
64
22
42
Body Mass Index, kg/m2 22.8 (2.7) 23.2 (3.0) 23.6 (3.7) 24.3 (5.2) 24 (4.4) 0.03
Males 23.8 (2.5) 23.7 (2.6) 23.8 (2.9) 25.5 (3.3) 24.1 (3.4) 0.3
Females 22.4 (2.7) 22.9 (3.2) 23.4 (4.6) 23.8 (5.9) 23.9 (4.9) 0.07
Waist (cm) 75.5 (8.4) 75.4 (8.4) 79.2 (9.1) 78 (11.3) 78.7 (12.4) 0.03
Males 83.2 (10.2) 81.5 (6) 82.7 (7.3) 86.7 (8.3 83.7 (9.9) 0.1
Females 72.6 (6.7) 72.7 (7.8) 74.3 (9) 73.5 (9.9) 76 (12.8) 0.1
Waist:Hip ratio 0.7 (0.07) 0.7 (0.07) 0.8 (0.06) 0.8 (0.08) 0.8 (0.07) 0.02
Males 0.8 (0.05) 0.8 (0.04) 0.8 (0.04) 0.8 (0.06) 0.8 (0.07) 0.05
Females 0.7 (0.05) 0.7 (0.05) 0.8 (0.05) 0.7 (0.05) 0.8 (0.05) 0.07
2Sum skinfold, mm 48.6 (17.6) 52 (16) 45.7 (18.3) 56.7 (23.2) 53.8 (24.5) 0.07
Males 40.4 (42) 41.7 (43) 36.6 (39) 50.4 (40) 37.7 (49) 0.06
Females 47.5 (36) 53 (32) 51 (38) 52.5 (46) 54.6 (41) 0.5
% Fat (skinfolds) 22.8 (5.4) 24.5 (5.2) 23.6 (6.1) 24.3 (5.5) 24.7 (5.6) 0.1
Males 22.2 (5.6) 22.3 (4.3) 23.9 (5.7) 24.9 (5.1) 23.6 (5.2) 0.2
Females 23.2 (5.4) 25.5 (5.2) 23.3 (6.8) 24 (5.7) 25.3 (5.8) 0.3
Blood pressure, mm Hg
Systolic 64 111 (9) 64 109 (10) 64 113 (10) 65 113 (11) 64 113 (13) 0.06
Males 20 118 (8) 20 112 (11) 36 116 (9) 21 118 (7) 22 119 (12) 0.2
Females 44 108 (8) 44 108 (9) 28 109 (10) 44 111 (11) 42 110 (13) 0.2
Diastolic 66 (6) 65 (7) 68 (8) 68 (8) 68 (9) 0.02
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n Q1* n Q2 n Q3 n Q4 n Q5 P ‡
Males 68 (6) 66 (7) 68 (8) 70 (6) 70 (10) 0.1
Females 64 (6.3) 64 (8) 67 (8) 67 (8) 66 (9) 0.1
Mean arterial pressure 83 (7) 81 (8) 85 (9) 85 (8.0) 85 (11) 0.02
Males 88 (6) 84 (7) 87 (9) 88 (6) 90 (10) 0.1
Females 81 (6.9) 80 (8) 82 (9) 83 (9) 83 (11) 0.1
Resting heart rate,
beats/min
64 (10) 65 (89) 66 (10) 67 (10) 69 (12) 0.003
Males 62 (7) 63 (7) 64 (9) 63 (9) 67 (12) 0.05
Females 64 (9) 67 (7) 66 (9) 67 (8) 69 (11) 0.02
†Total cholesterol, mmol/L 62 4.1 (0.8) 64 4.2 (0.8) 64 4.2 (0.7) 65 4.2 (0.9) 62 4.4 (0.9) 0.1
Males 19 4.1 (0.8) 20 4.3 (0.7) 36 4.3 (0.7) 21 4.5 (0.9) 21 4.4 (1.1) 0.5
Females 43 4.1 (0.8) 44 4.1 (0.8) 28 4.2 (0.8) 44 4 (0.9) 41 4.5 (0.8) 0.1
†LDL cholesterol, mmol/L 2.2 (0.7) 2.3 (0.7) 2.4 (0.7) 2.3 (0.8) 2.5 (0.8) 0.03
Males 2.5 (0.8) 2.5 (0.8) 2.5 (0.7) 2.7 (0.8) 2.5 (0.8) 0.6
Females 2.1 (0.7) 2.2 (0.7) 2.3 (0.8) 2.1 (0.8) 2.5 (0.7) 0.02
†HDL cholesterol, mmol/L 1.4 (0.4) 1.5 (0.4) 1.3 (0.3) 1.4 (0.3) 1.4 (0.3) 0.05
Males 1.2 (0.3) 1.4 (0.3) 1.3 (0.3) 1.3 (0.3) 1.2 (0.2) 1.0
Females 1.6 (0.4) 1.6 (0.4) 1.4 (0.3) 1.5 (0.3) 1.5 (0.3) 0.02
†2VLDL cholesterol 0.4 (0.2) 0.4 (0.3) 0.4 (0.3) 0.4 (0.2) 0.5 (0.3) 0.2
Males 0.4 (40) 0.4 (52) 0.4 (59) 0.4 (48) 0.5 (70) 0.1
Females 0.4 (45) 0.4 (49) 0.4 (40) 0.4 (46) 0.4 (50) 0.6
LDL:HDL cholesterol ratio 1.6 (0.8) 1.6 (0.7) 1.9 (0.9) 1.8 (0.9) 1.9 (0.7) 0.02
Males 2.2 (0.8) 1.9 (0.8) 2.1 (0.8) 2.2 (0.9) 2.1 (0.7) 0.8
Females 1.4 (0.6) 1.5 (0.7) 1.7 (1) 1.6 (0.8) 1.8 (0.7) 0.009
Total:HDL cholesterol ratio 3.0 (0.9) 2.8 (0.9) 3.3 (1.1) 3.1 (1.1) 3.3 (1.0) 0.01
Males 3.6 (0.9) 3.2 (0.9) 3.5 (1) 3.6 (1.1) 3.7 (1.1) 0.5
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n Q1* n Q2 n Q3 n Q4 n Q5 P ‡
Females 2.7 (0.7) 2.7 (0.8) 3 (1.2) 2.9 (1) 3.1 (0.8) 0.009
†2Trigycerides, mmol/L 1.0 (0.5) 1.0 (0.6) 1.0 (0.7) 1.0 (0.5) 1.1 (0.7) 0.2
Males 0.9 (40) 0.8 (52) 0.9 (59) 0.9 (48) 1.1 (70) 0.1
Females 0.9 (0.5) 0.8 (0.5) 0.8 (0.4) 0.9 (0.5) 0.9 (0.5) 0.6
†2Glucose, mmol/L 4.7 (0.4) 4.8 (0.46) 4.8 (0.48) 4.9 (0.62) 4.8 (0.43) 0.1
Males 4.9 (0.5) 4.9 (0.3) 4.9 (0.4) 5.3 (0.7) 5 (0.4) 0.06
Females 4.7 (0.4) 4.7 (0.5) 4.8 (0.6) 4.7 (0.5) 4.7 (0.4) 0.6
†2Insulin, pmol/L 25.7 (62) 27.8 (55) 25 (59) 36.8 (61) 33.4 (52) 0.02
Males 25 (44) 25 (55) 23.6 (51) 40.3 (68) 32 (57) 0.03
Females 25.7 (69) 29.9 (55) 28.5 (67) 36 (57) 35 (50) 0.2
2Insulin resistance, (HOMA) 0.8 (65) 0.8 (58) 0.8 (63) 1.1 (69) 1.0 (56) 0.03
Males 0.8 (50) 0.8 (58) 0.7 (53) 1.3 (81) 1 (59) 0.04
Females 0.8 (71) 0.9 (58) 0.9 (73) 1.1 (62) 1.1 (54) 0.2
†2CRP, mg/L 1.3 (2.3) 1.5 (2.8) 1.6 (2.8) 1.8 (3.0) 2.5 (5.3) 0.05
Males 0.9 (116) 0.8 (130) 0.7 (130) 0.9 (86) 0.8 (111) 0.5
Females 0.7 (115) 1.1 (117) 1.1 (119) 1.2 (132) 1.4 (127) 0.01
* Quintile 1 is the lowest quintile for dietary pattern score. ‡ P for trend across quintiles calculated with the dietary pattern score
modeled on a continuous scale in general linear models. Data are mean, SD, except: 1% (n) and 2geometric mean (coefficient of
variation). † Measurements obtained after 12 hours fasting.
220
Table 8-4 Vascular Variables at Baseline According to Quintiles of Health Conscious Dietary Pattern Score
n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Right Brachial Artery
Diameter, mm 63 3.4 (0.6) 65 3.3 (0.6) 63 3.1 (0.5) 65 3.1 (0.5) 61 3.1 (0.6) 0.001
Males 38 3.7 (0.4) 27 3.8 (0.4) 19 3.7 (0.4) 18 3.7 (0.4) 16 3.8 (0.6) 0.02
Females 25 2.9 (0.4) 38 2.9 (0.4) 44 2.9 (0.3) 47 2.9 (0.4) 45 2.9 (0.3) 0.07
Reactive hyperaemia, % 648 (240) 769 (257) 745 (232) 742 (248) 776 (324) 0.03
Males 607 (231) 656 (195) 694 (25) 618 (182) 639 (277) 0.7
Females 713 (245) 840 (268) 766 (224) 292 (255) 826 (328) 0.3
Flow-mediated dilatation,
mm
0.27 (0.1) 0.26 (0.1) 0.28 (.01) 0.26 (0.1) 0.27 (0.1) 0.8
Males 0.28 (0.1) 0.25 (0.1) 0.28 (0.1) 0.31 (0.12) 0.23 (0.1) 0.7
Females 0.27 (0.09) 0.27 (0.09) 0.27 (0.1) 0.28 (0.08) 0.28 (0.1) 0.6
Flow-mediated dilatation, % 7.7 (3.3) 7.9 (3.4) 8.8 (4.0) 9.2 (3.2) 8.3 (4.5) 0.09
Males 7.2 (3.3) 6.2 (3) 7.5 (3.1) 8.2 (3.7) 5.8 (2.9) 0.8
Females 8.5 (3.3) 9.1 (3.1) 9.4 (4.2) 9.5 (9.3) 9.2 (4.7) 0.4
Distension, mm 45 0.09 (0.04) 43 0.08 (0.03) 42 0.08 (0.04) 44 0.08 (0.03) 45 0.09 (0.04) 0.7
Males 28 0.1 (0.05) 17 0.1 (0.04) 10 0.08 (0.03) 13 0.08 (0.03) 12 0.1 (0.04) 0.7
Females 17 0.09 (0.04) 26 0.07 (0.03) 32 0.08 (0.04) 31 0.08 (0.03) 33 0.09 (0.05) 0.6
Distension, % 12.3 (6.0) 11.4 (3.9) 12.5 (5.9) 11.5 (5.3) 13.7 (6.6) 0.4
Males 10.8 (4.4) 10.9 (3.4) 8.9 (3.9) 9.5 (4) 11.5 (4) 0.6
Females 15.1 (7.3) 11.7 (4.3) 13.6 (6) 12.4 (5.6) 14.5 (7.1) 0.8
Distension coefficient (x10-
3.kPa-1)
9.0 (4.2) 8.4 (2.9) 9.1 (4.3) 8.5 (3.8) 10.5 (5.8) 0.2
Males 7.9 (3.2) 7.9 (2.4) 6.6 (2.9) 6.9 (2.9) 10.2 (8.1) 0.6
Females 11 (5) 8.7 (3.1) 10 (4.4) 10 (3.9) 10.6 (4.9) 0.8
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n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Right Common Carotid Artery
Diameter, mm 57 6.6 (0.6) 56 6.5 (0.5) 60 6.4 (0.5) 61 6.5 (0.5) 59 6.4 (0.5) 0.03
Males 37 6.8 (0.6) 21 6.7 (0.6) 17 6.8 (0.3) 18 6.9 (0.4) 17 6.8 (0.4) 0.9
Females 20 6.3 (0.4 35 6.3 (0.4) 43 6.3 (0.3) 43 6.2 (0.5) 42 6.3 (0.4) 0.7
Distension, mm 0.7 (0.2) 0.7 (0.1) 0.8 (0.2) 0.7 (0.1) 0.7 (0.2) 0.5
Males 0.7 (0.2) 0.7 (0.2) 0.8 (0.2) 0.7 (0.2) 0.8 (0.1) 0.3
Females 0.7 (0.1) 0.8 (0.1) 0.7 (0.2) 0.7 (0.1) 0.7 (0.1) 0.8
Distension, % 10.7 (2.7) 11.5 (2.4) 11.8 (2.7) 11.1 (2.7) 11.7 (2.4) 0.1
Males 10.8 (3.1) 10.8 (3.6) 11.7 (2.9) 9.9 (2.8) 12.4 (2.6) 0.4
Females 10.7 (1.8) 11.9 (2.2) 11.8 (2.6) 11.6 (2.6) 11.4 (2.4) 0.9
Distension coefficient (x10-
3.kPa-1)
32 .1 (0.7) 34.3 (6.5) 34.8 (8.1) 33.3 (7.5) 36.3 (13.4) 0.05
Males 30.2 (7.5) 30.7 (6) 30.5 (7.4) 28.2 (5.7) 37.8 (21.6) 0.1
Females 35.4 (5.7) 36.4 (5.8) 35.7 (8.3) 35.4 (7.2) 35.8 (8.3) 0.9
Intima-media thickness, mm 0.57 (0.1) 0.55 (0.07) 0.53 (0.05) 0.55 (0.07) 0.54 (0.09) 0.04
Males 0.58 (0.1) 0.56 (0.08) 0.52 (0.04) 0.56 (0.08) 0.57 (0.1) 0.8
Females 0.56 (0.08) 0.54 (0.06) 0.54 (0.07) 0.54 (0.06) 0.52 (0.06) 0.07
Carotid-radial PWV m/s 8.6 (1.1) 8.8 (1.6) 8.5 (1.2) 8.7 (1.3) 8.4 (1.2) 0.3
Males 8.6 (1.2) 8.6 (1.1) 8.9 (1.4) 9.1 (0.9) 8.9 (1) 0.2
Females 8.5 (0.8) 8.9 (1.8) 8.3 (1.1) 8.5 (1.3) 8.3 (1.2) 0.1
* Lowest quintile for dietary pattern score. ‡ P for trend across quintiles calculated with the dietary pattern score modelled on a
continuous scale in general linear models. Data are mean, SD.
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Table 8-5 Vascular Variables at Baseline According to Quintiles of Meat Based Dietary Pattern Score
n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Right Brachial Artery
Diameter, mm 62 3.1 (0.5) 63 3.0 (0.5) 65 3.2 (0.6) 63 3.3 (0.6) 62 3.3 (0.6) <0.001
Males 14 3.6 (0.6) 17 3.7 (0.4) 25 3.8 (0.4) 26 3.8 (0.4) 36 3.7 (0.4) 0.5
Females 48 2.9 (0.3) 47 2.8 (0.3) 40 2.8 (0.4) 37 3 (0.5) 27 2.8 (0.3) 0.8
Reactive hyperaemia, % 806 (236) 736 (221) 748 (361) 675 (173) 711 (180) 0.02
Males 657 (270) 550 (170) 726 (277) 642 (156) 614 (226) 0.9
Females 849 (209) 804 (198) 761 (402) 700 (183) 844 (265) 0.2
Flow-mediated dilatation,
mm
0.31 (0.1) 0.25 (0.09) 0.27 (0.09) 0.25 (0.08) 0.29 (0.1) 0.8
Males 0.31 (0.1) 0.25 (0.06) 0.25 (0.08) 0.28 (0.1) 0.28 (0.1) 0.4
Females 0.29 (0.1) 0.26 (0.1) 0.26 (0.1) 0.26 (0.08) 0.3 (0.1) 0.9
Flow-mediated dilatation, % 9.4 (4.1) 8 (3.5) 8 (3.3) 7.9 (3.2) 8.7 (4.2) 0.3
Males 8.8 (4) 5.1 (2) 6.4 (2.3) 7.2 (3.3) 7.4 (3.6) 0.7
Females 9.6 (4.2) 9 (3.4) 9 (3.5) 8.4 (3.1) 10.3 (4.5) 1.0
Distension, mm 42 0.08 (0.04) 52 0.09 (0.04) 39 0.09 (0.04) 32 0.09 (0.04) 44 0.08 (0.04) 1.0
Males 9 0.09 (0.04) 14 0.1 (0.04) 15 0.09 (0.05) 17 0.1 (0.04) 25 0.09 (0.03) 0.8
Females 33 0.08 (0.08) 38 0.09 (0.04) 24 0.09 (0.03) 25 0.08 (0.02) 19 0.08 (0.04) 0.6
Distension, % 12.2 (6.2) 13.2 (6.1) 13.3 (6.3) 11.8 (4.4) 11 (4.6) 0.1
Males 10 (4.7) 11 (3.1) 10 (4.5) 11.1 (5.4) 10.1 (2.9) 0.8
Females 12.7 (6.5) 13.9 (6.8) 15.4 (6.4) 12.3 (3.7) 12.3 (6) 0.6
Distension coefficient (x10-
3.kPa-1)
9.5 (6.0) 9.7 (4.3) 9,6 (4.4) 8.6 (8.2) 8.1 (3.4) 0.05
Males 9.7 (9.8) 8.1 (2.2) 7.3 (3.2) 8.1 (3.9) 7.3 (2.2) 0.2
Females 9.4 (4.7) 10.2 (4.7) 11.1 (4.5) 9 (2.7) 9.1 (4.4) 0.6
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n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Right Common Carotid Artery
Diameter, mm 56 6.4 (0.5) 62 6.5 (0.5) 58 6.5 (0.5) 57 6.5 (0.6) 60 6.5 (0.5) 0.4
Males 14 6.6 (0.6) 16 7 (0.5) 23 6.8 (0.4) 23 6.9 (0.5) 34 6.7 (0.4) 0.6
Females 42 6.3 (0.4) 46 6.3 (0.4) 35 6.3 (0.4) 34 6.2 (0.4) 26 6.2 (0.5) 0.2
Distension, mm 0.7 (0.2) 0.7 (0.1) 0.7 (0.1) 0.7 (0.2) 0.8 (0.2) 0.5
Males 0.7 (0.2) 0.8 (0.2) 0.7 (0.2) 0.8 (0.2) 0.8 (0.2) 0.2
Females 0.7 (0.2) 0.7 (0.1) 0.7 (0.1) 0.7 (0.2) 0.7 (0.1) 0.5
Distension, % 11.5 (2.9) 11.5 (2.5) 10.7 (2.4) 11.4 (2.4) 11.6 (2.8) 0.2
Males 10.6 (3.1) 10.8 (2.6) 10.3 (2.8) 11.5 (2.3) 11.4 (3.3) 0.2
Females 11.8 (2.8) 11.7 (2.4) 10.9 (2) 11.4 (2.5) 11.8 (1.9) 0.4
Distension coefficient (x10-
3.kPa-1)
36.5 (13.8) 34.8 (6.8) 32.6 (7.6) 33.1 (7.5) 34.0 (7.4) 0.07
Males 35 (4.8) 30.7 (5.4) 29.7 (7) 31.4 (6.3) 31.9 (7.7) 0.7
Females 37 (7.6) 36.2 (6.7) 34.6 (7.5) 34.2 (8.1) 36.7 (6.1) 0.3
Intima-media thickness, mm 0.54 (0.07) 0.55 (0.07) 0.55 (0.08) 0.55 (0.09) 0.55 (0.08) 0.5
Males 0.57 (0.1) 0.57 (0.07) 0.55 (0.09) 0.55 (0.1) 0.57 (0.09) 0.8
Females 0.53 (0.06) 0.54 (0.07) 0.54 (0.07) 0.54 (0.08) 0.52 (0.06) 0.8
Carotid-radial PWV m/s 8.3 (1.2) 8.6 (1.2) 9.0 (1.6) 8.5 (1.2) 8.6 (1.0) 0.4
Males 9 (1.4) 9.1 (1.1) 8.8 (1.3) 8.6 (1.2) 8.7 (1) 0.2
Females 8.2 (1.1) 8.3 (1.2) 9 (1.8) 8.5 (1.2) 8.5 (1.1) 0.2
* Lowest quintile for dietary pattern score. ‡ P for trend across quintiles calculated with the dietary pattern score modelled on a continuous
scale in general linear models. Data are mean, SD.
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Table 8-6 Vascular Variables at Baseline According to Quintiles of Snack Dietary Pattern Score
n Q1 n Q2 n Q3 n Q4 n Q5 p‡
Right Brachial Artery
Diameter, mm 61 3.1 (0.5) 63 3.1 (0.6) 64 3.4 (0.6) 65 3.1 (0.5) 64 3.3 (0.6) 0.3
Males 19 3.7 (0.3) 20 4.0 (0.3) 36 3.8 (0.4) 21 3.6 (0.5) 22 3.8 (0.5) 0.9
Females 42 2.9 (0.2) 43 2.8 (0.4) 28 2.8 (0.3) 44 2.8 (0.3) 42 3 (0.4) 0.2
Reactive hyperaemia, % 770 (257) 721 (332) 721 (228) 739 (256) 729 (242) 0.6
Males 643 (188) 624 (289) 660 (227) 624 (231) 620 (200) 0.8
Females 827 (265) 765 (344) 792 (210) 793 (252) 790 (244) 0.7
Flow-mediated dilatation,
mm
0.27 (0.1) 0.26 (0.1) 0.27 (0.1) 0.28 (0.1) 0.28 (0.1) 0.4
Males 0.23 (0.1) 0.25 (0.09) 0.27 (0.1) 0.3 (0.01) 0.3 (0.1) 0.03
Females 0.29 (0.09) 0.27 (0.09) 0.26 (0.08) 0.26 (0.1) 0.28 (0.1) 0.6
Flow-mediated dilatation, % 8.5 (3.7) 8.4 (3.7) 7.9 (3.3) 8.7 (4.1) 8.4 (3.9) 0.8
Males 5.9 (2.9) 6.4 (2.9) 7 (3.2) 8.3 (3.9) 7.1 (3.1) 0.06
Females 9.6 (3.4) 9.3 (3.7) 9 (3.2) 8.9 (4.2) 9.1 (4.1) 0.5
Distension, mm 45 0.07 (0.03) 40 0.09 (0.04) 49 0.09 (0.04) 38 0.09 (0.04) 47 0.09 (0.04) 0.05
Males 19 0.1 (0.04) 11 0.1 (0.05) 27 0.09 (0.05) 12 0.1 (0.04) 11 0.09 (0.03) 0.3
Females 26 0.07 (0.02) 29 0.08 (0.03) 22 0.09 (0.03) 26 0.09 (0.05) 36 0.1 (0.05) 0.002
Distension, % 10.6 (3.9) 12.5 (4.3) 12.2 (6.1) 13.7 (6.7) 12.7 (6.3) 0.07
Males 10 (3.1) 12.1 (4.4) 10.2 (4.6) 1.5 (3.9) 9.4 (3.3) 0.3
Females 10.8 (4.1) 12.7 (4.4) 14.8 (6.8) 14.6 (7.5) 14.9 (6.9) 0.003
Distension coefficient (x10-
3.kPa-1)
7.8 (2.8) 9.7 (5.2) 8.9 (4.3) 10.0 (4.7) 9.3 (4.4) 0.2
Males 7.4 (2.4) 10.6 (8.2) 7.4 (3.2) 8.4 (2.9) 6.9 (2.3) 0.2
Females 8 (2.9) 9.3 (3.4) 10.7 (4.7) 10.6 (5.2) 10.9 (4.8) 0.003
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n Q1 n Q2 n Q3 n Q4 n Q5 p‡
Right Common Carotid Artery
Diameter, mm 58 6.4 (0.47) 58 6.4 (0.45) 61 6.6 (0.50) 61 6.4 (0.54) 55 6.6 (0.57) 0.3
Males 16 6.8 (0.4) 18 6.6 (0.4) 36 6.8 (0.5) 19 6.8 (0.4) 21 6.9 (0.6) 0.2
Females 42 6.3 (0.4) 40 6.3 (0.4) 25 6.3 (0.3) 42 6.2 (0.5) 34 6.3 (0.4) 0.8
Distension, mm 0.8 (0.2) 0.8 (0.2) 0.7 (0.2) 0.7 (0.1) 0.7 (0.2) 0.05
Males 0.8 (0.2) 0.8 (0.2) 0.7 (0.2) 0.7 (0.2) 0.7 (0.2) 0.1
Females 0.7 (0.2) 0.8 (0.1) 0.7 (0.1) 0.7 (0.1) 0.7 (0.1) 0.2
Distension, % 11.7 (2.8) 11.8 (2.8) 11.0 (2.5) 11.6 (2.6) 10.6 (2.2) 0.08
Males 12.1 (3.2) 11.5 (2.5) 10.8 (2.5) 11 (2.6) 10.2 (2.4) 0.1
Females 11.5 (2.6) 12 (2.1) 11.4 (2.5) 11.8 (2.6) 10.8 (2) 0.5
Distension coefficient (x10-
3.kPa-1)
34.6 (7.4) 36.5 (13.1) 32.8 (7.4) 34.8 (8.0) 32.1 (7.1) 0.09
Males 32.7 (7.2) 35.8 (22.2) 30.7 (5.8) 31 (6.8) 29 (6.7) 0.1
Females 35.3 (7.4) 36.8 (6.1) 36 (8.4) 36.5 (8.1) 34.1 (6.6) 0.6
Intima-media thickness, mm 0.55 (0.09) 0.54 (0.07) 0.54 (0.07) 0.53 (0.07) 0.55 (0.59) 0.2
Males 0.59 (0.1) 0.54 (0.08) 0.56 (0.08) 0.54 (0.05) 0.6 (0.01) 0.9
Females 0.52 (0.07) 0.54 (0.07) 0.53 (0.06) 0.53 (0.08) 0.056 (0.06) 0.2
Carotid-radial PWV m/s 8.6 (1.0) 8.6 (1.7) 8.5 (1.1) 8.5 (1.1) 8.7 (1.4) 0.8
Males 8.6 (1.1) 9.3 (1.4) 8.7 (1.2) 8.5 (0.8) 8.9 (1.3) 0.9
Females 8.6 (1) 8.3 (1.7) 8.3 (1) 8.5 (1.2) 8.6 (1.5) 0.7
* Lowest quintile for dietary pattern score. ‡ P for trend across quintiles calculated with the dietary pattern score modelled on a continuous
scale in GLM. Data are mean, SD.
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Table 8-7 Regression coefficient (95% CI) for vascular variables according to quintiles of dietary pattern score1
Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
Right Common Carotid
Artery
IMT (mm)
Health Conscious
Model 1* n = 307 -0.03 (-0.06, 0.002) 0.07 -0.04 (-0.07, -0.01) 0.004 -0.03 (-0.06, 0.001) 0.06 -0.04 (-0.07, -0.1) 0.007 0.02
Males 0.003 (-0.06, 0.06) 0.9 -0.04 (-0.1, 0.02) 0.2 -0.01 (-0.05, 0.07) 0.8 -0.02 (-0.08, 0.05) 0.6 0.7
Females -0.05 (-0.1, -0.003) 0.04 -0.05 (-0.1, -0.009) 0.02 -0.04 (-0.09, 0) 0.05 -0.07 (-0.1, -0.03) 0.002 0.02
Model 2† n = 271 -0.02 (-0.05, 0.02) 0.4 -0.03 (-0.06, 0.006) 0.1 -0.009 (-0.04, 0.03) 0.6 -0.02 (-0.06, 0.02) 0.3 0.6
Males 0.002 (-0.06, 0.06) 1.0 -0.04 (-0.1, 0.03) 0.3 0.02 (-0.05, 0.08) 0.6 0.005 (-0.06, 0.07) 0.9 0.9
Females -0.03 (-0.08, 0.02) 0.2 -0.04 (-0.08, 0.007) 0.1 -0.03 (-0.07, 0.01) 0.2 -0.04 (-0.09, 0) 0.05 0.05
Meat Based
Model 1* 0.009 (-0.02, 0.04) 0.6 0.008 (-0.02, 0.03) 0.6 0.009 (-0.21, 0.04) 0.5 0.003 (-0.03, 0.03) 0.8 0.9
Model 2† 0.001 (-0.03, 0.03) 0.9 0.004 (-0.03, 0.3) 0.8 -0.002 (-0.03, 0.03) 0.9 -0.003 (-0.03, 0.03) 0.8 0.9
Snack
Model 1* -0.007 (-0.04, 0.02) 0.7 -0.01 (-0.04, 0.02) 0.5 -0.01 (-0.04, 0.02) 0.4 -0.02 (-0.1, 0.05) 0.2 0.2
Model 2† -0.01 (-0.04, 0.02) 0.5 -0.03 (=-.-6, 0.002) 0.07 -0.02 (-0.05, 0.009) 0.2 -0.01 (-0.02, 0.04) 0.5 0.8
Brachial Artery
Distension (mm)
Health Conscious
Model 1* -0.008 (-0.02, 0.009) 0.4 -0.005 (-0.02, 0.01) 0.6 -0.01 (-0.03, 0.002) 0.09 0.004 (-0.01, 0.02) 0.7 0.9
Model 2† -0.02 (-0.03, 0.002) 0.09 -0.007 (-0.03, 0.01) 0.4 -0.02 (-0.04, -0.002) 0.03 0 (-0.02, 0.02) 1.0 0.8
Meat Based
Model 1* -0.01 (-0.006, 0.03) 0.2 0.008 (-0.009,0.03) 0.4 0.002 (-0.02, 0.02) 0.8 -0.001 (-0.02, 0.02) 0.9 0.6
Model 2† 0.009 (-0.007, 0.03) 0.3 0.008 (-0.01, 0.03) 0.4 0.001 (-0.02, 0.02) 0.9 -0.005 (-0.23, 0.01) 0.6 0.4
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Snack
Model 1* 0.02 (0, 0.03) 0.06 0.02 (0, 0.03) 0.05 0.02 (-0.002, 0.03) 0.09 0.02(-0.001, 0.03) 0.07 0.1
Males 0.01 (-0.02, 0.05) 0.5 -0.003 (-0.04, 0.03) 0.9 -0.005 (-0.04, 0.03) 0.8 -0.01 (-0.05, 0.02) 0.5 0.2
Females 0.02 (-0.001, 0.04) 0.06 0.03 (0.005, 0.05) 0.02 0.02 (0.003, 0.04) 0.03 0.03 (0/01, 0.05) 0.003 0.003
Model 2† 0.02 (-0.002, 0.03) 0.09 0.02 (0.001, 0.04) 0.04 0.02 (-0.003, 0.03) 0.1 0.02 (0, 0.04) 0.05 0.1
Males 0.006 (-0.03, 0.44) 0.8 -0.004 (-0.04, 0.03) 0.8 -0.005 (-0.04, 0.03) 0.8 -0.02 (-0.06, 0.1) 0.2 0.1
Females 0.01 (-0.005, 0.03) 0.2 0.03 (0.006, 0.05) 0.1 0.02 (-0.003, 0.04) 0.1 0.03 (0.006, 0.05) 0.0 0.02
1For tables 8.7 – 8.11 quintile 1 is the lowest for dietary pattern score (referent set at 0). 2Beta coefficient values are calculated as highest
minus lowest quintiles based on general linear models. 3 p for trend across quintiles calculated in GLM with dietary pattern modelled
continuously (score). *Adjusted for baseline arterial diameter, skin and room temperature † Adjusted additionally for age, sex, social class,
physical activity, LDL cholesterol, triglycerides, WHR, mean arterial blood pressure, fasting insulin and energy intake.
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Table 8-8 Regression coefficients (95% CI) for CVD risk factors (obesity) according to quintiles of dietary
pattern score1
Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
Body Mass Index
Health conscious
Model 1*: n= 321 -1.6 (-3, -0.2) 0.02 -1.4 (-2.8, -0.1) 0.04 -1.1 (-2.5, 0.3) 0.1 -0.8 (-2.2, 0.5) 0.2 0.5
Model 2 † n= 213 -0.5 (-1.7, 0.8) 0.5 -0.5 (-1.7, 0.8) 0.5 -0.09, (-1.3, 1.2) 0.9 -0.8 (-0.5, 2.2) 0.2 0.2
Meat based
Model 1* -0.5 (-0.8, 1.9) 0.4 -1 (-0.4, 2.3) 0.2 -0.6 (0.8, 2.0) 0.4 -0.5 (-1.9, 0.9) 0.5 0.6
Model 2 † 0.5 (-0.7, 1.7) 0.4 0.5 (-0.7, 1.7) 0.4 0.09 (-1.1, 1.3) 0.9 -0.7 (-1.9, 0.5) 0.3 0.2
Snack
Model 1* 0.4 (-1, 1.7) 0.6 0.8 (-0.5, 2.2) 0.2 1.6 (0.2, 2.9) 0.03 1.1 (-0.2, 2.5) 0.1 0.03
Model 2 † 0.8 (-1.1, 1.4) 0.8 0.2 (-1.1, 1.4) 0.8 0.9 (-0.3, 2.2) 0.1 0.3 (-0.9, 1.6) 0.6 0.5
Waist circumference, cm
Health conscious
Model 1* -4.8 (-8.8,-1.4) 0.006 -6.5 (-10,-3) <0.001 -5.8 (-9.3,-2.4) 0.001 -5.7 (-9.1,-2.2) 0.001 0.002
Model 2 † -2.9 (-6.0, 0.3) 0.07 -3.5 (-6.7,-0.3) 0.03 -2.7 (-5.8, 0.5) 0.1 -2.9 (-6.2,0.3) 0.08 0.2
Meat based
Model 1* 1.3 (-2.2, 4.8) 0.5 3.8 (0.3, 7.3) 0.03 2.3 (-1.2, 5.8) 0.2 1.9 (-1.7, 5.4) 0.3 0.2
Model 2 † 0.2 (-2.6, 3.1) 0.9 1.5 (-1.3, 4.4) 0.3 -0.2 (-3.0, 2.6) 0.9 -1.5 (-4.4, 1.4) 0.1 0.3
Snack
Model 1* -1 (-3.6, 3.4) 0.9 3.7 (0.2,7.21) 0.04 2.4 (-1.1,5.9) 0.2 3.2 (-0.3,6.7) 0.07 0.03
Model 2 † 0.7 (-2.1, 3.6) 0.6 -0.3 (-2.6, 3.3) 0.9 -1.1 (-1.7, 3.9) 0.5 1.0 (-1.9, 4.0) 0.5 0.5
Waist:Hip ratio
Health conscious
Model 1* -0.04 (-0.06, 0.02) 0.001 -0.06 (-0.08, 0.04) <0.001 -0.05 (-0.07, 0.03) <0.001 -0.05 (-0.08, -0.03) <0.001 <0.001
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Model † -0.02 (-0.04, 0.00) 0.06 -0.03 (-0.05, 0.01) 0.003 -0.02 (-0.04, -0.002) 0.03 -0.02(-0.04,0.002) 0.08 0.1
Meat Based
Model 1* 0.004 (-0.2, 0.3) 0.7 0.03 (0.009 ,0.06) 0.008 0.02 (-0.005,0.04) 0.1 0.03 (0.009,0.06) 0.007 0.003
Model † 0.003 (-0.02, 0.2) 0.7 0.02 (-0.002, 0.03) 0.08 -0.00 (-0.02,0.02) 1 0 004 (-0.01.0.02) 0.7 0.8
Snack
Model 1* -0.003 (-0.3, 0.2) 0.8 0.03 (0.008, 0.06) 0.01 0.02 (-0.009,0.04) 0.2 0.02 (-0.002,0.05) 0.07 0.02
Model 2† 0.00 (-0.02, 0.02) 1 -0.002 (-0.02, 0.02) 0.8 0.008 (-0.01,0.03) 0.4 0.009 (-0.009,0.03) 0.4 0.2
*Unadjusted,† Adjusted for age, sex and energy intake.
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Table 8-9 Regression coefficients (95% CI) for CVD risk factors (blood pressure) according to quintiles of
dietary pattern score1
Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
Systolic (mm Hg)
Health conscious
Model 1* :n=321 -2.2 (-5.8, 1.5) 0.2 -3.9 (-7.6, -0.25) 0.04 -2.8 (-6.5, 0.87) 0.1 -7.4 (-11.1, -3.7) <0.001 <0.001
Model 2† :n=310 1 (-2.3, 4.4) 0.5 -0.08 (-3.5,3.3) 1 1.4 (-2, 4.8) 0.4 -3.6 (7.1, -0.1) 0.05 0.06
Meat Based
Model 1* 2.5 (-1.1, 6.2) 0.17 3.8 (0.15, 7.4) 0.04 6.5 (2.8, 10.1) 0.001 6.9 (3.2, 10.5) <0.001 <0.001
Model 2† 1.2 (-2.1,4.5) 0.5 1.4 (-1.9, 4.7) 0.4 4.6 (1.3, 7.9) 0.007 5.5 (2.1, 8.8) 0.001 <0.001
Snack
Model 1* -2.3 (-6, 1.5) 0.2 1.7 (-2, 5.4) 0.4 2 (-1.7, 5.7) 0.3 2 (-1.7, 5.7) 0.3 0.06
Model 2*† -2.4 (-5.8, 8.9) 0.2 -1 (-4.4, 2.4) 0.6 0.4 (-2.9, 3.8) 0.8 0.7 (-2.8, 4.1) 0.7 0.2
Diastolic (mm Hg)
Health conscious
Model 1* -1.6 (-4.2, 1.1) 0.2 -3.8 (-6.4, -1.1) 0.005 -1.8 (-6.4, -1.1) 0.2 -6.3 (-9, -3.7) <0.001 <0.001
Model 2† 0.4 (-2.1, 2.9) 0.7 -1.7 (-4.2, 0.8) 0.2 0.4 (-2.1, 3) 0.7 -4.6 (-7.3, 1.9) 0.001 0.002
Meat Based
Model 1* 0.96 (-1.7, 3.6) 0.06 2.6 (-0.1, 5.3) 0.06 2.4 (-0.3, 5.1) 0.08 3.7 (1.0, 6.4) 3 0.008 0.004
Model 2*† 0.2 (-2.4, 2.7) 0.9 1.2 9-1.3, 3.7) 0.4 1.5 (-1.1, 4) 0.3 3.5 (0.9, 6) 0.008 0.003
Snack
Model 1* -1 (-3.7, 1.7) 0.5 2 (-0.7, 4.7) 0.2 2.1 (-0.6, 4.8) 0.1 2 (-0.7, 4.7) 0.1 0.02
Model 2*† -1.2 (-3.7, 1.4) 0.4 0.5 (-2.1, 3.1) 0.7 1 (-1.6, 3.6) 0.4 0.7 (-1.9, 3.3) 0.6 0.1
Mean Arterial Pressure (mm
Hg)
Health conscious
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Model 1* -2.3 (-5.3, 0.78) 0.1 -4.1 (-7.1, -1.1) 0.008 -2.7 (-5.7, 0.3) 0.08 -6.8 (-9.9, -3.7) <0.001 <0.001
Model 2† 0.1 (-2.8, 3) 0.9 -1.5 (-4.4, 1.5) 0.3 0.3 (-2.6, 3.3) 0.8 -4.1 (-7.2, 2.1) 0.009 0.02
Meat Based
Model 1* 1.6 (-1.4, 4.7) 0.3 2.8 (-0.3, 5.9) 0.08 0.02 (-3.2, 2.6) 0.01 4.9 (1.8, 7.9) 0.002 0.004
Model 2† 0.8 (-2.1,3.7) 0.6 0.8 (-2.2, 5.5) 0.07 2.6 (-0.2, 5.5) 0.07 3.7 (0.8, 6.6) 0.01 0.002
Snack
Model 1* -1.6 (-5, 1.5) 0.3 1.6 (-1.5, 4.7) 0.3 1.8 (-1.2, 4.9) 0.2 2.2 (-0.8, 5.3) 0.2 0.5
Model 2† -2 (-4.9, 0.9) 0.2 -0.6 (-3.5, 2.4) 0.7 0.5 (-2.4, 3.4) 0.7 0.9 (-2.1, 3.9) 0.5 0.1
Heart Rate (beats per
minute)
Health conscious
Model 1* -1 (-4.5, 2.6) 0.6 -2.1 (-5.6, 1.5) 0.3 0.4 (-3.2, 4) 0.8 -5.7 (-9.3, -2.1) 0.002 0.02
Model 2† -0.6 (-4.3, 2.9) 0.7 -2.2 (-5.9, 1.4) 0.2 0.2 (-3.4, 3.8) 0.9 -5.3 (-9.2, 1.5) 0.007 0.02
Meat Based
Model 1* 2.6 (1, 6.3) 0.2 3.4 (-0.2, 2.7) 0.06 4.2 (0.6, 7.8) 0.03 2.6 (-1.04, 6.2) 0.2 0.1
Model 2† 3 (-0.6) 0.1 3.8 (0.2,7.4) 0.04 4.5 (1, 8.1) 0.01 3.6 (0.03, 7.3) 0.05 0.7
Snack
Model 1* 0.9 (-2.7, 4.5) 0.6 1.3 (-2.3, 5) 0.5 2.9 (-0.7, 6.5) 0.1 5.1 (1.5, 8.7) 0.006 0.003
Model 2† 0.3 (-3.3, 3.9) 0.9 2 (-1.7, 5.6) 0.3 1.4 (-2.2, 5.1) 0.4 3.2 (-0.5, 6.9) 0.09 0.04
*Unadjusted,† Adjusted for age, sex, height, WHR, physical activity, social class, smoking practice, LDL cholesterol, triglycerides and energy
intake.
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Table 8-10: Regression coefficients (95% CI) for CVD risk factors (fasting serum lipid concentrations) and
dietary pattern quintiles
Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
Total-cholesterol
Health conscious
Model 1* :n= 319 -0.4 (-0.7, -1) 0.01 -0.3 (-0.6, -0.06) 0.02 -0.2 (-0.5, 0.04) 0.09 -0.5 (-0.8, -0.2) 0.002 0.01
Model 2† n = 313 -0.3 (-0.6, 0.03) 0.04 -0.3 (-0.6, 0.04) 0.08 -0.1 (-0.4, 0.2) 0.3 -0.3 (-0.7, 0.006) 0.02 0.1
Meat Based
Model 1* -0.2 (-0.5, 0.08) 0.2 -0.07 (-0.4, 0.2) 0.7 -0.1 (-0.4, 0.2) 0.5 -0.09 (-0.4, 0.2) 0.5 0.7
Model 2† -0.3 (-0.6, 0.03) 0.08 -0.2 (-0.5, 0.1) 0.2 -0.2 (-0.5, 0.1) 0.3 -0.2 (-0.5, 0.1) 0.2 0.5
Snack
Model 1* 0.05 (-0.2,0.3) 0.7 0.1 (-0.2, 0.4) 0.4 0.07 (-0.2,0.4) 0.6 0.3 (0.01, 0.6) 0.04 0.1
Model 2† 0.01 (-0.3, 0.3) 0.9 -0.07 (-0.4, 0.2) 0.7 0.05 (-0.3, 0.3) 0.8 0.1 (-0.2, 0.4) 0.5 0.8
LDL-cholesterol
Health conscious
Model 1* -0.3 (-0.61, -0.07) 0.02 -0.4 (-9.63, -0.1) 0.008 -0.3 (-0.6, 0.01) 0.06 -0.4 (-0.67. -0.16) 0.002 0.01
Model 2† -0.2 (-0.2,0.07) 0.1 -0.2 (-0.5,0.02) 0.07- 0.09 (-0.4,0.2) 0.5 -0.3 (-0.6,-0.05) 0.02 0.2
Meat Based
Model 1* -0.1 (-0.4, 0.2) 0.5 0.05 (-0.2, 0.3) 0.7 -0.02 (-0.3,0.2) 0.9 -0.07 (-0.3, 0.2) 0.6 0.8
Model 2† -0.2 (-0.4, 0.1) 0.3 -0.08 (-0.3, 0.2) 0.6 -0.1 (-0.4, 0.2) 0.4 -0.2 (0.5, 0.09) 0.2 0.4
Snack
Model 1* 0.09 (-0.2, 0.4) 0.5 0.2 (-0.03, 0.5) 0.09 0.1 (-0.1, 0.4) 0.4 0.3 (0.05, 0.6) 0.02 0.03
Model 2† 0.04 (-0.2, 0.3) 0.8 0.03 (-0.2, 0.3) 0.8 0.05 (-0.2,0.3) 0.7 0.2 (-0.1, 0.5) 0.2 0.3
HDL-cholesterol
Health Conscious
Model 1* 0.1 (-0.01, 0.2) 0.08 0.1 (-0.01, 0.2) 0.08 0.1 (0.01, 0.3) 0.03 0.1 (-0.009, 0.2) 0.07 0.08
Model 2† 0.03 (-0.08, 0.1) 0.6 0.02 (-0.1, 0.1) 0.7 0.04 (-0.08, 0.2) 0.6 0.06 (-0.08, 0.2) 0.4 0.6
Meat Based
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Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
Model 1* -0.08 (-0.2, 0.05) 0.2 -0.1 (-0.2, 0.005) 0.04 -0.1 (-0.2, 0.01) 0.07 -0.04 (-0.2, 0.08) 0.5 0.4
Model 5† -0.05 (-0.2, 0.06) 0.4 -0.05 (-0.2, 0.07) 0.4 -0.05 (-0.2, 0.06) 0.4 0.05 (-0.07, 0.2) 0.4 0.8
Snack
Model 1* 0.07 (-0.05, 0.19) 0.27 -0.11 (-0.2, 0.01) 0.07 -0.05 (0.2, 0.07) 0.38 -0.08 (-0.2, 0.05) 0.2 0.05
Model 2† 0.09 (-0.02, 0.2) 0.1 -0.04 (-0.2, 0.08) 0.5 -0.02 (-0.1, 0.1) 0.7 -0.03 (-0.2, 0.10 0.7 0.1
VLDL-cholesterol
Health conscious
Model 1* -0.09 (-0.2, 0.01) 0.06 -0.1 (0.2, 0.001) 0.02 -0.1 (-0.2, -0.04) 0.009 -0.2 (-0.2,-0.6) <0.001 <0.001
Model 2† -0.07 (0.2, 0.03) 0.1 -0.05 (-0.1, 0.05) 0.2 -0.1 (-0.2, 0.004) 0.05 -0.1 (-0.2, -0.001) 0.02 0.06
Meat Based
Model 1* 0.04 (-0.06, 0.1) 0.08 0.01 (-0.08, 0.1) 0.06 0.04 (-0.06, 0.1) 0.09 0.03 (-0.07, 0.1) 0.3 0.7
Model 2† 0.03 (-0.07, 0.1) 0.6 -0.04 (-0.1, 0.05) 0.4 -0.004 (-0.1, 0.09) 0.9 -0.03 (-0.1, 0.06) 0.5 0.6
Snack
Model 1* -0.03 (-0.1, 0.07) 0.6 0.008 (-0.09, 0.1) 0.9 0 (-0.1, 0.1) 1 0.06 (-0.04, 0.2) 0.2 0.06
Model 2† -0.04 (-0.1, 0.05) 0.4 -0.06 (-0.2, 0.04) 0.2 -0.07 (-0.2, 0.03) 0.2 -0.03 (-0.1, 0.07) 0.5 0.5
Triacylglycerol
Health conscious
Model 1* -0.2 (-0.5, -0.02) 0.08 -0.2 (-0.4, 0.005) 0.06 -0.3 (-0.6, -0.8) 0.01 -0.3 (-0.6, -0.1) 0.002 <0.001
Model 2† -0.1 (-0.3, 0.06) 0.1 -0.1 (-0.3, 0.1) 0.2 -0.2 (-0.4, -0.007) 0.05 -0.2 (-0.5, 0) 0.02 0.06
Meat Based
Model 1* 0.09 (-0.2, 0.3) 0.3 0.03 (-0.2, 0.2) 0.5 0.08 (-0.1, 0.3) 0.3 0.06 (-0.2, 0.3) 0.3 0.6
Model 2† 0.06 (-0.1, 0.3) 0.5 -0.1 (-0.3, 0.1) 0.6 -0.009 (-0.2, 0.2) 0.7 -0.07 (-0.3, 0.1) 0.4 0.6
Snack
Model 1* -0.07 (-0.3, 0.1) 0.5 0.02 (-0.2, 0.2) 0.9 0.002 (-0.2, 0.2) 1 0.1 (-0.08, 0.3) 0.2 0.2
Model 2† -0.09 (-0.2, 0.1) 0.2 -0.1 (-0.3, 0.09) 0.2 -0.1 (-0.4, 0.06) 0.2 -0.08 (-0.3, 0.1) 0.5 0.6
*Unadjusted. † Adjusted for age, sex, WHR, physical activity, social class, smoking practice, mean arterial blood pressure, and energy
intake. All measurements based on fasting concentrations and in mmoL/L unless stated.
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Table 8-11: Regression coefficients (95% CI) for insulin, insulin resistance and C-reactive protein and
dietary pattern quintiles
Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
Insulin (pmol/L)
Health Conscious
Model 1* n= 319 -10.1 (-19.3, -0.8) 0.03 -5.2 (-14.6, 4.1) 0.3 -10.4 (-19.7, -1.1) 0.3 -10.4 (-19.7, -1) 0.03 0.04
Model 2† n = 313 -7.2 (-14.7, 0.3) 0.06 -4.4 (-12.2, 3.3) 0.3 -8.8 (-16, -1.1) 0.03 -8.5 (-17, 0.4) 0.05 0.1
Meat Based
Model 1* -2.4 (-11.8, 7) 0.6 5.2 (-4.2, 14.5) 0.3 4.7 (-4.7, 14.1) 0.3 -2.8 (-12.1, 6.6) 0.6 0.9
Model 2† -0.01 (-1.2, 1.2) 1 0.8 (-0.5, 2) 0.2 1 (-0.3, 2.2) 0.1 -0.08 (-1.4, 1.3) 0.9 0.3
Snack
Model 1* 1.5 (-7.8, 10.9) 0.7 0.5 (-8.8, 9.8) 0.9 12.6 (3.2, 21.9) 0.008 6.9 (-2.4, 16.3) 0.1 0.02
Model 2† 0.3 (-1, 1.5) 0.7 -0.7 (-2, 0.6) 0.3 1.1 (-0.2, 2.3) 0.1 0.2 (-1.2, 1.5) 0.8 0.2
HOMA
Health Conscious
Model 1* -0.5 (-0.9, -0.04) 0.03 -0.3 (-0.7, 0.2) 0.05 -0.5 (-0.9, -0.07) 0.02 -0.5 (-0.9, -0.08) 0.02 0.03
Model 2† -0.5 (-0.9, -0.04) 0.03 -0.3 (-0.7, 0.2) 0.2 -0.5 (-0.9, -0.07) 0.02 -0.5 (-0.9, -0.08) 0.02 0.3
Meat Based
Model 1* -0.1 (-0.6, 0.3) 0.5 0.2 (-0.2, 0.7) 0.3 0.2 (-0.2, 0.6) 0.4 -0.1 (-0.5, 0.3) 0.6 0.8
Model 2† 0.01 (-0.3, 0.3) 0.9 0.2 (-0.2, 0.6) 0.2 0.2 (-0.1, 0.6) 0.2 0.006 (-0.4, 0.4) 0.4 0.4
Snack
Model 1* 0.06 (-0.2, 0.3) 0.6 0.003 (-0.2, 0.2) 1 0.4 (0.2, 0.6) 0.001 0.2 (0.06, 0.5) 0.01 0.03
Model 2† -0.04 (-0.3, 0.4) 0.8 -0.2 (-0.5, 0.2) 0.3 0.3 (-0.05, 0.6) 0.09 0.006 (-0.4, 0.4) 0.9 0.3
C-reactive protein
Health Conscious
Model 1* -1.1 (-2.3, 0.1) 0.07 -0.003 (-1.2, 1.2) 1.0 0.1 (-1.1, 1.3) 0.8 -0.5 (-1.7, 0.7) 0.4 0.8
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Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
Model 2† -0.8 (-2.0, 0.5) 0.2 0.3 (-0.9, 1.6) 1.6 -0.3 (-0.9, 1.6) 0.6 0.03 (-1.3, 1.4) 1.0 0.4
Meat Based
Model 1* 1.0 (-0.2, 2.2) 1.0 0.8 (-0.4, 2.0) 0.2 0.9 (-0.3, 2.0) 0.2 0.5 (-0.7, 1.6) 0.4 0.6
Model 2† 1.1 (-0.05, 2.3) 0.06 0.5 (-0.7, 1.7) 0.5 0.9 (-0.3, 2.1) 0.1 0.6 (-0.6, 1.9) 0.3 0.4
Snack
Model 1* 0.2 (-0.9, 1.4) 0.7 0.3 (-0.9, 1.5) 0.6 0.4 (-0.6, 1.7) 0.4 1.2 (0.02, 2.4) 0.05 0.05
Males -0.2 (-1.8, 1.5) 0.8 -0.3 (-1.8, 1.1) 0.7 -0.5 (-2.1, 1.1) 0.5 -0.4 (-2.0, 1.2) 0.6 0.5
Females 0.4 (-1.2, 2.0) 0.6 0.9 (-0.9, 2.6) 0.4 1.0 (-0.6, 2.6) 0.2 2.0 (0.4, 3.6) 0.01 0.01
Model 2† 0.4 (-0.8, 1.6) 0.5 0.5 (-0.7, 1.7) 0.5 0.1 (-1.1, 1.3) 0.8 1.0 (-0.3, 2.2) 0.1 0.2
Males -0.2 (-0.2, 1.6)) 0.9 -0.3 (-1.9, 1.4) 0.8 -0.8 (-2.7, 0.9) 0.3 -0.5 (-2.4, 1.3) 0.6 0.4
Females 0.5 (-1.1, 2.1) 0.5 0.5 (-1.3, 2.3) 0.6 0.4 -1.1, 2.0) 0.6 1.6 (0, 3.3) 0.05 0.1
*Unadjusted,† Adjusted for age, sex, WHR, physical activity, social class, smoking practice,mean arterial blood pressure, LDL cholesterol,
triglycerides and energy intake. All measurements based on fasting concentration.
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Table 8-12 Pearson’s correlation coefficients for relationship between arterial IMT and distensibility with
CVD risk factors (blood pressure, heart rate and obesity)
SBP
(mm Hg)
DBP
(mm Hg)
MAP
(mm Hg)
Heart Rate
(BPM)
Waist
Circumference
Waist to
Hip Ratio
BMI
Common
Carotid Artery
IMT 0.31** 0.26** 0.31** -0.02 -0.23** -0.13* 0.05
Distensibility -0.45** -0.30** -0.39** -0.20** -0.30** -0.30** -0.26**
Brachial Artery
Distensibility
-0.28** -0.21** -0.25** -0.10 -0.18** -0.24** -0.13
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Table 8-13 Pearson’s correlation coefficients for relationship between arterial IMT and distensibility with
CVD risk factors (serum lipids, glucose and insulin)
Glucose
(mmol/L)
Insulin
(pmol/L)
Total
Cholesterol
(mmol/L)
HDL
Cholesterol
(mmol/L)
LDL
Cholesterol
(mmol/L)
VLDL
Cholesterol
(mmol/L)
TAG
(mmol/L)
Common Carotid
Artery
IMT 0.15** 0.06 0.08 0.13* -0.12* 0.08 0.08
Distensibility -0.28** -0.20** -0.17** 0.10* -0.21** -0.16** -0.20**
Brachial Artery
Distensibility -0.21** -0.16* -0.10 0.04 -0.14* -0.20** -0.20**
** correlation significant at the 0.01 and * 0.05 level (2-tailed).
Abbreviations in Tables: CCA-IMT, common carotid artery intima media thickness, SBP, systolic blood pressure, DBP, diastolic blood
pressure, MAP, mean arterial pressure, WC, waist circumference, WHR, waist to hip ratio, BMI, body mass index, Hg, mercury, BPM, beats
per minute.
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Table 8-14 Univariate linear regression models summarising associations between dietary patterns and
Framingham risk factors with measures of vascular health
Mean CCA IMT Brachial Artery Distension (mm) Flow Mediated Dilatation (%)
Risk Factor β 95% CI P R2 β 95% CI P R2 β 95% CI P R2
Age, y 0.006 0.004,0.007 <0.001 0.1 -0.001 -0.002, 0.000 0.1 0.01 -0.03 0.117, 0.056 0.5 -0.002
Men/women -0.03 -0.04, -0.008 0.8 0.03 -0.01 -0.02, 0.002 0.03 0.02 2.3 1.4, 3.1 <0.001 0.09
SBP, mm Hg 0.002 0.001, 0.003 <0.001 0.09 0.000 0.000, 0.001 0.6 0.002 -0.02 -0.057, 0.019 0.3 0.003
TC, mmol/L 0.007 -0.003, 0.017 0.6 0.003 -0.003 -0.008, 0.003 0.4 -0.001 -0.09 -0.57, 0.39 0.7 -0.003
HDL-C,
mmol/L
-0.03 -0.05, -0.004 0.2 0.02 -0.02 -0.03, 0.001 0.06 0.01 0.08 -0.32, 2.06 0.2 0.003
Cotinine,
ng/umol
0.000 0.000, 0.000 0.8 0.002 0.000 0.000, 0.000 0.5 -0.003 -0.004 -0.01, 0.002 0.2 0.007
Dietary
Pattern
Healthy -0.1 -0.012, 0.000 0.04 0.01 0.02 -0.004, 0.003 0.7 -0.004 0.09 -0.04, 0.55 0.09 0.006
Meaty 0.002 -0.004, 0.008 0.5 0.002 0.001 -0.004, 0.004 1.0 0.000 0.06 -0.45, 0.14 0.3 0.003
Snack 0.07 -0.003, 0.01 0.2 0.001 -0.1 0.000, 0.007 0.05 0.01 -0.01 -0.26, 0.32 0.8 0.000
Abbreviations in table: β, standardized coefficient, SBP, systolic blood pressure; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol.
The R2 values give the strength of the association between individual risk factors and vascular measures. The coefficient is the strength of the
association of the risk factor; for example, a healthy dietary pattern is associated with CCA-IMT such that for every increase in dietary pattern
score quintile CCA-IMT decreases by 0.01 mm. For every increase in 1 year of age CCA-IMT increases by 0.005 mm.
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Chapter 9
Relationships of n-3 Fatty Acids with Vascular Structure
and Function and Classical CVD Risk Factors
9.1 Introduction
It is well established that diet affects CVD but which nutrients are the most important
and there specific roles is unclear. Individual components within dietary patterns
have been associated with protective effects for vascular health and CVD risk factors
(Chapter 2, Section 2.3). These include n-3 PUFAs and in particular the n-3 long-
chain fatty acids DHA and EPA. This chapter reports associations of DHA and EPA
status, assessed according to erythrocyte membrane concentrations, with measures
of vascular structure and function and CVD risk factors.
9.1.1 Sociodemographic Characteristics
Subjects were divided into quintiles of red cell fatty acid concentration, expressed as
a percentage total red cell membrane fatty acids (%RBCFA). Subjects were closely
matched for demographic variables according to quintiles of fatty acid status (Tables
9-1 and 9-2). Individuals in the highest quintiles for DHA and EPA %RBCFA were
suggested to have healthier lifestyles demonstrated by a lower prevalence of
smoking in the highest compared with lowest quintile (current smokers in lowest and
highest quintiles of DHA status 25 (40%) and 6 (10%) respectively, P = 0.001).
9.1.2 Fatty Acid Status and Vascular Structure and Function
Vascular structure and function were related to fatty acid status with different effects
according to gender.
9.1.2.1 FMD and Fatty Acid Status
FMD decreased as DHA %RBCFA increased (P = 0.05) (Table 9-3). This effect was
confined to females (DHA %RBCFA x gender interaction on FMD: P = 0.003). In
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secondary analyses absolute FMD of the brachial artery adjusted for baseline
diameter, skin and room temperature was 0.08 mm (27%) lower for women in the
highest quintile of DHA %RBCFA compared with those in the lowest (mean
difference between highest and lowest quintile -0.08, 95% CI: -0.1 - 0.08 [P = 0.001])
(Table 9-5, Model 1). This effect remained significant in a model fully adjusted for
factors known to influence vascular health (age, social class, physical activity, LDL
cholesterol, TG, WHR, fasting insulin and energy intake (P for trend = 0.008)
(Table 9-5, Model 2).
9.1.2.2 Arterial distension and fatty acid status
Brachial and CCA distension increased as EPA status increased (P for trend = 0.02
and 0.03 respectively) (Table 9-4). For brachial artery distension this effect was
confined to males (gender x fatty acid quintile interaction on brachial artery
distension: P = 0.02). In secondary analyses these effects were attenuated and no
longer significant after adjustment for confounders (Table 9-5).
9.1.3 Fatty Acid Status and Cardiovascular Risk Factors
CVD risk factors including obesity, blood pressure, serum cholesterol, triglycerides
and insulin resistance were associated with fatty acid status. Relationships varied
according to fatty acid and were independent of gender.
9.1.3.1 Obesity
BMI decreased as DHA %RBCFA increased (P for trend = 0.01) (Table 9-1).
Central obesity, assessed on waist circumference and WHR, was significantly
related to DHA status. Waist circumference and WHR decreased with increasing
DHA status (P for trend = 0.003 and 0.002) (Table 9-1). These associations were
independent of gender (RBC DHA quintile x gender interaction on all variables:
[P > 0.07]). In secondary analyses that adjusted for factors known to influence
obesity risk (age, sex, social class, physical activity, and energy intake) the
relationships of DHA with BMI and waist circumference were attenuated. The
relationship between DHA and WHR remained significant (P = 0.03) (Table 9-6,
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Model 2). No linear trend was found for a relationship of EPA with waist
circumference or WHR (Table 9-6).
9.1.3.2 Blood Pressure and Heart Rate
Diastolic blood pressure decreased as DHA and EPA status increased (Tables 9-1
and 9-2). DBP was 5% lower in the highest compared with lowest quintiles for both
fatty acids (mean difference: 3 mm Hg, P for trend = 0.03 and 0.02 for DHA and EPA
respectively). There was no significant interaction of gender with %RBCFA on DBP
(P > 0.3 for both fatty acids). In secondary analyses relationships were attenuated
after adjustment for confounders that potentially influence BP (e.g. obesity and
fasting lipids) and no longer significant (Table 9-7, Model 2).
Resting heart rate decreased across quintiles of EPA %RBCFA (Table 9-2). There
was no significant interaction of gender with %RBCFA on heart rate (P > 0.6) (Table
9-7, Figure 9-1). The effect size was large – heart rate was 3 beats per minute
slower in the highest compared with the lowest quintile for EPA %RBCFA.
Furthermore, after adjustment for factors known to influence heart rate including
gender, physical activity level and CVD risk factors the effect was maintained and
showed a significant trend (P for trend = 0.05) (Table 9.7, Model 2).
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Figure 9-1 Resting heart rate according to quintiles of EPA status
9.1.3.3 Fasting Lipid Concentrations
Total cholesterol, LDL, VLDL and triglyceride concentrations decreased as DHA
status increased (P for trend < 0.05 for all variables) (Table 9-1). Improvements in
total to HDL and LDL to HDL cholesterol ratios were seen with increasing DHA
status (P for trend = 0.008 and 0.005 respectively) (Table 9-1). There were no
significant effects of gender (P for gender x %RBCFA quintile interaction: > 0.4 for all
variables). In secondary analyses, after adjustment for factors known to influence
cholesterol concentrations (e.g. obesity, blood pressure and insulin resistance)
effects were attenuated and no longer significant (Table 9-8).
VLDL cholesterol and triglycerides were lower in association with higher EPA status
(P for trend=0.004 for both variables) (Table 9-2). There were no significant
interactions between gender and EPA status for either outcome (P = 0.06). The
effect size was large (mean difference between highest and lowest quintiles: -
0.1mmol/L (25%) and -0.3mmol/L (30%) for VLDL and TAG respectively (P for
difference = 0.004 for both outcomes) (Table 9-2). Effects were attenuated after
adjustment for potential confounders but a trend remained (P for trend = 0.06 for
both outcomes) (Table 9-8, Model 2).
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9.1.3.4 Fasting Glucose and Insulin
Fasting glucose concentration was lower in association with DHA status (difference
between highest and lowest DHA quintiles 0.3mmol/L [P for trend < 0.001])
(Table 9-1). There was no significant effect of gender (RBC DHA quintile x gender
interaction on glucose: [P = 0.9]). The strength of the association was reduced after
adjustment for confounding factors but remained significant (P for trend = 0.001)
(Table 9-9, Model 2).
There was no association of fasting glucose with EPA status. However fasting
insulin concentration decreased as EPA status increased (P for trend = 0.008)
(Table 9-2). The difference in fasting insulin concentration between the highest and
lowest quintiles of EPA %RBCFA was 5pmol/L (20%) (Table 9-2). Insulin
resistance, as measured by HOMA also decreased with increasing EPA status (P for
trend = 0.02) (Table 9-2). After adjustment for potential confounders relationships of
EPA status to blood glucose and insulin resistance were no longer significant (Table
9-9, Model 2).
9.2 n-3 Fatty Acid Intake and Cardiovascular Health
Vascular health was not directly associated with dietary fatty acid intake assessed by
EPIC or the new FishFQ. However, n-3 fatty acid intake, estimated with the Fish
FFQ, was associated with fasting serum VLDL cholesterol and triglyceride
concentrations. VLDL and triglycerides were lower in higher quintiles of n-3 intake,
according to this FFQ, for both DHA and EPA (VLDL: P for trend between lowest and
highest quintiles: 0.03 and 0.005 and TAG 0.03 and 0.004 for DHA and EPA
respectively) (data not presented).
9.3 Summary of Results
This observational dietary study found significant relationships between n-3 fatty acid
status and vascular function. FMD was lower for women with higher DHA status.
This suggests DHA has gender effects and that these may further be dose
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responsive. Therefore, data from this study do not support the hypothesis that n-3
fatty acids have direct protective effects on FMD in healthy young people.
We also found a significant reduction in heart rate in association with EPA. This
effect was maintained after full adjustment for factors known to influence heart rate,
including gender, height, and smoking practice. The effect size was similar to that
reported previously but in the present study is seen in a younger population.274
The present study also found benefits for the lipid profile in association with higher
DHA and EPA status. TC, VLDL and TG decreased as DHA status increased and
VLDL and triglycerides both decreased significantly across quintiles of EPA status.
Most effects were attenuated and no longer significant after adjustment for potential
confounding factors. However, a trend remained for the relationship of EPA with
VLDL and TG. Both lipids decreased in association with higher EPA status. This
suggests that EPA may be one component within a healthy dietary pattern that
reduces CVD risk.
Fasting blood glucose concentration was lower in association with higher DHA status
suggesting possible benefits of DHA for risk markers of T2DM.
The study found important gender differences in relationships between n-3 fatty
acids and vascular health which warrant further investigation. Mechanisms are
unclear and are discussed in the concluding chapter where the implications of these
findings for clinical practice are discussed and recommendations for future research
are made.
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Table 9-1 Subject characteristics at baseline according to quintiles of DHA status
n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Erythrocyte DHA, % 63 3.1 (0.7) 62 4.5 (0.3) 66 5.3 (0.2) 61 6.2 (0.3) 62 7.8 (1.0)
Males 29 3.2 (0.7) 25 4.4 (0.3) 23 5.3 (0.2) 20 6.2 (0.3) 22 8 (1.3)
Females 34 3.2 (0.7) 37 4.5 (0.3) 43 5.3 (0.2) 40 6.2 (0.3) 41 7.8 (0.8)
1Male gender, %, (n) 45 (29) 40 (25) 35 (23) 33 (20) 35 (22) 0.07
Age, y 28.6 (4.5) 28.2 (4.3) 27.7 (5.1) 27.3 (4.8) 27.5 (4.8) 0.1
Males 28.8 (4.9 28.6 (4.4) 28.8 (5.1) 29.4 (4.7) 29.5 (4.8) 0.5
Females 28.5 (4.2) 28 (4.3) 27 (5) 26.2 (4.6) 26.4 (4.5) 0.01
1Education:
with degree, %, (n) 64 (41) 69 (43) 68 (45) 67 (41) 62 (39) 1
Males 29 59 (17) 25 68 (17) 23 48 (11) 20 70 (14) 22 73 (16) 0.5
Females 35 69 (24) 37 70 (26) 43 79 (34) 40 68 (27) 40 58 (23) 0.5
1Social class:
Non-manual, %, (n) 64 (41) 69 (43) 53 (35) 46 (28) 51 (32) 0.01
Males 55 (16) 44 (16) 44 (10) 60 (12) 59 (13) 0.9
Females 71 (25) 73 (27) 58 (25) 39 (16) 59 (19) 0.001
1Current Smoker, %, (n) 25 (16) 18 (11) 15 (10) 8 (5) 6 (4) 0.001
Males 38 (11) 24 (6) 30 (7) 40 (8) 36 (8) 0.7
Females 47 (16) 43 (16) 60 (26) 32 (13) 32 (13) 0.04
2Cotinine, ng/ml 44 3.3 (284) 48 2.0 (263) 38 1.3 (222) 30 1.1 (222) 34 1 (238) 0.02
Males 4.1 (322) 1 (217) 0.6 (1.8) 2.3 (3.2) 2.2 (3.2) 0.3
Females 2.8 (260) 3.4 (284) 2.3 (273) 0.8 (165) 0.5 (246) 0.04
Physical activity level, hours/day 64 2 (2.3) 62 1.2 (0.8) 65 1.8 (2.1) 61 1.7 (1.8) 63 1.7 (2.0) 0.9
Males 2.6 (2.4) 1.6 (1.6) 2.2 (2.3) 2.1 (1.9) 2.1 (1.9) 0.7
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n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Females 1.5 (2) 1 (1.8) 1.6 (2) 1.5 (1.7) 1.4 (1.8) 0.6
Anthropometry and body
composition
Males
Females
64
29
35
62
25
37
66
23
43
62
25
37
64
29
35
Body Mass Index, kg/m2 24.5 (4.5) 24 (4) 23.6 (4) 22.7 (3.0) 23.1 (3.6) 0.01
Males 24.2 (2.7) 24.4 (2.8) 24.5 (.3.) 23.1 (2.1) 24.6 (3.7) 0.8
Females 24.7 (5.6) 23.7 (5) 23.2 (4.3) 22.5 (3.3) 22.4 (3.3) 0.008
Waist (cm) 80 (11.9) 78.8 (10.4) 77.3 (9.6) 75 (9.6) 75.8 (9.5) 0.003
Males 84.2 (7.4) 84 (7.6) 85 (9) 81 (6.5) 82.3 (9.8) 0.2
Females 76.3 (13.*) 75.2 (10.5) 23.1 (7) 72 (7.8) 72.3 (7.3) 0.02
Waist:Hip ratio 0.8 (0.08) 0.79 (0.06) 0.78 (0.08) 0.77 (0.07) 0.76 (0.06) 0.002
Males 0.9 (0.05) 0.8 (0.05) 0.8 (0.07) 0.8 (0.05) 0.8 (0.06) 0.02
Females 0.8 (0.06) 0.8 (0.05) 0.7 (0.05) 0.7 (0.06) 0.7 (0.03) 0.1
2Sum skinfold, mm 49.4 (44) 49.2 (39) 49.8 (39) 42.8 (38) 46.5 (38) 0.09
Males 42.1(42) 46.1 (41) 41.7 (33) 34.5 (39) 38.9 (46) 0.1
Females 56.8 (41) 51.4 (37) 55.1 (35) 48 (40) 50 (38) 0.1
% Fat (sum skinfolds) 24.5 (5.3) 23.4 (5.7) 24.4 (5.3) 24.3 (6.1) 23.3 (5.4) 0.4
Males 23.3 (4.8) 22.6 (6) 24.8 (5.3) 23.10 (5.5) 23.3 (4.8) 0.8
Females 25.6 (5.5) 24 (5.4) 24 (5.3) 24.8 (6.5) 23.3 (5.7) 0.2
Blood pressure, mm Hg
Systolic 64 112 (11) 62 113 (10) 65 113 (11) 61 112 (12) 62 110 (10) 0.3
Males 29 115 (11) 25 116 (10) 23 118 (10) 20 117 (11) 22 116 (7) 0.6
Females 35 110 (10) 37 11 (10) 42 109 (11) 41 110 (11) 40 106 (10) 0.3
Diastolic 67 (7) 68 (8) 67 (7) 66 (9) 64 (8) 0.03
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n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Males 68 (7) 69 (7) 70 (8) 68 (10) 67 (7) 0.8
Females 66 (7) 67 (8) 66 (7) 65 (8) 62 (8) 0.03
Mean arterial pressure 84 (7) 84 (8) 85 (9) 84 (11) 82 (9) 0.3
Males 86 (6) 87 (7) 89 (10) 88 (11) 86 (6) 0.8
Females 82 (7) 82 (8) 83 (8) 82 (10) 79 (9) 0.3
Resting heart rate, beats/min) 67 (9) 68 (10) 68 (11) 67 (11) 65 (14) 0.4
Males 64 (9) 65 (12) 67 (13) 62 (7) 66 (18) 0.4
Females 67 (9) 69 (9) 68 (10) 70 (11) 64 (11) 0.4
†Total cholesterol, mmol/L 64 4.3 (1) 61 4.3 (0.7) 66 4.4 (0.9) 60 4.1 (0.7) 62 4.1 (0.7) 0.03
Males 29 4.4 (1) 24 4.3 (0.5) 23 4.3 (1) 20 4.3 (0.8) 21 4.3 (0.8) 0.3
Females 35 4.2 (0.9) 37 4.2 (0.8) 43 4.4 (0.9) 40 4 (0.7) 41 4 (0.7) 0.09
†LDL cholesterol, mmol/L 2.5 (0.8) 2.4 (0.7) 2.4 (0.9) 2.3 (0.7) 2.2 (0.7) 0.03
Males 2.6 (0.8) 2.6 (0.5) 2.6 (0.9) 2.6 (0.8) 2.5 (0.7) 0.6
Females 2.4 (0.8) 2.3 (0.8) 2.4 (0.9) 2.2 (0.6) 2.1 (0.7) 0.03
†HDL cholesterol, mmol/L 1.4 (0.4) 1.4 (0.4) 1.5 (0.4) 1.4 (0.3) 1.5 (0.3) 0.2
Males 1.3 (0.3) 1.2 (0.3) 1.3 (0.4) 1.3 (0.3) 1.3 (0.3) 0.7
Females 1.5 (0.4) 1.5 (0.4) 1.7 (0.3) 1.4 (0.3) 1.6 (0.3) 0.6
†2VLDL cholesterol 0.4 (54) 0.2 (46) 0.4 (44) 0.4 (57) 0.4 (47) 0.04
Males 0.5 (47) 0.5 (56) 0.3 (49) 0.4 (71) 0.4 (52) 0.5
Females 0.4 (60) 0.4 (39) 0.4 (41) 0.4 (49) 0.3 (43) 0.03
Total:HDL cholesterol ratio 3.3 (1.2) 3.3 (1.1) 3.0 (1.0) 3.1 (0.8) 2.9 (0.8) 0.008
Males 3.5 (1) 3.8 (1) 3.5 (1.2) 3.5 (0.9) 3.4 (1) 0.4
Females 3.2 (1.3) 3 (1) 2.8 (0.7) 2.9 (0.7) 2.7 (0.6) 0.02
LDL:HDL cholesterol ratio 2.0 (0.9) 1.9 (0.9) 1.7 (0.9) 1.6 (0.7) 1.8 (0.8) 0.005
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n Q1* n Q2 n Q3 n Q4 n Q5 p‡
Males 2.1 (0.8) 2.2 (0.8) 2.2 (1) 2.1 (0.7) 2 (0.8) 0.4
Females 1.9 (1) 1.7 (0.9) 1.5 (0.7) 1.6 (0.6) 1.4 (0.6) 0.01
†2Trigycerides, mmol/L 0.5 (54) 0.9 (46) 0.8 (43) 0.8 (57) 0.8 (47) 0.04
Males 1 (47) 0.8 (56) 0.8 (49) 0.8 (71) 0.8 (52) 0.6
Females 0.9 (0.6) 0.9 (0.4) 0.8 (0.4) 0.7 (0.5) 0.8 (0.4) 0.03
†2Glucose, mmol/L 4.9 (0.5) 4.9 (0.5) 4.8 (0.5) 4.7 (0.4) 4.6 (0.5) <0.001
Males 5.1 (0.6) 5 (0.4) 5 (0.4) 4.9 (0.4) 4.8 (0.5) 0.02
Females 4.8 (0.5) 4.9 (0.5) 4.6 (0.4) 4.6 (0.4) 4.6 (0.5) 0.001
†2Insulin, pmol/L 30.6 (74) 27.8 (63) 31.3 (47) 31.3 (55) 31.3 (55) 0.2
Males 27 (69) 25.7 (58) 27.8 (53) 29.9 (54) 29.9 (52) 0.8
Females 33.4 (78) 30.6 (66) 31.3 (44) 32 (56) 30 (57) 0.2
†2Insulin resistance, (HOMA) 1 (84) 0.9 (68) 0.9 (52) 0.5 (58) 0.9 (56) 0.09
Males 0.9 (77) 0.8 (62) 0.9 (58) 0.9 (61) 0.9 (57) 0.6
Females 1 (84) 0.9 (72) 0.9 (48) 1 (57) 0.9 (56) 0.08
†2CRP, mg/L 1.03 (112) 1.0 (130) 0.8 (110) 1.0 (17) 1.1 (140) 0.7
Males 0.8 (91) 0.8 (103) 0.8 (117) 0.7 (130) 0.9 (147) 0.3
Females 1.2 (125) 1 (144) 0.9 (109) 1.2 (107) 1.1 (139) 0.8
* Quintile 1 is the lowest. Fatty acid status assessed by erythrocyte membrane concentration and expressed as % total fatty acids
(RBCFA%). ‡ P for trend calculated with RBCFA% quintile modeled on a continuous scale in general linear models. Data are mean, SD,
except: 1% (n) and 2geometric mean (coefficient of variation). † Measurements obtained after 12 hours fasting.
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Table 9-2 Subject characteristics at baseline according to quintiles of EPA status
n Q1* n Q2 n Q3 n Q4 n Q5 p ‡
Erythrocyte EPA, % 63 0.5 (0.1) 65 0.7 (0.05) 67 0.9 (0.06) 58 1.1 (1.0) 63 1.8 (0.50)
Males 23 0.5 (0.1) 25 0.7 (0.04) 19 0.8 (0.07) 26 1.1 (0.09) 26 1.9 (0.7)
Females 40 0.5 (0.09) 40 0.7 (0.05) 48 0.9 (0.06) 32 1.1 (0.1) 37 1.8 (0.4)
1Male gender, %, (n) 37 (23) 38 (25) 28 (19) 45 (26 41 (26) 0.02
Age, y 27.7 (4.6) 27.6 (4.6) 28.4 (4.6) 27.9 (4.8) 27.7 (4.6) 0.9
Males 28.3 (4.6) 29.1 (4.7) 29.9 (4.8) 28.7 (4.6) 29 (5) 0.7
Females 27.3 (4.5) 26.7 (4.2) 27.8 (4.4) 27.2 (5) 26.8 (5.2) 0.8
1Education:
with degree, %, (n) 70 (44) 71 (46) 69 (46) 48 (28) 71 (45) 0.6
Males 65 (15) 64 (16) 68 (13) 46 (12) 73 (19) 0.8
Females 73 (29) 75 (30) 72 (33) 50 (16) 70 (26) 0.6
1Social class:
Non-manual, %, (n) 56 (35) 63 (41) 55 (37) 57 (33) 52 (33) 0.5
Males 43 (10) 60 (15) 68 (13) 62 (16) 50 (13) 0.7
Females 62 (25) 65 (26) 50 (24) 53 (17) 54 (20) 0.3
1Current Smoker, %, (n) 48 (30) 45 (29) 37 (25) 33 (19) 33 (21) 0.004
Males 39 (9) 36 (9) 21 (4) 35 (9) 35 (9) 0.1
Females 54 (21) 50 (20) 44 (20) 31 (10) 32 (12) 0.02
2Cotinine, ng/ml 3.4 (278) 2.0 (259) 0.8 (234) 2.2 (247) 0.8 (240) 0.04
Males 3.5 (325) 1 (197) 0.5 (188) 3.3 (297) 1.2 (290) 1.0
Females 3.4 (255) 3 (286) 1.1 (253) 1.7 (202) 0.6 (178) 0.04
Physical activity level, hours/day 1.92 (2.3) 1.4 (1.9) 1.7 (2) 1.5 (1.8) 1.7 (0.1) 0.8
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n Q1* n Q2 n Q3 n Q4 n Q5 p ‡
Males 2.4 (2.4) 2.3 (2.4) 2.2 (2.2) 1.9 (1.7) 2 (1.7) 0.3
Females 1.7 (2.3) 0.9 (1.3) 1.5 (1.9) 1.3 (1.8) 1.6 (1.7) 0.7
Anthropometry and body
composition
Body Mass Index, kg/m2 24.1 (4.5) 23.5 (4.3) 24.2 (4.2) 22.8 (3.0) 23.3 (3.3) 0.1
Males 24 (2.5) 24.6 (2.8) 25.2 (2.6) 23.4 (3.3) 24.1 (3.3) 0.6
Females 24.2 (5.3) 22.8 (5) 24 (4.6) 22.3 (2.7) 22.7 (3.3) 0.1
Waist (cm) 79 (11.9) 76 (10.2) 78.9 (10.4) 76.7 (8.2) 76.2 (9.3) 0.2
Males 84.7 (6.6) 84.1 (8.2) 86 (7.9) 81.4 (8.6) 82 (8.7) 0.1
Females 75 7 (13.1) 70.9 (7.8) 75.9 (9.9) 72.8 (5.5) 72.2 (7.6) 0.3
Waist:Hip ratio 0.79 (0.07) 0.78 (0.08) 0.79 (0.07) 0.77 (0.06) 0.77 (0.06) 0.2
Males 0.9 (0.04) 0.9 (0.06) 0.84 (0.06) 0.83 (0.06) 0.81 (0.05) 0.1
Females 0.8 (0.06) 0.7 (0.05) 0.8 (0.05) 0.7 (0.04) 0.7 (0.04) 0.3
2Sum skinfold, mm 48.5 (42) 46.2 (40) 53.4 (37) 42 (44) 47.5 (40) 0.4
Males 40.4 (43) 39.3 (40) 49.4 (33) 36.6 (45) 41 (38) 0.8
Females 54.1 (38) 51.4 (36) 55.1 (39) 50 (39) 52.4 (38) 0.5
% Fat (sum skinfold) 24.2 (4.8) 23.8 (5.6) 23 (4.9) 24.6 (5.6) 24 (5.5) 0.6
Males 23.8 (4.9) 23.4 (5.6) 21.6 (4.1) 23.7 (6.4) 24 (4.8) 0.8
Females 24.4 (4.8) 24 (5.6) 23.5 (5.1) 25.3 (6.8) 24.6 (6.2) 0.6
Blood pressure, mm Hg
Systolic 63 110 (10) 65 113 (10) 67 113 (13) 58 112 (11) 62 111 (10) 0.8
Males 23 114 (11) 25 118 (10) 19 119 (10) 26 117 (10) 26 115 (8) 1.0
Females 40 108 (10) 40 110 (8) 48 111 (13) 32 107 (10) 36 108 (11) 0.5
Diastolic 67 (6) 67 (7) 68 (9) 66 (8) 64 (8) 0.02
Males 69 (6) 68 (8) 72 (8) 68 (8) 66 (7) 0.3
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n Q1* n Q2 n Q3 n Q4 n Q5 p ‡
Females 66 (7) 66 (6) 67 (10) 64 (7) 63 (9) 0.02
Mean arterial pressure 83 (7) 85 (8) 85 (11) 84 (10) 82 (9) 0.3
Males 87 (6) 87 (10) 90 (7) 88 (9) 85 (7) 0.7
Females 82 (7) 83 (7) 83 (11) 80 (9) 80 (9) 0.2
Resting heart rate, beats/min) 66 (10) 68 (9) 69 (12) 65 (11) 64 (13) 0.03
Males 64 (9) 66 (10) 66 (11) 65 (13) 64 (10) 0.3
Females 68 (10) 69 (8) 70 (12) 66 (9) 64 (9) 0.05
†Total cholesterol, mmol/L 63 4.2 (0.9) 64 4.4 (0.8) 65 4.2 (0.8) 58 4.2 (0.8) 62 4.2 (0.8) 0.2
Males 23 4.3 (0.7) 24 4.5 (1.1) 19 4.2 (0.7) 26 4.3 (0.8) 25 4.4 (0.8) 0.5
Females 40 4.2 (1) 40 4.3 (0.7) 47 4.3 (0.9) 32 4.1 (0.8) 37 4 (0.7) 0.2
†LDL cholesterol, mmol/L 2.4 (0.8) 2.4 (0.7) 2.4 (0.7) 2.2 (0.9) 2.3 (0.7) 0.4
Males 2.5 (0.7) 2.6 (0.9) 2.6 (0.6) 2.5 (0.9) 2.6 (0.7) 0.8
Females 2.3 (0.8) 2.3 (0.5) 2.4 (0.8) 2 (0.8) 2.2 (0.7) 0.1
†HDL cholesterol, mmol/L 1.4 (0.4) 1.5 (0.3) 1.4 (0.4) 1.5 (0.3) 1.5 (0.3) 0.3
Males 1.3 (0.2) 1.3 (0.3) 1.1 (0.2) 1.3 (0.3) 1.4 (0.3) 0.2
Females 1.5 (0.4) 1.6 (0.3) 1.5 (0.4) 1.6 (0.3) 1.5 90.3) 0.4
†2VLDL cholesterol 0.4 (53) 0.4 (49) 0.4 (48) 0.4 (51) 0.3 (47) 0.004
Males 0.5 (53) 0.4 (58) 0.4 (47) 0.4 (58) 0.4 (57) 0.2
Females 0.4 (53) 0.4 (42) 0.4 (48) 0.4 (46) 0.3 (38) 0.003
Total:HDL cholesterol ratio 3.2 (1.2) 3.1 (0.9) 3.3 (1.0) 3.0 (1.0) 3.0 (1.0) 0.1
Males 3.5 (0.9) 3.6 (1.1) 3.9 (0.8) 3.4 (1.1) 3.3 (1) 0.5
Females 3.1 (1.3) 2.8 (0.5) 3.1 (0.9) 2.6 (0.8) 2.7 (0.7) 0.05
LDL:HDL cholesterol ratio 1.8 (0.9) 1.8 (0.7) 1.9 (0.8) 1.6 (0.9) 1.7 (0.7) 0.2
Males 2 (0.7) 2.1 (0.9) 2.4 (07) 2 (0.9) 2 (0.8) 0.7
Females 1.8 (1) 1.5 (0.5) 1.7 (0.8) 1.3 (0.7) 1.5 (0.6) 0.06
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n Q1* n Q2 n Q3 n Q4 n Q5 p ‡
†2Trigycerides, mmol/L 1.0 (53) 0.9 (49) 0.9 (48) 0.8 (51) 0.7 (47) 0.004
Males 1 (54) 1 (58) 1 (47) 0.8 (58) 0.8 (57) 0.2
Females 1 (53) 0.8 (42) 0.9 (48) 0.8 (46) 0.7 (38) 0.003
†2Glucose, mmol/L 4.8 (0.5) 4.8 (0.5) 4.8 (0.5) 4.9 (0.5) 4.7 (0.5) 0.4
Males 4.9 (0.4) 5 (0.6) 5.1 (0.4) 5 (0.5) 4.9 (0.4) 0.6
Females 0.4
†2Insulin, pmol/L 32 (74) 29.9(59) 33.4 (63) 33.4 (48) 27 (46) 0.008
Males 25.7 (67) 27.8 (71) 30.6 (57) 27 (55) 30 (36) 0.6
Females 35.4 (75) 32 (51) 34.8 (42) 28.5 (51) 25 (60) 0.007
†2Insulin resistance, (HOMA) 1 (78) 1 (64) 1 (67) 0.9 (55) 0.8 (46) 0.02
Males 0.8 (71) 0.9 (79) 1 (61) 0.9 (63) 0.9 (39) 0.6
Females 1.1 (81) 0.9 (54) 1 (70) 0.9 (48) 0.7 (49) 0.01
†2CRP, mg/L 6.4 (166) 3.1 (150) 7.6 (154) 6.7 (203) 5.9 (192) 0.7
Males 0.8 (100) 0.7 (95) 0.6 (110) 0.8 (133) 1.1 (132) 0.06
Females 1.2 (127) 1.1 (105) 1.2 (119) 1.2 (136) 0.8 (139) 0.7
* Quintile 1 is the lowest. Fatty acid status assessed by erythrocyte membrane concentration and expressed as % total fatty acids
(RBCFA%). ‡ P for trend calculated with RBCFA% quintile modelled on a continuous scale in general linear models. Data are mean, SD,
except: 1% (n) and 2geometric mean (coefficient of variation). † Measurements obtained after 12 hours fasting.
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Table 9-3 Vascular variables at baseline according to quintiles of DHA status
n Q1* n Q2 n Q3 n Q4 n Q5 P ‡
Right Brachial Artery
Diameter, mm 64 3.4 (0.5) 62 3.2 (0.5) 65 3.2 (0.6) 60 3.1 (0.6) 60 3.2 (0.5) 0.03
Males 29 3.8 (0.4) 25 3.6 (0.4) 23 3.8 (0.4) 20 3.7 (0.5) 21 3.7 (0.4) 0.7
Females 35 3 (0.3) 37 2.9 (0.3) 42 2.9 (0.4) 40 2.8 (0.4) 39 2.9 (0.2) 0.07
Reactive hyperaemia, % 746 (255) 701 (288) 720 (250) 758 (237 754 (293) 0.5
Males 625 (170) 606 (304) 620 (178) 701 (287) 647 (170) 0.4
Females 852 (272) 762 (265) 771 (268) 788 (207) 814 (331) 0.8
Flow-mediated dilatation, mm 0.28 (0.1) 0.27 (0.1) 0.28 (0.1) 0.28 (0.1) 0.25 (0.1) 0.05
Males 0.26 (0.1) 0.26 (0.07) 0.28 (0.1) 0.29 (0.1) 0.28 (0.1) 0.2
Females 0.3 (0.1) 0.27 (0.09) 0.28 (0.1) 0.28 (0.1) 0.23 (0.09) 0.003
Flow-mediated dilatation, % 8.4 (3.8) 8.2 (3.3) 8.5 (3.9) 9.0 (4.1) 7.6 (3.6) 0.4
Males 6.5 (2.9) 6.8 (2.4) 6.9 (3.6) 7.7 (3.2) 7.3 (4.2) 0.2
Females 10.1 (3.6) 9.1 (3.5) 9.4 (3.9) 9.7 (4.3) 7.8 (3.2) 0.04
Distension, mm 41 0.09 (0.03) 44 0.09 (0.04) 44 0.09 (0.04) 43 0.08 (0.03) 41 0.1 (0.04) 0.5
Males 20 0.09 (0.03) 14 0.1 (0.05) 14 0.09 (0.04) 16 0.08 (0.04) 15 0.1 (0.04) 0.8
Females 21 0.08 (0.04) 30 0.08 (0.04) 30 0.08 (0.04) 27 0.08 (0.02) 26 0.089 (0.05) 0.6
Distension, % 11.4 (4.5) 12.9 (5.6) 12.3 (6.9) 11.4 (4.8) 13.5 (5.8) 0.3
Males 9.7 (3) 12.5 (4.6) 10 (4.1) 8.5 (3.9) 12 (3.8) 0.8
Females 13.1 (5.2) 13.1 (6.1) 13.4 (7.7) 13.1 (4.5) 14.3 (6.6) 0.5
Distension coefficient (x10-3.kPa-1) 8.9 (5.2) 9.4 (3.9) 9.0 (4.9) 8.4 (3.5) 10 (4.2) 0.5
Males 8.2 (6.5) 9.2 (3.2) 7.2 (2.9) 6.2 (2.8) 8.9 (2.8) 0.4
Females 9.6 (3.7) 9.5 (4.2) 9.8 (5.4) 9.6 (3.2) 10.6 (4.8) 0.4
Right Common Carotid Artery
254
n Q1* n Q2 n Q3 n Q4 n Q5 P ‡
Diameter, mm 53 6.5 (0.5) 57 6.5 (0.6) 60 6.5 (0.5) 60 6.4 (0.5) 57 6.4 (0.5) 0.07
Males 24 6.8 (0.4) 21 6.9 (0.6) 22 6.9 (0.6) 20 6.8 (0.4) 21 6.7 (0.5) 0.6
Females 29 6.4 (0.4) 35 6.3 (0.4) 38 6.3 (0.4) 40 6.3 (0.4) 36 6.2 (0.4) 0.1
Distension, mm 0.7 (0.1) 0.7 (0.1) 0.7 (0.2) 0.7 (0.2) 0.8 (0.2) 0.4
Males 0.7 (0.2) 0.7 (0.2) 0.8 (0.2) 0.7 (0.2) 0.8 (0.2) 0.6
Females 0.7 (0.1) 0.7 (0.1) 0.7 (0.2) 0.7 (0.2) 0.8 (0.2) 0.3
Distension, % 11.2 (2.5) 11.3 (2.1) 11 (3) 11.6 (2.6) 11.8 (2.6) 0.4
Males 11 (3.3) 10.7 (2.2) 11.2 (3.4) 10.9 (2.8) 11.4 (2.7) 0.9
Females 11.4 (1.7) 11.6 (2) 10.9 (2.8) 11.9 (2.5) 12.1 (2.6) 0.7
Distension coefficient (x10-3.kPa-1) 34.8 (13.7) 34.6 (6.7) 33 (8.4) 34 (8) 35 (7.1) 0.9
Males 33.3 (19.2) 32 (6.4) 30.7 (7.5) 30.5 (8.1) 31.2 (5.7) 0.4
Females 36.1 (6.5) 36.2 (6.5) 34.3 (8.6) 35.6 (7.5) 37 (7) 0.7
Intima-media thickness, mm 0.55 (0.09) 0.54 (0.09) 0.56 (0.08) 0.53 (0.06) 0.55 (0.08) 0.8
Males 0.57 (0.09) 0.55 (0.08) 0.58 (0.1) 0.54 (0.06) 0.57 (0.1) 0.9
Females 0.53 (0.07) 0.54 (0.09) 0.5 (0.05) 0.53 (0.05) 0.5 (0.07) 0.9
Carotid-radial PWV m/s 8.7 (1.1) 8.5 (1) 8.8 (1.1) 8.7 (1.8) 8.3 (1.2) 0.2
Males 8.6 (1.1) 8.6 (1) 9.1 (1) 9.2 (1.4) 8.6 (1.3) 0.5
Females 8.8 (1.1) 8.4 (1) 8.6 (1.2) 8.5 (1.9) 8.1 (1.1) 0.06
* Quintile 1 is the lowest. Fatty acid status assessed by erythrocyte membrane concentration and expressed as % total fatty acids (RBCFA%). ‡
P for trend calculated with RBCFA% quintile modelled on a continuous scale in general linear models. Data are mean, SD.
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Table 9-4 Vascular variables at baseline according to quintiles of EPA status
n Q1* n Q2 n Q3 n Q4 n Q5 P ‡
Right Brachial Artery
Diameter, mm 62 3.2 (0.5) 65 3.2 (0.6) 66 3.2 (0.6) 58 3.3 (0.6) 60 3.2 (0.5) 0.9
Males 23 3.7 (0.5) 25 3.8 (0.4) 19 3.8 (0.4) 26 3.7 (0.4) 25 3.7 (0.4) 0.4
Females 39 2.9 (0.3) 40 2.9 (0.4) 47 2.9 (0.3) 32 2.9 (0.4) 35 2.9 (0.3) 0.9
Reactive hyperaemia, % 790 (269) 736 (263) 707 (241) 737 (227) 716 (316) 0.2
Males 630 (211) 636 (263) 656 (210) 672 (256) 602 (188) 0.8
Females 879 (259) 800 (246) 728 (252) 788 (190) 800 (363) 0.2
Flow-mediated dilatation, mm 0.27 (0.1) 0.27 (0.1) 0.3 (0.1) 0.27 (0.1) 0.25 (0.1) 0.2
Males 0.2 (0.09) 0.3 (0.1) 0.3 (0.09) 0.3 (0.1) 0.3 (0.1) 0.6
Females 0.29 (0.1) 0.26 (0.1) 0.3 (0.1) 0.3 (0.1) 0.2 (0.08) 0.03
Flow-mediated dilatation, % 8.2 (3.6) 8.3 (3.7) 9.5 (4.1) 8 (3.5) 7.8 (3.6) 0.3
Males 6 (2.8) 7.2 (2.9) 6.9 (2.6) 7.1 (3.2) 7.6 (4.3) 0.5
Females 9.5 (3.4) 8.9 (3.9) 10.5 (4.2) 8.7 (3.6) 7.9 (3) 0.1
Right Brachial Artery Distension
Distension, mm 37 0.08 (0.03) 52 0.09 (0.04) 49 0.08 (0.04) 35 0.08 (0.03) 40 0.1 (0.04) 0.02
Males 13 0.09 (0.04) 20 0.09 (0.04) 13 0.08 (0.05) 17 0.09 (0.03) 16 0.1 (0.03) 0.05
Females 24 0.07 (0.03) 32 0.09 (0.05) 36 0.08 (0.03) 18 0.07 (0.02) 24 0.1 (0.04) 0.2
Distension, % 11.3 (4.3) 13 (7.5) 11.3 (4.6) 11 (4.1) 14.6 (5.5) 0.08
Males 10 1 (3.8) 9.7 (4.1) 9 (4.5) 10.4 (3.9) 12.9 (3) 0.02
Females 11.9 (4.5) 15.2 (8.4) 12.2 (4.4) 11.6 (4.3) 15.7 (6.5) 0.3
Distension coefficient (x10-3.kPa-1) 8.9 (5.3) 9.5 (5.2) 8.3 (3.3) 8.1 (3) 10.7 (4) 0.2
Males 9.1 (8) 7.1 (3) 6.5 (3.2) 7.6 (2.8) 9.5 (2.2) 0.4
Females 8.8 (3.3) 11 95.7) 9 (8.1) 8.5 (3.1) 11.5 (4.7) 0.3
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n Q1* n Q2 n Q3 n Q4 n Q5 P ‡
Right Common Carotid Artery
Diameter, mm 55 6.5 (0.5) 59 6.4 (0.5) 61 6.5 (0.5) 53 6.5 (0.5) 59 6.5 (0.5) 0.7
Males 20 6.7 (0.4) 22 6.8 (0.4) 17 7 (0.5) 26 6.8 (0.5) 24 6.8 (0.5) 0.5
Females 35 6.4 (0.5) 37 6.1 (0.4) 44 6.3 (0.4) 27 6.3 (0.4) 35 6.3 (0.4) 0.6
Distension, mm 0.7 (0.2) 0.7 (0.1) 0.7 (0.1) 0.7 (0.1) 0.8 (0.2) 0.03
Males 0.8 (0.2) 0.7 (0.2) 0.7 (0.2) 0.8 (0.2) 0.8 (0.2) 0.08
Females 0.7 (0.2) 0.7 (0.1) 0.7 (0.1) 0.7 (0.1) 0.8 (0.2) 0.09
Distension, % 11.2 (3) 11.2 (2.2) 11.2 (2.3) 11.2 (2.2) 12.1 (2.9) 0.7
Males 11.4 (3.4) 10.3 (2.5) 9.4 (2.7) 11.3 (2.4) 12.2 (3) 0.3
Females 11 (2.8) 11.6 (1.9) 11.8 (2.1) 11.2 (2) 12 (2.9) 0.9
Distension coefficient (x10-3.kPa-1) 36.1 (14) 33.1 (7.3) 33.9 (8.2) 32.9 (6.1) 35.1 (7.2) 0.7
Males 36.4 (20.4) 28.1 (5.8) 27.8 (7.2) 31.4 (6.8) 33.6 (6.2) 0.2
Females 35.9 (9) 36.1 (6.4) 36.1 (7.5) 34.4 (5.1) 36.2 (7.8) 0.9
Intima-media thickness, mm 0.54 (0.06) 0.56 (0.09) 0.54 (0.07) 0.55 (0.09) 0.54 (0.07) 1.0
Males 0.57 (0.05) 0.57 (0.1) 0.54 (0.08) 0.57 (0.1) 0.55 (0.08) 0.7
Females 0.52 (0.06) 0.55 (0.08) 0.54 (0.06) 0.54 (0.07) 0.53 (0.07) 0.9
Carotid-radial PWV m/s 8.7 (1.2) 8.7 (1.3) 8.6 (1.6) 8.4 (1.0) 8.5 (1.2) 0.3
Males 8.7 (1.3) 9.1 (1.4) 8.6 (0.9) 8.5 (0.9) 8.9 (1.3) 0.9
Females 8.7 (1.2) 8.4 (1.2) 8.6 (1.8) 8.3 (1.1) 8.2 (1.1) 0.1
* Quintile 1 is the lowest. Fatty acid status assessed by erythrocyte membrane concentration and expressed as % total fatty acids
(RBCFA%). ‡ P for trend calculated with RBCFA% quintile modelled on a continuous scale in general linear models. Data are mean, SD.
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Table 9-5 Regression coefficient (95% CI) for vascular variables according to quintiles1 of fatty acids status
Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
Right brachial artery
Flow Mediated Dilatation (mm)
DHA
Model 1*: n=301 0.02 (-0.05, 0.02) 0.4 0 (-0.03, 0.04) 1 0 (-0.04, 0.04) 1 -0.04 (-0.07, -0.001) 0.04 0.2
Males: n=115 -0.01 (-0.07, 0.05) 0.7 0.02 (-0.04, 0.07) 0.5 0.03 (-0.03, 0.09) 0.3 0.02 (-0.04, 0.07) 0.7 0.7
Females: n= 186 -0.03 (-0.08, 0.01) 0.2 -0.02 (-0.06, 0.03) 0.4 -0.02 (-0.07, -0.02) 0.3 -0.08 (-0.1, 0.03) 0.001 0.006
Model 2† n=293 -0.02 (-0.05, 0.02) 0.4 0.01 (-0.03, 0.05) 0.6 0.004 (-0.03, 0.04) 0.8 -0.03 (-0.06, 0.01) 0.1 0.4
Males: n= 110 -0.002 (-0.06, 0.06) 0.9 0.05 (-0.01, 0.1) 0.1 0.04 (-0.02, 0.09) 0.2 0.04 (-0.02 (0.1) 0.2 0.08
Females: n=183 -0.04 (-0.08, 0.01) 0.1 -0.01 (-0.06, 0.03) 0.5 -0.03 (-0.07, 0.02) 0.3 -0.07 (-0.1, -0.03) 0.002 0.008
EPA
Model 1* 0.004 (-0.03, 0.04) 0.8 0.03 (-0.01, 0.06) 0.1 -0.001 (-0.04, 0.04) 1 -0.02 (-0.05, 0.02) 0.3 0.3
Males 0.05 (-0.004, 0.1) 0.07 0.04 (-0.02, 0.1) 0.2 0.03 (-0.03, 0.09) 0.3 0.04 (-0.02, 0.09) 0.2 0.6
Females -0.03 (-0.07, 0.02) 0.2 0.02 (-0.02, 0.06) 0.4 -0.02 (-0.07, 0.03) 0.4 -0.06 (-0.1, -0.01) 0.02 0.0
Model 2† 0.01 (-0.03, 0.04) 0.6 0.03 (-0.01, 0.06) 0.2 0.003 (-0.03, 0.04) 0.9 -0.01 (-0.05, 0.03) 0.6 0.6
Males 0.05 (-0.01, 0.1) 0.1 0.04 (-0.02, 0.1) 0.2 0.04 (-0.03, 0.09) 0.3 0.05 (-0.01, 0.1) 0.1 0.02
Females -0.02 (-0.07, 0.03) 0.4 0.01 -0.03, 0.06) 0.5 -0.02 (-0.06, 0.03) 0.5 -0.05 (-0.1, 0.01) 0.03 0.09
Distension (mm)
DHA
Model 1* 0.01 (-0.01, 0.02) 0.5 0 (0.02, 0.02) 1 -0.004 (-0.02, 0.01) 0.7 0.01 (-0.01, 0.03) 0.4 0.8
Males 0.02 (-0.01, 0.05) 0.2 -0.002 (-0.03, 0.03) 0.9 -0.01 (-0.04, 0.01) 0.3 0.01 (-0.01, 0.04) 0.3 0.9
Females -0.002 (-0.02, 0.02) 0.9 -0.001 (-0.02, 0.02) 0.9 0.002 (-0.02, 0.02) 0.8 0.002 (-0.02, 0.02) 0.9 0.7
Model 2† 0.003 (-0.02, 0.02) 0.8 -0.001 (-0.02, 0.02) 0.9 -0.004 (-0.02, 0.01) 0.7 0.007 (-0.01, 0.02) 0.5 0.7
Males -0.02 (-0.02, 0.05) 0.4 -0.004 (-0.04, 0.03) 0.8 -0.01 (-0.04, 0.02) 0.3 -0.02 (-0.02, 0.05) 0.3 0.9
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Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
Females -0.004 (-0.03, 0.02) 0.7 0 (-0.02, 0.02) 1 0.006 (-0.1, 0.03) 0.6 0.004 (-0.02, 0.03) 0.7 0.4
EPA
Model 1* 0.01 (-0.01, 0.03) 0.001 (-0.02, 0.02) 0.9 0 (-0.02, 0.02) 1 0.02 (0.005, 0.04) 0.01 0.1
Males 0.001 (-0.03, 0.03) 1 -0.01 (-0.04, 0.02) 0.6 0.002 (-0.03, 0.03) 0.9 0.02 (-0.01, 0.05) 0.2 0.2
Females 0.02 (-0.004, 0.04) 0.1 .006 (-0.02, 0.03) 0.6 0.003 (-0.03, 0.02) 0.8 0.02 (0.001, 0.05) 0.04 0.3
Model 2† 0.01 (-0.01, 0.03) 0.3 0.002 (-0.02, 0.02) 0.9 -0.001 (-0.02, 0.02) 0.9 0.02 (0.003, 0.04) 0.02 0.1
Males 0.01 (-0.03, 0.04) 0.7 0 (-0.04, 0.04) 1 0.01 (-0.02, 0.05) 0.5 0.02 (-0.01, 0.06) 0.2 0.1
Females 0.01 (-0.008, 0.03) 0.2 0.008 (-0.01, 0.03) 0.5 0 (-0.02, 0.02) 1 0.02 (0.001, 0.05) 0.05 0.2
Right common carotid artery
Distension (mm)
DHA
Model 1* 0 (-0.06, 0.06) 1 -0.02 (-0.08, 0.05) 0.6 0.02 (-0.04, 0.08) 0.6 0.02 (-0.04, 0.09) 0.5 0.4
Model 2† -0.003 (-0.06, 0.06) 0.9 -0.05 (-0.1, 0.1) 0.1 -0.01 (-0.07, 0.05) 0.6 -0.01 (-0.07, 0.05) 0.8 0.8
EPA
Model 1* -0.01 (-0.08, 0.05) 0.7 -0.001 (-0.06, 0.06) 1 0.002 (-0.06, 0.07) 1 0.06 (-0.004, 0.1) 0.07 0.05
Model 2† -0.01 (-0.07, 0.05) 0.7 0.004 (-0.06, 0.06) 0.9 -0.004 (-0.06, 0.06) 0.9 0.04 (-0.02, 0.1) 0.2 0.1
1For tables 9-5 – 9-9 quintile 1 is the lowest for fatty acid status (%RBCFA) (referent set at 0). Beta coefficient values2 calculated as highest
minus lowest (referent) quintile based on general linear models. ‡ P for trend across quintiles calculated with %RBCFA quintile modelled
continuously. *Adjusted for baseline arterial diameter skin and room temperature. † Adjusted for baseline arterial diameter skin and room
temperature age, sex, social class, physical activity, LDL cholesterol, triglycerides, WHR, fasting insulin and energy intake. Gender x fatty acid
quintile interaction: P = 0.002 for FMD and 0.02 for EPA on brachial artery distension.
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Table 9-6 Regression coefficients for CVD risk factors (obesity) according to quintiles1 of fatty acids status
Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
Body Mass Index
DHA
Model 1*: n=313 -0.5 (-1.9, 0.9) 0.5 -0.9 (-2.2, 0.5) 0.2 -1.8 (-3.2, -0.5) 0.009 -1.4 (-2.7, 0.01) 0.05 0.01
Model 2 †: n=297 -0.08 (-1.3, 1.1) 0.9 -0.1 (-1.3, 1.0) 0.8 -1.03 (-2.2, 0.2) 0.09 -0.2 (-1.4, 1) 0.7 0.3
EPA
Model 1* -0.6 (-2, 0.7) 0.4 0.08 (-1.3, 1.4) 0.9 -1.3 (-2.7, 0.07) 0.06 -0.9 (-2.2, 0.5) 0.2 0.1
Model 2 † -0.3 (-1.5, 0.9) 0.6 0.3 (-0.9, 1.5) 0.6 -0.5 (-1.7, 0.8) 0.5 0.4 (-0.9, 1.6) 0.6 0.6
Waist circumference, cm
DHA
Model 1* -1.2 (-4.8, 2.3) 0.5 -2.6 (-6.1,0.8) 0.1 -5.1 (-8.6, -1.5) 0.005 -4.1 (-7.6, -6) 0.02 0.003
Model 2 † -0.3 (-3, 2.5) 0.9 -0.5 (-3.2, 2.3) 0.7 -2.8 (-5.6, -0.2) 0.05 -1.3 (-4.1, 1.5) 0.4 0.1
EPA
Model 1* -2.9 (-6.5, 0.6) 0.1 -0.3 (-3.8, 3.3) 0.9 -2.3 (-6, 1.3) 0.2 -2.8 (-6.3, 0.8) 0.1 0.2
Model 2 † -3.0 (-5.8, -0.2) 0.03 -0.3 (-2.7, 2.8) 1 -1.7 (-4.5, 1.2) 0.3 -1.1 (-3.9, 1.8) 0.5 0.9
Waist:Hip ratio
DHA
Model 1* -0.1 (-0.04, 0.14) 0.4 -0.02 (-0.05, 0.002) 0.07 -0.03 (-0.6, -0.007) 0.01 -0.03 (-0.06, 0.008) 0.009 0.002
Model 2 *† -0.002 (-0.02, 0.02) 0.9 -0.008 (-0.03, 0.009) 0.3 -0.02 (0.04, -0.001) 0.04 -0.01 (-0.03, 0.003) 0.1 0.03
EPA
Model 1* -0.02 (-0.04, 0.009) 0.2 -0.004 (-0.03, 0.02) 0.7 -0.01 (-0.04, 0.01) 0.3 -0.02 (-0.04, 0.005) 0.1 0.2
Model 2 † -0.02 (-0.04, 0.001) 0.06 0 (-0.02, 0.02) 1 -0.02 (-0.04, 0.001) 0.06 -0.02 (-0.03, 0.002) 0.08 0.1
*Unadjusted,† Adjusted for age, sex and energy intake. Gender x fatty acid quintile interaction: P > 0.07 for all variables.
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Table 9-7 Regression coefficients for CVD risk factors (blood pressure) according to quintiles1 of fatty acid
status
Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
Diastolic Blood Pressure
(mm Hg)
DHA
Model 1* : n=313 1.3 (-1.5, 4.1) 0.4 0.7 (-2.0, -3.4) 0.6 -0.7 (-3.5, 2.0) 0.6 -2.5 (-5.3, 0.3) 0.08 0.03
Model 2*†: n=393 2.0 (-0.5, 4.5) 0.1 2.1 (-0.3, 4.6) 0.1 0.7 (-1.8, 3.2) 0.6 -1.1 (-3.6, 1.4) 0.4 0.2
EPA
Model 1* 1.4 (-2.9, 2.6) 0.9 0.9 (-1.8, 3.6) 0.5 -1.4 (-4.3, 1.4) 0.3 -3 (-5.7, -0.2) 0.04 0.02
Model 2*† 0.8 (-1.7, 3.3) 0.5 1.2 (-1.2, 3.6) 0.3 -0.4 (-3.0, 2.1) 0.7 -1.3 (-3.8, 1.2) 0.3 0.2
Resting Heart Rate (beats
per minute)
DHA
Model 1* -2.0 (-1.7, 5.6) 0.3 1.9 (-1.7, 5.5) 0.3 1.8 (-1.8, 5.5) 0.3 -1.9 (-5.6, 1.7) 0.3 0.4
Model 2*† 2.0 (-1.5, 5.6) 0.3 2.0 (-1.5, 5.5) 0.3 0.5 (-3.1, 4.1) 0.8 -2.4 (-6.0, 1.2) 0.2 0.1
EPA
Model 1* 1.3 (-2.3, 5.0) 0.5 2.3 (-1.3, 5.9) 0.2 -1.07 (-4.8, 2.7) 0.6 -3.5 (-7.3, 0.2) 0.06 0.03
Model 2*† 1.1 (-2.5, 4.6) 0.6 1.2 (-2.3, 4.7) 0.5 -1.0 (-4.7, 2.7) 0.6 -3.2 (-6.8, 0.5) 0.1 0.05
*Adjusted for skin and room temperature † Adjusted additionally for age, sex, social class, physical activity, LDL cholesterol, triglycerides, height,
WHR, fasting insulin smoking practice and energy intake. Gender x RBCFA% quintile interaction for unadjusted models: P > 0.3 for all variables.
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Table 9-8 Regression coefficients for CVD risk factors (fasting lipid concentrations) according to quintiles1 of
fatty acid status
Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
Total-cholesterol (mmol/L)
DHA
Model 1* :n=317 0.05 (-0.3, 0.3) 0.8 0.07 (-0.02, 0.4) 0.6 -0.2 (0.5, 0.1) 0.2 -0.3 (-0.5, 0.02) 0.06 0.003
Model 2 † :n=299 -0.03 (-0.3, 0.3) 0.9 0.1 (-0.2, 0.4) 0.4 -0.2 (-0.5, 0.1) 0.3 -0.2 (-0.5, 0.1) 0.2 0.1
EPA
Model 1* -0.2 (-0.1, 0.5) 0.3 -0.03 (-0.3, 0.3) 0.9 -0.04 (-0.3, 0.3) 0.8 -0.1 (-0.4, 0.2) 0.4 0.2
Model 2 † 0.2 (-0.1, 0.5) 0.2 0.004 (-0.3, 0.3) 1 0.04 (-0.3, 0.4) 0.8 -0.007 (-0.3, 0.3) 1 0.6
LDL cholesterol
DHA
Model 1* 0.1 (-0.4, 0.2) 0.4 -0.06 (-0.3, 0.2) 0.7 -0.2 (-0.5, 0.06)0.1 0.1 -0.3 (-0.6, -0.02) 0.04 0.008
Model 2 † -0.06 (-0.3, 0.2) 0.7 0.05 (-0,2, 0.3) 0.7 -0.1 (-0.4, 0.2) 0.5 -0.2 (-0.4, 0.08) 0.3 0.2
EPA
Model 1* 0.06 (-0.2, 0.3) 0.7 0.04 (-0.2, 0.3) 0.8 -0.1 (-0.4, 0.1) 0.3 -0.04 (-0.3, 0.2) 0.8 0.4
Model 2 † 0.1 (-0.1, 0.4) 0.3 0.04 (-0.2, 0.3) 0.7 -0.05 (-0.3, 0.2) 0.7 -0.05 (0-0.2, 0.3) 0.7 0.8
VLDL-cholesterol
DHA
Model 1* -0.04 (-0.1, 0.06) 0.5 -0.1 (-0.2, -0.005) 0.04 -0.07 (-0.2, 0.03) 0.1 -0.1 (-0.2, 0) 0.05 0.04
Model 2 † -0.03 (-0.1, 0.06) 0.5 -0.09 (-0.2, -0.002) 0.05 -0.05 (-0.1, 0.04) 0.3 -0.05 (-0.1, 0.04) 0.3 0.2
EPA
Model 1* -0.05 (-0.1, 0.04) 0.3 -0.06 (-0.2, 0.03) 0.2 -0.09 (-0.2, 0.01) 0.08 -0.1 (-0.2, -0.05) 0.004 0.07
Model 2 † -0.05 (-0.1, 0.04) 0.3 -0.08 (-0.2, 0.01) 0.09 -0.06 (-0.2, 0.03) 0.2 -0.1 (-0.2, -0.004) 0.03 0.06
Triacylglycerol
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Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
DHA
Model 1* -0.08 (-0.3, 0.1) 0.5 -0.2 (-0.4, -0.01) 0.04 -0.2 (-0.4, 0.06) 0.2 -0.2 (-0.4, 0) 0.05 0.04
Model 2 † -0.07 (-0.3, 0.1) 0.5 -0.2 (-0.4, 0.03) 0.05 -0.1 (-0.3, 0.09) 0.3 -0.2 (-0.3, 0.08) 0.03 0.2
EPA
Model 1* -0.01 (-0.3, 0.1) 0.3 -0.1 (-0.3, -0.07) 0.2 -0.2 (-0.4, 0.03) 0.2 -0.3 (-0.5, -0.1) 0.004 0.004
Model 2 † -0.1 (-0.3, 0.09) 0.3 -0.2 (-0.4, 0.03) 0.09 -0.1 (-0.3, 0.08) 0.2 -0.2 (-0.4, 0.009) 0.04 0.06
*Unadjusted,† Adjusted for age, sex, social class, physical activity, waist to hip ratio, mean arterial blood pressure, fasting insulin and energy
intake. Gender x RBCFA% quintile interaction for unadjusted models P > 0.1 for all variables.
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Table 9-9 Regression coefficients for CVD risk factors (Type 2 DM) according to quintiles1 of fatty acid status
Q2 P2 Q3 P2 Q4 P2 Q5 P2 p‡
Glucose (mmol/L)
DHA
Model 1* :n=317 -0.05 (-0.2, 0.1) 0.6 -0.2 (-0.3, 0.01) 0.03 -0.3 (-0.4, -0.09) 0.003 -0.3 (-0.5, -0.1) <0.001 <0.001
Model 2 † :n=299 0.02 (-0.1, 0.2) 0.8 -0.08 (0.2, 0.07) 0.3 -0.2 (-0.3, 0.004) 0.06 -0.2 (-0.4, -0.06) 0.004 0.001
EPA
Model 1* -0.05 (-0.2, 0.1) 0.6 -0.006 (-0.2, 0.2) 0.9 0.05 (-0.1, 0.2) 0.6 -0.1 (-0.3, 0.05) 0.2 0.4
Model 2 † 0.03 (-0.2, 0.1) 0.8 0.02 (-0.2, 0.2) 0.9 0.08 (-0.1, 0.2) 0.4 -0.08 (-0.2, 0.09) 0.4 0.8
Insulin (pmol/L)
DHA
Model 1* -6.7 (-16.2, 2.8) 0.2 -7.7 (-17. 1.6) 0.1 -5.1 (-14.6, 4.5) 0.3 -7.4 (-16.9, 2) 0.1 0.2
Model 2 † -5.3 (-13, 2.5) 0.2 -6.1 (-13.8, 1.6) 0.1 -1.1 (-9, 6.8) 0.8 -1.9 (-9.7, 5.8) 0.6 0.1
EPA
Model 1* -4.8 (14.2, 4.5) 0.3 -1.1 (-10.4, 8.2) 0.8 -10 (-19.6, -0.4) 0.04 -11.7 (-21.1, -2.3) 0.02 0.008
Model 2 † -0.8 (-8.6, 7.0) 0.8 2.7 (-5.1, 10.5) 0.5 -2.8 (-10.9, 8.3) 0.5 -3.8 (-11.8, 4.1) 0.3 0.3
HOMA
DHA
Model 1* -0.3 (-0.6, 0.09) 0.1 -0.3 (-0.7, 00.2) 0.06 -0.3 (-0.6, 0.09) 0.1 -0.3 (-0.7, 0.02) 0.07 0.09
Model 2 † -0.2 (-0.5, 0.1) 0.2 -0.2 (-0,5, 0.05) 0.1 -0.09 (-0.4, 0.2) 0.5 -0.09 (-0.4, 0.2) 0.6 0.8
EPA
Model 1* -0.1 (-0.5, 0.2) 0.4 -0.06 (-0.4, 0.3) 0.7 -0.3 (-0.7, 0.05) 0.09 -0.4 (-0.8, -0.03) 0.03 0.02
Model 2 † -0.02 (-0.3, 0.3) 0.9 0.09 (-0.2, 0.4) 0.6 -0.05 (-0.4, 0.3) 0.7 -0.08 (-0.4, 0.2) 0.6 0.5
*Unadjusted,† Adjusted for age, sex, social class, physical activity, waist to hip ratio, mean arterial blood pressure, fasting LDL cholesterol,
triglycerides and energy intake. Gender x RBCFA% quintile interaction for unadjusted models: P > 0.2 for all variables.
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Chapter 10
Validation of a FFQ to estimate n-3 LC-PUFA intake using red
cell membrane fatty acids and multiple 24 hour dietary recalls
“True ideas are those that we can assimilate, validate, corroborate, and verify.
False ideas are those that we cannot.”
William James
10.1 Introduction
As discussed in Chapter 4, Section 4.6, the aim of dietary validation studies is to
estimate the validity of methods used to assess dietary intake, by comparing
associations between data derived from test instruments and a reference method
that is accepted to accurately reflect true intake.628 The validity of this approach
relies on two assumptions: 1) that random errors between questionnaires and
reference methods are independent and 2) random errors within reference
methods are also random and independent. It is possible, however, that random
errors of questionnaires and reference methods are positively correlated, leading
to overestimation of validity. For example, both FFQs and 24-hour recall
methods rely on the participant’s ability to recall and describe foods eaten
accurately and both may share potential sources of error. Conversely,
covariance between replicate reference measurements (i.e. multiple day
recordings) can lead to underestimation of the validity of a questionnaire under
test. For example, failure to record foods that have actually been consumed on a
day-to-day basis or a true change in dietary behaviour on recording days may
result in underestimation of attenuation in the reference method. This, in turn,
would result in underestimation of the test reference method’s accuracy.
Therefore, it is questionable whether random errors of reference dietary
assessment methods are independent of those attached to FFQs. Under free
living conditions, true intake is unknown and assessments of validity are relative.
Therefore, studies that use reference dietary assessment methods to assess the
validity of new questionnaires are more correctly termed comparison studies.
Biochemical markers of nutrient intake, in which sources of random error differ
from those of dietary assessment methods, are increasingly used in dietary
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validity studies to minimise risks of correlated error. Individual fatty acid
concentrations in erythrocyte membranes are useful biomarkers of fatty acid
intake as they provide an objective marker and do not rely on participants’
abilities to recall intake or their compliance with methods recording consumption.
Red cell membrane fatty acid concentrations are also reported to reflect long-
term intake and are therefore better markers of habitual diet (Chapter 4, Section
4.6.1). Furthermore, they are not prone to the same measurement errors as
dietary assessment methods including inaccuracies in portion size estimation and
food composition database values.
Although FFQs are available which have been validated in the UK population,530,
552 none is available that has been assessed objectively for dietary intake of n-3
LC-PUFA. FFQs that cover a wide range of foods can be long and complicated,
imposing a considerable burden on participants and therefore compromising
reliability of the method. Shortening the questionnaire, to group foods together,
can lead to a loss of detailed information and underestimation of intake of specific
nutrients. However, where measurement of a single or few nutrients is required a
shorter FFQ focussing on those nutrients may be more practical.
Outside the UK, some attempts have been made to develop FFQs for measuring
either dietary fish556, 559, 561, 629 or fatty acid intake553, 555, 557, 558, 560, 565, 630-632 but to
our knowledge no validated tool is available in the UK where the population and
dietary habits differ from those in countries where previous questionnaires have
been validated. Therefore this chapter investigates the association between fish
intake from a newly developed questionnaire and biomarker status.
A major aim of this PhD was to develop a FFQ designed to estimate habitual
intake of n-3 LC-PUFA in the UK population (FishFQ). Dietary intake data
collected by FFQs and multiple 24-hour dietary recalls as part of the RCT were
analysed and compared. Red blood cell membranes were analysed for their fatty
acid content to provide an objective assessment of n-3 LC-PUFA status. If
shown to be valid, the FishFQ will be useful in both clinical and research settings
where a validated dietary assessment tool is urgently required.
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10.2 Subjects & Methods
A total of 324 healthy young adults took part in the study. Background diet was
assessed using the EPIC FFQ. 323 subjects completed the FFQ at baseline and
one hundred and twenty five subjects took part in the validation study which
required: 1) completion of a specifically designed FishFQ, 2) completion of
multiple 24-hour records of dietary recall and 3) a fasting blood sample for
measurement of n-3 fatty acid erythrocyte membrane concentration. Ninety-one
subjects completed both dietary assessment methods required for the validation
study and provided a venous blood sample for analysis of red cell membrane
fatty acids. Demographic variables and information relating to lifestyle practices,
health behaviours and medical history were collected as part of the main RCT.
Primary and secondary outcomes including, vascular, haematological
anthropometric and body composition measurements were carried out by trained
researchers and erythrocyte membrane fatty acid concentrations were measured.
Full details of study procedures can be found in Chapter 5.
Fatty acid intakes from the EPIC and Fish FFQs were calculated using the
microdiet nutritional analysis programme, version 2.8.8 (Downlee systems,
England). Nutrient intake was estimated using data from the 4th, 5th and 6th
editions of McCance and Widdowson’s “The Composition of Foods”, Royal
Society of Chemistry, Ministry of Agriculture Fisheries and Foods520, and its
supplements. The 5th edition includes the seventh supplement that provides
detailed fatty acid data.367 24-hour recalls were analysed as described in
Chapter 6, Section 6.4.4. Energy intake based on 24-hour recall was used to
identify subjects with extremes indicating implausible energy intakes (>16 800kj/d
and <3360kj/d for males and >14700 kj/d and <2100 kj/d for females.633 No
individual was excluded on this basis. Fatty acid intakes are from food alone
(exclusion criteria for participation in the RCT included use of n-3 supplements,
(Chapter 5, Section 5.2.3).
10.3 Results
Subject characteristics at study baseline are reported in Table 10-1. There were
no significant differences between participants and non-participants for most
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variables with the exception of smoking and glucose concentration. A greater
percentage of non participants were current smokers compared with participants
(n = 104/233, 45% vs. n = 24/91, 26% for non- and participants respectively
[P < 0.002]). Fasting blood glucose was 6% higher in participants (5 vs.
4.7mmol/L in participants and non-participants respectively [P < 0.001]).
10.3.1 Agreement Between Fish and EPIC FFQs
After recruitment of the first 100 subjects agreement between the new
questionnaire and the EPIC FFQ was assessed using the Bland and Altman
technique.607 Estimates of nutrient intake were based on standard portion sizes.
Eighty eight out of one hundred subjects completed both the EPIC and FishFQ at
baseline. The FishFQ gave higher estimates of EPA and DHA intake compared
with the EPIC FFQ. The two methods were significantly correlated (r = 0.31,
P < 0.01) but agreement between them was poor.
For DHA mean (SD) intake using the EPIC FFQ was 0.15g/d (0.19) and using the
new FFQ 0.79g/d (0.48). The mean (SD) of the differences between the two
methods (bias) was -0.63g/d (0.46). Limits of agreement, calculated as 2 x SD
were (-1.55 to 0.29) (Figure 10-1).
With respect to EPA the mean (SD) intake based on EPIC was 0.11g/d (0.14)
and 0.68g/d (0.47) using the new FFQ, mean (SD) bias was -0.57g/d (0.48) and
95% limits of agreement -1.52 to 0.39 (Figure 10-2). This represents poor
agreement and suggests that the two methods cannot be used interchangeably.
From this analysis it is not possible to conclude which method provides the most
accurate assessment. Compared with the EPIC FFQ, the Fish FFQ gave 4-5 fold
higher mean estimates of n-3 LC PUFA intake possibly because the broader
(EPIC) questionnaire does not separate n-3 LC PUFA foods within food groups.
However, it is also possible that n-3 LC PUFA intake was overestimated using
the new questionnaire. Further research to test the ability of the new food
frequency questionnaires to assess n-3 LC PUFA intake against biomarkers
would help to elucidate this.
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10.3.2 Standard versus estimated portion size
Comparisons between estimates of fish intake using the EPIC and Fish FFQs
based on standard portion sizes and amounts depicted in photographs were
carried out in a subset of 138 subjects who provided information on portion size
using the photographic portion size atlas. Estimates of n-3 LC PUFA foods were
higher when standard portions were applied to calculate daily amounts consumed
in grams compared with portions based on estimates from photographs. The two
methods were significantly correlated (r = 0.31, P = 0.01) and agreement
between them (analysed using the Bland and Altman (1986) method) was
reasonable. For DHA mean (SD) intake using standard portions was 0.45g/d
(0.34) and using portions depicted in photographs 0.41g/d (0.29) The mean (SD)
of the differences between the two methods (bias) was -0.04g/d (0.37). Limits of
agreement were quite wide at (-0.74 to 0.74g/d) suggesting a high degree of
variation for some subjects (Figure 10-3).
This relatively small bias means that the two methods can be used
interchangeably. Therefore, in view of extra costs and greater burden on study
participants and researchers with the provision and use of a photographic atlas it
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was decided that validation of the FishFQ would be based on standard portion
size estimations.
10.3.3 Validation Studies
Ninety-one subjects completed the FishFQ and provided 5 24-hour recalls of
dietary intake. Thirteen subjects were excluded for various reasons including:
inadequate completion of the FishFQ (n = 6) and implausible data (n = 7) (e.g.
ticked more than one frequency category in a single line entry). Data were
considered implausible where outliers introduced positive skewness or kurtosis
with significant effects during exploratory analyses. Therefore, a total of seventy
eight subjects were included in the validation analyses reported below (Figure
10-4).
Figure 10-4 Participant flow through dietary assessment protocol
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10.3.3.1 Correlations of FFQs with biomarkers of LC-PUFA intake
Pearson’s correlation coefficients between the EPIC and Fish FFQs, are shown
in Table 10-2. Correlations between the FishFQ and the biomarker were
moderate to high (r = 0.34, 0.38 and 0.43 for DHA, EPA and DHA+EPA
respectively [P < 0.01]). In contrast most correlations between measurements
of n-3 LC-PUFA intake using the EPIC FFQ and the biomarker were lower
ranging from r = 0.22 for DHA [P < 0.05] to r = 0.40 [P < 0.01] for EPA and r =
0.27 [P < 0.01] for combined DHA and EPA. This suggests that overall the new
FishFQ provides a more accurate assessment of n-3 LC-PUFA intake than the
EPIC FFQ. Adjustments for age, sex and energy intake did not consistently
improve correlations.
10.3.3.2 Validation of FishFQ using the method of Triads
Because adjustments for age, sex and energy intake did not consistently
improve correlations, unadjusted correlation coefficients between the two
dietary assessments and the biomarkers of fatty acid status were used to
calculate validity coefficients. Relative validity of the FishFQ was assessed
using the method of triads which uses triangular comparisons between a dietary
assessment method under test (FishFQ), a reference method (multiple 24-hour
dietary recalls) and a biochemical marker (erythrocyte membrane fatty acids
(RBC FA) to compute validity coefficients (Chapter 6, Section 6.5.4.1 and
Figure 6-2).
Triangular validation methodology assumes that correlations between the three
measurements reflect a linear relationship of each method with the true intake
(Figure 10-5). The correlation coefficient between the test instrument (FishFQ)
and the biomarker provides a lower limit for estimation of validity. The method
of triads improves the estimation of validity and provides an upper limit.
Equations for calculation of validity estimations used in the present validation
study are reported in Appendix 4-1.
The 95% confidence intervals for the validity coefficient were estimated using
bootstrap sampling where 200 samples of equal size (n = 78) were obtained
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with replacement from the study participants. Analyses were carried out in
PASW, version 18 (SPSS Inc., Chicago, IL, USA). Validity coefficients for the
FishFQ were 0.54 for DHA, 0.48 for EPA and 0.56 for combined EPA/DHA.
Validity coefficients for the 24 hour recall method were generally higher than the
FishFQ and the biomarker had the greatest validity (Table 10-4)
Figure 10-5 Sample correlations and validity coefficients for triangular
comparisons between FFQ (Q), 24-h recall (R) and biomarker (M). T
represents the hypothetical true intake
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10.3.4 Reliability
Reproducibility of the EPIC and FishFQs was assessed by comparing values
obtained at study baseline with those collected after the 4-month intervention
period. 155 subjects completed the final version of the FishFQ at study
baseline and 4 months later following the intervention period. 272 subjects
completed the EPIC FFQ at both time points. Pearson’s correlation coefficients
between the two administrations of the EPIC and FishFQ are shown in Tables
10-5 and 10-6.
10.3.5 Agreement According to Bland and Altman Analysis
Agreement was further assessed using the Bland and Altman method as
described in Chapter 6, Section 6.3.5.1. Both questionnaires showed good
agreement. Mean bias for DHA was 6% and 5% for the Fish and EPIC FFQ
respectively (Table 10-7 and 10-8, Appendix 4-3). Limits of agreement were
wide (± 0.96g/d and ± 0.38g/d for the Fish and EPIC FFQ respectively (Table
10-7 and 10-8). The small bias in DHA intake, estimated at two time points,
demonstrates good agreement at the group level and suggests that both
questionnaires provide acceptable estimates of intake in this population.
However, the wide limits of agreement suggest this good agreement does not
extend to individuals.
10.3.6 Classification to Population Distribution
Agreement between the Fish and EPIC FFQ and biomarkers of fatty acid status
was assessed in 78 participants for whom complete sets of data were available
(completed both FFQs and provided a blood sample at baseline and post-
intervention). The proportions of individuals classified in the same third of the
distribution (exact agreement) and into extreme thirds of the distribution (gross
misclassification) were calculated. Using the FishFQ exact agreement with
biomarker status was reported in 57% of subjects for DHA and 56% for EPA at
study baseline. Classification according to EPIC was less accurate (44% for
DHA and 46% for EPA) (Table 10-8). Exact agreement between intake
assessments and fatty acid status according to biomarkers improved for the
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Fish and EPIC FFQ post intervention. Using the FishFQ exact agreement with
biomarker status was reported in 58% of subjects for DHA and 60% for EPA.
Exact agreement between intake assessment using the EPIC FFQ and fatty
acid status according to biomarkers was 55% for DHA and 47% for EPA) (Table
10-8).
These findings suggest the Fish and EPIC FFQ can accurately place individuals
according to their estimated DHA and EPA intake. Furthermore, the superior
agreement found between the FishFQ and biomarkers suggests the new
questionnaire may offer a less costly and time consuming method for ranking
individuals according to DHA and EPA intake.
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Table 10-1 Characteristics at baseline comparing participants in
validation study with non participants
Participants Non Participants P
n 91 233
Age, y 27.6 (4.8) 27.9 (4.7) 0.4
1Male gender, % , n 38 (35) 35 (85) 0.7
1Non-manual, %, n 55 (50) 58 (135) 0.4
1Current smoker, % , n 26 (24) 45 (104) 0.002
Body mass index, kg/m2 23.7 (4.3) 23.5 (3) 0.6
% fat (skinfolds) 23.6 (5.5) 24.1 (5.5) 0.5
Sum skinfolds, mm 53.7 (19.0) 50.5 (20.9) 0.2
Waist circumference, cm 77.4 (10.4) 77.3 (10.0) 1.0
Waist:Hip ratio 0.8 (0.07) 0.78 (0.07) 0.5
Blood pressure, mm Hg
Systolic 112 (10) 111 (11) 0.8
Diastolic 66 (7) 67 (8) 0.4
Mean Arterial 84 (8.) 84 (9) 0.9
Pulse Pressure 46.0 (6) 45.0 (6) 0.2
Heart rate, beats/min 66 (10) 66 (11) 0.7
Total cholesterol, mmol/L 4.2 (0.8) 4.3(0.8) 0.4
LDL cholesterol, mmol/L 2.4 (0.8) 2.4 (0.8) 0.9
HDL cholesterol, mmol/L 1.4 (0.4) 1.5 (0.3) 0.4
VLDL cholesterol 0.5 (0.3) 0.4 (0.3) 0.9
Total:HDL cholesterol ratio 3.2 (1.1) 3.1 (0.1) 0.6
LDL:HDL cholesterol ratio 1.8 (0.9) 1.7 (0.8) 0.4
Triglyceride, mmol/L 1.0 (0.6) 1.0 (0.6) 0.9
Glucose, mmol/L 5.0 (0.5) 4.7 (0.5) <0.001
Insulin, pmol/L 35.8 (42.0) 29.7 (17.6) 0.07
Insulin resistance (HOMA) 1.2 (1.6) 0.89 (0.6) 0.1
CRP, mg/L 1.8 (3.2) 1.7 (3.4) 0.67
Cotinine, ng/ml 22.6 (73.2) 25.3 (79.3) 0.8
Data are mean (SD) except: 1 % (n) <5% loss of n for some variables.
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Table 10-2 N-3 Fatty Acid Intake and correlation coefficients between
EPIC and Fish FFQ and erythrocyte n-3 fatty Acids. (n = 78)
Intake, g/d,
mean (sd)
Pearson’s correlation coefficients
Unadjusted Adjusted**
Fatty
Acids
Fish
FQ
EPIC
FFQ
FishFQ
vs.
Biomarker
EPIC FFQ
vs
Biomarker
FishFQ
vs
Biomarker
EPIC FFQ
vs
Biomarker
DHA 0.41
(0.2)
0.21
(0.2)
0.34 0.22* 0.33 0.20*
EPA1 0.47
(0.3)
0.26
(0.2)
0.38 0.40 0.35 0.40
EPA +
DHA
0.82
(0.5)
0.47
(0.5)
0.43 0.27 0.37 0.28
All data except1 were loge transformed before analyses. All correlations significant at 0.01 level (two tailed) except *
significant at 0.05 level. ** Adjusted for age, sex and energy intake in regression analyses.
Table 10-3 Pearson’s correlation coefficients (95% confidence
intervals) between FishFQ, 24-Hour recall and erythrocyte
n-3 fatty acids(n = 78)
FishFFQ vs.
24 Hour Recall
24 Hour Recall
vs. Biomarker
FishFFQ
vs. Biomarker
DHA 0.35 (0.14, 0.52) 0.41 (0.20, 0.60) 0.34 (0.08, 0.57)
1EPA 0.30 (0.09, 0.52) 0.50 (0.26, 0.66) 0.38 (0.20, 0.58)
EPA+DHA 0.35 (0.16, 0.51) 0.48 (0.21, 0.68) 0.43 (0.14, 0.63)
Data are loge transformed except1 and presented as correlation coefficient (95% confidence interval). All
correlations significant at 0.01 level (two tailed).
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Table 10-4 Validity coefficient of the FishFQ, 24-Hour Recalls (24-HR) and biomarker of n-3 LC-PUFA intake as calculated
by the method of triads and the 95% CI (n = 78)
Validity coefficients Range of Validity coefficients†
PQT 95% CI PRT 95% CI PMT 95% CI PQT PRT PMT
DHA 0.54 (0.22,0.92) 0.65 (0.32, 1.28) 0.63 (0.29, 1.08) 0.34 – 0.54 0.41 – 0.65 0.34 – 0.63
EPA 0.48 (0.26, 0.76) 0.63 (0.33, 1.00) 0.80 (0.48, 1.44) 0.38 – 0.48 0.50 – 0.63 0.38 – 0.80
EPDHA 0.56 (0.32, 0.88) 0.63 0.37, 1.04) 0.77 0.37, 1.23) 0.43– 0.56 0.48 – 0.63 0.43 – 0.77
† The lower limit for the FishFQ and the biomarker is the correlation between the Fish FQ and the biomarker, and the lower limit for the 24-HR is the correlation between the
biomarker and the 24-HR. The upper limit is calculated by the method of triads.
pQT, validity coefficient of the FishFQ, pRT, validity coefficient of the 24-H recall, pMT, validity coefficient of the biomarker.
All data natural log transformed. 5% confidence intervals computed from 200 Bootstrap samples
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Table 10-5 Pearson’s correlation coefficients for the FishFQ administered on two occasions at 4 month interval
(n=155)
Fish FQ Visit 1 Fish FQ Visit 2 R Difference
(% mean intake)
Fatty Acid Mean sd Range Mean sd Range
DHA (g/day) 0.54 0.66 0 – 4.23 0.51 0.55 0 – 4.59 0.74 6%
EPA (g/day) 0.57 0.48 0 – 2.77 0.50 0.46 0 – 3.56 0.55 15%
Table 10-6 Pearson’s correlation coefficients for the EPIC FFQ administered on two occasions at 4 month interval
(n= 272)
EPIC FFQ Visit 1 EPIC FFQ Visit 2 R
Difference
(% mean intake)
Fatty Acid Mean sd Range Mean sd Range
DHA (g/day) 0.22 0.21 0.00 – 1.49 0.20 0.21 0.00 – 1.61 0.64 5%
EPA (g/day) 0.29 0.36 0.00 – 4.52 0.29 0.36 0.00 – 3.52 0.32 3%
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Table 10-7 The relative bias and limits of agreement for measurement of DHA and EPA estimated by Fish and EPIC
FFQ at visit 1 and visit 2
FishFQ EPIC FFQ
DHA (g/day) EPA (g/day) DHA (g/day) EPA (g/day)
Bias 0.03 0.08 0.01 0.01
Limits of agreement ± 0.96 ± 0.91 ± 0.38 ± 0.83
Bias as percentage mean intake 6% 15% 5% 3%
Table 10-8 Agreement between fatty acid intakes estimated by Fish and EPIC FFQ and status according to
biomarkers
Fatty
Acid
Baseline Post-intervention
Fish FQ and biomarker EPIC FFQ and biomarker Fish FQ and biomarker EPIC FFQ and biomarker
Exact
(%)
GM
(%)
k P Exact
(%)
GM
(%)
k P Exact
(%)
GM
(%)
k P Exact
(%)
GM
(%)
k P
DHA 57 8 0.3 <0.01 44 12 0.3 <0.01 58 7 0.4 <0.001 55 2 0.3 <0.001
EPA 56 11 0.2 0.03 46 16 0.2 0.01 60 9 0.4 <0.001 47 19 0.2 0.006
All correlations significant at 0.01 level. DHA= Docosahexaenoic acid, EPA=Eicosapentaenoic Acid. GM = gross misclassification 1Fatty acids expressed as % total
erythrocyte membrane fatty acids. †<5% missing data for some variables. k = kappa value
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10.4 Summary
The new questionnaire estimated dietary intake of n-3 LC-PUFA well compared
with results from previous studies. Correlation with the reference dietary
assessment method was moderate and comparable to that found in other studies
for DHA and EPA. More rigorous evaluation using an independent biomarker of n-
3 LC-PUFA status suggests validity may be even higher.
The questionnaire also demonstrated good reproducibility indicating a high level of
precision. Importantly, agreement between assessments of n-3 LC-PUFA intake
using the new questionnaire and fatty acid status according to the biomarker was
also good and the questionnaire was able to place more than 50% of participants
into the same thirds of the distribution when intake was assessed by FFQ and fatty
acid status evaluated through red cell membrane concentration. Only about 10%
of participants were misclassified. This compares closely with other studies where
exact agreement was also reported for about 50% of participants.555, 632
10.5 Discussion of Results
Less than 20 studies have validated dietary methods for assessment of n-3 fatty
acids using biomarkers and a universally accepted marker of n-3 LC-PUFA status
has yet to be identified.634 Biomarkers considered to produce reliable estimates
include subcutaneous adipose tissue, plasma and erythrocyte fatty acid
concentrations. Studies comparing effects of supplementation with fatty acids on
different compartments have concluded that erythrocyte membrane concentration
is a better index for monitoring long-term intake of n-3 fatty acids, whereas plasma
phospholipids are more sensitive to short-term changes.635
Fifteen published reports of validation studies comparing FFQs with biomarkers of
fatty acid status are currently available.634 Four of these have assessed validity
against RBC FA concentrations.632, 636-638 Eight studies used plasma fatty acids or
phospholipids.545, 546, 553, 555, 556, 558, 638, 639 Only two studies compared intake
assessed using FFQ with subcutaneous fat concentrations.542, 640 Correlation
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coefficients between biomarkers and fatty acid intakes estimated from FFQs are
similar but vary according to the chosen biomarker. Studies that have used RBC
FA concentrations as a biomarker report unadjusted correlation coefficients in the
range of 0.23-0.36 for EPA and 0.19-0.54 for DHA. Where plasma fatty acids are
used correlation coefficients are generally higher and range from 0.25-0.56.
Correlations with adipocyte fatty acids are low ranging from 0.15 to 0.32.
Although it is not clear why biomarker correlations vary, fatty acids in plasma may
be present in many forms (for example as part of cholesterol esters, triglycerides or
phospholipids) and are affected by dietary intake and therefore more variable.
Equally the more complex array of fatty acids in adipose tissue compared with
erythrocyte membranes means that assays are more prone to error.544
Many FFQs are designed to capture usual (habitual) dietary intake and therefore
collect information on a wide range of foods. For example in studies discussed
above FFQs included between 66 and 360 foods. However, only two
questionnaires were specifically designed to ask about foods high in n-3
LCPUFA.558, 632 Only one study specifically asking about n-3 foods used RBC FA
as the reference biomarker.553 Most studies used correlation analysis to estimate
validity and only one study applied the methods of triads to provide an upper
limit.555
Sullivan and colleagues (2006) reported correlation coefficients between DHA and
EPA intake, assessed with a FFQ specifically designed to measure n-3 LCPUFA
intake, and RBC FA concentrations of r = 0.39 and 0.4 respectively (n = 53). This
agrees closely with the findings of the present study that found similar correlations
of r = 0.34 and r = 0.38 for DHA and EPA respectively.
The one other study identified that used the method of triads to validate a tool for
dietary n-3 assessment validated a generalized FFQ against weighed food records
and plasma fatty acids.555 This study reported validity coefficients for the FFQ of
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0.62 and 0.54 for DHA and EPA respectively (n = 43). These coefficients are
slightly higher, although still in the same range, than those found in the present
study (0.54 and 0.48 for DHA and EPA respectively). The reason for this is
unclear. One possibility is that McNaughton used weighed records as the
reference dietary assessment and plasma fatty acid concentration as a biomarker.
Weighed records provide a snapshot assessment of dietary intake and plasma
fatty acids reflect recent rather than habitual intake. Therefore high correlation
between these two methods may have improved the overall estimate of validity.
One possible drawback with the study of McNaughton is that FFQs are designed to
assess habitual intake rather than to provide a snapshot of recent intake.
Therefore comparison against weighed records and plasma fatty acids which both
measure recent intake may not have been appropriate. This is supported by the
fact that correlation coefficients between the FFQ and biomarkers reported by
McNaughton were lower than in the present study (r = 0.32 and r = 0.21 for DHA
and EPA respectively compared with r = 0.34 and 0.38 in the present study).
Our study shows that the FishFQ can be used in both clinical and research settings
to identify individuals with low, medium or high intakes of n-3 LC-PUFA. This is
important because reliable estimates of intake are needed to interpret research
findings correctly and underpin public health messages. In clinical practice,
accurate assessment of intake is needed to inform dietetic interventions and
identify individuals at increased risk of nutritional deficiencies. The new FFQ can
also be used to classify individuals at increased risk. For example, where
relationships between n-3 fatty acid consumption and specific diseases have been
identified including cardiovascular disease641 and prostatic cancer637 The findings
of this study have recently been presented at the Summer Meeting of the Nutrition
Society and the abstract has been accepted for publication in the Proceedings of
the Nutrition Society (Appendix 4-2).
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Chapter 11
Overall Discussion and Conclusions
Life is the art of drawing sufficient conclusions from insufficient premises.
Samuel Butler
11.1 Summary of Findings
In Chapter 5, Section 5.1.1, the main hypotheses for the RCT and epidemiological
dietary study were set out. The aim of the RCT was to test the hypothesis that n-3
PUFA supplementation improves vascular function and CVD risk factors in healthy
young adults. The epidemiological study tested the hypotheses that dietary
patterns and components within them (specifically n-3 LC-PUFA) are associated
with vascular structure and function and CVD risk factors.
No validated tool for assessment of n-3 LC-PUFA was available in the UK.
Therefore, I designed and developed a new food frequency specifically to assess
n-3 LCPUFA intake in this population of young healthy adults. I hypothesized that
this new FFQ would demonstrate acceptable validity when compared against a
reference dietary assessment method (multiple 24-hour dietary recalls) and
biomarkers of n-3 LC-PUFA intake.
In Chapter 7 a RCT investigating the impact of DHA supplementation on FMD and
surrogate markers of atherosclerosis in healthy young people found a small but
negative effect on FMD in men. However, DHA supplementation had beneficial
effects on CVD risk factors. Blood pressure was reduced in men randomized to
receive 1.6g/d DHA for 4 months and VLDL and TG were reduced in men and
women.
In Chapter 8 I identified 3 dietary patterns in the study participants. In univariate
analyses these dietary patterns were associated with measures of vascular
structure (carotid artery intima media thickness and brachial artery distensibility)
284
and CVD risk factors including BP, heart rate, serum lipid concentrations, fasting
insulin concentration (a marker of T2DM risk) and CRP (a marker of inflammation
and endothelial activation). After adjustment for risk factors known to influence
vascular health and CVD in multivariate models many relationships were
attenuated and no longer significant. However, independent associations of
dietary patterns with CCA-IMT, brachial artery distensibility, BP, heart rate, VLDL
and TG concentrations remained.
In secondary analyses associations of dietary patterns with vascular structure and
CVD risk factors differed according to gender. Associations of dietary patterns with
CCA-IMT and brachial artery distensibility were confined to women. There were no
significant gender interactions with dietary patterns on CVD risk factors except for
CRP where the relationship was again confined to women. However, this
association was no longer significant after adjustment for other CVD risk factors
suggesting that associations of diet with endothelial inflammation and activation
are mediated through other CVD risk factors.
Dietary patterns were not directly associated with endothelial function assessed
through measurement of FMD. However, many CVD risk factors showed
moderate to strong correlations with vascular structure. In particular, BP was
strongly related to CCA distensibility. This suggests that associations of habitual
diet with FMD are likely to operate through other CVD risk factors including
increased BP, heart rate, and VLDL and TG concentrations.
In Chapter 9 I found that fatty acid status, assessed by red cell membrane
concentration, was associated with FMD in women. Unexpectedly, as DHA status
increased FMD decreased. Relationships were also found between fatty acid
status and CVD risk factors including obesity, BP, heart rate, serum lipid
concentrations and fasting glucose and insulin. In univariate analyses higher DHA
status was associated with lower BMI, WC, WHR, BP, TC, LDL, VLDL, TG and
fasting blood glucose (FBG). After adjustment for potential confounding factors
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many associations were attenuated and no longer significant. However,
relationships between higher DHA status and WHR and FBG persisted in fully
adjusted models (Tables 9-6 and 9-9).
Higher EPA status was associated with lower diastolic blood pressure, VLDL, TG
and resting heart rate. After adjustment for confounding factors, a trend remained
for the association of EPA status with VLDL, TG and HR. This suggests that n-3
fatty acids may be dietary components within a healthy dietary pattern that are
associated with benefits for the lipid profile and reductions in CVD risk.
In Chapter 10 the new FishFQ was found to be a valid and reliable tool for
assessment of n-3 LC-PUFA intake in this population of young UK adults. The
FishFQ demonstrated acceptable validity when compared with multiple 24-hour
dietary recalls and biomarkers of fatty acid status using triangular comparisons.
The FishFQ was also able to correctly classify individuals as low, intermediate or
high n-3 LC-PUFA consumers. More than half were placed in the same thirds of
the population distribution according to intake assessment and fatty acid status.
In summary, the RCT found that DHA directly affected FMD negatively in men.
Benefits of DHA supplementation were found for blood pressure but these were
confined to men. Significant reductions in triglyceride and VLDL concentrations
were found in women and men.
In the epidemiolgoical study, dietary patterns were associated with vascular
structure in women. No direct associations of dietary patterns with FMD were
apparent. However, dietary patterns were associated with a range of CVD risk
factors. Relationships between dietary patterns and BP, VLDL and TG remained
after adjustment for confounding factors demonstrating independent associations
of dietary patterns with these risk factors. Findings from the RCT and
epidemiological study are summarised in Figure 11-1 and 11-2 and discussed in
Section 11.2 below.
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Figure 11-1 Diagram summarising relationships of diet with vascular structure and function and CVD risk
factors identified in the epidemiological study
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Figure 11-2 Diagram summarising effects of DHA supplementation on vascular structure and function and CVD
risk factors in the RCT
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11.2 Discussion of Results
11.2.1 Dietary Patterns and Vascular Function
The finding that dietary patterns were not directly associated with brachial artery
FMD was not unexpected. In Chapter 2 an evidence review concluded that dietary
components have both protective (e.g. flavonoids) and detrimental (e.g. saturated
fat) effects on endothelial function. However, evidence from long-term trials was
lacking. Whilst some observational studies have reported relationships of healthy
dietary patterns with markers of EF these were all in older adults.183, 287, 642, 643 No
previous study of dietary patterns and FMD in healthy young people has been
reported.
Other studies, although in older adults, support our findings and report no
relationship between healthy diets and FMD. For example, Hodson and
colleagues (2010) reported that the DASH diet, high in fruit, vegetables,
wholegrains and low fat dairy foods, reduced BP but did not benefit FMD raising
the possibility that benefits of a healthy diet for FMD operate via effects on other
CVD risk factors.241 Similarly Ambring (2004) found no benefits for FMD in a
Swedish population following a Mediterranean diet.233
Markers of endothelial activation and inflammation can be used as surrogate
measures of EF. Several studies have evaluated such markers to assess
relationships between diet and plasma biomarkers of endothelial dysfunction.287,
644, 645 The present study found that CRP (a marker of endothelial activation)
increased as scores on the snack dietary pattern increased. In the Multi-Ethnic
Study of Atherosclerosis (MESA), Nettleton and colleagues (2006) reported that a
dietary pattern termed “fats and processed meats” characterised by high loadings
for fats, oils, processed meats and fried potatoes, was positively associated with
CRP (P for trend <0.001).642 A second pattern, characterised by beans, tomatoes,
refined cereals and high fat dairy products, was positively associated with soluble
intracellular adhesion molecule (sICAM) -1 (P for trend 0.007). In contrast more
healthy dietary patterns, characterised by high loadings for fruits, vegetables and
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wholegrains were associated with lower concentrations of these and other
markers.
Lopez-Garcia (2004) also found that a ‘prudent’ diet characterized by higher
intakes of fruit, vegetables, legumes, fish, poultry and wholegrains was associated
with lower concentrations of CRP (P = 0.02) and E-selectin (P = 0.001) (a marker
of endothelial dysfunction).183 Conversely, a ‘western’ dietary pattern
characterised by higher intakes of red and processed meats, confectionary, fries
and refined grains was positively associated with CRP (P < 0.02) and E-selectin (P
< 0.001) as well as with soluble adhesion molecules sICAM-1 (P < 0.002) and
sVCAM-1 (P = 0.02).
These observations support the hypothesis that dietary patterns are associated
with EF indirectly and relationships are mediated through classical CVD risk
factors.
11.2.2 Dietary Patterns and Vascular Structure
The finding that dietary patterns were associated with vascular structure was
expected and has been shown in previous studies.281, 626, 646 For example, The
Insulin Resistance Atherosclerosis (ARIC) Study found that a dietary pattern
characterised by higher intakes of less healthy foods (e.g. low fibre bread and
cereal, red and processed meat, tomato foods and sweetened beverages) and
lower intakes of more healthy foods (e.g. wine, rice and pasta and poultry) was
associated with increased CCA-IMT in middle-aged adults (1 SD increase in
dietary pattern score corresponding to 13 µm increase in CCA-IMT).281 Our study
is the first to identify this association in healthy young people. This is important
because dietary patterns are established early in life and likely to track. Evidence
to support this comes from the Young Finns Study where a traditional dietary
pattern characterized by low intakes of fruits and vegetables in children aged 3-18
years was associated with increased IMT in adulthood.646
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An unexpected finding in this present study was that higher arterial distensibility
was associated with a snack dietary pattern in women. Possible explanations
include ambiguity regarding the interpretation of this dietary pattern as healthy or
not. For example, the snack pattern loaded high on convenient fish products and
combination meals. Whilst some convenience foods may be high in nutrients that
when taken in excess adversely affect CV health such as saturated fats others may
not. In recent years the food industry has moved towards producing convenience
foods that meet healthy eating guidelines. Examples include foods termed
“Healthy Options” or labelled “Be Good to Your Self” widely available in most
supermarkets. Therefore, convenient fish products that loaded high on the snack
pattern may have contained oily fish. Similarly, convenience foods may have been
healthy options as described above that were low in saturated fat and high in fruits
and vegetables.
In secondary analyses the effect of a snack dietary pattern on CCA distensibility
was confined to females raising the possibility of separate gender effects. An
important consideration is the possibility that foods characterising the snack dietary
pattern differ according to gender. For example in men convenience foods may be
high in saturated fats whereas in women they may be a healthier option as
discussed above.
Surprisingly, we found tomatoes were characteristic and loaded high on the meaty
dietary pattern; a finding that appeared counter to current perceptions of unhealthy
dietary components. However, as proposed by Liese and colleagues (2010), this
could be explained by the inclusion of tomatoes in (usually high fat) convenience
foods including pizza and hamburger relish.281 In contrast the meat based dietary
pattern in this study did not include sweetened beverages as in the less healthful
diet described by Liese et al (2010).281 Rather, these loaded high in the snack
pattern.
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11.2.3 Dietary patterns and classical CVD risk factors
In the present study, benefits for obesity, blood pressure, serum lipid
concentrations and insulin resistance were suggested by reductions in these risk
factors as scores on the healthy dietary pattern increased. In contrast, CVD risk
factors were associated with higher scores on the meat and snack dietary patterns.
A healthy dietary pattern was associated with lower BP and a less healthy dietary
pattern with higher BP, a major determinant of arterial stiffness.31 Therefore, diet
may influence the development of vascular disease through effects on BP.
Dietary patterns have been shown to offer protection against high BP in previous
studies; most notably, the DASH dietary pattern characterised by high intake of
fruit, vegetables and low-fat dairy products, including wholegrains, poultry fish and
nuts and low intake of red meat, sweets and sweetened beverages, has been
associated with lower systolic and diastolic BP (5.5mm Hg and 3.0mm Hg
respectively).387 These associations are similar to those reported in the present
study.
As in the present study, dietary patterns have been reported to benefit the lipid
profile. For example, Hoffman and colleagues (2004) found HDL decreased
across quintiles for a dietary pattern characterized by high consumption of meat,
margarine and vegetable fats and oils. No trend was seen across quintiles of
dietary pattern score for any other lipid fractions.627 In contrast, reductions in TC,
LDL, VLDL and TAG were seen across quintiles of health conscious dietary pattern
score in this present study.
The present study also found associations of healthy dietary patterns with risk
markers for T2DM. A higher score on a healthy dietary pattern was associated
with lower fasting insulin concentration. This is supported by previous studies. For
example, Fung and colleagues (2001) reported from the US Health Professionals
Study that a “Prudent” dietary pattern, high in fruit, vegetables, wholegrains and
poultry was associated with lower insulin concentrations.644
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This epidemiological study found that diet was directly associated with measures of
vascular structure such as CCA-IMT and arterial distensibility. A clear association
of dietary patterns with vascular structure suggests diet may influence vascular
health directly. Associations of dietary patterns with CVD risk factors including BP,
HR, VLDL and TG were also found. This suggests diet may also influence
vascular health through CVD risk factors. Path analyses would help elucidate
these relationships. Sex differences were apparent and these warrant further
investigation. Further follow up of this cohort into middle- and older-age, when
clinical signs of CVD are likely to present, would clarify this relationship.
11.2.4 n-3 Fatty Acids and Vascular Function
Associations of n-3 fatty acids with FMD observed in the epidemiological dietary
study were supported by findings of the RCT. In the epidemiological study, higher
DHA status was associated with lower FMD in women and the RCT found that
supplementation with DHA adversely affected FMD in men. These findings were
not completely unexpected as a previous study reported lower FMD in women who
were high fish consumers270 and n-3 LC-PUFA supplementation has been shown
to increase the concentration of soluble e-selectin, a marker of endothelial
activation, in younger compared to older men.234, 247 This suggests DHA has
different effects on endothelial function according to gender.
11.2.5 n-3 Fatty Acids and Vascular Structure
There was no association of n-3 fatty acid status on vascular structure in this study.
This was unexpected as previous studies have reported associations of n-3
LC-PUFA with CCA-IMT. However, most of these studies have been conducted in
patients who already had established CAD647-649 and findings from observational
studies in healthy people are conflicting. For example, Djousse and colleagues
(2003) found no associations of fish or n-3 PUFA consumption with IMT in a large
cohort (n = 1,575) of healthy Caucasians.273 Conversely, Ebbesson and
colleagues (2008) reported a protective effect of fish intake on IMT in Alaskan
Eskimos, age 35 and older (n = 686).274 These two studies differed in many ways.
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Djousse (2003) studied individuals participating in a North American study (NHLBI
Family Heart Study) who were chosen either at random or on the basis of a higher
than expected risk of CAD. Ebbesson (2008) studied an indigenous population of
Inupiat Eskimos who were largely village dwellers with a hunter-gatherer existence.
Therefore, comparisons between these two studies are difficult to make as
differences in lifestyle and health status may also have influenced vascular health.
Furthermore, reliable conclusions cannot be drawn from the few studies currently
published and further research is needed to define the relationship between n-3
LC-PUFA consumption and vascular structure.
11.2.6 n-3 fatty acids and CVD risk factors
As with many previous studies benefits of n-3 LC-PUFA for classical CVD risk
factors were suggested by associations of higher DHA status with lower levels of
risk factors.
In the epidemiological study higher DHA status was associated with lower waist to
hip ratio and FBG. TG and VLDL were lower in association with higher scores on
the healthy dietary pattern and with higher EPA status. Evidence to support
benefits of higher n-3 fatty acid status for CVD risk factors comes from the RCT
where BP was lower in men and TG and VLDL were significantly lower in both
sexes following supplementation with DHA. This is consistent with previous
reports where DHA reduced TG concentration.299, 386, 569 Although the reasons for
sex differences are unclear our data our consistent with earlier studies and meta-
analyses that showed low to moderate doses of DHA can reduce blood pressure in
healthy people without affecting vascular function.260, 386
Heart rate was lower in association with higher EPA status and the strength was
similar to that reported in a previous study.274 However, for the first time in the
present study this is seen in a young, healthy population. Improvements in heart
rate have been reported previously with high doses of EPA and DHA
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supplementation650 and at lower doses, similar to that used in the RCT reported
here.651
11.2.7 Mechanisms for Relationships of Diet with Endothelial Health
11.2.7.1 Dietary Patterns
In the epidemiological study dietary patterns were directly associated with vascular
structure but not with FMD. This is surprising because endothelial dysfunction is
the earliest preclinical sign of vascular disease and is widely reported to precede
structural changes in the vascular endothelium.11, 652 However, it is important to
note that the study population were young healthy people in whom vascular
changes may not yet be detectable. In the present study mean IMT was 0.5 mm
which is at the lower end of the range in healthy young people.653, 654 Furthermore,
IMT shows little change in early life and increases in carotid IMT are reported to
occur only once adulthood is reached. Therefore it is possible that a healthy diet
helps maintain vascular integrity, which is reflected in a lower IMT, whilst a less
healthy diet leads to very small changes that have no clinical impact in early adult
life.
Dietary intervention studies have consistently shown that FMD is influenced in the
short term by the fat content of a meal, probably as a consequence of increased
triglyceride-rich lipoproteins and remnants that occurs following a high fat meal.303
As discussed in Chapter 3, Section 3.7.2.1, these particles have a central role in
atherogenesis and it is possible that repeated transient adverse effects on FMD
lead to vascular changes in the long term. Hence, relationships between dietary
patterns and FMD become apparent only in older adults.
A healthy dietary pattern was favourably associated with CVD risk factors. In
particular, BP, HR, VLDL and TG were lower in association with higher scores on
this pattern. These risk factors have previously been reported to adversely
influence vascular function.655 In this young healthy population, free from clinical
CVD, these risk factors were within the normal range for most participants.
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Therefore, it is likely that benefits of diet for endothelial health operate via
CVD risk factors. In the absence of research investigating relationships between
habitual diet and FMD in healthy young people conclusions are difficult to draw.
However, it is likely that direct adverse associations of diet with FMD have yet to
emerge.
11.2.7.1 n-3 Fatty Acids
In the RCT DHA was found to have a direct adverse effect on FMD in men. This
was unexpected as improved FMD has been suggested as a key mechanism for
the protective effect of n-3 LC-PUFA on the progression of atherosclerosis.180, 235,
243, 256, 353, 430, 434, 571-575, 578 Mechanisms include direct vasodilatory effects reported
in several short-term dietary intervention studies.222, 226, 235
11.2.8 Gender effects
The epidemiological study found that dietary patterns were associated with
vascular structure in women but not in men. This may be due in part to a lower risk
of CVD in premenopausal women compared with men (Chapter 1, Section
1.5.5.1). Benefits are largely proposed to operate through the female hormone
oestrogen that has been shown to reduce oxidative stress and increase NO
production.656, 657 48 Premenopausal women also have higher concentrations of
cardioprotective HDL than men. These features are likely to have favourable
influences on the development of atherosclerosis. It is also widely reported that
women are more likely to comply with dietary guidelines than men.658, 659 In the
present study the proportion of women in higher quintiles of the healthy dietary
pattern score was greater than men. Therefore, small sample size with respect to
men may partially explain the absence of an association of the healthy dietary
pattern and vascular structure in men.
Our observation that higher DHA status in women was associated with a lower
FMD was unexpected as reduced FMD is significantly related to male gender.652
However, our finding is supported by Anderson, (2010) who reported a lower FMD
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in women who consumed the highest quantity of fish.270 A possible explanation is
that high levels of methyl mercury found in fish may decrease the beneficial effects
of n-3 LC-PUFA. Evidence for this comes from the Kuopio heart study where a
protective effect of n-3 LC-PUFA on the risk of sudden cardiac death was
attenuated by methyl mercury status.288 It is possible therefore that in our study
and that of Anderson (2010) high fish consumers also had high methyl mercury
levels.
A further possible explanation is that hormonal fluctuations that occur during the
menstrual cycle affected FMD in women in the present study.660-662 Oral
contraceptive use may also affect FMD.623 In the present study we were not able
to consider effects of the menstrual cycle or the use of oral contraceptives and it is
possible that in this young population, where all females were premenopausal, that
the menstrual phase was a confounding factor not accounted for.
The effect of DHA supplementation on men is also supported by earlier data
showing detrimental effects of n-3 LC-PUFA on endothelial activation in men.234, 622
The mechanism for different effects in men and women is unclear. Women have
greater tissue DHA content than men622 and a higher capacity to metabolise α-
linolenic acid to DHA 623 However, research that aims to establish optimal fatty
acid status in relation to vascular function is lacking.
The combined findings from this epidemiological dietary study and RCT suggest
important gender differences in relationships between n-3 fatty acids and vascular
function which warrant further investigation. Our finding in the RCT of a 20% lower
FMD in DHA supplemented men and in the epidemiological study that higher DHA
status was associated with 27% lower FMD in women suggest that future trials of
n-3 LC-PUFA need to be powered to detect possible gender differences in
cardiovascular outcomes.
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11.2.9 Dietary Assessment of n-3 LC-PUFA
In Chapter 10 a newly developed FFQ for assessment of dietary n-3 was found to
be a valid tool. Moderate correlations were reported between each of the three
dietary assessment methods and red cell membrane EPA concentration. An
acceptable degree of correlation was also found for the FishFQ and 24-hour recall
method with respect to DHA. Validity coefficients, obtained using the method of
triads, for the FishFQ were moderate and compared favourably with previous
studies. These results are discussed fully in Chapter 10, Section 10-4.
The FishFQ therefore provides a useful tool for assessment of n-3 LC-PUFA
intake.
11.3 Implications for Public Health
11.3.1 Epidemiological Study
Our finding that a healthy dietary pattern is associated with lower risk of CVD, the
number one cause of death in many developed countries, in young people has
considerable public health implications. Dietary patterns are established early in
life and track over time throughout childhood646 and adulthood.663 Therefore
associations of diet with CVD are likely to persist with age. It is important that
educational interventions to encourage the adoption of healthy dietary patterns
start early and are incorporated into school curriculums from pre-school to
adulthood. It is also important that consistent public health messages are provided
to encourage healthy eating throughout the life course.
In this observational study a higher status for DHA was associated with lower FMD
in women. This is consistent with the findings of a cross-sectional analysis in 3045
middle-aged adults where the highest quartile of non-fried fish consumption was
associated with a smaller FMD in women, compared to the lowest quartile.270
Collectively these findings raise concerns regarding advice for fish consumption.
Current recommendations in the UK from SACN provide guidance at a population
level. In view of concerns regarding toxicity these recommendations suggest
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separate requirements for children and for women already pregnant or planning to
conceive. Findings from the present study, supported by previous data also
suggest separate guidelines for men and women (regardless of pregnancy status)
may be appropriate.
Whilst conclusions regarding causality cannot be drawn from this observational
dietary study, our findings are supported by data from the RCT conducted in
parallel with the epidemiological dietary study.
11.3.2 Randomised Controlled Trial
To our knowledge, the present study includes the largest RCT to test the impact of
DHA supplementation on endothelial function and CVD risk factors in a healthy
young population. Our data support the hypothesis that higher DHA consumption
has benefits for CVD risk factors such as blood pressure and VLDL and triglyceride
concentrations. However, the effects of DHA are unlikely to include benefits for
endothelial function at intakes achievable through dietary sources. Rather, our
findings, which are supported by those in others, suggest caution should be
applied when recommending supplements as adverse effects on FMD are
possible.
Although the clinical implications of lower TG in young adults is uncertain,
hypertriglyceridemia has been proposed as an independent risk factor for CVD664,
665 and a target for interventions to reduce cardiovascular risk.666 The cumulative
effect of higher n-3 DHA intake on triglyceride levels may therefore help in the
primary prevention of CVD.
The clinical implications of sex differences are unclear. However, the joint findings
in the present study of lower FMD for both women and men in association with
higher DHA status raises questions with regard to an optimal intake for this fatty
acid.
11.3.2 Dietary Assessment
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Reliable assessment of LC-PUFA intake is essential in studies that aim to evaluate
relationships between n-3 intake and health outcomes. It is also important in
clinical practice where knowledge of intake is essential in the assessment of
dietary adequacy. This is particularly relevant to secondary prevention of CVD
where n-3 is most clearly shown to have benefits. The FishFQ is easy to
administer and places minimal burden on study participants, clinical patients,
researchers and clinicians. Therefore it is a useful addition in dietary n-3
assessment that can be used in research and clinical practice.
11.4 Strengths and Limitations
11.4.1 Epidemiological Study
The strengths of the epidemiological study include the use of trained investigators
most of whom were qualified in nutrition and/or dietetics and the use of biomarkers
that enabled the most rigorous evaluation possible within the financial and time
constraints of the study. Fatty acid status was validated by measurement of red
cell membrane concentrations. This supported associations of higher fatty acid
status with reduced concentrations of triglyceride and other atherogenic
lipoproteins (e.g. VLDL).
There are also some limitations to consider however. Firstly, the sample may not
have been representative of the wider population. A high proportion of participants
were students and most were in higher social classes.
As discussed in Chapter 4, Section 4.5.3, dietary assessment is subject to error at
several levels. There were additional sources of error in the present study. For
example, measurement periods differed for dietary assessments based on FFQ
and 24 hour recall. It was not possible to collect 24 hour dietary recalls during
different seasons. Therefore foods contributing to usual n-3 LC-PUFA intake may
have been missed. However, the use of biomarkers of fatty acid status with
uncorrelated measurement error helped to minimise bias.
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11.4.2 Randomised Controlled Trial
Randomised controlled trials provide the best form of evidence for the
effectiveness of interventions. They enable researchers to control for a range of
variables, minimize risk of bias and allow determination of causality. The main
strengths of this RCT were study design, a large sample size, parallel group,
double-blind, objective evidence of good compliance with dietary intervention, and
objective, validated outcomes such as FMD. However, the RCT has several
potential limitations. First, we studied a young population at low risk of CVD in
whom dietary affects on CVD risk factors may not yet be apparent and where DHA
supplementation may not improve further an already largely healthy endothelium.
However, the study population was similar to our previous cross-sectional study
which found strong associations between red cell DHA concentration and brachial
artery FMD. 568 Moreover, the lack of any effect of DHA supplementation together
with previous data from older adults at moderate CVD risk253 suggest that DHA
supplementation is unlikely to improve FMD in healthy adults irrespective of
underlying cardiovascular risk.
Second, to aid compliance DHA supplements were given for only 4 months.
Although longer periods of supplementation may be necessary for effects on some
measures of vascular structure such as carotid IMT, 569 previously the effects of n-3
LC-PUFA supplementation on endothelial function have been suggested in
interventions ranging from two weeks 256 to 8 months.243 Finally, because previous
studies suggested stronger effects of DHA than EPA on vascular function,243, 430, 568
we supplemented with only DHA and not also with EPA. However, the
independent vascular effects of EPA and DHA are poorly understood, and require
further investigation.667
11.4.3 Validation Study
Estimates of n-3 fatty acid intake using the new FishFQ were higher compared with
EPIC and 24 hour recalls and could represent an overestimate. However, it is also
possible that separation of foods previously grouped together and the inclusion of a
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wider range of n-3 rich foods enabled more accurate assessment. Furthermore,
the 24 hour recall method provides cross-sectional data that may not reflect usual
diet. The questionnaire demonstrated good reproducibility when re-administered
four months later in the same population and correctly classified a high proportion
of participants according to fatty acid status as measured by percentage total red
cell membrane fatty acids.
11.5 Recommendations for future research
In view of potentially important gender differences it is recommended that further
studies are powered to investigate separate effects of diet on CVD according to
gender.
Longer term evaluation of relationships between diet and atherosclerosis is
recommended. This could include follow up of the present cohort to investigate
tracking of dietary patterns and risk factors.
Evaluation of diet throughout the life stages and its relationship with FMD is
recommended. This includes analysis of the association of dietary patterns in
childhood with FMD later in life.
n-3 supplementation studies at doses obtainable at usual dietary intakes are
needed to further inform the role of n-3 fatty acids in primary prevention of
atherosclerosis. These should be adequately powered to accommodated analyses
by gender and should include supplementation with DHA and EPA.
Further studies of dietary n-3 consumption and effects on vascular health are
needed with particular attention to interactions with methyl mercury.
Further validation of dietary assessment methods is essential in all studies
evaluating diet and relationships with CVD risk factors including vascular structure
and function.
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11.6 Conclusions
Diet has important effects on vascular health and CVD risk factors. In particular
healthy dietary patterns may protect the vascular endothelium from structural
changes associated with atherosclerosis. The mechanism is likely mediated
through reductions in CVD risk factors including BP and atherogenic lipoproteins.
Dietary n-3 fatty acids may also protect vascular health but direct associations and
effects of supplementation are not apparent in young healthy adults and it is likely
that their effect is mediated through conventional CVD risk factors. In contrast high
intakes or supplementation may be detrimental for vascular function. Although it
should be considered that supplementation may reduce overall CVD risk by
achieving a reduction in other CVD risk factors. Most importantly, a reduction in
TG seen in association with higher n-3 status and as a result of DHA
supplementation, at a dose within the normal dietary range, supports the role of n-3
LC-PUFA in primary prevention of CVD.
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Appendix 1-1 Search strategy for MEDLINE using OVID interface
Dates January 1992 to June 2012
Limits English language and humans
1. Exp atherosclerosis
2. Cardiovascular risk
3. Coronary artery disease
4. exp vascular endothelium/
5. exp vascular endothelial function/
6. exp vascular endothelial dysfunction/
7. endothelial dependent relaxation/
8. exp endothelium dependent vasodilatation/
9. exp endothelium independent relaxation /
10. exp endothelium independent vasodilatation/
11. exp flow mediated vasodilatation/
12. exp FMD/
13. exp/EF
14. exp.vascular structure
15. exp.pulse wave velocity
16. exp Sodium nitroprusside/
17. exp forearm blood flow/
18. exp acetylcholine/
19. exp vessel wall volume/
20. exp IMT carotid/
21. icam vcam
22. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
or 15 or 16 or 17 or 18 or 19 or 20 or 21
23. *diet/
24. *nutrition/
25. *food/
26. *meal/
27. dietary supplements/
28. 23 or 24 or 25 or 26 or 27
29. 22 and 28
30. exp intervention studies/
31. exp randomised controlled trials/
32. exp cohort studies/
33. exp comparative studies/
34. exp prospective studies
35. 30 or 31 or 32 or 33 or 34
36. 22 and 35
37. 28 and 36
38. 29 and 35
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Appendix 1-2 Tables of Studies Included in Systematic Review of Diet and Endothelial Health
Table 2-1 Studies investigating effects of short-term (single meal or supplement) dietary interventions on
endothelial structure and/or function in healthy individuals
Author, Setting, (year) Study Design Dietary Intervention Outcome Measures Results
Bondonno,
Australia, (2011).
R, CO trial in 30 healthy men
and women
Effects of four energy
matched treatments
(control, apple, spinach
and apple + spinach) on
vascular function
compared.
Brachial artery EDV
assessed by FMD.
Compared to control all
treatments resulted in higher
FMD. Increase for apple:
(1.1%, 95% CI: 0.7 – 1.5,
p<0.05)
Fahs,
US, (2010).
R, PC study of 20 healthy men
and women (10 in each group).
HF meal plus 1g EPA
and DHA or placebo.
Brachial artery EDV
assessed by FMD and
arterial stiffness.
FMD significantly impaired
following HF meal with
placebo (p=0.03). No effect
on arterial stiffness.
Vauzour,
UK, (2010).
R, CO, PC study of 15 healthy
adult men and women.
Champagne wine
compared with control
matched for alcohol,
CHO and fruit derived
content given as single
ingestions.
Brachial artery EDV and
EIDV measured using
iontophoresis.
Independent vascular
reactivity increased more at 4
(p=0.030) and 8 (p=0.045)
hours following champagne
consumption compared with
control.
Crecelius.
USA, (2010).
PC study of 14 healthy older
men.
Acute administration of
various doses of
ascorbic acid during 10
minute exercise period.
FBF measured using
Doppler ultrasound.
Ascorbic acid administration
increased FBF minimally
during exercise via an
increase in NO availability
(p=NS).
Tousoulis,
Greece, (2010).
R, parallel study. 37 healthy
participants, mean age 28 years
(26 men 11 women).
50 mls maize, cod liver,
olive or soya oil or water
given as single test
meal.
FMD in the right forearm
using gauge-strain
plethysmography and
serum concentrations of
VCAM-1 measured pre and
post prandially.
Cod liver oil and soya oil
improved hyperaemia after 1
hour compared with control
(p<0.05). Olive oil reduced
FMD. No effect on VCAM-1.
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Author, Setting, (year) Study Design Dietary Intervention Outcome Measures Results
Jackson,
UK, (2009).
24 healthy men (12 younger
(<50 years) and 12 older (>50
years).
Single meal test meal
providing 5.4g EPA and
DHA.
Peripheral microvascular
EDV and IEDV after Ach
and SNP infusion assessed
before and after meal.
Fish meal improved EF in
younger men 4 hours after
Ach and SNP (p<0.04).
Kelly,
Singapore, (2008).
R, CO, PC study in 26 healthy
volunteers (18 men and 8
women).
Beverage containing 2g
vitamin C compared with
lemon juice placebo.
PWF following GTN. No effect of vitamin C on any
measures of vascular
structure or function.
Alexopoulos,.
Greece, (2008).
Controlled study of 14 healthy
adults, mean age 30 years.
Green tea beverage. Brachial artery EDV
assessed by FMD.
FMD increased 30 minutes
after tea consumption (3.69%
[p<0.02]).
Jochman,
Germany (2008).
R, CO, PC study of 21 healthy
men and women.
Black and green tea
beverages.
Brachial artery FMD FMD increased after both
green and black tea.
Difference in FMD 5.0 (95%
CI 3.0, 7.0, p<0.001) and 4.4
(95% CI 2.3, 6.5; p<0.001)
respectively.
Armah,.
UK, (2008).
R, controlled study of 25 healthy
men; mean age 46 years.
Single test meal
comparing fish oil (5.4g
EPA/DHA) with placebo
oil.
EDV and IEDV assessed
for measurement of SNP
induced RH.
SNP induced RH increased
with n-3-PUFA compared
with standard diet (p=0.024).
Berry,
UK, (2008).
Controlled study of 17 healthy
men; mean age 18-40 years.
High stearic acid
compared with high
oleic acid meals.
Brachial artery FMD. FMD decreased with oleic
compared with stearic acid -
3.0% (95% CI -4.4, -1.6,
p<0.001).
Mariotti,.
France, (2007).
R, CO, PC study of 9 healthy
young men – age not reported.
50g meal supplemented
either with (intervention)
or without (control) 3g
L-arginine added.
Brachial artery FMD, CCA
distensibility and PWV
measured with vascular
ultrasound.
No alteration in EF related to
timing or content of test
meals.
Shimabukuro,
Japan, (2007).
Controlled study of 12 healthy
adults; mean age 36 years, (6
men and 6 women).
High CHO, compared
with HF and standard
meal.
FBF measured during RH
before and after meals.
Peak FBF decreased after
high fat meal (p<0.01). No
difference after high CHO or
standard meal.
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Nicholls,
Australia, (2006).
Controlled study of 14 healthy
adults; aged 18-40 years; (sex
not reported).
High SFA compared
with high PUFA (fatty
acids not defined) meal.
FBF and EDV assessed by
brachial artery FMD.
No difference.
Padilla,
USA, (2006).
Controlled study of 8 healthy
men and women; mean age 26
years. (5 men, 3 women).
Effect of aerobic
exercise on LF, and
HFM induced decreases
in FMD
Brachial artery EDV
assessed by FMD 4 hours
post intervention.
FMD increased after HFM
following exercise (5.61%,
p=0.005). No difference
following LF and HFM only.
Tushuizen,
Netherlands, (2006).
Controlled study of seventeen
healthy men, mean age 25.4
years.
Standardized HFM (50 g
fat, 55 g CHO and 30 g
protein) given twice
(lunch and breakfast).
Brachial artery EDV
assessed by FMD pre and
post meal.
FMD significantly impaired
following 2nd HFM (6.9%
vs.3.7%, p<0.05).
Westphal,
Germany, (2006).
Controlled study of 16 healthy
young adults; aged 19-23 years,
(8 men, 8 women).
Effects of HFM, HFM +
soya protein, HFM+
casein compared.
Brachial artery EDV
assessed by FMD.
FMD decreased after HFM
(maximum decrease 58%).
Addition of protein to meals
attenuated effect (p<0.01).
Karatzi,
Greece, (2005).
R, CO, DB, PC study of 16
healthy subjects (8 men and 8
women) mean age 29 years.
Coffee containing 80 mg
caffeine compared with
decaffeinated coffee
control.
Arterial stiffness assessed
using PWA to give
augmentation index (AI).
AI index increased more
following caffeine
consumption (indicating
unfavourable effects)
compared with placebo (p=
0.001).
Tsai,
Taiwan, (2004).
Controlled study of 16 healthy
males; mean age 30 years.
HFM. Brachial artery EDV
assessed by FMD.
FMD decreased after high fat
meal (data not presented).
Vlachopoulos,
Australia, (2003).
R, CO, PC study of 20 healthy
subjects.
250 mg caffeine
compared to placebo.
Arterial stiffness assessed
using PWA to give
augmentation index (AI).
PWV increased by 0.51 m/s
and AI by 6.8% for
intervention compared with
control group (p<0.001 for
both variables),indicating an
unfavourable effect of
caffeine.
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Waring,
UK, (2003).
R, DB, PC study of 20 healthy
adults.
300 mg caffeine
compared with placebo.
Arterial stiffness assessed
using pulse wave analysis
to give augmentation index
(AI).
Acute caffeine intake
increased AI significantly
compared with placebo (7 ±
2%, p<0.05).
Steer,
Sweden, (2003).
Controlled study of 26 healthy
adults; aged 20-30 years.
High, medium and
increased fat meals
compared.
FBF determined with
venous occlusion
plethysmography. EDV
and EIDV assesed.
EDV increased after LF
(p<0.01). FBF and EDV
decreased after HFM (p<0.01
and p<0.05 respectively.
Bae,
South Korea, (2003).
Controlled study of 10 healthy
males; mean age 26 years.
HFM. Brachial artery FMD. No effect on FMD 3-4 hours
post meal.
Fisher,
US, (2003).
Controlled study of 27 healthy
men and women (11 males and
16 women), mean age 44 years.
920 mls cocoa
consumed in four oral
doses over a 5-day
period.
PWA assessed 90 minutes
following cocoa
consumption.
After 5 days of cocoa
consumption PWA increased
(p= 0.009).
Nappo,
Italy, (2002).
Controlled study of 20 healthy
adults, mean age 44 years (10
in each group).
Two single meals given
at 1 week intervals
comparing high fat with
high CHO diet.
Inflammatory markers and
VAM.
High fat meal increased
TNFα, IL6, ICAM-1 and 
VCAM-1.
De Roos,
Netherlands, (2002).
Controlled study of 21 healthy
young males; aged > 35 years,
High SFA compared
with high-trans-fatty acid
meal.
Brachial artery EDV
assessed by FMD.
No difference between
meals.
Hashimoto,
Japan, 2001.
Controlled study of 11 healthy
men, mean age 34 years.
Participants randomised
to 1 of four beverages:
Japanese vodka, red
wine with alcohol, red
wine without alcohol or
water.
Brachial artery FMD
measured 30 and 120
minutes following ingestion.
Significant increases in RH
120 minutes after ingestion
of red wine without (increase
0.1% [p<0.01]) and with
alcohol (increase 0.6%,
p<0.01).
Marchesi,
Italy, (2000).
Controlled study of ten young
healthy men, mean age 23
years.
Post-prandial (2, 4, 6
and 8 hours) effects of
HFM on FMD.
Brachial artery FMD
measured before and after
meals.
FMD decreased from 14.5 ±
6.6% fasting to 3.5 ± 1.5%
and 4.0 ± 2.2% at 2 and 4
hours (p<0.01).
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Vogel,
US, (2000).
R, CO, PC study in 10 healthy
participants aged 28-56 years.
5 meals with 50g fat
from various sources:
olive oil, rapeseed oil,
canned red salmon.
Brachial artery FMD
measured before and 3
hours after meals.
FMD reduced after olive oil
meal, 31% (14.3 ± 4.2% to
9.9 ± 4.5%, p=0.008).
Cuevas,
Chile, (2000).
Controlled study of 11 healthy
men; aged 20-28 years.
HFM +/- red wine
compared with standard
diet +/- red wine.
Brachial artery EDV
assessed by FMD.
FMD decreased with HFM
minus red wine compared
with control diet (p=0.014).
Raitakari,
Australia, (2000).
Controlled study of 7 healthy
men and women; aged 18-45
years, (4 men, 3 women).
SFA rich compared with
MUFA meal.
FBF and brachial artery
EDV assessed by FMD.
FBF increased after both
meals (p<0.001 for all
meals). No difference in FMD
according to meals.
Djousse,
USA, (1999).
Controlled study of 13 healthy
men and women; mean age 32
years.
HFM with wine
compared with HFM and
control beverage.
Brachial artery EDV
assessed by FMD.
No difference between wine
and control beverage.
Ong,
UK, (1999).
R, DB, CO study in 10 healthy
males; aged 30.
HF/L-CHO compared
with LF/H-CHO meal.
Brachial artery EDV
assessed by FMD.
FMD decreased after HF/L-
CHO compared with LF/H-
CHO meal, (1.2% vs. 4.3%
p=0.02)
Williams,
New Zealand, (1999).
Controlled study of 10 healthy
males; aged 34-52 years.
LFM, HFM and deep
fried meals compared.
Brachial artery EDV
assessed by FMD.
FMD decreased after deep
fried meal (5.9 ± 2.3% vs. 0.8
± 2.2 %, p=0.0003). No
difference with high fat or low
fat meal.
Vogel,
USA, (1997).
Controlled study of 10 healthy
adults; age and sex not
reported.
HF compared with LF
meal.
Brachial artery EDV
assessed by FMD.
FMD decreased after high fat
(difference from baseline to 4
hours compared with low fat
meal -11%, p<0.05).
Abbreviations in table: R, randomised; CO, crossover; DB, double-blind; PC, placebo controlled; LF, low fat, HF, high fat; CHO, carbohydrate; L-CHO, low carbohydrate, H-CHO, high
carbohydrate; MUFA, mono-unsaturated fatty acids; PUFA, polyunsaturated fatty acids; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; EDV, endothelium-dependent
vasodilatation; EIDV, endothelium-independent vasodilatation; FMD, flow mediated dilatation; FBF, forearm blood flow; PWA, pulse wave amplitude; PWV, pulse wave velocity; AI,
augmentation index; RH-PAT, reactive hyperaemia peripheral arterial tonometry; VAM, vascular adhesion molecule; sVCAM-1, soluble vascular cell adhesion molecule-1; sICAM, soluble
intracellular adhesion molecule-1; CCA, common carotid artery; IMT, intima media thickness; Acth, Acetylcholine; SNP, sodium nitroprusside; NO, nitric oxide; GTN, glyceryl trinitrate; TNF-α, 
tumour necrosis factor alpha; IL-6, interleukin 6.
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Table 2-2 Studies investigating effects of longer-term dietary interventions (two weeks to two years) on endothelial function
in healthy individuals
Author, Setting (year) Study Design Dietary Intervention
and Assessment
Outcome Measures Results
Thies,
UK, (2012).
RCT in 225 healthy volunteers
(94 men and 131 women).
Three dietary groups:
low (control) or high
tomato-based and
control plus 10 g/d
lycopene supplement for
12 weeks.
Arterial stiffness. No effect on arterial stiffness.
Sanders,
UK, (2011).
RCT in 312 healthy
participants, aged 45-70
years.
EPA/DHA supplements
(0.4, 0.9 and 1.8 g/d)
compared with olive oil
placebo for 1 year.
3-day FR.
Brachial artery EDV
assessed by FMD.
No difference in FMD between
intervention and control groups.
Marin,
Spain, (2011).
RCT in 20 healthy elderly
participants (10 men, 10
women).
High SFA diet, L, H-
CHO diet and MedDt
compared after 4 weeks
intervention.
3-day WFR and FFQ.
EMP and EPC measured to
assess endothelial
activation.
MedDt led to lower EMP and higher EPC
concentrations compared with other
diets (p<0.001).
Morand,
France, (2011).
RCT in 24 healthy men aged
50-65 years.
Hesperidin (flavonoid)
compared with orange
juice and placebo given
for 3 four-week periods.
Not reported.
MV RH assessed following
each treatment period. PP
effects assessed at start of
each treatment period.
Hesperidin and orange juice both
improved post-PP RH compared with
placebo (p< 0.05).
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Kim,
Korea, (2011).
RCT in 126 healthy men aged
22–57 years.
Intervention group
randomised to receive
15 mg lycopene/day for
8 weeks (n =37)
compared with placebo
controls (n = 41).
Not reported.
EDV assessed by RH-PAT.
Oxidative stress assessed
by measurement of sICAM-
1 and sVCAM-1.
RH-PAT increased: 23% (1.49 ± 0.09 vs.
1.79 ± 0.12 p = 0.03). VAM decreased
in intervention vs. control group (p
<0.05).
Din,
UK, (2011).
RCT in 30 healthy men mean
age 23 years.
Intervention group
allocated to 15 g/day
walnuts compared with
no walnuts for 4 weeks.
Arterial stiffness assessed
using PWA to determine AI.
No difference in AI according to
randomised group.
Hodson,
UK, (2009).
RCT in 27 healthy men and
women aged 25–60 years.
Intervention group
randomised to DASH
diet or control group for
30 days.
Not reported.
Brachial artery EDV
assessed by FMD.
No effect on FMD.
Van Mierlo,
Netherlands, (2010).
RCT in 35 healthy males aged
18-45 years.
Three 2-week
intervention periods with
1-week washout periods
comparing wine grape
with grape only solids.
Not reported.
Brachial artery EDV
assessed by FMD.
FMD increased with wine grape solids:
(difference -0.4%: 95% CI 1.8, 0.9; p =
0.77) compared with placebo.
Shai,
Israel, 2010.
RCT in 140 subjects
participating in the DIRECT-
Carotid trial (123 men, 17
women), mean age 50 years.
Participants allocated
either to LF MedDt or
low CHO for 2 years.
Semi-quantitative FFQ.
CCA-IMT and VWV. Reduction in VWV reported with both
diets: (mean difference -58.1 mm, 95%
CI: -81.10 - 81.0. (p <0.001).
Tarcin,
Turkey, (2009).
Case-control study comparing
23 healthy vitamin D deficient
men and women aged 23
years (65% male), mean age
23 years with matched
controls.
300,000 IU vitamin D
given intramuscularly
monthly for 3 months.
No dietary assessment
reported.
Brachial artery EDV
assessed by FMD.
Significant increase in FMD for treatment
group mean increase 10.4, SD 3.3%,
(p<0.001).
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Pot,
Netherlands, (2009).
RCT in 77 healthy
participants, mean age 59
years.
1.3 g/day EPA+DHA or
placebo (sunflower oil)
for 12 weeks.
Dietary assessment
not applicable.
Fasting serum
concentrations of sVCAM,
sICAM.
No effect of fatty acids on VAMs.
Grassi,
Italy, (2009).
RCT in 19 healthy men aged
19–70 years.
Black tea given in doses
ranging from 100-800
mg/day for 5 weeks.
Dietary assessment
not applicable.
Brachial artery EDV
assessed by FMD.
FMD increased after all doses and in a
dose dependant manner (P = 0.0001).
Sari,
Turkey, (2009).
Controlled CO study of 32
healthy adult men aged 21-24
years.
MedDiet for 4 weeks + 4
weeks enriched with
pistachio.
Nut consumption and
use of supplements
assessed.
Brachial artery EDV
assessed by FMD.
EDV increased after pistachio-enriched
diet compared with MedDt (P = 0.002).
Miller,
USA, (2009).
CO study of 18 healthy men
and women; mean age 31
years, (9 men, 9 women).
HF/L-CHO (Atkins), Med
Dt (South Beach) and LF
(Ornish) diets compared
using 3, 4-week dietary
interventions with 4-
week wash out.
3-day food record per
intervention period.
Brachial artery EDV
assessed by FMD.
Inverse correlation of FMD with SFA
(r = 0.33; P = 0.016)
Rallidis,
Greece, (2009).
RCT in 82 healthy men and
women (age not reported).
MedDt +/- dietary
advice and adherence
monitoring for 2 months.
3-day diet records and
24 hour dietary recall.
Brachial artery EDV
assessed by FMD.
FMD increased in intervention compared
with control group: (2.05%; 95% CI: 0.97
– 3.13%).
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Hall,
UK, (2008).
Controlled study of 110
healthy adults; aged 30-70
years (sex not reported).
High-SFA, compared
with high-MUFA
compared with LF/H-
CHO.
Duration: 6 months.
Not reported.
Brachial artery FMD, DVP
and PWV.
No differences in FMD or PWV. DVP
decreased with LF/high CHO compared
with high SFA and MUFA.
Theobald,
UK (2007).
RCT in 38 healthy women
aged 40-65 years.
DHA (0.7 g/d in 1.5 g/d
capsule) compared with
olive oil placebo (1.5
g/d). Given for 3 months.
3-day dietary record.
EIDV assessed following
GTN administration.
Arterial stiffness assessed
from digital pulse volume.
No effects of DHA on measures of
vascular structure or function.
Rueda-Clausen,
Colombia, (2007).
RCT in 10 healthy men; aged
18-23 years.
HF meals: palm, olive,
sunflower oil +/- deep
frying.
Duration: 9 weeks.
Weekly 24 hour dietary
recalls.
Brachial artery EDV
assessed by FMD.
FMD decreased after each meal (32.1%;
95% CI: 28.0 – 36.2), no further effect of
deep frying.
Shah,
US, (2007).
RCT in 26 healthy men and
women; mean age 31 years,
(17 men, 9 women).
Supplemental n-3-PUFA
(fish oil) compared with
corn oil.
Duration: 14 days.
Not reported.
Brachial artery EDV and
EIDV assessed by FMD.
FMD and EIDV increased with FO
compared with corn oil (20.4% ± 13.2%
vs. 9.9% ± 5.4%; P = 0.036).
Cazzola,
Italy, (2007).
P, DB study in 93 healthy
young men, mean age 26
years.
1.35 or 2.7 or 4.05 g
EPA/day, compared with
placebo (corn oil) for 12
weeks.
Not reported.
Fasting serum
concentrations sVCAM-1,
sICAM-1, E-selectin.
4.05 g/d EPA/DHA increased sE-selectin
in younger men.
Egert,
Germany, (2007).
P, SB study in 48 healthy
participants aged 18-45 years,
(13 men, 35 women).
Dietary study comparing
6 g ALA, 3 g EPA or
DHA/day for 3 weeks.
3-day dietary record.
Fasting serum
concentrations sVCAM-1,
sICAM-1, sE-selectin.
No effect on outcomes.
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Walser,
US, (2006).
P, SB study study in 13
healthy participants.
EPA (3 g/d + DHA (2
g/d), compared with
placebo (safflower oil)
for 6 weeks.
Not reported.
Exercise-induced increases
in brachial artery diameter
and blood flow.
Fish oil enhanced contraction-induced
increases in brachial artery diameter,
blood flow and conductance.
Keogh,
Australia, (2005).
R, CO trial of 40 healthy
adults; aged 40–75 years, (19
men, 21 women).
Low fat/high CHO vs
high fat (high SFA), high
MUFA , compared with
high PUFA.
Duration: 3 x 4 weeks.
3-day WFR.
Brachial artery EDV
assessed by FMD.
FMD decreased on SFA compared with
all other diets.
Turner,
Denmark, (2004).
RCT in 75 healthy volunteers
aged 40-60 years.
Assigned to dried garlic
powder containing 10.8
mg alliin (~ 3 cloves)
compared with placebo.
Not reported.
Arterial stiffness assessed
with PWV measurement.
No significant decreases in outcomes
between garlic and placebo groups.
Sharman,
Australia, (2004).
R, CO study of 16 healthy
men (mean age 58 years).
Supplement of 600 mg/d
alpha-lipoic acid given
on two separate
occasions compared
with placebo.
Not reported.
Arterial stiffness assessed
through pulse form analysis
(PWV and AI).
No significant changes on any measures
of arterial stiffness.
Eschen,
Denmark, (2004).
P, DB study in 60 healthy
participants, mean age 38
years.
5.9 g or 1.7 g/d
EPA+DHA, compared
with placebo (olive oil)
given for 12 weeks.
Not reported.
Fasting serum
concentrations sVCAM-1,
sICAM-1, sE-selectin.
5.9 g/d EPA+DHA decreased sP-selectin
in men.
Ambring,
Sweden, (2004).
R, CO study of 22 healthy
men and women (12 men, 10
women) aged 30-51 years.
MedDt given for 4 weeks
compared with usual
Swedish diet.
Not reported.
EIDV assessed with FBF. No difference between dietary groups.
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Rasool, Malaysia,
(2003).
RCT in 20 postmenopausal
women, mean age 54.6 years.
Supplement of
tocopherol (400 IU) daily
compared with placebo
at intervals of 5 weeks.
Not reported.
Arterial stiffness assessed
through measurement of
PWV.
No effect on PWV.
Khan,
Scotland, (2003).
R, CO trial in 173 healthy men
and women; aged 40-65 years
(117 men, 56 women).
Supplemental n-3-
PUFA, vs MUFA/PUFA,
vs EPO, vs Soya bean
oil. LF/H-CHO
tuna/EPO mix corn oil vs
control. Duration: 8
months.
FFQ and 24 hour
dietary recall.
EDV and EIDV measured
in forearm skin with
iontophoresis.
EDV increased after tuna FO
supplementation (P = 0.02).
Lind,
Sweden, (2002).
Controlled, CO study of 19
healthy men and women;
aged 30-65, (13 men, 6
women).
High SFA, compared
with high n-3-PUFA.
Duration: 4 week cross
over.
Not reported.
FBF. FBF increased after high SFA diet
compared with high n-3-PUFA
(P < 0.05).
Sejda,
Czech Republic, (2002).
Controlled CO study of 11
healthy men and women;
mean age 24 years, (6 men, 5
women).
LF compared with HF
diet.
Duration: 4 weeks
3-day FR – 5 points.
Brachial artery EDV
assessed by FMD.
No difference.
De Roos,
Netherlands, (2002).
R, study of 29 healthy young
men and women; mean age
30 years (10 men, 19 women).
High SFA, compared
with trans-MUFA.
Duration: 4 weeks.
Duplicate meals.
Brachial artery EDV
assessed by FMD.
FMD decreased more after trans-MUFA
compared with H-SFA (difference 0.7%;
95% CI: -0.6 – 1.9)
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Miles,
UK, (2001).
Randomized controlled trial in
28 healthy participants
grouped according to age: <40
and >55 years.
1.2g/d fish oil:
EPA+DHA or placebo oil
(palm and soya oil mix)
given for 12 weeks.
Not reported.
Fasting plasma sICAM-1,
sVCAM-1, sE-selectin.
Fish oil increased sE-selectin in young
males (median increase 38%; P = 0.043)
and decreased in older males (median
decrease 11%; P = 0.075). sVCAM
decreased in older males (median
decrease 20%; P =0.043).
Thies,
UK, (2001).
P, DB study in 46 healthy
participants, mean age 63
years.
2 g ALA or 0.7g GLA,
AA or DHA/day, or 1
g/day. EPA/DHA or
placebo (palm and
sunflower oil mix) given
for 12 weeks.
Not reported.
Fasting plasma sICAM-1,
sVCAM-1, sE-selectin.
ALA and EPA/DHA decreased sE-
selectin and sVCAM-1.
Teede,
US, (2001).
R, DB trial in 213 healthy
subjects (108 men, 105
women) aged 50-75 years.
40 g soy protein (118 mg
isoflavones) compared
with casein placebo for 3
months.
Not reported.
PWV and brachial artery
FMD.
Compared with casein, PWV improved
in soy group (P < 0.01). FMD declined
in males in soy group (P < 0.02).
Chin,
Australia, (1993).
P, SB, PC trial in 29 healthy
males, age 18-32 years.
5, 10 or 20 g MaxEPA
(0.18 g EPA + 1.2 g
DHA/day, vs placebo.
Duration: 4 weeks.
Not reported.
Peripheral microvascular
function assessed using
iontophoresis and venous
occlusion
plethysmography.
Fish oil suppressed vasoconstriction in a
dose-response manner: (20 g reduced
by 72%, 10 g by 67%, 5 g by 33%)
Abbreviations in table: RCT, randomised controlled trial; R, randomised; P, parallel; CO, crossover; DB, double-blind; SB, single blind; PC, placebo controlled; LF, low fat; HF, high fat; MedDt, Mediterranean
diet; DASH, dietary approaches to stop hypertension; CHO, carbohydrate; FA, fatty acids; SFA, saturated fatty acids; MUFA, mono-unsaturated fatty acids; PUFA, polyunsaturated fatty acids, EPA,
eicosapentaenoic acid; DHA, docosahexaenoic acid; ALA, alpha linolenic acid; FFQ, food frequency questionnaire; FR, food record; WFR, weighed food record; EDV, endothelium-dependent vasodilatation;
EIDV, endothelium-independent vasodilatation; FMD, flow mediated dilatation; FBF, forearm blood flow; PWA, pulse wave amplitude; PWV, pulse wave velocity; AI, augmentation index; DVP, digital volume
pulse analysis; MV, microvascular; RH-PAT, reactive hyperaemia peripheral arterial tonometry; VAM, vascular adhesion molecule; sVCAM-1, soluble vascular cell adhesion molecule-1; sICAM, soluble
intracellular adhesion molecule-1; CCA, common carotid artery; IMT, intima media thickness; VWV, vessel wall volume; GTN, glyceryl trinitrate.
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Table 2-3 Observational studies investigating relationships between diet and endothelial structure and function in healthy people
Authors, Setting (year) Subjects Methods Dietary Assessment Results
van de Laar,
Netherlands, (2012a).
Longitudinal cohort study of 373
healthy individuals age 13-36
years.
Dietary intake assessed
during adolescence and
adulthood. CCA
stiffness (distensibility
coefficient) measured at
age 36 years.
Semi-quantitative FFQ. Arterial distensibility related to lower
fibre consumption (-1.9; 95% CI: -3.1 -
0.7).
van de Laar,
Netherlands, (2012b).
Longitudinal cohort study of 373
healthy individuals age 13-36
years.
Dietary intake as above
used to categorise
participants in tertiles
according to adherence
to MedDt (aMED).
Semi-quantitative FFQ Low aMED associated with lower arterial
distensibility (-0.32, 95% CI: -0.60 - -
0.06).
Crichton
Australia, (2012).
Cross sectional study of 587
participants in the Maine-
Syracuse Longitudinal Study.
Relationship between
dairy food intake and
PWV assessed.
Intake of dairy food
assessed using the
Nutrition and Health
Questionnaire.
Linear decrease in carotid-femoral PWV
seen with increased dairy consumption
indicating beneficial effect.
Jablonski,
US, (2010).
Cross-sectional study of 75
middle aged/older men and
women.
Plasma 25-
hydroxyvitamin D and
1,25 dihydroxy vitamin D
used as a biomarkers of
vitamin D status.
3-day food records. Plasma 25-hydroxyvitamin D was
positively associated with brachial artery
FMD (P < 0.01). No significant
association found for 1,25 dihydroxy
vitamin D.
AlMheid,
US, (2011).
Cross-sectional study in 554
healthy men and women.
Plasma 25-
hydroxyvitamin D was
used as a biomarker of
vitamin D status.
None reported. Plasma 25-hydroxyvitamin D was
independently associated with higher
FMD (P < 0.006).
De Oliveira Otto,
US, (2011).
5,181 healthy men and women
from multi-ethnic backgrounds
aged 45-84 years, (47% male).
Relationships between
micronutrients (iron, Zn,
Mg, β-carotene, vitamins 
A, C and E) and CCA-
IMT.
Semi-quantitative FFQ. No associations of any micronutrient with
CCA-IMT were found.
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Liese,
US, (2010).
Prospective cohort study of 802
healthy men and women (44%
male) participating in the Insulin
Resistance Atherosclerosis
Study (IRAS).
Relationships of dietary
patterns to CCA-IMT.
Semi-quantitative FFQ.
Data divided to quartiles
according to dietary pattern
score.
Less healthy dietary pattern associated
with increased CCA-IMT (highest minus
lowest Q = -7.8%, P = 0.005).
Yang,
South Korea, (2010).
Cross sectional analysis of
4,564 healthy adults aged 40-89
years.
Zinc intake and
relationship with CCA-
IMT investigated.
Trained investigators used
validated FFQ to collect
dietary information. Zinc
intake categorised by
quintiles.
Zinc intake inversely related to CCA-IMT
(5th vs 1st Q, OR 0.64, 95% CI 0.45 –
0.90, P for trend=0.07).
Juonala,
Finland, (2010).
1809 young adults participating
in the prospective longitudinal
young Finns study.
Dieatary data collected
at age 3-18 years
Habitual lifelong diet and
CCA-IMT at age 24-39
years evaluated.
Dietary data collected at
several time points using
FFQ completed by parents
at age 3-9 and participants
at age 12-18 years.
Infrequent fruit consumption (-5, 95% CI:
9 - 1, P = 0.03) associated with
accelerated IMT progression.
Aatola
Finland, (2010).
1622 young adults participating
in the prospective longitudinal
young Finns study.
Dietary data collected at
age 3-18 years used to
study relationships of
habitual lifelong diet with
PWV at age 24-39
years.
Dietary data collected at
several time points using
non and semi-quantitative
FFQ completed by parents
at age 3-9 and participants
at age 12-18 years.
Healthy dietary patterns in childhood
(high in fruits and vegetables) related to
lower PWV an indicator of lower arterial
stiffness in adults.
Landberg,
US, (2011).
2115 women aged 43-70 years. A sub-group
participating in the US
nurses study assessed
for flavonoid intake and
biomarkers of
inflammation.
Semi-quantitative FFQ. Women in the highest intake quintile of
flavonol compared with those in the
lowest had 4% lower sVCAM (Q1: 578
µg/L, Q5: 557 µg/L: P trend =0.012).
Mah et al,
USA, (2011).
8 healthy lean and obese
males.
Cross-sectional study
investigating
relationships between
plasma antioxidant
vitamin status (C and E)
and FMD.
3-day food records. Plasma vitamin C concentration was
lower (38%) in obese men who also had
lower FMD compared with controls.
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Authors, Setting (year) Subjects Methods Dietary Assessment Results
Anderson,
US, (2010).
3,045 healthy adults, aged 45-
84 years.
Relationship between
consumption of non-fried
fish and plasma
phospholipid measures
of long-chain n-3 fatty
acids with brachial artery
FMD in men and women
across racial-ethnic
groups.
Semi-quantitative FFQ. Inverse association between the highest
quartile of non-fried fish consumption
and smaller brachial artery diameter in
men and a smaller FMD in women.
Kesse-Guyot,
France, (2010)
1,026 healthy middle-aged
adults aged 35-60 years.
Relationships between
dietary patterns and
aortic stiffness assessed
with PWV and CCA-IMT.
3-days of 24 hour dietary
recalls. PCA applied and 4
dietary patterns identified.
Dietary pattern characterised by high
meat and alcohol associated with
increased arterial stiffness. No
association with CCA-IMT.
Mikkila,
Finland, (2009).
785 young adults participating in
the prospective longitudinal
young Finns study.
Dietary intake data
collected at baseline,
age 3-18 years applied
to study relationships of
habitual lifelong diet with
PWV at age 24-39
years.
Dietary data collected at
several time points using
non and semi-quantitative
FFQ completed by parents
at age 3-9 and participants
at age 12-18 years.
Higher scores on a traditional dietary
pattern and lower scores on a more
healthy pattern associated with
increased IMT in men only (P < 0.01).
He,
US, (2009).
5,569 healthy men and women
aged 45-84 years, (48% male).
Relationships between
n-3-PUFA and fish with
biomarkers of
inflammation and
endothelial activation.
Semi-quantitative FFQ. Inverse association - n-3 PUFA and fish
associated with decreased biomarker
concentrations.
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Ebbeson,
US, (2008).
686 healthy men and women
aged > 35 years.
Relationships between
n-3 fatty acid
consumption and CCA-
IMT examined.
Semi-quantitative FFQ. IMT was negatively associated with
gram intake of n-3 LC-PUFA (P = 0.05).
Nakamura,
Japan, (2007).
250 healthy Japanese men
aged 40-49 years.
Relationships between
fish consumption and
CCA-IMT examined.
Groups categorised
according to frequency
of fish intake (<
compared with > 4 times
per week.
Lifestyle questionnaire that
included questions about
fish consumption.
CCA-IMT significantly higher in the low
compared with the high fish consumption
group (0.623 vs. 0.0605 mm, P = 0.03).
Nettleton,
US, (2007).
5,089 healthy men and women
from multi-ethnic backgrounds
aged 45-84 years, (47% male).
Relationships between
dietary patterns with
biomarkers of
inflammation and
endothelial activation.
Semi-quantitative FFQ. Dietary pattern characterized by whole
grains and fruit inversely associated with
biomarkers of inflammation (CRP, IL-6,
Hcy).
Lopez-Garcia,
US, (2004a)
727 healthy women, aged 43-69
years.
Relationships between
dietary patterns and
biomarkers of
inflammation and
endothelial activation.
Semi-quantitative FFQ. Positive association of Western dietary
pattern with markers of endothelial
dysfunction.
Lopez-Garcia,
USA, (2004b)
727 healthy women, aged 43-69
years.
Relationships between
intake of n-3 fatty acids
and biomarkers of
inflammation and
endothelial activation.
Semi-quantitative FFQ. Inverse association of n-3 LC-PUFA with
biomarkers.
Djousse,
US, (2003).
1,575 healthy men and women
participating in the National
Heart, Lung and Blood Institute
Family Heart Study.
Association between
dietary linolenic acid and
presence of
atherosclerotic plaques.
Semi-quantitative FFQ. Higher consumption of total linolenic acid
associated with a lower prevalence of
plaques (OR for highest compared with
lowest quartile = 0.47; 95% CI: 0.30 -
0.73).
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Rissanen,
Finland, 2003.
1,028 healthy men participating
in Khupio ischaemic risk factor
study Finland.
Serum lycopene
concentration measured
and relationship
between CCA-IMT
evaluated.
N/A. Men in lowest quartile for serum
lycopene had higher CCA-IMT compared
with other men (P = 0.005)
Van der Schouw,
Netherlands, (2002).
433 post-menopausal women,
mean age 49-70 years.
Relationships between
dietary isoflavone and
lignin intake and aortic
stiffness assessed
through measurement of
PWV.
Semi-quantitative FFQ.
Data divided into quartiles
(Q).
Isoflavones and lignin both associated
with decreased PWV (-0.51 m/s; 95% CI:
-1.00 -0.03, P trend 0.07) and -0.42 m/s;
95% CI: -0.93 - 0.11) for highest minus
lowest Q respectively.
Yamada,
Japan, (2000).
470 healthy men and women
aged 30-89 years from two
distinct populations: a fishing
and a farming village.
Dietary n-3 fatty acids
related to CCA-IMT.
48-hour dietary recalls. n-3 fatty acids for the combined
population was not associated with CCA-
IMT.
Rissanen,
Finland, (2000).
520 middle-aged men and
women aged 45-69 years.
Groups classified
according to 2
categories – above or
below median plasma
lycopene concentration.
Relationship between
CCA-IMT evaluated.
N/A. Higher lycopene concentrations
associated with reduced CCA-IMT in
men (mean difference 17.8%;
P = 0.003).
Ma,
US, (1995).
15,248 men and women aged
45-64 years participating in the
atherosclerosis Risk in
Communities (ARIC) study.
Relationship between
serum magnesium and
CCA-IMT assessed.
Semi-quantitative FFQ. Lower CCA-IMT reported for women in
association with dietary magnesium
intake (0.0048 mm decrease in IMT for
each 0.1mmol/l decrease in serum Mg, P
= 0.02).
Kritchevsky,
US, (1995).
11,307 men and women aged
45-64 years participating in the
ARIC study.
Relationship between
dietary and
supplemental
antioxidants and CCA-
IMT examined.
Semi-quantitative FFQ. Inverse relationship between vitamin C
and IMT in older subjects (>55 years)
(trend across intake quintiles P = 0.019
and P = 0.035 for men and women
respectively.
Abbreviations in table: MedDiet, Mediterranean diet; Zn, zinc; Mg, magnesium; LC-PUFA, long chain polyunsaturated fatty acid; PCA, principal component analysis; FFQ, food frequency questionnaire;
FMD, flow mediated dilatation; FBF, forearm blood flow; PWV, pulse wave velocity, VAM, vascular adhesion molecule; sVCAM-1, soluble vascular cell adhesion molecule-1; CCA, common carotid artery;
IMT, intima media thickness; CRP, C-reactive protein; IL-6, interleukin 6; Hcy, homocysteine.
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Appendix 2-1 Letter to GP for tracing previous participants
Date
Address
Dear Dr
RE: Patient name
Date of Birth
RE: The Influence of n-3 Fatty Acid Supplementation on Vascular and
Cognitive Function in Healthy Young Adults; a Randomised Controlled
Trial
I would be very grateful for your help in an important MRC funded study in
contacting the above patient.
He/she is a part of a cohort born at the Cambridge Maternity Hospital between
1969 and 1975 chosen because of their excellent birth and growth records. We
are now planning a new study, which aims to assess whether supplementation
with the n-3 fatty acid, DHA (docosahexaenoic acid), affects vascular and
cognitive function. To do this we need to trace the members of the original
cohort.
We understand from the NHS Register that the above patient is now registered
with your practice. Therefore we would be very grateful if you could post the
enclosed letter and brief information sheet to your patient (stamped envelope
provided). We have also prepared the attached cover note for you to enclose
with the letter. To maintain confidentiality, we will not know the participant’s
address unless they choose to reply to our letter. The study has been approved
by national and local ethics committees and is summarised in the enclosed
information sheet and letter to the potential participants.
Your help with this important study is very much appreciated. The Principal
Investigator (Dr A Singhal, Senior Lecturer and Honorary Consultant
Paediatrician, Great Ormond Street Hospital) would be happy to answer any
questions you may have. He can be contacted at a.singhal@ich.ucl.ac.uk, tel
020 7905 2389.
Thank you for your time and cooperation.
Yours sincerely,
Ms Julie Lanigan
Clinical Trials Co-ordinator
MRC Childhood Nutrition Research Centre
Tel: 0207 905 2770
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Appendix 2-2 Letter of invitation to participate in study
Name
Address
Date
Dear
Several years ago you very kindly helped us, the MRC nutrition research centre at the
Institute of Child Health (Great Ormond Street Hospital, London), with a study which
looked at the effect of diet and other factors on the health of blood vessels.
We would now like to ask for your help again in an important research project to see if
eating more of a type of fat (found mainly in oily fish) has benefits for blood vessels and
brain function. To do this we are asking adults between the ages of 18 and 36 years to
take part in a dietary supplementation study. Before and after taking the supplement
we will ask you to have your blood vessel function measured using the same safe and
painless method we used in the earlier study that you took part in. Just to remind you,
this method uses an ultrasound scan (similar to the scan used to look at unborn
babies). We also wish to do some tests of patterns of brain function, which are
computer based and easy to do.
We believe that the information collected could be of great benefit in finding ways to
lessen the risk of heart disease and will help us to find out whether fatty acid
supplements have benefits for blood vessel and brain function.
We have enclosed a brief information sheet telling you all about the study we wish to
do. If you would like to know more about the study or would like to take part please
could you fill in the form and return it in the stamped addressed envelope provided. If
you wish, you can also contact Ms Julie Lanigan (who is the research dietitian looking
after this study) by phone (Telephone No: 020 7905 2770) for any further information.
Should you wish to know more about the study, I (Julie Lanigan) will telephone you
over the next few weeks and look forward to talking to you and to answering any
questions you may have. All information will be in the strictest confidence. We will
refund all travel expenses and provide lunch and refreshments during the days you will
be with us. You will also be given £50 to thank you for your time and inconvenience.
Thank you for taking the time to read this letter.
Yours sincerely
Julie Lanigan BSc SRD Dr Atul Singhal MD MRCP
Trials Co-ordinator Senior Lecturer
Senior Dietitian Honorary Consultant Paediatrician
Institute of Child Health Institute of Child Health
Tel: 0207 905 2770 Tel: 0207 905 2389
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Reply Slip
I would like to know more about the omega-3 study. I can be contacted at
the address below:
Name……………………………………………………………………………………
Address…………………………………………………………………………………
…………………………………………………………………………………………..
…………………………………………………………………………………………..
…………………………………………………………………………………………..
Telephone (day)………………………………….
Telephone (eve)…………………………………
Mobile…………………………………………
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Appendix 2-3 Poster informing of study and inviting
participation
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Appendix 2-4 Patient Information Sheet
INFORMATION SHEET
The Influence of Omega-3 Fatty Acid Supplementation on Vascular and
Cognitive Function in Healthy Young Adults; a Randomised Controlled
Trial
You are being invited to take part in a research study. Before you decide it is
important for you to understand why the research is being done and what it will
involve. Please take the time to read the following information clearly and
discuss it with others if you wish. Ask us if there is anything that is not clear or if
you would like more information. Take time to decide whether or not you wish
to take part.
1. The aim of the study.
The aim of this project is to find out whether the amount of omega-3
polyunsaturated fatty acids in the diet (found mainly in oily fish, nuts and
spreads) has any effect on:
1) blood vessel function and 2) brain function.
2. Why is the study being done?
Many studies have shown that a type of fat, (known as omega-3
polyunsaturated fat) found in fish, such as tuna, salmon, mackerel and herring
has benefits on the brain, blood vessels and health of the heart. Much of this
information has come either from studying older people, populations where fish
intake is higher than in the West, or from studies where diets are supplemented
with extra omega-3. We also suspect that these benefits are stronger in people
with certain genes. We would like to find out whether supplementing the diet of
healthy young adults with omega-3 fatty acids can beneficially influence brain
function and improve the health of blood vessels.
3. Why am I suitable for this study?
As heart and blood vessel disease is more common in later life, selecting young
people (18-36) is more likely to include healthy individuals. Some of you have
helped us before and we already have some information on factors affecting
blood vessel health including genes. About 260 people will take part in this
study.
4. How is the study being done?
Because we do not know for definite whether this fatty acid is beneficial for
healthy people we need to make comparisons. People taking part in the study
will be put into one of two groups. One group will receive the fatty acid
supplement and the other group will receive another type of oil (olive oil) and
then compared. The groups will be selected by chance using a computer.
Neither you nor the researchers will know which group you have been put into.
This type of study is known as a randomised controlled trial.
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If you decide to take part we will ask you, on two or three separate occasions, to
travel to the study centre in London or Cambridge. We will reimburse your travel
expenses and provide you with lunch and refreshments.
Those people who have not been seen by us before will need to make a
preliminary visit to have a blood test before doing any other tests. This blood
test will give us information about one of your genes, which we need to ensure
that the two groups have similar numbers of people with the same genetic
characteristics.
For all subjects on your first visit we will:
a) ask you to sign a form, after the study has been clearly explained to you,
which tells us that you are willing to take part.
b) ask you some questions about your family and medical background and
your lifestyle such as smoking and drinking. This information will be
confidential.
We would like everyone to do the following measurements before and
after taking a dietary supplement for 16 weeks. We will:
a) take a small amount of blood from a vein in the arm (if you agree) so that
factors thought to affect the chances of blood vessel disease, e.g.
cholesterol and blood fats, can be measured. If possible we would like
you not to have anything to eat or drink (except water) on the morning of
your appointment or if it’s going to be a long journey 4 hours before
coming to the study centre. Food and drink will be available all day at the
centre. Blood may be stored and tested at a later date. We will also
assess genes that affect heart disease, brain function and how much fat
you have (body composition). These genes are not directly relevant to
health. For subjects we have not seen before, the blood test before
supplementation will be combined in the blood test from the preliminary
visit. So all subjects will only have two blood tests.
b) ask you to provide a small sample of saliva (by briefly holding a cotton
wool ball inside your mouth) to assess exposure to cigarette smoking.
c) ask you to rest on a bed for 10 minutes and then measure your blood
pressure and heart rate. We will then look at the main blood vessel in
the right arm and measure its width and how fast your pulse travels down
the arm using an ultrasound scanner (which is not in any way painful or
unpleasant and is the same as the scan used to look at unborn babies).
A tight cuff will be inflated around the lower arm for 5 minutes, and then
released (you may feel some tingling in the fingers before the cuff is
released). The change in blood vessel size will be measured. This
measurement has been done in over 3000 people, including children as
young as 5 years of age and is painless and harmless. We will also look
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at and measure the size of the main artery in the neck, using the same
scanner.
c) estimate the amount of water, muscle and fat in your body through
simple painless techniques:
i) Bio-electrical impedence
Pads will be attached to the right hand and foot. An electrical signal will
be measured to determine the amount of water and muscle in the body.
This measurement is completely painless and harmless and has been
done thousands of times before (even in small babies).
ii) Deuterium dilution
The measurement involves collecting a small sample of saliva before and
after drinking a small amount of water (containing a stable, non-
radioactive and naturally occurring isotope-deuterium). The test is
harmless and has been done thousands of times (even in small babies).
iii) Skinfold thickness measurements
This involves measuring the thickness of a small fold of skin at four
points: biceps (front upper arm); triceps (back upper arm); sub-scapular
(below the shoulder blade) and supra-illiac (front of hip).
We would also like to measure your height and weight, and hip, waist,
arm and leg circumferences. You do not have to undress for any of
these measurements.
d) ask you to step up and down for 3-5 minutes to measure your level of
fitness and complete an exercise questionnaire.
e) spend some time with a dietitian who will ask you some questions about
your usual food intake. You will also be asked to tell us what you ate for
one day 7 times throughout the study. (This record will be analysed by a
dietitian and a nutritional assessment report will be sent to you).
For the patterns of brain function part (mainly in the afternoon) we will ask you
to:
a) do some written tests of memory and thinking and
b) do some computer tests that are similar to computer games.
All of the things we have asked you to do are easy and will take about 5-6 hours
over the day you are at the centre. There will be rest breaks where food and
drink will be provided.
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5. Supplement
After the first measurements you will be given some dietary supplements (fatty
acid or olive oil) to take at home for the next 16 weeks. Neither yourself nor the
researchers will know which of the two supplements you have been given. The
supplement can be bought over the counter, has been used many times and is
not known to cause any problems, although in a small number of people on rare
occasions there might be a slight increase in wind. One of the study team will
telephone or text you during the supplementation period to make sure you
aren’t having any problems. We will ask you to come back to the centre after
the supplement period when all the tests will be repeated. At this point you will
be given £50 to thank you for your time and inconvenience.
Please don’t take any over the counter fatty acid supplements during the study.
5. Are there any risks and discomforts?
We do not think there is any risk to you. The cuff around the arm for the scan
may be a little uncomfortable but is not painful (the scan has been done in
children as young as 5 years of age). Although a cream will be used to numb
the skin for blood taking there still may be some discomfort and bruising. There
may be on occasions a slight increase in wind whilst taking the supplement.
The Metropolitan MREC, one of 13 national research ethics committees, has
given its approval.
6. Who will have access to the case/research records?
All information which is collected about you during the course of the research
will be kept strictly confidential. Any information about you will be identified only
with a study number and will not have your name and address on it.
7. What are the potential benefits?
The study will not necessarily bring any immediate benefits to you although
omega-3 fatty acids have been shown to benefit health of the heart in older
people. It is hoped that the study will help us to know whether increasing intake
of omega-3 fatty acids is beneficial to health. We think that the study may also
help you because if your chance of blood vessel disease later on is higher than
normal you can be advised on how to reduce the risk for the future. For
example we will measure your blood pressure and cholesterol which may be
useful for you to know. We will also assess your diet and a dietitian will provide
you with a nutritional assessment.
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8. Do I have to take part?
It is up to you to decide whether or not to take part. If you decide to take part
you will be given this information sheet to keep and be asked to sign a consent
form. If you decide to take part you are still free to withdraw at any time. You
are free to opt out of the study at any point, including the blood test. If you
decide to withdraw or not to take part, this will have no effect on the standard of
care you receive.
9. Who is organising and funding the research?
The research is being organised by the Childhood Nutrition Research Centre at
the Institute of Child Health & Great Ormond Street NHS Trust, London. This
group is funded by the Medical Research Council (MRC).
10. What will happen to the results of the research study?
The results of the study will be published in a medical journal. This may be quite
some time after you have taken part but we will keep you informed with a
newsletter. You will not be personally identified in any publications. If you wish,
we can tell you whether or not you took the fatty acid supplement once the
study is complete.
11. Who do I speak to if a problem arises?
If you have any complaints about the way in which this research project has
been, or is being conducted, please, in the first instance, discuss them with the
researcher.
Details of how to contact the Principal Researcher
Dr Atul Singhal, MRC Childhood Research Centre, Institute of Child Health, 30
Guilford Street, London WC1N 1EH. Telephone 020 7905 2389
Details of local Researcher who will discuss the study with you
Ms Julie Lanigan, MRC Childhood Nutrition Research Centre, Institute of Child
Health, 30 Guilford Street, London WC1N 1EH. Telephone 020 7905 2770.
In the case of urgent queries, a local researcher can be contacted at any time
on 020 7242 4479.
Thank you for taking the time to read this information sheet and for taking part
in the study should you choose to do so.
29th January 2004
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Appendix 2-5 Study consent form
Great Ormond Street Hospital for Children NHS Trust and Institute of Child Health
Research Ethics Committee
Consent Form for Adults Participating in Research Studies
Title: The Influence of n-3 Fatty Acid Supplementation on Vascular and Cognitive
Function in Healthy Young Adults; a Randomized Controlled Trial
NOTES FOR PARTICIPANTS
1. You have been asked to take part in a research study. The person organising that
study is responsible for explaining the project to you before you give consent.
2. Please ask the researcher any questions you may have about this project, before you
decide whether you wish to participate.
3. If you decide, now or at any other stage, that you do not wish to participate in the
research project, that is entirely your right, and if you are a patient it will not in any way
prejudice any present or future treatment.
4. You will be given an information sheet which describes the research project. This
information sheet is for you to keep and refer to. Please read it carefully.
5. If you have any complaints about the way in which this research project has been or is
being conducted, please, in the first instance, discuss them with the researcher. If the
problems are not resolved, or you wish to comment in any other way, please contact the
Chairman of the Research Ethics Committee, by post via The Research and
Development Office, Institute of Child Health, 30 Guilford Street, London WC1N 1EH or
if urgent by telephone on 0207 905 2620 and the committee administration will put you
in contact with him.
CONSENT
I______________________________________
agree that the Research Project named above has been explained to me to my satisfaction, and
I give my permission take part in this study. I have read both the notes written above and the
Information Sheet provided, and understand what the research study involves.
SIGNED (Subject) DATE
_______________________________________ _____________________
SIGNED (Researcher) DATE
_______________________________________ _____________________
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Appendix 2-6 Consent form to provide a blood sample
The Influence of n-3 Fatty Acid Supplementation on Vascular and Cognitive Function in Healthy
Young Adults; a Randomized Controlled Trial
Participants Consent Form for Blood Test
Name ____________________________________________
Thank you for reading the information about our research project. If you would like to
take part please read and sign this form and initial the boxes.
1. I have read the information sheet on this project and have been given a copy to keep. I
have been able to ask questions about the project and I understand why the research is
being done and any risks involved.
2. I agree to give a sample of blood for research in this project. I understand how the sample
will be collected, that giving a sample for this research is voluntary and that I am free to
change my mind for use of the sample at anytime without giving a reason and without my
medical treatment or legal rights being affected.
3. I understand that I, and my doctor, will be informed if the results of any medical tests done
as part of the research are important for my health.
4. I understand that I will not benefit financially if this research leads to the development of a
new treatment or medical test.
5. I agree the sample I have given is a gift. The sample I have given and the information
gathered about me can be stored at the MRC Childhood Nutrition Centre for possible use in
future projects, as described in the attached information sheet. I understand that some of
these projects may be carried out by researchers other than those who ran the first project,
including researchers working for commercial companies.
6. I understand that the project and future research using the sample I give may include
genetic research aimed at understanding the genetic influences on disease, but the results
of these investigations are unlikely to have any implications for me personally.
Name of Participant: Date Signature
Name of person taking consent: Date Signature
Would you like to be sent information Yes No
about the progress of this project ?
Thank you for agreeing to take part in this research
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Appendix 2-7 Study Flow Chart
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Appendix 2-8 Compliance Monitoring Form
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Appendix 2-9 Lifestyle questionnaire
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Appendix 3-1 EPIC FFQ example page
343
Appendix 3-2 Instruction Manual for EPIC FFQ analysis
Please see flap inside back cover
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Appendix 3-3 Prototype FishFQ
Appendix 3-4 FishFQ Evaluation Questionnaire
Omega 3 Supplementation Study
Childhood Nutrition Research Centre
Food Frequency Questionnaire evaluation for
Rating scale: (1) - strongly agree (2) - agree (3) - d
1. The content of the questionnaire was clearly explained to me
(1) (2) (3)
2. The questionnaire was easy to understand
(1) (2) (3)
3. The length of the questionnaire was acceptable
(1) (2) (3)
4. I had to ask a member of the research team for help to fill out th
(1) (2) (3)
5. All of the foods I expected to see on the questionnaire were inc
(1) (2) (3)
6. Some foods that I usually eat and I thought were good sourc
included
(1) (2) (3)
Please list any foods you felt should be included on the comments page
7. The explanations and help the researchers gave were
Rating scale: A. excellent / B. good / C. fair / D. poor
(A) (B) (C) (D)
Comments:345
m
isagree please circle
e questionnaire
luded
es of Omega 3 were not
below.
Please circle:
Omega3
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Appendix 3-5 The Final FishFQ used in the study
347
Appendix 3-6 Fish Frequency Questionnaire & Portion Size
Booklet
Please see flap inside back cover.
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Appendix 4-1 Method of Triads – calculations
Method of Triads – Calculation of Validity Coefficients
DHA
PQT = √ rQR x r MQ/rRM PRT = √ rQR x r RM/rQM PMT = √ rMQ x r RM/rQR
0.35 x 0.34/0.41 = 0.35 x 0.41/0.34 = 0.34 x 0.41/0.35
0.35 x 0.83 = 0.35 x 1.2 = 0.34 x 1.17 =
0.29 0.42 0.39
√0.29 = 0.54 √0.42 = 0.65 √0.39 = 0.63
EPA
PQT = √ rQR x r MQ/rRM PRT = √ rQR x r RM/rQM PMT = √ rMQ x r RM/rQR
0.30 x 0.38/0.50 = 0.30 x 0.50/0.38= 0.38 x 0.50/0.30=
0.30 x 0.76 = 0.30 x 1.3 = 0.38 x 1.6=
0.23 0.39 0.63
√0.23 = 0.48   √0.39 = 0.63 √0.63 = 0.80
DHA/EPA
PQT = √ rQR x r MQ/rRM PRT = √ rQR x r RM/rQM PMT = √ rMQ x r RM/rQR
0.35 x 0.43/0.48= 0.35 x 0.48/0.43 = 0.43 x 0.48/0.35
0.35 x 0.9 = 0.35 x 1.12 = 0.43 x 1.4 =
√0.31 = 0.56 √0.39 = 0.63 √0.6 = 0.77
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Appendix 4-2 Abstract accepted for publication in the
Proceedings of the Nutrition Society
Validation of a new food frequency questionnaire for measurement of dietary n-3 long chain
fatty acids using the method of Triads. By J. Lanigan1, S. Low1, M. Kokoreli, K. Northstone2
and A Singhal1, Childhood Nutrition Research Centre, University College London Institute of Child
Health, 30 Guilford Street, London, WC1N 1EH and 2School of Social and Community Medicine,
University of Bristol
Long chain n-3 polyunsaturated fatty acids (n-3 LCPUFA) docosahexaenoic acid (DHA: 22:6 n-3)
and eicosapentaenoic acid (EPA: 20:5 n-3), present in high concentrations in certain types of fish,
are reported to have benefits for cardiovascular disease (CVD). However, currently there is no
validated instrument to measure dietary n-3 LCPUFA in the UK. A generalised food frequency
questionnaire (FFQ), such as that used in the European Prospective Investigation of Cancer
(EPIC)498, may estimate intake inaccurately because foods high in n-3 LCPUFA are grouped
together. The aim of this study was to assess whether a new FFQ which separated foods high in n-
3 LCPUFA was a valid and reliable method for assessing n-3 intake in a group of young, healthy
UK adults.
Participants (n=78) in a randomised controlled trial investigating the effects of n-3 LCPUFA
supplementation on CVD risk factors completed a new questionnaire (FishFQ), adapted from the
EPIC FFQ, designed to collect dietary data on foods with the highest concentration of n-3 LCPUFA.
The FishFQ comprised 31 food items and allowed separation of fish into white and oily, and
discriminated between canned and fresh fish. The questionnaire was self administered after
instructions were given by trained researchers.
Relative validity of the FishFQ was assessed using the method of triads which uses triangular
comparisons between a dietary assessment method under test (FishFQ), a reference method
(multiple 24 hour dietary recalls) and a biochemical marker (red cell membrane fatty acids) to
compute validity coefficients (VCs)628. Reliability was evaluated with Pearson’s correlation
coefficient at 4 month re-test interval.
VCs were similar for dietary assessment methods and biomarkers of n-3 LCPUFA intake. The
highest VC for DHA was found for the 24 hour recall method whereas for the biomarker a higher VC
was found for EPA. Reliability was high for both fatty acids: r.0.74 and r 0.55 for DHA and EPA
respectively.
Validity coefficients Range of Validity coefficients†
PQT 95% CI PRT 95% CI PMT 95% CI PQT PRT PMT
DHA 0.54 (0.22,0.92) 0.65 (0.32, 1.28) 0.63 (0.29, 1.08) 0.34 – 0.54 0.41 – 0.65 0.34 – 0.63
EPA 0.48 (0.26, 0.76) 0.63 0.33, 1.00) 0.80 0.48, 1.44) 0.38 – 0.48 0.50 – 0.63 0.38 – 0.80
† The lower limit for the FishFQ and the biomarker is the correlation between the Fish FQ and the biomarker, and the lower
limit for the 24-HR is the correlation between the biomarker and the 24-HR. The upper limit is calculated by the method of
triads. pQT, validity coefficient of the FishFQ, pRT, validity coefficient of the 24-H recall, pMT, validity coefficient of the
biomarker. All data natural log transformed. 5% confidence intervals computed from 200 Bootstrap samples
Validity was comparable to findings from other studies which report VC’s in the range of 0.22-
0.60 for fatty acids. Reliability was also high compared with previous studies involving FFQ’s.
Overall VC’s for the FishFQ were high suggesting it is a valid method for dietary assessment of n-3
LCPUFA.
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Appendix 4-3 Graphical Representations of Bland and Altman
Analyses to assess Agreement between Fish and EPIC FFQs
Administered on 2 Separate Occasions
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